id	sid	tid	token	lemma	pos
ajst-32576	1	1	220	220	NUM
ajst-32576	1	2	treatment	treatment	NOUN
ajst-32576	1	3	of	of	ADP
ajst-32576	1	4	brain	brain	NOUN
ajst-32576	1	5	metastases	metastasis	NOUN
ajst-32576	1	6	in	in	ADP
ajst-32576	1	7	non	non	ADJ
ajst-32576	1	8	-	-	ADJ
ajst-32576	1	9	small	small	ADJ
ajst-32576	1	10	cell	cell	NOUN
ajst-32576	1	11	lung	lung	NOUN
ajst-32576	1	12	cancer	cancer	NOUN
ajst-32576	1	13	haiying	haiye	VERB
ajst-32576	1	14	xue	xue	PROPN
ajst-32576	1	15	1	1	NUM
ajst-32576	1	16	,	,	PUNCT
ajst-32576	1	17	a	a	DET
ajst-32576	1	18	,	,	PUNCT
ajst-32576	1	19	†	†	PROPN
ajst-32576	1	20	,	,	PUNCT
ajst-32576	1	21	yuzhu	yuzhu	PROPN
ajst-32576	1	22	chen	chen	PROPN
ajst-32576	1	23	2	2	NUM
ajst-32576	1	24	,	,	PUNCT
ajst-32576	1	25	†	†	PROPN
ajst-32576	1	26	1	1	NUM
ajst-32576	1	27	school	school	NOUN
ajst-32576	1	28	of	of	ADP
ajst-32576	1	29	medicine	medicine	NOUN
ajst-32576	1	30	,	,	PUNCT
ajst-32576	1	31	sun	sun	PROPN
ajst-32576	1	32	yat	yat	PROPN
ajst-32576	1	33	-	-	PUNCT
ajst-32576	1	34	sen	sen	PROPN
ajst-32576	1	35	university	university	PROPN
ajst-32576	1	36	,	,	PUNCT
ajst-32576	1	37	shenzhen	shenzhen	PROPN
ajst-32576	1	38	guangdong	guangdong	PROPN
ajst-32576	1	39	,	,	PUNCT
ajst-32576	1	40	518107	518107	NUM
ajst-32576	1	41	,	,	PUNCT
ajst-32576	1	42	china	china	PROPN
ajst-32576	1	43	2	2	NUM
ajst-32576	1	44	department	department	NOUN
ajst-32576	1	45	of	of	ADP
ajst-32576	1	46	oncology	oncology	NOUN
ajst-32576	1	47	,	,	PUNCT
ajst-32576	1	48	beijing	beijing	PROPN
ajst-32576	1	49	chest	chest	PROPN
ajst-32576	1	50	hospital	hospital	NOUN
ajst-32576	1	51	,	,	PUNCT
ajst-32576	1	52	capital	capital	PROPN
ajst-32576	1	53	medical	medical	PROPN
ajst-32576	1	54	university	university	PROPN
ajst-32576	1	55	,	,	PUNCT
ajst-32576	1	56	beijing	beijing	NOUN
ajst-32576	1	57	tuberculosis	tuberculosis	NOUN
ajst-32576	1	58	and	and	CCONJ
ajst-32576	1	59	thoracic	thoracic	NOUN
ajst-32576	1	60	tumor	tumor	PROPN
ajst-32576	1	61	research	research	PROPN
ajst-32576	1	62	institute	institute	PROPN
ajst-32576	1	63	,	,	PUNCT
ajst-32576	1	64	beijing	beijing	PROPN
ajst-32576	1	65	101149	101149	NUM
ajst-32576	1	66	,	,	PUNCT
ajst-32576	1	67	china	china	PROPN
ajst-32576	1	68	a	a	DET
ajst-32576	1	69	xuehy6@mail2.sysu.edu.cn	xuehy6@mail2.sysu.edu.cn	PROPN
ajst-32576	1	70	†haiying	†haiye	VERB
ajst-32576	1	71	xue	xue	PROPN
ajst-32576	1	72	and	and	CCONJ
ajst-32576	1	73	yuzhu	yuzhu	PROPN
ajst-32576	1	74	chen	chen	PROPN
ajst-32576	1	75	have	have	AUX
ajst-32576	1	76	made	make	VERB
ajst-32576	1	77	the	the	DET
ajst-32576	1	78	same	same	ADJ
ajst-32576	1	79	contribution	contribution	NOUN
ajst-32576	1	80	to	to	ADP
ajst-32576	1	81	this	this	DET
ajst-32576	1	82	article	article	NOUN
ajst-32576	1	83	.	.	PUNCT
ajst-32576	2	1	abstract	abstract	ADJ
ajst-32576	2	2	.	.	PUNCT
ajst-32576	3	1	non	non	ADJ
ajst-32576	3	2	-	-	ADJ
ajst-32576	3	3	small	small	ADJ
ajst-32576	3	4	cell	cell	NOUN
ajst-32576	3	5	lung	lung	NOUN
ajst-32576	3	6	cancer	cancer	NOUN
ajst-32576	3	7	is	be	AUX
ajst-32576	3	8	the	the	DET
ajst-32576	3	9	most	most	ADV
ajst-32576	3	10	common	common	ADJ
ajst-32576	3	11	subtype	subtype	NOUN
ajst-32576	3	12	of	of	ADP
ajst-32576	3	13	lung	lung	NOUN
ajst-32576	3	14	cancer	cancer	NOUN
ajst-32576	3	15	,	,	PUNCT
ajst-32576	3	16	and	and	CCONJ
ajst-32576	3	17	brain	brain	NOUN
ajst-32576	3	18	metastases	metastasis	NOUN
ajst-32576	3	19	are	be	AUX
ajst-32576	3	20	a	a	DET
ajst-32576	3	21	frequent	frequent	ADJ
ajst-32576	3	22	and	and	CCONJ
ajst-32576	3	23	devastating	devastating	ADJ
ajst-32576	3	24	complication	complication	NOUN
ajst-32576	3	25	with	with	ADP
ajst-32576	3	26	poor	poor	ADJ
ajst-32576	3	27	prognosis	prognosis	NOUN
ajst-32576	3	28	.	.	PUNCT
ajst-32576	4	1	the	the	DET
ajst-32576	4	2	blood	blood	NOUN
ajst-32576	4	3	-	-	PUNCT
ajst-32576	4	4	brain	brain	NOUN
ajst-32576	4	5	barrier	barrier	NOUN
ajst-32576	4	6	and	and	CCONJ
ajst-32576	4	7	blood	blood	NOUN
ajst-32576	4	8	-	-	PUNCT
ajst-32576	4	9	tumor	tumor	NOUN
ajst-32576	4	10	barrier	barrier	NOUN
ajst-32576	4	11	limit	limit	VERB
ajst-32576	4	12	intracranial	intracranial	ADJ
ajst-32576	4	13	drug	drug	NOUN
ajst-32576	4	14	delivery	delivery	NOUN
ajst-32576	4	15	,	,	PUNCT
ajst-32576	4	16	resulting	result	VERB
ajst-32576	4	17	in	in	ADP
ajst-32576	4	18	suboptimal	suboptimal	ADJ
ajst-32576	4	19	therapeutic	therapeutic	ADJ
ajst-32576	4	20	effects	effect	NOUN
ajst-32576	4	21	.	.	PUNCT
ajst-32576	5	1	recent	recent	ADJ
ajst-32576	5	2	advances	advance	NOUN
ajst-32576	5	3	in	in	ADP
ajst-32576	5	4	molecular	molecular	ADJ
ajst-32576	5	5	targeted	target	VERB
ajst-32576	5	6	therapy	therapy	NOUN
ajst-32576	5	7	and	and	CCONJ
ajst-32576	5	8	immunotherapy	immunotherapy	NOUN
ajst-32576	5	9	have	have	VERB
ajst-32576	5	10	markedly	markedly	ADV
ajst-32576	5	11	improved	improve	VERB
ajst-32576	5	12	survival	survival	NOUN
ajst-32576	5	13	,	,	PUNCT
ajst-32576	5	14	particularly	particularly	ADV
ajst-32576	5	15	in	in	ADP
ajst-32576	5	16	patients	patient	NOUN
ajst-32576	5	17	harboring	harbor	VERB
ajst-32576	5	18	egfr	egfr	ADV
ajst-32576	5	19	or	or	CCONJ
ajst-32576	5	20	alk	alk	VERB
ajst-32576	5	21	alterations	alteration	NOUN
ajst-32576	5	22	,	,	PUNCT
ajst-32576	5	23	where	where	SCONJ
ajst-32576	5	24	next	next	ADJ
ajst-32576	5	25	-	-	PUNCT
ajst-32576	5	26	generation	generation	NOUN
ajst-32576	5	27	tyrosine	tyrosine	NOUN
ajst-32576	5	28	kinase	kinase	PROPN
ajst-32576	5	29	inhibitors	inhibitor	NOUN
ajst-32576	5	30	demonstrate	demonstrate	VERB
ajst-32576	5	31	strong	strong	ADJ
ajst-32576	5	32	intracranial	intracranial	ADJ
ajst-32576	5	33	activity	activity	NOUN
ajst-32576	5	34	.	.	PUNCT
ajst-32576	6	1	radiotherapy	radiotherapy	NOUN
ajst-32576	6	2	remains	remain	VERB
ajst-32576	6	3	essential	essential	ADJ
ajst-32576	6	4	for	for	ADP
ajst-32576	6	5	local	local	ADJ
ajst-32576	6	6	control	control	NOUN
ajst-32576	6	7	,	,	PUNCT
ajst-32576	6	8	while	while	SCONJ
ajst-32576	6	9	chemotherapy	chemotherapy	NOUN
ajst-32576	6	10	contributes	contribute	VERB
ajst-32576	6	11	mainly	mainly	ADV
ajst-32576	6	12	to	to	ADP
ajst-32576	6	13	systemic	systemic	ADJ
ajst-32576	6	14	disease	disease	NOUN
ajst-32576	6	15	management	management	NOUN
ajst-32576	6	16	.	.	PUNCT
ajst-32576	7	1	increasingly	increasingly	ADV
ajst-32576	7	2	,	,	PUNCT
ajst-32576	7	3	multidisciplinary	multidisciplinary	ADJ
ajst-32576	7	4	and	and	CCONJ
ajst-32576	7	5	combination	combination	NOUN
ajst-32576	7	6	strategies	strategy	NOUN
ajst-32576	7	7	are	be	AUX
ajst-32576	7	8	shaping	shape	VERB
ajst-32576	7	9	the	the	DET
ajst-32576	7	10	treatment	treatment	NOUN
ajst-32576	7	11	paradigm	paradigm	NOUN
ajst-32576	7	12	.	.	PUNCT
ajst-32576	8	1	nevertheless	nevertheless	ADV
ajst-32576	8	2	,	,	PUNCT
ajst-32576	8	3	challenges	challenge	NOUN
ajst-32576	8	4	such	such	ADJ
ajst-32576	8	5	as	as	ADP
ajst-32576	8	6	drug	drug	NOUN
ajst-32576	8	7	resistance	resistance	NOUN
ajst-32576	8	8	,	,	PUNCT
ajst-32576	8	9	bbb	bbb	NOUN
ajst-32576	8	10	limitations	limitation	NOUN
ajst-32576	8	11	,	,	PUNCT
ajst-32576	8	12	and	and	CCONJ
ajst-32576	8	13	neurocognitive	neurocognitive	ADJ
ajst-32576	8	14	preservation	preservation	NOUN
ajst-32576	8	15	persist	persist	NOUN
ajst-32576	8	16	.	.	PUNCT
ajst-32576	9	1	this	this	DET
ajst-32576	9	2	review	review	NOUN
ajst-32576	9	3	summarizes	summarize	VERB
ajst-32576	9	4	current	current	ADJ
ajst-32576	9	5	therapeutic	therapeutic	ADJ
ajst-32576	9	6	strategies	strategy	NOUN
ajst-32576	9	7	for	for	ADP
ajst-32576	9	8	nsclc	nsclc	NOUN
ajst-32576	9	9	with	with	ADP
ajst-32576	9	10	brain	brain	NOUN
ajst-32576	9	11	metastases	metastasis	NOUN
ajst-32576	9	12	,	,	PUNCT
ajst-32576	9	13	highlights	highlight	VERB
ajst-32576	9	14	their	their	PRON
ajst-32576	9	15	strengths	strength	NOUN
ajst-32576	9	16	and	and	CCONJ
ajst-32576	9	17	limitations	limitation	NOUN
ajst-32576	9	18	,	,	PUNCT
ajst-32576	9	19	and	and	CCONJ
ajst-32576	9	20	discusses	discuss	VERB
ajst-32576	9	21	future	future	ADJ
ajst-32576	9	22	directions	direction	NOUN
ajst-32576	9	23	for	for	ADP
ajst-32576	9	24	optimizing	optimize	VERB
ajst-32576	9	25	patient	patient	ADJ
ajst-32576	9	26	outcomes	outcome	NOUN
ajst-32576	9	27	.	.	PUNCT
ajst-32576	10	1	keywords	keyword	NOUN
ajst-32576	10	2	:	:	PUNCT
ajst-32576	10	3	non	non	ADJ
ajst-32576	10	4	-	-	ADJ
ajst-32576	10	5	small	small	ADJ
ajst-32576	10	6	cell	cell	NOUN
ajst-32576	10	7	lung	lung	NOUN
ajst-32576	10	8	cancer	cancer	NOUN
ajst-32576	10	9	;	;	PUNCT
ajst-32576	10	10	brain	brain	NOUN
ajst-32576	10	11	metastases	metastasis	NOUN
ajst-32576	10	12	;	;	PUNCT
ajst-32576	10	13	treatment	treatment	NOUN
ajst-32576	10	14	;	;	PUNCT
ajst-32576	10	15	targeted	target	VERB
ajst-32576	10	16	therapy	therapy	NOUN
ajst-32576	10	17	.	.	PUNCT
ajst-32576	11	1	1	1	X
ajst-32576	11	2	.	.	X
ajst-32576	11	3	introduction	introduction	NOUN
ajst-32576	11	4	lung	lung	NOUN
ajst-32576	11	5	cancer	cancer	NOUN
ajst-32576	11	6	is	be	AUX
ajst-32576	11	7	the	the	DET
ajst-32576	11	8	most	most	ADV
ajst-32576	11	9	common	common	ADJ
ajst-32576	11	10	malignant	malignant	ADJ
ajst-32576	11	11	tumor	tumor	NOUN
ajst-32576	11	12	worldwide	worldwide	ADV
ajst-32576	11	13	,	,	PUNCT
ajst-32576	11	14	among	among	ADP
ajst-32576	11	15	which	which	PRON
ajst-32576	11	16	non	non	ADJ
ajst-32576	11	17	-	-	ADJ
ajst-32576	11	18	small	small	ADJ
ajst-32576	11	19	cell	cell	NOUN
ajst-32576	11	20	lung	lung	NOUN
ajst-32576	11	21	cancer	cancer	NOUN
ajst-32576	11	22	(	(	PUNCT
ajst-32576	11	23	nsclc	nsclc	NOUN
ajst-32576	11	24	)	)	PUNCT
ajst-32576	11	25	accounts	account	NOUN
ajst-32576	11	26	for	for	ADP
ajst-32576	11	27	approximately	approximately	ADV
ajst-32576	11	28	85	85	NUM
ajst-32576	11	29	%	%	NOUN
ajst-32576	11	30	[	[	X
ajst-32576	11	31	1	1	NUM
ajst-32576	11	32	]	]	PUNCT
ajst-32576	11	33	.	.	PUNCT
ajst-32576	12	1	the	the	DET
ajst-32576	12	2	brain	brain	NOUN
ajst-32576	12	3	is	be	AUX
ajst-32576	12	4	one	one	NUM
ajst-32576	12	5	of	of	ADP
ajst-32576	12	6	the	the	DET
ajst-32576	12	7	most	most	ADV
ajst-32576	12	8	common	common	ADJ
ajst-32576	12	9	metastatic	metastatic	ADJ
ajst-32576	12	10	sites	site	NOUN
ajst-32576	12	11	,	,	PUNCT
ajst-32576	12	12	affecting	affect	VERB
ajst-32576	12	13	10–25	10–25	NUM
ajst-32576	12	14	%	%	NOUN
ajst-32576	12	15	of	of	ADP
ajst-32576	12	16	patients	patient	NOUN
ajst-32576	12	17	at	at	ADP
ajst-32576	12	18	diagnosis	diagnosis	NOUN
ajst-32576	12	19	and	and	CCONJ
ajst-32576	12	20	more	more	ADJ
ajst-32576	12	21	than	than	ADP
ajst-32576	12	22	half	half	NOUN
ajst-32576	12	23	during	during	ADP
ajst-32576	12	24	the	the	DET
ajst-32576	12	25	course	course	NOUN
ajst-32576	12	26	of	of	ADP
ajst-32576	12	27	disease	disease	NOUN
ajst-32576	12	28	[	[	X
ajst-32576	12	29	2	2	NUM
ajst-32576	12	30	]	]	PUNCT
ajst-32576	12	31	.	.	PUNCT
ajst-32576	13	1	brain	brain	NOUN
ajst-32576	13	2	metastases	metastasis	NOUN
ajst-32576	13	3	(	(	PUNCT
ajst-32576	13	4	bm	bm	NOUN
ajst-32576	13	5	)	)	PUNCT
ajst-32576	13	6	often	often	ADV
ajst-32576	13	7	cause	cause	VERB
ajst-32576	13	8	intracranial	intracranial	ADJ
ajst-32576	13	9	hypertension	hypertension	NOUN
ajst-32576	13	10	and	and	CCONJ
ajst-32576	13	11	focal	focal	ADJ
ajst-32576	13	12	neurological	neurological	ADJ
ajst-32576	13	13	deficits	deficit	NOUN
ajst-32576	13	14	,	,	PUNCT
ajst-32576	13	15	severely	severely	ADV
ajst-32576	13	16	compromising	compromise	VERB
ajst-32576	13	17	quality	quality	NOUN
ajst-32576	13	18	of	of	ADP
ajst-32576	13	19	life	life	NOUN
ajst-32576	13	20	and	and	CCONJ
ajst-32576	13	21	survival	survival	NOUN
ajst-32576	13	22	.	.	PUNCT
ajst-32576	14	1	without	without	ADP
ajst-32576	14	2	treatment	treatment	NOUN
ajst-32576	14	3	,	,	PUNCT
ajst-32576	14	4	median	median	ADJ
ajst-32576	14	5	overall	overall	ADJ
ajst-32576	14	6	survival	survival	NOUN
ajst-32576	14	7	is	be	AUX
ajst-32576	14	8	only	only	ADV
ajst-32576	14	9	about	about	ADV
ajst-32576	14	10	one	one	NUM
ajst-32576	14	11	month	month	NOUN
ajst-32576	14	12	[	[	X
ajst-32576	14	13	3	3	NUM
ajst-32576	14	14	]	]	PUNCT
ajst-32576	14	15	.	.	PUNCT
ajst-32576	15	1	the	the	DET
ajst-32576	15	2	blood	blood	NOUN
ajst-32576	15	3	–	–	PUNCT
ajst-32576	15	4	brain	brain	NOUN
ajst-32576	15	5	barrier	barrier	NOUN
ajst-32576	15	6	(	(	PUNCT
ajst-32576	15	7	bbb	bbb	PROPN
ajst-32576	15	8	)	)	PUNCT
ajst-32576	15	9	,	,	PUNCT
ajst-32576	15	10	composed	compose	VERB
ajst-32576	15	11	of	of	ADP
ajst-32576	15	12	endothelial	endothelial	ADJ
ajst-32576	15	13	cells	cell	NOUN
ajst-32576	15	14	,	,	PUNCT
ajst-32576	15	15	tight	tight	ADJ
ajst-32576	15	16	junctions	junction	NOUN
ajst-32576	15	17	,	,	PUNCT
ajst-32576	15	18	pericytes	pericyte	NOUN
ajst-32576	15	19	,	,	PUNCT
ajst-32576	15	20	astrocytes	astrocyte	NOUN
ajst-32576	15	21	,	,	PUNCT
ajst-32576	15	22	and	and	CCONJ
ajst-32576	15	23	the	the	DET
ajst-32576	15	24	basement	basement	NOUN
ajst-32576	15	25	membrane	membrane	NOUN
ajst-32576	15	26	,	,	PUNCT
ajst-32576	15	27	maintains	maintain	VERB
ajst-32576	15	28	central	central	ADJ
ajst-32576	15	29	nervous	nervous	ADJ
ajst-32576	15	30	system	system	NOUN
ajst-32576	15	31	homeostasis	homeostasis	NOUN
ajst-32576	15	32	.	.	PUNCT
ajst-32576	16	1	in	in	ADP
ajst-32576	16	2	the	the	DET
ajst-32576	16	3	setting	setting	NOUN
ajst-32576	16	4	of	of	ADP
ajst-32576	16	5	brain	brain	NOUN
ajst-32576	16	6	metastases	metastasis	NOUN
ajst-32576	16	7	,	,	PUNCT
ajst-32576	16	8	structural	structural	ADJ
ajst-32576	16	9	and	and	CCONJ
ajst-32576	16	10	functional	functional	ADJ
ajst-32576	16	11	changes	change	NOUN
ajst-32576	16	12	give	give	VERB
ajst-32576	16	13	rise	rise	NOUN
ajst-32576	16	14	to	to	ADP
ajst-32576	16	15	the	the	DET
ajst-32576	16	16	blood	blood	NOUN
ajst-32576	16	17	–	–	PUNCT
ajst-32576	16	18	tumor	tumor	NOUN
ajst-32576	16	19	barrier	barrier	NOUN
ajst-32576	16	20	(	(	PUNCT
ajst-32576	16	21	btb	btb	NOUN
ajst-32576	16	22	)	)	PUNCT
ajst-32576	16	23	.	.	PUNCT
ajst-32576	17	1	although	although	SCONJ
ajst-32576	17	2	more	more	ADV
ajst-32576	17	3	permeable	permeable	ADJ
ajst-32576	17	4	than	than	ADP
ajst-32576	17	5	the	the	DET
ajst-32576	17	6	bbb	bbb	PROPN
ajst-32576	17	7	,	,	PUNCT
ajst-32576	17	8	the	the	DET
ajst-32576	17	9	btb	btb	NOUN
ajst-32576	17	10	exhibits	exhibit	NOUN
ajst-32576	17	11	marked	mark	VERB
ajst-32576	17	12	heterogeneity	heterogeneity	NOUN
ajst-32576	17	13	,	,	PUNCT
ajst-32576	17	14	leading	lead	VERB
ajst-32576	17	15	to	to	ADP
ajst-32576	17	16	uneven	uneven	ADJ
ajst-32576	17	17	drug	drug	NOUN
ajst-32576	17	18	distribution	distribution	NOUN
ajst-32576	17	19	and	and	CCONJ
ajst-32576	17	20	limited	limited	ADJ
ajst-32576	17	21	efficacy	efficacy	NOUN
ajst-32576	17	22	of	of	ADP
ajst-32576	17	23	systemic	systemic	ADJ
ajst-32576	17	24	therapies	therapy	NOUN
ajst-32576	17	25	[	[	X
ajst-32576	17	26	4	4	NUM
ajst-32576	17	27	]	]	PUNCT
ajst-32576	17	28	.	.	PUNCT
ajst-32576	18	1	current	current	ADJ
ajst-32576	18	2	treatment	treatment	NOUN
ajst-32576	18	3	options	option	NOUN
ajst-32576	18	4	include	include	VERB
ajst-32576	18	5	surgery	surgery	NOUN
ajst-32576	18	6	,	,	PUNCT
ajst-32576	18	7	whole	whole	ADJ
ajst-32576	18	8	-	-	PUNCT
ajst-32576	18	9	brain	brain	NOUN
ajst-32576	18	10	radiotherapy	radiotherapy	NOUN
ajst-32576	18	11	(	(	PUNCT
ajst-32576	18	12	wbrt	wbrt	PROPN
ajst-32576	18	13	)	)	PUNCT
ajst-32576	18	14	,	,	PUNCT
ajst-32576	18	15	stereotactic	stereotactic	ADJ
ajst-32576	18	16	radiosurgery	radiosurgery	NOUN
ajst-32576	18	17	(	(	PUNCT
ajst-32576	18	18	srs	srs	PROPN
ajst-32576	18	19	)	)	PUNCT
ajst-32576	18	20	,	,	PUNCT
ajst-32576	18	21	chemotherapy	chemotherapy	NOUN
ajst-32576	18	22	,	,	PUNCT
ajst-32576	18	23	targeted	target	VERB
ajst-32576	18	24	therapy	therapy	NOUN
ajst-32576	18	25	,	,	PUNCT
ajst-32576	18	26	and	and	CCONJ
ajst-32576	18	27	immunotherapy	immunotherapy	NOUN
ajst-32576	18	28	,	,	PUNCT
ajst-32576	18	29	most	most	ADJ
ajst-32576	18	30	of	of	ADP
ajst-32576	18	31	which	which	PRON
ajst-32576	18	32	are	be	AUX
ajst-32576	18	33	applied	apply	VERB
ajst-32576	18	34	in	in	ADP
ajst-32576	18	35	combination	combination	NOUN
ajst-32576	18	36	.	.	PUNCT
ajst-32576	19	1	advances	advance	NOUN
ajst-32576	19	2	in	in	ADP
ajst-32576	19	3	molecular	molecular	ADJ
ajst-32576	19	4	profiling	profiling	NOUN
ajst-32576	19	5	and	and	CCONJ
ajst-32576	19	6	targeted	target	VERB
ajst-32576	19	7	agents	agent	NOUN
ajst-32576	19	8	have	have	AUX
ajst-32576	19	9	shifted	shift	VERB
ajst-32576	19	10	the	the	DET
ajst-32576	19	11	treatment	treatment	NOUN
ajst-32576	19	12	paradigm	paradigm	NOUN
ajst-32576	19	13	from	from	ADP
ajst-32576	19	14	purely	purely	ADV
ajst-32576	19	15	palliative	palliative	ADJ
ajst-32576	19	16	local	local	ADJ
ajst-32576	19	17	interventions	intervention	NOUN
ajst-32576	19	18	toward	toward	ADP
ajst-32576	19	19	individualized	individualized	ADJ
ajst-32576	19	20	,	,	PUNCT
ajst-32576	19	21	multidisciplinary	multidisciplinary	ADJ
ajst-32576	19	22	strategies	strategy	NOUN
ajst-32576	19	23	integrating	integrate	VERB
ajst-32576	19	24	systemic	systemic	ADJ
ajst-32576	19	25	and	and	CCONJ
ajst-32576	19	26	local	local	ADJ
ajst-32576	19	27	therapies	therapy	NOUN
ajst-32576	19	28	.	.	PUNCT
ajst-32576	20	1	systematically	systematically	ADV
ajst-32576	20	2	summarizing	summarize	VERB
ajst-32576	20	3	the	the	DET
ajst-32576	20	4	progress	progress	NOUN
ajst-32576	20	5	and	and	CCONJ
ajst-32576	20	6	shortcomings	shortcoming	NOUN
ajst-32576	20	7	in	in	ADP
ajst-32576	20	8	this	this	DET
ajst-32576	20	9	field	field	NOUN
ajst-32576	20	10	is	be	AUX
ajst-32576	20	11	of	of	ADP
ajst-32576	20	12	great	great	ADJ
ajst-32576	20	13	significance	significance	NOUN
ajst-32576	20	14	for	for	ADP
ajst-32576	20	15	optimizing	optimize	VERB
ajst-32576	20	16	clinical	clinical	ADJ
ajst-32576	20	17	decision	decision	NOUN
ajst-32576	20	18	-	-	PUNCT
ajst-32576	20	19	making	make	VERB
ajst-32576	20	20	and	and	CCONJ
ajst-32576	20	21	improving	improve	VERB
ajst-32576	20	22	patient	patient	ADJ
ajst-32576	20	23	prognosis	prognosis	NOUN
ajst-32576	20	24	.	.	PUNCT
ajst-32576	21	1	2	2	X
ajst-32576	21	2	.	.	X
ajst-32576	21	3	therapeutic	therapeutic	ADJ
ajst-32576	21	4	mechanisms	mechanism	NOUN
ajst-32576	21	5	the	the	DET
ajst-32576	21	6	blood	blood	NOUN
ajst-32576	21	7	–	–	PUNCT
ajst-32576	21	8	brain	brain	NOUN
ajst-32576	21	9	barrier	barrier	NOUN
ajst-32576	21	10	plays	play	VERB
ajst-32576	21	11	a	a	DET
ajst-32576	21	12	pivotal	pivotal	ADJ
ajst-32576	21	13	role	role	NOUN
ajst-32576	21	14	in	in	ADP
ajst-32576	21	15	maintaining	maintain	VERB
ajst-32576	21	16	intracerebral	intracerebral	ADJ
ajst-32576	21	17	homeostasis	homeostasis	NOUN
ajst-32576	21	18	.	.	PUNCT
ajst-32576	22	1	its	its	PRON
ajst-32576	22	2	barrier	barrier	NOUN
ajst-32576	22	3	function	function	NOUN
ajst-32576	22	4	is	be	AUX
ajst-32576	22	5	reflected	reflect	VERB
ajst-32576	22	6	in	in	ADP
ajst-32576	22	7	two	two	NUM
ajst-32576	22	8	main	main	ADJ
ajst-32576	22	9	aspects	aspect	NOUN
ajst-32576	22	10	:	:	PUNCT
ajst-32576	22	11	first	first	ADJ
ajst-32576	22	12	,	,	PUNCT
ajst-32576	22	13	tight	tight	ADJ
ajst-32576	22	14	junctions	junction	NOUN
ajst-32576	22	15	between	between	ADP
ajst-32576	22	16	endothelial	endothelial	ADJ
ajst-32576	22	17	cells	cell	NOUN
ajst-32576	22	18	form	form	VERB
ajst-32576	22	19	a	a	DET
ajst-32576	22	20	physical	physical	ADJ
ajst-32576	22	21	barrier	barrier	NOUN
ajst-32576	22	22	that	that	PRON
ajst-32576	22	23	prevents	prevent	VERB
ajst-32576	22	24	macromolecules	macromolecule	NOUN
ajst-32576	22	25	and	and	CCONJ
ajst-32576	22	26	most	most	ADJ
ajst-32576	22	27	drugs	drug	NOUN
ajst-32576	22	28	from	from	ADP
ajst-32576	22	29	entering	enter	VERB
ajst-32576	22	30	the	the	DET
ajst-32576	22	31	brain	brain	NOUN
ajst-32576	22	32	;	;	PUNCT
ajst-32576	22	33	second	second	X
ajst-32576	22	34	,	,	PUNCT
ajst-32576	22	35	a	a	DET
ajst-32576	22	36	system	system	NOUN
ajst-32576	22	37	of	of	ADP
ajst-32576	22	38	uptake	uptake	NOUN
ajst-32576	22	39	and	and	CCONJ
ajst-32576	22	40	efflux	efflux	VERB
ajst-32576	22	41	transporters	transporter	NOUN
ajst-32576	22	42	regulates	regulate	VERB
ajst-32576	22	43	transmembrane	transmembrane	ADJ
ajst-32576	22	44	exchange	exchange	NOUN
ajst-32576	22	45	,	,	PUNCT
ajst-32576	22	46	allowing	allow	VERB
ajst-32576	22	47	essential	essential	ADJ
ajst-32576	22	48	nutrients	nutrient	NOUN
ajst-32576	22	49	in	in	ADP
ajst-32576	22	50	while	while	SCONJ
ajst-32576	22	51	expelling	expel	VERB
ajst-32576	22	52	potentially	potentially	ADV
ajst-32576	22	53	harmful	harmful	ADJ
ajst-32576	22	54	substances	substance	NOUN
ajst-32576	22	55	.	.	PUNCT
ajst-32576	23	1	following	follow	VERB
ajst-32576	23	2	the	the	DET
ajst-32576	23	3	development	development	NOUN
ajst-32576	23	4	of	of	ADP
ajst-32576	23	5	brain	brain	NOUN
ajst-32576	23	6	221	221	NUM
ajst-32576	23	7	metastases	metastasis	NOUN
ajst-32576	23	8	,	,	PUNCT
ajst-32576	23	9	the	the	DET
ajst-32576	23	10	bbb	bbb	PROPN
ajst-32576	23	11	undergoes	undergo	VERB
ajst-32576	23	12	structural	structural	ADJ
ajst-32576	23	13	and	and	CCONJ
ajst-32576	23	14	functional	functional	ADJ
ajst-32576	23	15	changes	change	NOUN
ajst-32576	23	16	,	,	PUNCT
ajst-32576	23	17	evolving	evolve	VERB
ajst-32576	23	18	into	into	ADP
ajst-32576	23	19	the	the	DET
ajst-32576	23	20	blood	blood	NOUN
ajst-32576	23	21	–	–	PUNCT
ajst-32576	23	22	tumor	tumor	NOUN
ajst-32576	23	23	barrier	barrier	NOUN
ajst-32576	23	24	.	.	PUNCT
ajst-32576	24	1	although	although	SCONJ
ajst-32576	24	2	the	the	DET
ajst-32576	24	3	btb	btb	NOUN
ajst-32576	24	4	exhibits	exhibit	VERB
ajst-32576	24	5	higher	high	ADJ
ajst-32576	24	6	permeability	permeability	NOUN
ajst-32576	24	7	than	than	ADP
ajst-32576	24	8	the	the	DET
ajst-32576	24	9	intact	intact	ADJ
ajst-32576	24	10	bbb	bbb	NOUN
ajst-32576	24	11	,	,	PUNCT
ajst-32576	24	12	persistent	persistent	ADJ
ajst-32576	24	13	efflux	efflux	NOUN
ajst-32576	24	14	transporter	transporter	NOUN
ajst-32576	24	15	activity	activity	NOUN
ajst-32576	24	16	results	result	NOUN
ajst-32576	24	17	in	in	ADP
ajst-32576	24	18	limited	limited	ADJ
ajst-32576	24	19	intracranial	intracranial	ADJ
ajst-32576	24	20	drug	drug	NOUN
ajst-32576	24	21	accumulation	accumulation	NOUN
ajst-32576	24	22	,	,	PUNCT
ajst-32576	24	23	thereby	thereby	ADV
ajst-32576	24	24	restricting	restrict	VERB
ajst-32576	24	25	the	the	DET
ajst-32576	24	26	efficacy	efficacy	NOUN
ajst-32576	24	27	of	of	ADP
ajst-32576	24	28	chemotherapy	chemotherapy	NOUN
ajst-32576	24	29	and	and	CCONJ
ajst-32576	24	30	certain	certain	ADJ
ajst-32576	24	31	targeted	target	VERB
ajst-32576	24	32	agents	agent	NOUN
ajst-32576	24	33	[	[	X
ajst-32576	24	34	5	5	NUM
ajst-32576	24	35	]	]	PUNCT
ajst-32576	24	36	(	(	PUNCT
ajst-32576	24	37	figure	figure	NOUN
ajst-32576	24	38	1	1	NUM
ajst-32576	24	39	)	)	PUNCT
ajst-32576	24	40	.	.	PUNCT
ajst-32576	25	1	molecular	molecular	ADJ
ajst-32576	25	2	targeted	target	VERB
ajst-32576	25	3	therapies	therapy	NOUN
ajst-32576	25	4	inhibit	inhibit	VERB
ajst-32576	25	5	oncogenic	oncogenic	ADJ
ajst-32576	25	6	signaling	signal	VERB
ajst-32576	25	7	pathways	pathway	NOUN
ajst-32576	25	8	driven	drive	VERB
ajst-32576	25	9	by	by	ADP
ajst-32576	25	10	alterations	alteration	NOUN
ajst-32576	25	11	such	such	ADJ
ajst-32576	25	12	as	as	ADP
ajst-32576	25	13	egfr	egfr	NOUN
ajst-32576	25	14	and	and	CCONJ
ajst-32576	25	15	alk	alk	VERB
ajst-32576	25	16	,	,	PUNCT
ajst-32576	25	17	thereby	thereby	ADV
ajst-32576	25	18	blocking	block	VERB
ajst-32576	25	19	tumor	tumor	NOUN
ajst-32576	25	20	cell	cell	NOUN
ajst-32576	25	21	survival	survival	NOUN
ajst-32576	25	22	and	and	CCONJ
ajst-32576	25	23	proliferation	proliferation	NOUN
ajst-32576	25	24	at	at	ADP
ajst-32576	25	25	their	their	PRON
ajst-32576	25	26	source	source	NOUN
ajst-32576	25	27	.	.	PUNCT
ajst-32576	26	1	for	for	ADP
ajst-32576	26	2	instance	instance	NOUN
ajst-32576	26	3	,	,	PUNCT
ajst-32576	26	4	egfr	egfr	ADJ
ajst-32576	26	5	mutations	mutation	NOUN
ajst-32576	26	6	activate	activate	VERB
ajst-32576	26	7	downstream	downstream	ADJ
ajst-32576	26	8	pi3k	pi3k	PROPN
ajst-32576	26	9	/	/	SYM
ajst-32576	26	10	akt	akt	PROPN
ajst-32576	26	11	/	/	SYM
ajst-32576	26	12	mtor	mtor	PROPN
ajst-32576	26	13	and	and	CCONJ
ajst-32576	26	14	ras	ras	PROPN
ajst-32576	26	15	/	/	SYM
ajst-32576	26	16	raf	raf	PROPN
ajst-32576	26	17	/	/	SYM
ajst-32576	26	18	mek	mek	PROPN
ajst-32576	26	19	/	/	SYM
ajst-32576	26	20	erk	erk	PROPN
ajst-32576	26	21	cascades	cascade	NOUN
ajst-32576	26	22	,	,	PUNCT
ajst-32576	26	23	which	which	PRON
ajst-32576	26	24	are	be	AUX
ajst-32576	26	25	closely	closely	ADV
ajst-32576	26	26	associated	associate	VERB
ajst-32576	26	27	with	with	ADP
ajst-32576	26	28	tumor	tumor	NOUN
ajst-32576	26	29	growth	growth	NOUN
ajst-32576	26	30	and	and	CCONJ
ajst-32576	26	31	cell	cell	NOUN
ajst-32576	26	32	cycle	cycle	NOUN
ajst-32576	26	33	progression	progression	NOUN
ajst-32576	26	34	.	.	PUNCT
ajst-32576	27	1	epidermal	epidermal	ADJ
ajst-32576	27	2	growth	growth	NOUN
ajst-32576	27	3	factor	factor	NOUN
ajst-32576	27	4	receptor	receptor	NOUN
ajst-32576	27	5	tyrosine	tyrosine	PROPN
ajst-32576	27	6	kinase	kinase	PROPN
ajst-32576	27	7	inhibitors	inhibitor	NOUN
ajst-32576	27	8	(	(	PUNCT
ajst-32576	27	9	egfr	egfr	NOUN
ajst-32576	27	10	-	-	PUNCT
ajst-32576	27	11	tkis	tkis	NOUN
ajst-32576	27	12	)	)	PUNCT
ajst-32576	27	13	suppress	suppress	VERB
ajst-32576	27	14	tumor	tumor	NOUN
ajst-32576	27	15	growth	growth	NOUN
ajst-32576	27	16	by	by	ADP
ajst-32576	27	17	inhibiting	inhibit	VERB
ajst-32576	27	18	egfr	egfr	ADJ
ajst-32576	27	19	activation	activation	NOUN
ajst-32576	27	20	and	and	CCONJ
ajst-32576	27	21	subsequent	subsequent	ADJ
ajst-32576	27	22	signaling	signal	VERB
ajst-32576	27	23	(	(	PUNCT
ajst-32576	27	24	figure	figure	NOUN
ajst-32576	27	25	2	2	NUM
ajst-32576	27	26	)	)	PUNCT
ajst-32576	27	27	.	.	PUNCT
ajst-32576	28	1	new	new	ADJ
ajst-32576	28	2	-	-	PUNCT
ajst-32576	28	3	generation	generation	NOUN
ajst-32576	28	4	tkis	tkis	NOUN
ajst-32576	28	5	not	not	PART
ajst-32576	28	6	only	only	ADV
ajst-32576	28	7	enhance	enhance	VERB
ajst-32576	28	8	systemic	systemic	ADJ
ajst-32576	28	9	efficacy	efficacy	NOUN
ajst-32576	28	10	but	but	CCONJ
ajst-32576	28	11	also	also	ADV
ajst-32576	28	12	penetrate	penetrate	VERB
ajst-32576	28	13	the	the	DET
ajst-32576	28	14	bbb	bbb	NOUN
ajst-32576	28	15	effectively	effectively	ADV
ajst-32576	28	16	,	,	PUNCT
ajst-32576	28	17	demonstrating	demonstrate	VERB
ajst-32576	28	18	superior	superior	ADJ
ajst-32576	28	19	activity	activity	NOUN
ajst-32576	28	20	against	against	ADP
ajst-32576	28	21	brain	brain	NOUN
ajst-32576	28	22	metastases	metastasis	NOUN
ajst-32576	28	23	.	.	PUNCT
ajst-32576	29	1	in	in	ADP
ajst-32576	29	2	contrast	contrast	NOUN
ajst-32576	29	3	,	,	PUNCT
ajst-32576	29	4	most	most	ADJ
ajst-32576	29	5	conventional	conventional	ADJ
ajst-32576	29	6	chemotherapeutics	chemotherapeutic	NOUN
ajst-32576	29	7	have	have	VERB
ajst-32576	29	8	poor	poor	ADJ
ajst-32576	29	9	bbb	bbb	ADJ
ajst-32576	29	10	penetration	penetration	NOUN
ajst-32576	29	11	due	due	ADP
ajst-32576	29	12	to	to	ADP
ajst-32576	29	13	high	high	ADJ
ajst-32576	29	14	molecular	molecular	ADJ
ajst-32576	29	15	weight	weight	NOUN
ajst-32576	29	16	and	and	CCONJ
ajst-32576	29	17	low	low	ADJ
ajst-32576	29	18	lipophilicity	lipophilicity	NOUN
ajst-32576	29	19	,	,	PUNCT
ajst-32576	29	20	limiting	limit	VERB
ajst-32576	29	21	their	their	PRON
ajst-32576	29	22	intracranial	intracranial	ADJ
ajst-32576	29	23	effect	effect	NOUN
ajst-32576	29	24	.	.	PUNCT
ajst-32576	30	1	consequently	consequently	ADV
ajst-32576	30	2	,	,	PUNCT
ajst-32576	30	3	they	they	PRON
ajst-32576	30	4	are	be	AUX
ajst-32576	30	5	primarily	primarily	ADV
ajst-32576	30	6	applied	apply	VERB
ajst-32576	30	7	for	for	ADP
ajst-32576	30	8	systemic	systemic	ADJ
ajst-32576	30	9	control	control	NOUN
ajst-32576	30	10	.	.	PUNCT
ajst-32576	31	1	consequently	consequently	ADV
ajst-32576	31	2	,	,	PUNCT
ajst-32576	31	3	they	they	PRON
ajst-32576	31	4	are	be	AUX
ajst-32576	31	5	primarily	primarily	ADV
ajst-32576	31	6	applied	apply	VERB
ajst-32576	31	7	for	for	ADP
ajst-32576	31	8	systemic	systemic	ADJ
ajst-32576	31	9	control	control	NOUN
ajst-32576	31	10	.	.	PUNCT
ajst-32576	32	1	intrathecal	intrathecal	ADJ
ajst-32576	32	2	administration	administration	NOUN
ajst-32576	32	3	can	can	AUX
ajst-32576	32	4	bypass	bypass	VERB
ajst-32576	32	5	the	the	DET
ajst-32576	32	6	bbb	bbb	NOUN
ajst-32576	32	7	entirely	entirely	ADV
ajst-32576	32	8	,	,	PUNCT
ajst-32576	32	9	enabling	enable	VERB
ajst-32576	32	10	direct	direct	ADJ
ajst-32576	32	11	drug	drug	NOUN
ajst-32576	32	12	delivery	delivery	NOUN
ajst-32576	32	13	into	into	ADP
ajst-32576	32	14	cerebrospinal	cerebrospinal	ADJ
ajst-32576	32	15	fluid	fluid	NOUN
ajst-32576	32	16	and	and	CCONJ
ajst-32576	32	17	offering	offer	VERB
ajst-32576	32	18	therapeutic	therapeutic	ADJ
ajst-32576	32	19	benefits	benefit	NOUN
ajst-32576	32	20	for	for	ADP
ajst-32576	32	21	leptomeningeal	leptomeningeal	NOUN
ajst-32576	32	22	metastases	metastasis	NOUN
ajst-32576	32	23	.	.	PUNCT
ajst-32576	33	1	radiotherapy	radiotherapy	NOUN
ajst-32576	33	2	remains	remain	VERB
ajst-32576	33	3	a	a	DET
ajst-32576	33	4	cornerstone	cornerstone	NOUN
ajst-32576	33	5	of	of	ADP
ajst-32576	33	6	local	local	ADJ
ajst-32576	33	7	treatment	treatment	NOUN
ajst-32576	33	8	by	by	ADP
ajst-32576	33	9	inducing	induce	VERB
ajst-32576	33	10	dna	dna	ADJ
ajst-32576	33	11	damage	damage	NOUN
ajst-32576	33	12	with	with	ADP
ajst-32576	33	13	high	high	ADJ
ajst-32576	33	14	-	-	PUNCT
ajst-32576	33	15	energy	energy	NOUN
ajst-32576	33	16	radiation	radiation	NOUN
ajst-32576	33	17	,	,	PUNCT
ajst-32576	33	18	leading	lead	VERB
ajst-32576	33	19	to	to	ADP
ajst-32576	33	20	rapid	rapid	ADJ
ajst-32576	33	21	tumor	tumor	NOUN
ajst-32576	33	22	shrinkage	shrinkage	NOUN
ajst-32576	33	23	and	and	CCONJ
ajst-32576	33	24	symptom	symptom	NOUN
ajst-32576	33	25	relief	relief	NOUN
ajst-32576	33	26	.	.	PUNCT
ajst-32576	34	1	whole	whole	ADJ
ajst-32576	34	2	-	-	PUNCT
ajst-32576	34	3	brain	brain	NOUN
ajst-32576	34	4	radiotherapy	radiotherapy	NOUN
ajst-32576	34	5	(	(	PUNCT
ajst-32576	34	6	wbrt	wbrt	PROPN
ajst-32576	34	7	)	)	PUNCT
ajst-32576	34	8	is	be	AUX
ajst-32576	34	9	suited	suit	VERB
ajst-32576	34	10	for	for	ADP
ajst-32576	34	11	diffuse	diffuse	NOUN
ajst-32576	34	12	or	or	CCONJ
ajst-32576	34	13	multiple	multiple	ADJ
ajst-32576	34	14	metastases	metastasis	NOUN
ajst-32576	34	15	,	,	PUNCT
ajst-32576	34	16	whereas	whereas	SCONJ
ajst-32576	34	17	stereotactic	stereotactic	ADJ
ajst-32576	34	18	radiosurgery	radiosurgery	NOUN
ajst-32576	34	19	(	(	PUNCT
ajst-32576	34	20	srs	srs	PROPN
ajst-32576	34	21	)	)	PUNCT
ajst-32576	34	22	delivers	deliver	VERB
ajst-32576	34	23	precise	precise	ADJ
ajst-32576	34	24	high	high	ADJ
ajst-32576	34	25	-	-	PUNCT
ajst-32576	34	26	dose	dose	NOUN
ajst-32576	34	27	radiation	radiation	NOUN
ajst-32576	34	28	to	to	ADP
ajst-32576	34	29	limited	limited	ADJ
ajst-32576	34	30	lesions	lesion	NOUN
ajst-32576	34	31	,	,	PUNCT
ajst-32576	34	32	striking	strike	VERB
ajst-32576	34	33	a	a	DET
ajst-32576	34	34	balance	balance	NOUN
ajst-32576	34	35	between	between	ADP
ajst-32576	34	36	tumor	tumor	NOUN
ajst-32576	34	37	control	control	NOUN
ajst-32576	34	38	and	and	CCONJ
ajst-32576	34	39	preservation	preservation	NOUN
ajst-32576	34	40	of	of	ADP
ajst-32576	34	41	neurological	neurological	ADJ
ajst-32576	34	42	function	function	NOUN
ajst-32576	34	43	[	[	X
ajst-32576	34	44	6	6	NUM
ajst-32576	34	45	]	]	PUNCT
ajst-32576	34	46	.	.	PUNCT
ajst-32576	35	1	immune	immune	ADJ
ajst-32576	35	2	checkpoint	checkpoint	NOUN
ajst-32576	35	3	inhibitors	inhibitor	NOUN
ajst-32576	35	4	(	(	PUNCT
ajst-32576	35	5	icis	icis	NOUN
ajst-32576	35	6	)	)	PUNCT
ajst-32576	35	7	reactivates	reactivate	VERB
ajst-32576	35	8	anti	anti	ADJ
ajst-32576	35	9	-	-	ADJ
ajst-32576	35	10	tumor	tumor	ADJ
ajst-32576	35	11	immunity	immunity	NOUN
ajst-32576	35	12	by	by	ADP
ajst-32576	35	13	blocking	block	VERB
ajst-32576	35	14	pd-1	pd-1	ADP
ajst-32576	35	15	/	/	SYM
ajst-32576	35	16	pd	pd	NOUN
ajst-32576	35	17	-	-	PROPN
ajst-32576	35	18	l1	l1	PROPN
ajst-32576	35	19	or	or	CCONJ
ajst-32576	35	20	ctla-4	ctla-4	NOUN
ajst-32576	35	21	signaling	signal	VERB
ajst-32576	35	22	.	.	PUNCT
ajst-32576	36	1	disruption	disruption	NOUN
ajst-32576	36	2	of	of	ADP
ajst-32576	36	3	the	the	DET
ajst-32576	36	4	bbb	bbb	NOUN
ajst-32576	36	5	in	in	ADP
ajst-32576	36	6	metastatic	metastatic	ADJ
ajst-32576	36	7	lesions	lesion	NOUN
ajst-32576	36	8	facilitates	facilitate	VERB
ajst-32576	36	9	immune	immune	ADJ
ajst-32576	36	10	cell	cell	NOUN
ajst-32576	36	11	infiltration	infiltration	NOUN
ajst-32576	36	12	,	,	PUNCT
ajst-32576	36	13	thereby	thereby	ADV
ajst-32576	36	14	enabling	enable	VERB
ajst-32576	36	15	icis	icis	NOUN
ajst-32576	36	16	to	to	PART
ajst-32576	36	17	produce	produce	VERB
ajst-32576	36	18	durable	durable	ADJ
ajst-32576	36	19	responses	response	NOUN
ajst-32576	36	20	both	both	CCONJ
ajst-32576	36	21	intracranially	intracranially	ADV
ajst-32576	36	22	and	and	CCONJ
ajst-32576	36	23	systemically	systemically	ADV
ajst-32576	36	24	[	[	X
ajst-32576	36	25	7	7	NUM
ajst-32576	36	26	]	]	PUNCT
ajst-32576	36	27	.	.	PUNCT
ajst-32576	37	1	3	3	X
ajst-32576	37	2	.	.	X
ajst-32576	37	3	treatment	treatment	NOUN
ajst-32576	37	4	3.1	3.1	NUM
ajst-32576	37	5	monotherapy	monotherapy	NOUN
ajst-32576	37	6	3.1.1	3.1.1	NUM
ajst-32576	37	7	.	.	PUNCT
ajst-32576	38	1	molecular	molecular	ADJ
ajst-32576	38	2	targeted	target	VERB
ajst-32576	38	3	therapy	therapy	NOUN
ajst-32576	38	4	molecular	molecular	ADJ
ajst-32576	38	5	targeted	target	VERB
ajst-32576	38	6	therapy	therapy	NOUN
ajst-32576	38	7	has	have	AUX
ajst-32576	38	8	brought	bring	VERB
ajst-32576	38	9	major	major	ADJ
ajst-32576	38	10	breakthroughs	breakthrough	NOUN
ajst-32576	38	11	for	for	ADP
ajst-32576	38	12	patients	patient	NOUN
ajst-32576	38	13	with	with	ADP
ajst-32576	38	14	nsclc	nsclc	NOUN
ajst-32576	38	15	brain	brain	NOUN
ajst-32576	38	16	metastases	metastasis	NOUN
ajst-32576	38	17	,	,	PUNCT
ajst-32576	38	18	significantly	significantly	ADV
ajst-32576	38	19	improving	improve	VERB
ajst-32576	38	20	intracranial	intracranial	ADJ
ajst-32576	38	21	disease	disease	NOUN
ajst-32576	38	22	control	control	NOUN
ajst-32576	38	23	and	and	CCONJ
ajst-32576	38	24	overall	overall	ADJ
ajst-32576	38	25	survival	survival	NOUN
ajst-32576	38	26	(	(	PUNCT
ajst-32576	38	27	os	os	NOUN
ajst-32576	38	28	)	)	PUNCT
ajst-32576	38	29	in	in	ADP
ajst-32576	38	30	populations	population	NOUN
ajst-32576	38	31	with	with	ADP
ajst-32576	38	32	driver	driver	NOUN
ajst-32576	38	33	gene	gene	NOUN
ajst-32576	38	34	mutations	mutation	NOUN
ajst-32576	38	35	.	.	PUNCT
ajst-32576	39	1	3.1.1.1	3.1.1.1	X
ajst-32576	39	2	.	.	X
ajst-32576	39	3	egfr	egfr	PROPN
ajst-32576	39	4	-	-	PUNCT
ajst-32576	39	5	tkis	tkis	PROPN
ajst-32576	39	6	egfr	egfr	NOUN
ajst-32576	39	7	is	be	AUX
ajst-32576	39	8	one	one	NUM
ajst-32576	39	9	of	of	ADP
ajst-32576	39	10	the	the	DET
ajst-32576	39	11	most	most	ADV
ajst-32576	39	12	critical	critical	ADJ
ajst-32576	39	13	targets	target	NOUN
ajst-32576	39	14	in	in	ADP
ajst-32576	39	15	nsclc	nsclc	NOUN
ajst-32576	39	16	brain	brain	NOUN
ajst-32576	39	17	metastases	metastasis	NOUN
ajst-32576	39	18	.	.	PUNCT
ajst-32576	40	1	approximately	approximately	ADV
ajst-32576	40	2	50	50	NUM
ajst-32576	40	3	%	%	NOUN
ajst-32576	40	4	of	of	ADP
ajst-32576	40	5	asian	asian	ADJ
ajst-32576	40	6	patients	patient	NOUN
ajst-32576	40	7	and	and	CCONJ
ajst-32576	40	8	10%-15	10%-15	NUM
ajst-32576	40	9	%	%	NOUN
ajst-32576	40	10	of	of	ADP
ajst-32576	40	11	caucasian	caucasian	ADJ
ajst-32576	40	12	patients	patient	NOUN
ajst-32576	40	13	carry	carry	VERB
ajst-32576	40	14	egfr	egfr	ADJ
ajst-32576	40	15	mutations	mutation	NOUN
ajst-32576	40	16	[	[	X
ajst-32576	40	17	8	8	NUM
ajst-32576	40	18	]	]	PUNCT
ajst-32576	40	19	.	.	PUNCT
ajst-32576	41	1	egfr	egfr	ADJ
ajst-32576	41	2	-	-	PUNCT
ajst-32576	41	3	targeted	target	VERB
ajst-32576	41	4	agents	agent	NOUN
ajst-32576	41	5	have	have	AUX
ajst-32576	41	6	undergone	undergo	VERB
ajst-32576	41	7	several	several	ADJ
ajst-32576	41	8	generations	generation	NOUN
ajst-32576	41	9	of	of	ADP
ajst-32576	41	10	development	development	NOUN
ajst-32576	41	11	.	.	PUNCT
ajst-32576	42	1	first	first	ADJ
ajst-32576	42	2	-	-	PUNCT
ajst-32576	42	3	generation	generation	NOUN
ajst-32576	42	4	tkis	tkis	NOUN
ajst-32576	42	5	(	(	PUNCT
ajst-32576	42	6	gefitinib	gefitinib	NOUN
ajst-32576	42	7	,	,	PUNCT
ajst-32576	42	8	erlotinib	erlotinib	NOUN
ajst-32576	42	9	and	and	CCONJ
ajst-32576	42	10	icotinib	icotinib	NOUN
ajst-32576	42	11	)	)	PUNCT
ajst-32576	42	12	are	be	AUX
ajst-32576	42	13	reversible	reversible	ADJ
ajst-32576	42	14	tkis	tkis	NOUN
ajst-32576	42	15	,	,	PUNCT
ajst-32576	42	16	second	second	ADJ
ajst-32576	42	17	-	-	PUNCT
ajst-32576	42	18	generation	generation	NOUN
ajst-32576	42	19	tkis	tkis	NOUN
ajst-32576	42	20	(	(	PUNCT
ajst-32576	42	21	afatinib	afatinib	NOUN
ajst-32576	42	22	and	and	CCONJ
ajst-32576	42	23	dacomitinib	dacomitinib	NOUN
ajst-32576	42	24	)	)	PUNCT
ajst-32576	42	25	are	be	AUX
ajst-32576	42	26	irreversible	irreversible	ADJ
ajst-32576	42	27	inhibitors	inhibitor	NOUN
ajst-32576	42	28	with	with	ADP
ajst-32576	42	29	additional	additional	ADJ
ajst-32576	42	30	her2	her2	NOUN
ajst-32576	42	31	activity	activity	NOUN
ajst-32576	42	32	,	,	PUNCT
ajst-32576	42	33	third	third	ADJ
ajst-32576	42	34	-	-	PUNCT
ajst-32576	42	35	generation	generation	NOUN
ajst-32576	42	36	osimertinib	osimertinib	NOUN
ajst-32576	42	37	not	not	PART
ajst-32576	42	38	only	only	ADV
ajst-32576	42	39	target	target	VERB
ajst-32576	42	40	sensitive	sensitive	ADJ
ajst-32576	42	41	mutations	mutation	NOUN
ajst-32576	42	42	and	and	CCONJ
ajst-32576	42	43	the	the	DET
ajst-32576	42	44	t790	t790	NUM
ajst-32576	42	45	m	m	NOUN
ajst-32576	42	46	resistance	resistance	NOUN
ajst-32576	42	47	mutation	mutation	NOUN
ajst-32576	42	48	but	but	CCONJ
ajst-32576	42	49	also	also	ADV
ajst-32576	42	50	demonstrate	demonstrate	VERB
ajst-32576	42	51	superior	superior	ADJ
ajst-32576	42	52	bbb	bbb	NOUN
ajst-32576	42	53	penetration	penetration	NOUN
ajst-32576	42	54	.	.	PUNCT
ajst-32576	43	1	studies	study	NOUN
ajst-32576	43	2	have	have	AUX
ajst-32576	43	3	shown	show	VERB
ajst-32576	43	4	that	that	SCONJ
ajst-32576	43	5	all	all	DET
ajst-32576	43	6	generations	generation	NOUN
ajst-32576	43	7	of	of	ADP
ajst-32576	43	8	egfr	egfr	ADJ
ajst-32576	43	9	-	-	PUNCT
ajst-32576	43	10	tkis	tkis	NOUN
ajst-32576	43	11	exhibit	exhibit	NOUN
ajst-32576	43	12	intracranial	intracranial	ADJ
ajst-32576	43	13	efficacy	efficacy	NOUN
ajst-32576	43	14	in	in	ADP
ajst-32576	43	15	patients	patient	NOUN
ajst-32576	43	16	with	with	ADP
ajst-32576	43	17	brain	brain	NOUN
ajst-32576	43	18	metastases	metastasis	NOUN
ajst-32576	43	19	.	.	PUNCT
ajst-32576	44	1	with	with	ADP
ajst-32576	44	2	first	first	ADJ
ajst-32576	44	3	-	-	PUNCT
ajst-32576	44	4	generation	generation	NOUN
ajst-32576	44	5	tkis	tkis	NOUN
ajst-32576	44	6	,	,	PUNCT
ajst-32576	44	7	patients	patient	NOUN
ajst-32576	44	8	with	with	ADP
ajst-32576	44	9	baseline	baseline	ADJ
ajst-32576	44	10	brain	brain	NOUN
ajst-32576	44	11	metastases	metastasis	NOUN
ajst-32576	44	12	achieve	achieve	VERB
ajst-32576	44	13	a	a	DET
ajst-32576	44	14	median	median	ADJ
ajst-32576	44	15	intracranial	intracranial	ADJ
ajst-32576	44	16	progression	progression	NOUN
ajst-32576	44	17	-	-	PUNCT
ajst-32576	44	18	free	free	ADJ
ajst-32576	44	19	survival	survival	NOUN
ajst-32576	44	20	(	(	PUNCT
ajst-32576	44	21	mipfs	mipfs	PROPN
ajst-32576	44	22	)	)	PUNCT
ajst-32576	44	23	of	of	ADP
ajst-32576	44	24	approximately	approximately	ADV
ajst-32576	44	25	9	9	NUM
ajst-32576	44	26	months	month	NOUN
ajst-32576	44	27	and	and	CCONJ
ajst-32576	44	28	a	a	DET
ajst-32576	44	29	median	median	ADJ
ajst-32576	44	30	os	os	NOUN
ajst-32576	44	31	of	of	ADP
ajst-32576	44	32	26–29	26–29	NUM
ajst-32576	44	33	months	month	NOUN
ajst-32576	45	1	[	[	X
ajst-32576	45	2	9	9	NUM
ajst-32576	45	3	-	-	SYM
ajst-32576	45	4	11	11	NUM
ajst-32576	45	5	]	]	PUNCT
ajst-32576	45	6	.	.	PUNCT
ajst-32576	46	1	in	in	ADP
ajst-32576	46	2	real	real	ADJ
ajst-32576	46	3	-	-	PUNCT
ajst-32576	46	4	world	world	NOUN
ajst-32576	46	5	studies	study	NOUN
ajst-32576	46	6	,	,	PUNCT
ajst-32576	46	7	the	the	DET
ajst-32576	46	8	second	second	ADJ
ajst-32576	46	9	-	-	PUNCT
ajst-32576	46	10	generation	generation	NOUN
ajst-32576	46	11	agent	agent	NOUN
ajst-32576	46	12	afatinib	afatinib	NOUN
ajst-32576	46	13	yielded	yield	VERB
ajst-32576	46	14	an	an	DET
ajst-32576	46	15	mpfs	mpf	NOUN
ajst-32576	46	16	of	of	ADP
ajst-32576	46	17	13–14	13–14	NUM
ajst-32576	46	18	months	month	NOUN
ajst-32576	46	19	and	and	CCONJ
ajst-32576	46	20	an	an	DET
ajst-32576	46	21	os	os	NOUN
ajst-32576	46	22	of	of	ADP
ajst-32576	46	23	nearly	nearly	ADV
ajst-32576	46	24	30	30	NUM
ajst-32576	46	25	months	month	NOUN
ajst-32576	46	26	,	,	PUNCT
ajst-32576	46	27	though	though	SCONJ
ajst-32576	46	28	it	it	PRON
ajst-32576	46	29	was	be	AUX
ajst-32576	46	30	associated	associate	VERB
ajst-32576	46	31	with	with	ADP
ajst-32576	46	32	relatively	relatively	ADV
ajst-32576	46	33	high	high	ADJ
ajst-32576	46	34	incidences	incidence	NOUN
ajst-32576	46	35	of	of	ADP
ajst-32576	46	36	diarrhea	diarrhea	NOUN
ajst-32576	46	37	and	and	CCONJ
ajst-32576	46	38	rash	rash	ADJ
ajst-32576	47	1	[	[	X
ajst-32576	47	2	12].among	12].among	NUM
ajst-32576	47	3	all	all	DET
ajst-32576	47	4	egfr	egfr	ADJ
ajst-32576	47	5	-	-	PUNCT
ajst-32576	47	6	tkis	tkis	NOUN
ajst-32576	47	7	,	,	PUNCT
ajst-32576	47	8	osimertinib	osimertinib	NOUN
ajst-32576	47	9	demonstrates	demonstrate	VERB
ajst-32576	47	10	significantly	significantly	ADV
ajst-32576	47	11	superior	superior	ADJ
ajst-32576	47	12	intracranial	intracranial	ADJ
ajst-32576	47	13	disease	disease	NOUN
ajst-32576	47	14	control	control	NOUN
ajst-32576	47	15	compared	compare	VERB
ajst-32576	47	16	with	with	ADP
ajst-32576	47	17	earlier	early	ADJ
ajst-32576	47	18	generations	generation	NOUN
ajst-32576	47	19	.	.	PUNCT
ajst-32576	48	1	its	its	PRON
ajst-32576	48	2	mipfs	mipfs	PROPN
ajst-32576	48	3	is	be	AUX
ajst-32576	48	4	three	three	NUM
ajst-32576	48	5	times	time	NOUN
ajst-32576	48	6	longer	long	ADJ
ajst-32576	48	7	than	than	ADP
ajst-32576	48	8	that	that	PRON
ajst-32576	48	9	of	of	ADP
ajst-32576	48	10	gefitinib	gefitinib	NOUN
ajst-32576	48	11	,	,	PUNCT
ajst-32576	48	12	with	with	ADP
ajst-32576	48	13	manageable	manageable	ADJ
ajst-32576	48	14	toxicity	toxicity	NOUN
ajst-32576	48	15	,	,	PUNCT
ajst-32576	48	16	and	and	CCONJ
ajst-32576	48	17	it	it	PRON
ajst-32576	48	18	has	have	AUX
ajst-32576	48	19	become	become	VERB
ajst-32576	48	20	a	a	DET
ajst-32576	48	21	first	first	ADJ
ajst-32576	48	22	-	-	PUNCT
ajst-32576	48	23	line	line	NOUN
ajst-32576	48	24	standard	standard	ADJ
ajst-32576	48	25	regimen	regimen	NOUN
ajst-32576	48	26	recommended	recommend	VERB
ajst-32576	48	27	by	by	ADP
ajst-32576	48	28	international	international	ADJ
ajst-32576	48	29	guidelines	guideline	NOUN
ajst-32576	48	30	[	[	X
ajst-32576	48	31	13	13	NUM
ajst-32576	48	32	,	,	PUNCT
ajst-32576	48	33	14	14	NUM
ajst-32576	48	34	]	]	PUNCT
ajst-32576	48	35	.	.	PUNCT
ajst-32576	49	1	222	222	NUM
ajst-32576	49	2	3.1.1.2	3.1.1.2	NUM
ajst-32576	49	3	.	.	PUNCT
ajst-32576	49	4	alk	alk	PROPN
ajst-32576	49	5	-	-	PUNCT
ajst-32576	49	6	tkis	tkis	NOUN
ajst-32576	49	7	alk	alk	NOUN
ajst-32576	49	8	fusions	fusion	NOUN
ajst-32576	49	9	are	be	AUX
ajst-32576	49	10	detected	detect	VERB
ajst-32576	49	11	in	in	ADP
ajst-32576	49	12	4	4	NUM
ajst-32576	49	13	%	%	NOUN
ajst-32576	49	14	of	of	ADP
ajst-32576	49	15	nsclc	nsclc	NOUN
ajst-32576	49	16	patients	patient	NOUN
ajst-32576	49	17	[	[	X
ajst-32576	49	18	15	15	NUM
ajst-32576	49	19	]	]	PUNCT
ajst-32576	49	20	.	.	PUNCT
ajst-32576	50	1	first	first	ADJ
ajst-32576	50	2	-	-	PUNCT
ajst-32576	50	3	generation	generation	NOUN
ajst-32576	50	4	crizotinib	crizotinib	NOUN
ajst-32576	50	5	has	have	AUX
ajst-32576	50	6	limited	limit	VERB
ajst-32576	50	7	central	central	ADJ
ajst-32576	50	8	nervous	nervous	ADJ
ajst-32576	50	9	system	system	NOUN
ajst-32576	50	10	(	(	PUNCT
ajst-32576	50	11	cns	cns	NOUN
ajst-32576	50	12	)	)	PUNCT
ajst-32576	50	13	penetration	penetration	NOUN
ajst-32576	50	14	and	and	CCONJ
ajst-32576	50	15	low	low	ADJ
ajst-32576	50	16	intracranial	intracranial	ADJ
ajst-32576	50	17	efficacy	efficacy	NOUN
ajst-32576	50	18	,	,	PUNCT
ajst-32576	50	19	second	second	ADJ
ajst-32576	50	20	-	-	PUNCT
ajst-32576	50	21	generationtkis	generationtkis	NOUN
ajst-32576	50	22	such	such	ADJ
ajst-32576	50	23	as	as	ADP
ajst-32576	50	24	alectinib	alectinib	NOUN
ajst-32576	50	25	and	and	CCONJ
ajst-32576	50	26	brigatinib	brigatinib	NOUN
ajst-32576	50	27	offer	offer	VERB
ajst-32576	50	28	improved	improve	VERB
ajst-32576	50	29	cns	cns	NOUN
ajst-32576	50	30	activity	activity	NOUN
ajst-32576	50	31	and	and	CCONJ
ajst-32576	50	32	markedly	markedly	ADV
ajst-32576	50	33	enhance	enhance	VERB
ajst-32576	50	34	intracranial	intracranial	ADJ
ajst-32576	50	35	disease	disease	NOUN
ajst-32576	50	36	control	control	NOUN
ajst-32576	50	37	,	,	PUNCT
ajst-32576	50	38	third	third	ADJ
ajst-32576	50	39	-	-	PUNCT
ajst-32576	50	40	generation	generation	NOUN
ajst-32576	50	41	lorlatinib	lorlatinib	NOUN
ajst-32576	50	42	covers	cover	VERB
ajst-32576	50	43	a	a	DET
ajst-32576	50	44	broad	broad	ADJ
ajst-32576	50	45	spectrum	spectrum	NOUN
ajst-32576	50	46	of	of	ADP
ajst-32576	50	47	resistance	resistance	NOUN
ajst-32576	50	48	mutations	mutation	NOUN
ajst-32576	50	49	and	and	CCONJ
ajst-32576	50	50	possesses	possess	VERB
ajst-32576	50	51	the	the	DET
ajst-32576	50	52	strongest	strong	ADJ
ajst-32576	50	53	bbb	bbb	NOUN
ajst-32576	50	54	penetration	penetration	NOUN
ajst-32576	50	55	and	and	CCONJ
ajst-32576	50	56	cns	cns	NOUN
ajst-32576	50	57	activity	activity	NOUN
ajst-32576	50	58	among	among	ADP
ajst-32576	50	59	alk	alk	NOUN
ajst-32576	50	60	inhibitors	inhibitor	NOUN
ajst-32576	50	61	.	.	PUNCT
ajst-32576	51	1	in	in	ADP
ajst-32576	51	2	patients	patient	NOUN
ajst-32576	51	3	with	with	ADP
ajst-32576	51	4	brain	brain	NOUN
ajst-32576	51	5	metastases	metastasis	NOUN
ajst-32576	51	6	treated	treat	VERB
ajst-32576	51	7	with	with	ADP
ajst-32576	51	8	crizotinib	crizotinib	NOUN
ajst-32576	51	9	,	,	PUNCT
ajst-32576	51	10	the	the	DET
ajst-32576	51	11	mpfs	mpf	NOUN
ajst-32576	51	12	is	be	AUX
ajst-32576	51	13	only	only	ADV
ajst-32576	51	14	6–11	6–11	NOUN
ajst-32576	51	15	months	month	NOUN
ajst-32576	51	16	,	,	PUNCT
ajst-32576	51	17	with	with	ADP
ajst-32576	51	18	limited	limited	ADJ
ajst-32576	51	19	intracranial	intracranial	ADJ
ajst-32576	51	20	activity	activity	NOUN
ajst-32576	51	21	and	and	CCONJ
ajst-32576	51	22	a	a	DET
ajst-32576	51	23	high	high	ADJ
ajst-32576	51	24	risk	risk	NOUN
ajst-32576	51	25	of	of	ADP
ajst-32576	51	26	resistance	resistance	NOUN
ajst-32576	51	27	[	[	X
ajst-32576	51	28	16	16	NUM
ajst-32576	51	29	,	,	PUNCT
ajst-32576	51	30	17	17	NUM
ajst-32576	51	31	]	]	PUNCT
ajst-32576	51	32	.	.	PUNCT
ajst-32576	52	1	in	in	ADP
ajst-32576	52	2	contrast	contrast	NOUN
ajst-32576	52	3	,	,	PUNCT
ajst-32576	52	4	when	when	SCONJ
ajst-32576	52	5	alectinib	alectinib	NOUN
ajst-32576	52	6	is	be	AUX
ajst-32576	52	7	used	use	VERB
ajst-32576	52	8	in	in	ADP
ajst-32576	52	9	patients	patient	NOUN
ajst-32576	52	10	with	with	ADP
ajst-32576	52	11	baseline	baseline	PROPN
ajst-32576	52	12	bm	bm	PROPN
ajst-32576	52	13	,	,	PUNCT
ajst-32576	52	14	the	the	DET
ajst-32576	52	15	mpfs	mpf	NOUN
ajst-32576	52	16	extendes	extende	NOUN
ajst-32576	52	17	to	to	ADP
ajst-32576	52	18	27.7	27.7	NUM
ajst-32576	52	19	months	month	NOUN
ajst-32576	52	20	,	,	PUNCT
ajst-32576	52	21	significantly	significantly	ADV
ajst-32576	52	22	reducing	reduce	VERB
ajst-32576	52	23	the	the	DET
ajst-32576	52	24	risk	risk	NOUN
ajst-32576	52	25	of	of	ADP
ajst-32576	52	26	intracranial	intracranial	ADJ
ajst-32576	52	27	progression	progression	NOUN
ajst-32576	52	28	[	[	X
ajst-32576	52	29	18	18	NUM
ajst-32576	52	30	,	,	PUNCT
ajst-32576	52	31	19	19	NUM
ajst-32576	52	32	]	]	PUNCT
ajst-32576	52	33	.	.	PUNCT
ajst-32576	53	1	brigatinib	brigatinib	PROPN
ajst-32576	53	2	achieves	achieve	VERB
ajst-32576	53	3	a	a	DET
ajst-32576	53	4	3	3	NUM
ajst-32576	53	5	-	-	PUNCT
ajst-32576	53	6	year	year	NOUN
ajst-32576	53	7	intracranial	intracranial	ADJ
ajst-32576	53	8	progression	progression	NOUN
ajst-32576	53	9	-	-	PUNCT
ajst-32576	53	10	free	free	ADJ
ajst-32576	53	11	survival	survival	NOUN
ajst-32576	53	12	(	(	PUNCT
ajst-32576	53	13	ipfs	ipf	NOUN
ajst-32576	53	14	)	)	PUNCT
ajst-32576	53	15	rate	rate	NOUN
ajst-32576	53	16	of	of	ADP
ajst-32576	53	17	31	31	NUM
ajst-32576	53	18	%	%	NOUN
ajst-32576	53	19	and	and	CCONJ
ajst-32576	53	20	a	a	DET
ajst-32576	53	21	3	3	NUM
ajst-32576	53	22	-	-	PUNCT
ajst-32576	53	23	year	year	NOUN
ajst-32576	53	24	os	os	NOUN
ajst-32576	53	25	rate	rate	NOUN
ajst-32576	53	26	exceeding	exceed	VERB
ajst-32576	53	27	74	74	NUM
ajst-32576	53	28	%	%	NOUN
ajst-32576	53	29	,	,	PUNCT
ajst-32576	53	30	and	and	CCONJ
ajst-32576	53	31	both	both	DET
ajst-32576	53	32	alectinib	alectinib	NOUN
ajst-32576	53	33	and	and	CCONJ
ajst-32576	53	34	brigatinib	brigatinib	NOUN
ajst-32576	53	35	have	have	AUX
ajst-32576	53	36	been	be	AUX
ajst-32576	53	37	recommended	recommend	VERB
ajst-32576	53	38	as	as	ADP
ajst-32576	53	39	first	first	ADJ
ajst-32576	53	40	-	-	PUNCT
ajst-32576	53	41	line	line	NOUN
ajst-32576	53	42	treatment	treatment	NOUN
ajst-32576	53	43	options	option	NOUN
ajst-32576	53	44	[	[	X
ajst-32576	53	45	20	20	NUM
ajst-32576	53	46	]	]	PUNCT
ajst-32576	53	47	.	.	PUNCT
ajst-32576	54	1	lorlatinib	lorlatinib	NOUN
ajst-32576	54	2	provides	provide	VERB
ajst-32576	54	3	durable	durable	ADJ
ajst-32576	54	4	intracranial	intracranial	ADJ
ajst-32576	54	5	control	control	NOUN
ajst-32576	54	6	,	,	PUNCT
ajst-32576	54	7	with	with	ADP
ajst-32576	54	8	a	a	DET
ajst-32576	54	9	5	5	NUM
ajst-32576	54	10	-	-	PUNCT
ajst-32576	54	11	year	year	NOUN
ajst-32576	54	12	ipfs	ipf	NOUN
ajst-32576	54	13	rate	rate	NOUN
ajst-32576	54	14	of	of	ADP
ajst-32576	54	15	83	83	NUM
ajst-32576	54	16	%	%	NOUN
ajst-32576	54	17	,	,	PUNCT
ajst-32576	54	18	making	make	VERB
ajst-32576	54	19	it	it	PRON
ajst-32576	54	20	particularly	particularly	ADV
ajst-32576	54	21	suitable	suitable	ADJ
ajst-32576	54	22	for	for	ADP
ajst-32576	54	23	patients	patient	NOUN
ajst-32576	54	24	with	with	ADP
ajst-32576	54	25	brain	brain	NOUN
ajst-32576	54	26	metastases	metastasis	NOUN
ajst-32576	54	27	or	or	CCONJ
ajst-32576	54	28	drug	drug	NOUN
ajst-32576	54	29	resistance	resistance	NOUN
ajst-32576	55	1	[	[	X
ajst-32576	55	2	17	17	NUM
ajst-32576	55	3	,	,	PUNCT
ajst-32576	55	4	21	21	NUM
ajst-32576	55	5	]	]	PUNCT
ajst-32576	55	6	.	.	PUNCT
ajst-32576	56	1	3.1.1.3	3.1.1.3	NUM
ajst-32576	56	2	.	.	PUNCT
ajst-32576	56	3	inhibitors	inhibitor	NOUN
ajst-32576	56	4	for	for	ADP
ajst-32576	56	5	other	other	ADJ
ajst-32576	56	6	mutations	mutation	NOUN
ajst-32576	56	7	some	some	DET
ajst-32576	56	8	targeted	target	VERB
ajst-32576	56	9	drugs	drug	NOUN
ajst-32576	56	10	for	for	ADP
ajst-32576	56	11	rare	rare	ADJ
ajst-32576	56	12	driver	driver	NOUN
ajst-32576	56	13	mutations	mutation	NOUN
ajst-32576	56	14	also	also	ADV
ajst-32576	56	15	demonstrate	demonstrate	VERB
ajst-32576	56	16	cns	cns	NOUN
ajst-32576	56	17	activity	activity	NOUN
ajst-32576	56	18	.	.	PUNCT
ajst-32576	57	1	for	for	ADP
ajst-32576	57	2	patients	patient	NOUN
ajst-32576	57	3	with	with	ADP
ajst-32576	57	4	ros1	ros1	PROPN
ajst-32576	57	5	fusions	fusion	NOUN
ajst-32576	57	6	(	(	PUNCT
ajst-32576	57	7	1%-2	1%-2	NUM
ajst-32576	57	8	%	%	NOUN
ajst-32576	57	9	)	)	PUNCT
ajst-32576	57	10	,	,	PUNCT
ajst-32576	57	11	entrectinib	entrectinib	NOUN
ajst-32576	57	12	and	and	CCONJ
ajst-32576	57	13	repotrectinib	repotrectinib	NOUN
ajst-32576	57	14	achieve	achieve	VERB
ajst-32576	57	15	an	an	DET
ajst-32576	57	16	intracranial	intracranial	ADJ
ajst-32576	57	17	objective	objective	ADJ
ajst-32576	57	18	response	response	NOUN
ajst-32576	57	19	rate	rate	NOUN
ajst-32576	57	20	(	(	PUNCT
ajst-32576	57	21	iorr	iorr	NOUN
ajst-32576	57	22	)	)	PUNCT
ajst-32576	57	23	exceeding	exceed	VERB
ajst-32576	57	24	50	50	NUM
ajst-32576	57	25	%	%	NOUN
ajst-32576	57	26	[	[	X
ajst-32576	57	27	22	22	NUM
ajst-32576	57	28	,	,	PUNCT
ajst-32576	57	29	23	23	NUM
ajst-32576	57	30	]	]	PUNCT
ajst-32576	57	31	.	.	PUNCT
ajst-32576	58	1	for	for	ADP
ajst-32576	58	2	braf	braf	NOUN
ajst-32576	58	3	v600e	v600e	PROPN
ajst-32576	58	4	mutation	mutation	NOUN
ajst-32576	58	5	(	(	PUNCT
ajst-32576	58	6	1%-2	1%-2	NUM
ajst-32576	58	7	%	%	NOUN
ajst-32576	58	8	)	)	PUNCT
ajst-32576	58	9	,	,	PUNCT
ajst-32576	58	10	combined	combine	VERB
ajst-32576	58	11	braf	braf	NOUN
ajst-32576	58	12	/	/	SYM
ajst-32576	58	13	mek	mek	PROPN
ajst-32576	58	14	inhibitors	inhibitor	NOUN
ajst-32576	58	15	such	such	ADJ
ajst-32576	58	16	as	as	ADP
ajst-32576	58	17	dabrafenib	dabrafenib	NOUN
ajst-32576	58	18	plus	plus	CCONJ
ajst-32576	58	19	trametinib	trametinib	NOUN
ajst-32576	58	20	has	have	AUX
ajst-32576	58	21	shown	show	VERB
ajst-32576	58	22	efficacy	efficacy	NOUN
ajst-32576	58	23	[	[	X
ajst-32576	58	24	24	24	NUM
ajst-32576	58	25	,	,	PUNCT
ajst-32576	58	26	25	25	NUM
ajst-32576	58	27	]	]	PUNCT
ajst-32576	58	28	.	.	PUNCT
ajst-32576	59	1	although	although	SCONJ
ajst-32576	59	2	ntrk	ntrk	ADJ
ajst-32576	59	3	fusions	fusion	NOUN
ajst-32576	59	4	are	be	AUX
ajst-32576	59	5	rare	rare	ADJ
ajst-32576	59	6	,	,	PUNCT
ajst-32576	59	7	entrectinib	entrectinib	NOUN
ajst-32576	59	8	and	and	CCONJ
ajst-32576	59	9	larotrectinib	larotrectinib	NOUN
ajst-32576	59	10	both	both	PRON
ajst-32576	59	11	exhibit	exhibit	VERB
ajst-32576	59	12	favorable	favorable	ADJ
ajst-32576	59	13	cns	cns	NOUN
ajst-32576	59	14	activity	activity	NOUN
ajst-32576	59	15	[	[	X
ajst-32576	59	16	26	26	NUM
ajst-32576	59	17	]	]	PUNCT
ajst-32576	59	18	.	.	PUNCT
ajst-32576	60	1	in	in	ADP
ajst-32576	60	2	metex14	metex14	NOUN
ajst-32576	60	3	skipping	skip	VERB
ajst-32576	60	4	mutations	mutation	NOUN
ajst-32576	60	5	(	(	PUNCT
ajst-32576	60	6	3%-4	3%-4	NUM
ajst-32576	60	7	%	%	NOUN
ajst-32576	60	8	)	)	PUNCT
ajst-32576	60	9	,	,	PUNCT
ajst-32576	60	10	capmatinib	capmatinib	NOUN
ajst-32576	60	11	demonstrates	demonstrate	VERB
ajst-32576	60	12	a	a	DET
ajst-32576	60	13	high	high	ADJ
ajst-32576	60	14	iorr	iorr	NOUN
ajst-32576	61	1	[	[	X
ajst-32576	61	2	27	27	NUM
ajst-32576	61	3	,	,	PUNCT
ajst-32576	61	4	28	28	NUM
ajst-32576	61	5	]	]	PUNCT
ajst-32576	61	6	.	.	PUNCT
ajst-32576	62	1	for	for	ADP
ajst-32576	62	2	ret	ret	PROPN
ajst-32576	62	3	fusions	fusion	NOUN
ajst-32576	62	4	(	(	PUNCT
ajst-32576	62	5	1%-2	1%-2	NUM
ajst-32576	62	6	%	%	NOUN
ajst-32576	62	7	)	)	PUNCT
ajst-32576	62	8	,	,	PUNCT
ajst-32576	62	9	selpercatinib	selpercatinib	NOUN
ajst-32576	62	10	achieves	achieve	VERB
ajst-32576	62	11	an	an	DET
ajst-32576	62	12	iorr	iorr	NOUN
ajst-32576	62	13	of	of	ADP
ajst-32576	62	14	more	more	ADJ
ajst-32576	62	15	than	than	ADP
ajst-32576	62	16	80	80	NUM
ajst-32576	62	17	%	%	NOUN
ajst-32576	62	18	[	[	X
ajst-32576	62	19	29	29	NUM
ajst-32576	62	20	]	]	PUNCT
ajst-32576	62	21	.	.	PUNCT
ajst-32576	63	1	moreover	moreover	ADV
ajst-32576	63	2	,	,	PUNCT
ajst-32576	63	3	novel	novel	ADJ
ajst-32576	63	4	antibody	antibody	NOUN
ajst-32576	63	5	-	-	PUNCT
ajst-32576	63	6	drug	drug	NOUN
ajst-32576	63	7	conjugates	conjugate	NOUN
ajst-32576	63	8	(	(	PUNCT
ajst-32576	63	9	adcs	adcs	ADJ
ajst-32576	63	10	)	)	PUNCT
ajst-32576	63	11	,	,	PUNCT
ajst-32576	63	12	such	such	ADJ
ajst-32576	63	13	as	as	ADP
ajst-32576	63	14	the	the	DET
ajst-32576	63	15	her2	her2	PROPN
ajst-32576	63	16	-	-	PUNCT
ajst-32576	63	17	targeted	target	VERB
ajst-32576	63	18	drug	drug	NOUN
ajst-32576	63	19	trastuzumab	trastuzumab	NOUN
ajst-32576	63	20	deruxtecan	deruxtecan	ADJ
ajst-32576	63	21	,	,	PUNCT
ajst-32576	63	22	have	have	AUX
ajst-32576	63	23	shown	show	VERB
ajst-32576	63	24	promising	promising	ADJ
ajst-32576	63	25	activity	activity	NOUN
ajst-32576	63	26	against	against	ADP
ajst-32576	63	27	intracranial	intracranial	ADJ
ajst-32576	63	28	lesions	lesion	NOUN
ajst-32576	63	29	[	[	X
ajst-32576	63	30	30	30	NUM
ajst-32576	63	31	]	]	PUNCT
ajst-32576	63	32	.	.	PUNCT
ajst-32576	64	1	in	in	ADP
ajst-32576	64	2	contrast	contrast	NOUN
ajst-32576	64	3	,	,	PUNCT
ajst-32576	64	4	kras	kras	PROPN
ajst-32576	64	5	g12c	g12c	PROPN
ajst-32576	64	6	-	-	PUNCT
ajst-32576	64	7	targeted	target	VERB
ajst-32576	64	8	agents	agent	NOUN
ajst-32576	64	9	have	have	VERB
ajst-32576	64	10	limited	limit	VERB
ajst-32576	64	11	efficacy	efficacy	NOUN
ajst-32576	64	12	,	,	PUNCT
ajst-32576	64	13	and	and	CCONJ
ajst-32576	64	14	immunotherapy	immunotherapy	NOUN
ajst-32576	64	15	or	or	CCONJ
ajst-32576	64	16	chemotherapy	chemotherapy	NOUN
ajst-32576	64	17	remains	remain	VERB
ajst-32576	64	18	the	the	DET
ajst-32576	64	19	mainstay	mainstay	NOUN
ajst-32576	64	20	of	of	ADP
ajst-32576	64	21	treatment	treatment	NOUN
ajst-32576	64	22	for	for	ADP
ajst-32576	64	23	such	such	ADJ
ajst-32576	64	24	patients	patient	NOUN
ajst-32576	64	25	.	.	PUNCT
ajst-32576	65	1	overall	overall	ADJ
ajst-32576	65	2	,	,	PUNCT
ajst-32576	65	3	new	new	ADJ
ajst-32576	65	4	-	-	PUNCT
ajst-32576	65	5	generation	generation	NOUN
ajst-32576	65	6	egfr	egfr	ADJ
ajst-32576	65	7	-	-	PUNCT
ajst-32576	65	8	tkis	tkis	NOUN
ajst-32576	65	9	and	and	CCONJ
ajst-32576	65	10	alk	alk	PROPN
ajst-32576	65	11	-	-	PUNCT
ajst-32576	65	12	tkis	tkis	NOUN
ajst-32576	65	13	provide	provide	VERB
ajst-32576	65	14	excellent	excellent	ADJ
ajst-32576	65	15	intracranial	intracranial	ADJ
ajst-32576	65	16	control	control	NOUN
ajst-32576	65	17	and	and	CCONJ
ajst-32576	65	18	durable	durable	ADJ
ajst-32576	65	19	survival	survival	NOUN
ajst-32576	65	20	benefits	benefit	NOUN
ajst-32576	65	21	.	.	PUNCT
ajst-32576	66	1	landmark	landmark	PROPN
ajst-32576	66	2	phase	phase	PROPN
ajst-32576	66	3	iii	iii	NUM
ajst-32576	66	4	trials	trial	NOUN
ajst-32576	66	5	,	,	PUNCT
ajst-32576	66	6	such	such	ADJ
ajst-32576	66	7	as	as	ADP
ajst-32576	66	8	aeneas	aenea	NOUN
ajst-32576	66	9	and	and	CCONJ
ajst-32576	66	10	crown	crown	NOUN
ajst-32576	66	11	studies	study	NOUN
ajst-32576	66	12	,	,	PUNCT
ajst-32576	66	13	have	have	AUX
ajst-32576	66	14	established	establish	VERB
ajst-32576	66	15	the	the	DET
ajst-32576	66	16	pivital	pivital	ADJ
ajst-32576	66	17	role	role	NOUN
ajst-32576	66	18	of	of	ADP
ajst-32576	66	19	osimertinib	osimertinib	NOUN
ajst-32576	66	20	and	and	CCONJ
ajst-32576	66	21	lorlatinib	lorlatinib	NOUN
ajst-32576	66	22	in	in	ADP
ajst-32576	66	23	the	the	DET
ajst-32576	66	24	management	management	NOUN
ajst-32576	66	25	of	of	ADP
ajst-32576	66	26	driver	driver	NOUN
ajst-32576	66	27	gene	gene	NOUN
ajst-32576	66	28	-	-	PUNCT
ajst-32576	66	29	positive	positive	ADJ
ajst-32576	66	30	nsclc	nsclc	NOUN
ajst-32576	66	31	brain	brain	NOUN
ajst-32576	66	32	metastases	metastasis	NOUN
ajst-32576	66	33	.	.	PUNCT
ajst-32576	67	1	for	for	ADP
ajst-32576	67	2	rare	rare	ADJ
ajst-32576	67	3	driver	driver	NOUN
ajst-32576	67	4	gene	gene	NOUN
ajst-32576	67	5	mutations	mutation	NOUN
ajst-32576	67	6	,	,	PUNCT
ajst-32576	67	7	studies	study	NOUN
ajst-32576	67	8	such	such	ADJ
ajst-32576	67	9	as	as	ADP
ajst-32576	67	10	trident-1	trident-1	NUM
ajst-32576	67	11	have	have	AUX
ajst-32576	67	12	also	also	ADV
ajst-32576	67	13	shown	show	VERB
ajst-32576	67	14	encouraging	encouraging	ADJ
ajst-32576	67	15	efficacy	efficacy	NOUN
ajst-32576	67	16	.	.	PUNCT
ajst-32576	68	1	therefore	therefore	ADV
ajst-32576	68	2	,	,	PUNCT
ajst-32576	68	3	molecular	molecular	ADJ
ajst-32576	68	4	targeted	target	VERB
ajst-32576	68	5	therapy	therapy	NOUN
ajst-32576	68	6	has	have	AUX
ajst-32576	68	7	become	become	VERB
ajst-32576	68	8	the	the	DET
ajst-32576	68	9	cornerstone	cornerstone	NOUN
ajst-32576	68	10	of	of	ADP
ajst-32576	68	11	treatment	treatment	NOUN
ajst-32576	68	12	for	for	ADP
ajst-32576	68	13	nsclc	nsclc	NOUN
ajst-32576	68	14	patients	patient	NOUN
ajst-32576	68	15	with	with	ADP
ajst-32576	68	16	brain	brain	NOUN
ajst-32576	68	17	metastases	metastasis	NOUN
ajst-32576	68	18	harboring	harbor	VERB
ajst-32576	68	19	driver	driver	NOUN
ajst-32576	68	20	gene	gene	NOUN
ajst-32576	68	21	alterations	alteration	NOUN
ajst-32576	68	22	.	.	PUNCT
ajst-32576	69	1	3.1.2	3.1.2	X
ajst-32576	69	2	.	.	PUNCT
ajst-32576	70	1	chemotherapy	chemotherapy	VERB
ajst-32576	70	2	the	the	DET
ajst-32576	70	3	overall	overall	ADJ
ajst-32576	70	4	efficacy	efficacy	NOUN
ajst-32576	70	5	of	of	ADP
ajst-32576	70	6	systemic	systemic	ADJ
ajst-32576	70	7	chemotherapy	chemotherapy	NOUN
ajst-32576	70	8	in	in	ADP
ajst-32576	70	9	nsclc	nsclc	NOUN
ajst-32576	70	10	brain	brain	NOUN
ajst-32576	70	11	metastases	metastasis	NOUN
ajst-32576	70	12	remains	remain	VERB
ajst-32576	70	13	limited	limited	ADJ
ajst-32576	70	14	.	.	PUNCT
ajst-32576	71	1	most	most	ADJ
ajst-32576	71	2	chemotherapeutic	chemotherapeutic	ADJ
ajst-32576	71	3	agents	agent	NOUN
ajst-32576	71	4	penetrate	penetrate	VERB
ajst-32576	71	5	the	the	DET
ajst-32576	71	6	bbb	bbb	NOUN
ajst-32576	71	7	poorly	poorly	ADV
ajst-32576	71	8	,	,	PUNCT
ajst-32576	71	9	and	and	CCONJ
ajst-32576	71	10	efflux	efflux	VERB
ajst-32576	71	11	transporters	transporter	NOUN
ajst-32576	71	12	further	far	ADV
ajst-32576	71	13	reduce	reduce	VERB
ajst-32576	71	14	their	their	PRON
ajst-32576	71	15	intracranial	intracranial	ADJ
ajst-32576	71	16	concentrations	concentration	NOUN
ajst-32576	71	17	,	,	PUNCT
ajst-32576	71	18	resulting	result	VERB
ajst-32576	71	19	in	in	ADP
ajst-32576	71	20	insufficient	insufficient	ADJ
ajst-32576	71	21	activity	activity	NOUN
ajst-32576	71	22	against	against	ADP
ajst-32576	71	23	cns	cns	NOUN
ajst-32576	71	24	lesions	lesion	NOUN
ajst-32576	71	25	.	.	PUNCT
ajst-32576	72	1	moreover	moreover	ADV
ajst-32576	72	2	,	,	PUNCT
ajst-32576	72	3	patients	patient	NOUN
ajst-32576	72	4	with	with	ADP
ajst-32576	72	5	brain	brain	NOUN
ajst-32576	72	6	metastases	metastasis	NOUN
ajst-32576	72	7	are	be	AUX
ajst-32576	72	8	often	often	ADV
ajst-32576	72	9	excluded	exclude	VERB
ajst-32576	72	10	from	from	ADP
ajst-32576	72	11	large	large	ADJ
ajst-32576	72	12	-	-	PUNCT
ajst-32576	72	13	scale	scale	NOUN
ajst-32576	72	14	clinical	clinical	ADJ
ajst-32576	72	15	trials	trial	NOUN
ajst-32576	72	16	,	,	PUNCT
ajst-32576	72	17	leading	lead	VERB
ajst-32576	72	18	to	to	ADP
ajst-32576	72	19	relatively	relatively	ADV
ajst-32576	72	20	scarce	scarce	ADJ
ajst-32576	72	21	high	high	ADJ
ajst-32576	72	22	-	-	PUNCT
ajst-32576	72	23	quality	quality	NOUN
ajst-32576	72	24	evidence	evidence	NOUN
ajst-32576	72	25	in	in	ADP
ajst-32576	72	26	this	this	DET
ajst-32576	72	27	population	population	NOUN
ajst-32576	72	28	.	.	PUNCT
ajst-32576	73	1	commonly	commonly	ADV
ajst-32576	73	2	used	use	VERB
ajst-32576	73	3	agents	agent	NOUN
ajst-32576	73	4	include	include	VERB
ajst-32576	73	5	platinum	platinum	NOUN
ajst-32576	73	6	-	-	PUNCT
ajst-32576	73	7	based	base	VERB
ajst-32576	73	8	compounds	compound	NOUN
ajst-32576	73	9	,	,	PUNCT
ajst-32576	73	10	taxanes	taxane	NOUN
ajst-32576	73	11	,	,	PUNCT
ajst-32576	73	12	and	and	CCONJ
ajst-32576	73	13	pemetrexed	pemetrexe	VERB
ajst-32576	73	14	,	,	PUNCT
ajst-32576	73	15	which	which	PRON
ajst-32576	73	16	are	be	AUX
ajst-32576	73	17	mainly	mainly	ADV
ajst-32576	73	18	primarily	primarily	ADV
ajst-32576	73	19	administered	administer	VERB
ajst-32576	73	20	for	for	ADP
ajst-32576	73	21	the	the	DET
ajst-32576	73	22	control	control	NOUN
ajst-32576	73	23	of	of	ADP
ajst-32576	73	24	extracranial	extracranial	ADJ
ajst-32576	73	25	disease	disease	NOUN
ajst-32576	73	26	.	.	PUNCT
ajst-32576	74	1	several	several	ADJ
ajst-32576	74	2	studies	study	NOUN
ajst-32576	74	3	have	have	AUX
ajst-32576	74	4	indicated	indicate	VERB
ajst-32576	74	5	that	that	SCONJ
ajst-32576	74	6	chemotherapy	chemotherapy	NOUN
ajst-32576	74	7	achieves	achieve	VERB
ajst-32576	74	8	only	only	ADV
ajst-32576	74	9	modest	modest	ADJ
ajst-32576	74	10	outcomes	outcome	NOUN
ajst-32576	74	11	in	in	ADP
ajst-32576	74	12	patients	patient	NOUN
ajst-32576	74	13	with	with	ADP
ajst-32576	74	14	brain	brain	NOUN
ajst-32576	74	15	metastases	metastasis	NOUN
ajst-32576	74	16	.	.	PUNCT
ajst-32576	75	1	for	for	ADP
ajst-32576	75	2	instance	instance	NOUN
ajst-32576	75	3	,	,	PUNCT
ajst-32576	75	4	in	in	ADP
ajst-32576	75	5	trials	trial	NOUN
ajst-32576	75	6	such	such	ADJ
ajst-32576	75	7	as	as	ADP
ajst-32576	75	8	keynote-021	keynote-021	NOUN
ajst-32576	75	9	,	,	PUNCT
ajst-32576	75	10	189	189	NUM
ajst-32576	75	11	,	,	PUNCT
ajst-32576	75	12	and	and	CCONJ
ajst-32576	75	13	407	407	NUM
ajst-32576	75	14	,	,	PUNCT
ajst-32576	75	15	patients	patient	NOUN
ajst-32576	75	16	with	with	ADP
ajst-32576	75	17	bm	bm	PROPN
ajst-32576	75	18	had	have	VERB
ajst-32576	75	19	an	an	DET
ajst-32576	75	20	mpfs	mpf	NOUN
ajst-32576	75	21	of	of	ADP
ajst-32576	75	22	4.1	4.1	NUM
ajst-32576	75	23	months	month	NOUN
ajst-32576	75	24	and	and	CCONJ
ajst-32576	75	25	an	an	DET
ajst-32576	75	26	os	os	NOUN
ajst-32576	75	27	of	of	ADP
ajst-32576	75	28	7.6	7.6	NUM
ajst-32576	75	29	months	month	NOUN
ajst-32576	75	30	[	[	X
ajst-32576	75	31	31	31	NUM
ajst-32576	75	32	]	]	PUNCT
ajst-32576	75	33	.	.	PUNCT
ajst-32576	76	1	among	among	ADP
ajst-32576	76	2	patients	patient	NOUN
ajst-32576	76	3	with	with	ADP
ajst-32576	76	4	kras	kras	PROPN
ajst-32576	76	5	g12c	g12c	PROPN
ajst-32576	76	6	mutation	mutation	NOUN
ajst-32576	76	7	and	and	CCONJ
ajst-32576	76	8	cns	cns	NOUN
ajst-32576	76	9	involvement	involvement	NOUN
ajst-32576	76	10	,	,	PUNCT
ajst-32576	76	11	docetaxel	docetaxel	PROPN
ajst-32576	76	12	resulted	result	VERB
ajst-32576	76	13	in	in	ADP
ajst-32576	76	14	an	an	DET
ajst-32576	76	15	mpfs	mpf	NOUN
ajst-32576	76	16	of	of	ADP
ajst-32576	76	17	2.9	2.9	NUM
ajst-32576	76	18	months	month	NOUN
ajst-32576	76	19	[	[	X
ajst-32576	76	20	32	32	NUM
ajst-32576	76	21	]	]	PUNCT
ajst-32576	76	22	.	.	PUNCT
ajst-32576	77	1	similarly	similarly	ADV
ajst-32576	77	2	,	,	PUNCT
ajst-32576	77	3	the	the	DET
ajst-32576	77	4	combination	combination	NOUN
ajst-32576	77	5	of	of	ADP
ajst-32576	77	6	pemetrexed	pemetrexed	NOUN
ajst-32576	77	7	plus	plus	CCONJ
ajst-32576	77	8	carboplatin	carboplatin	NOUN
ajst-32576	77	9	resulted	result	VERB
ajst-32576	77	10	in	in	ADP
ajst-32576	77	11	an	an	DET
ajst-32576	77	12	mpfs	mpf	NOUN
ajst-32576	77	13	of	of	ADP
ajst-32576	77	14	approximately	approximately	ADV
ajst-32576	77	15	4.1	4.1	NUM
ajst-32576	77	16	months	month	NOUN
ajst-32576	77	17	in	in	ADP
ajst-32576	77	18	those	those	PRON
ajst-32576	77	19	with	with	ADP
ajst-32576	77	20	bm	bm	PROPN
ajst-32576	78	1	[	[	X
ajst-32576	78	2	33	33	NUM
ajst-32576	78	3	]	]	PUNCT
ajst-32576	78	4	.	.	PUNCT
ajst-32576	79	1	although	although	SCONJ
ajst-32576	79	2	systemic	systemic	ADJ
ajst-32576	79	3	chemotherapy	chemotherapy	NOUN
ajst-32576	79	4	has	have	VERB
ajst-32576	79	5	limited	limit	VERB
ajst-32576	79	6	impact	impact	NOUN
ajst-32576	79	7	on	on	ADP
ajst-32576	79	8	intracranial	intracranial	ADJ
ajst-32576	79	9	disease	disease	NOUN
ajst-32576	79	10	control	control	NOUN
ajst-32576	79	11	,	,	PUNCT
ajst-32576	79	12	it	it	PRON
ajst-32576	79	13	remains	remain	VERB
ajst-32576	79	14	a	a	DET
ajst-32576	79	15	viable	viable	ADJ
ajst-32576	79	16	option	option	NOUN
ajst-32576	79	17	when	when	SCONJ
ajst-32576	79	18	targeted	target	VERB
ajst-32576	79	19	therapies	therapy	NOUN
ajst-32576	79	20	or	or	CCONJ
ajst-32576	79	21	immunotherapies	immunotherapy	NOUN
ajst-32576	79	22	are	be	AUX
ajst-32576	79	23	unavailable	unavailable	ADJ
ajst-32576	79	24	.	.	PUNCT
ajst-32576	80	1	intrathecal	intrathecal	ADJ
ajst-32576	80	2	injection	injection	NOUN
ajst-32576	80	3	aims	aim	VERB
ajst-32576	80	4	to	to	PART
ajst-32576	80	5	bypass	bypass	VERB
ajst-32576	80	6	the	the	DET
ajst-32576	80	7	bbb	bbb	NOUN
ajst-32576	80	8	by	by	ADP
ajst-32576	80	9	directly	directly	ADV
ajst-32576	80	10	delivering	deliver	VERB
ajst-32576	80	11	drugs	drug	NOUN
ajst-32576	80	12	into	into	ADP
ajst-32576	80	13	the	the	DET
ajst-32576	80	14	cerebrospinal	cerebrospinal	ADJ
ajst-32576	80	15	fluid	fluid	NOUN
ajst-32576	80	16	,	,	PUNCT
ajst-32576	80	17	thereby	thereby	ADV
ajst-32576	80	18	achieving	achieve	VERB
ajst-32576	80	19	high	high	ADJ
ajst-32576	80	20	local	local	ADJ
ajst-32576	80	21	drug	drug	NOUN
ajst-32576	80	22	exposure	exposure	NOUN
ajst-32576	80	23	for	for	ADP
ajst-32576	80	24	patients	patient	NOUN
ajst-32576	80	25	with	with	ADP
ajst-32576	80	26	leptomeningeal	leptomeningeal	ADJ
ajst-32576	80	27	metastases	metastasis	NOUN
ajst-32576	80	28	.	.	PUNCT
ajst-32576	81	1	intrathecal	intrathecal	ADJ
ajst-32576	81	2	pemetrexed	pemetrexed	NOUN
ajst-32576	81	3	,	,	PUNCT
ajst-32576	81	4	for	for	ADP
ajst-32576	81	5	example	example	NOUN
ajst-32576	81	6	,	,	PUNCT
ajst-32576	81	7	has	have	AUX
ajst-32576	81	8	shown	show	VERB
ajst-32576	81	9	clinical	clinical	ADJ
ajst-32576	81	10	benefit	benefit	NOUN
ajst-32576	81	11	in	in	ADP
ajst-32576	81	12	certain	certain	ADJ
ajst-32576	81	13	patients	patient	NOUN
ajst-32576	81	14	with	with	ADP
ajst-32576	81	15	egfr	egfr	ADJ
ajst-32576	81	16	-	-	PUNCT
ajst-32576	81	17	mutant	mutant	ADJ
ajst-32576	81	18	leptomeningeal	leptomeningeal	NOUN
ajst-32576	81	19	metastases	metastasis	NOUN
ajst-32576	81	20	,	,	PUNCT
ajst-32576	81	21	leading	lead	VERB
ajst-32576	81	22	to	to	ADP
ajst-32576	81	23	symptom	symptom	NOUN
ajst-32576	81	24	relief	relief	NOUN
ajst-32576	81	25	and	and	CCONJ
ajst-32576	81	26	prolonged	prolonged	ADJ
ajst-32576	81	27	survival	survival	NOUN
ajst-32576	81	28	[	[	X
ajst-32576	81	29	34	34	NUM
ajst-32576	81	30	]	]	PUNCT
ajst-32576	81	31	.	.	PUNCT
ajst-32576	82	1	however	however	ADV
ajst-32576	82	2	,	,	PUNCT
ajst-32576	82	3	223	223	NUM
ajst-32576	82	4	common	common	ADJ
ajst-32576	82	5	adverse	adverse	ADJ
ajst-32576	82	6	effects	effect	NOUN
ajst-32576	82	7	include	include	VERB
ajst-32576	82	8	myelosuppression	myelosuppression	NOUN
ajst-32576	82	9	and	and	CCONJ
ajst-32576	82	10	nausea	nausea	NOUN
ajst-32576	82	11	,	,	PUNCT
ajst-32576	82	12	while	while	SCONJ
ajst-32576	82	13	additional	additional	ADJ
ajst-32576	82	14	risks	risk	NOUN
ajst-32576	82	15	such	such	ADJ
ajst-32576	82	16	as	as	ADP
ajst-32576	82	17	infection	infection	NOUN
ajst-32576	82	18	,	,	PUNCT
ajst-32576	82	19	bleeding	bleeding	NOUN
ajst-32576	82	20	,	,	PUNCT
ajst-32576	82	21	and	and	CCONJ
ajst-32576	82	22	neurological	neurological	ADJ
ajst-32576	82	23	injury	injury	NOUN
ajst-32576	82	24	require	require	VERB
ajst-32576	82	25	careful	careful	ADJ
ajst-32576	82	26	monitoring	monitoring	NOUN
ajst-32576	82	27	.	.	PUNCT
ajst-32576	83	1	although	although	SCONJ
ajst-32576	83	2	intrathecal	intrathecal	ADJ
ajst-32576	83	3	administration	administration	NOUN
ajst-32576	83	4	offers	offer	VERB
ajst-32576	83	5	particular	particular	ADJ
ajst-32576	83	6	advantages	advantage	NOUN
ajst-32576	83	7	for	for	ADP
ajst-32576	83	8	leptomeningeal	leptomeningeal	NOUN
ajst-32576	83	9	disease	disease	NOUN
ajst-32576	83	10	,	,	PUNCT
ajst-32576	83	11	its	its	PRON
ajst-32576	83	12	efficacy	efficacy	NOUN
ajst-32576	83	13	against	against	ADP
ajst-32576	83	14	parenchymal	parenchymal	ADJ
ajst-32576	83	15	brain	brain	NOUN
ajst-32576	83	16	metastases	metastasis	NOUN
ajst-32576	83	17	is	be	AUX
ajst-32576	83	18	limited	limit	VERB
ajst-32576	83	19	,	,	PUNCT
ajst-32576	83	20	and	and	CCONJ
ajst-32576	83	21	clinical	clinical	ADJ
ajst-32576	83	22	application	application	NOUN
ajst-32576	83	23	necessitates	necessitate	VERB
ajst-32576	83	24	a	a	DET
ajst-32576	83	25	cautious	cautious	ADJ
ajst-32576	83	26	balance	balance	NOUN
ajst-32576	83	27	between	between	ADP
ajst-32576	83	28	therapeutic	therapeutic	ADJ
ajst-32576	83	29	benefit	benefit	NOUN
ajst-32576	83	30	and	and	CCONJ
ajst-32576	83	31	potential	potential	ADJ
ajst-32576	83	32	risks	risk	NOUN
ajst-32576	83	33	.	.	PUNCT
ajst-32576	84	1	3.1.3	3.1.3	NUM
ajst-32576	84	2	.	.	PUNCT
ajst-32576	84	3	radiotherapy	radiotherapy	NOUN
ajst-32576	84	4	radiotherapy	radiotherapy	NOUN
ajst-32576	84	5	is	be	AUX
ajst-32576	84	6	a	a	DET
ajst-32576	84	7	key	key	ADJ
ajst-32576	84	8	local	local	ADJ
ajst-32576	84	9	treatment	treatment	NOUN
ajst-32576	84	10	option	option	NOUN
ajst-32576	84	11	for	for	ADP
ajst-32576	84	12	nsclc	nsclc	NOUN
ajst-32576	84	13	brain	brain	NOUN
ajst-32576	84	14	metastases	metastasis	NOUN
ajst-32576	84	15	,	,	PUNCT
ajst-32576	84	16	primarily	primarily	ADV
ajst-32576	84	17	including	include	VERB
ajst-32576	84	18	whole	whole	ADJ
ajst-32576	84	19	-	-	PUNCT
ajst-32576	84	20	brain	brain	NOUN
ajst-32576	84	21	radiotherapy	radiotherapy	NOUN
ajst-32576	84	22	(	(	PUNCT
ajst-32576	84	23	wbrt	wbrt	PROPN
ajst-32576	84	24	)	)	PUNCT
ajst-32576	84	25	and	and	CCONJ
ajst-32576	84	26	stereotactic	stereotactic	ADJ
ajst-32576	84	27	radiosurgery	radiosurgery	NOUN
ajst-32576	84	28	(	(	PUNCT
ajst-32576	84	29	srs	srs	PROPN
ajst-32576	84	30	)	)	PUNCT
ajst-32576	84	31	.	.	PUNCT
ajst-32576	85	1	wbrt	wbrt	PROPN
ajst-32576	85	2	enables	enable	VERB
ajst-32576	85	3	simultaneous	simultaneous	ADJ
ajst-32576	85	4	coverage	coverage	NOUN
ajst-32576	85	5	of	of	ADP
ajst-32576	85	6	multiple	multiple	ADJ
ajst-32576	85	7	lesions	lesion	NOUN
ajst-32576	85	8	,	,	PUNCT
ajst-32576	85	9	with	with	ADP
ajst-32576	85	10	reported	report	VERB
ajst-32576	85	11	intracranial	intracranial	ADJ
ajst-32576	85	12	response	response	NOUN
ajst-32576	85	13	rates	rate	NOUN
ajst-32576	85	14	of	of	ADP
ajst-32576	85	15	70%–90	70%–90	NOUN
ajst-32576	85	16	%	%	NOUN
ajst-32576	85	17	.	.	PUNCT
ajst-32576	86	1	it	it	PRON
ajst-32576	86	2	can	can	AUX
ajst-32576	86	3	prolong	prolong	VERB
ajst-32576	86	4	pfs	pfs	PROPN
ajst-32576	86	5	to	to	ADP
ajst-32576	86	6	some	some	DET
ajst-32576	86	7	extent	extent	NOUN
ajst-32576	86	8	and	and	CCONJ
ajst-32576	86	9	alleviate	alleviate	VERB
ajst-32576	86	10	neurological	neurological	ADJ
ajst-32576	86	11	symptoms	symptom	NOUN
ajst-32576	86	12	,	,	PUNCT
ajst-32576	86	13	however	however	ADV
ajst-32576	86	14	,	,	PUNCT
ajst-32576	86	15	long	long	ADJ
ajst-32576	86	16	-	-	PUNCT
ajst-32576	86	17	term	term	NOUN
ajst-32576	86	18	use	use	NOUN
ajst-32576	86	19	is	be	AUX
ajst-32576	86	20	associated	associate	VERB
ajst-32576	86	21	with	with	ADP
ajst-32576	86	22	risks	risk	NOUN
ajst-32576	86	23	of	of	ADP
ajst-32576	86	24	cognitive	cognitive	ADJ
ajst-32576	86	25	decline	decline	NOUN
ajst-32576	86	26	and	and	CCONJ
ajst-32576	86	27	high	high	ADJ
ajst-32576	86	28	recurrence	recurrence	NOUN
ajst-32576	86	29	rates	rate	NOUN
ajst-32576	86	30	[	[	X
ajst-32576	86	31	35	35	NUM
ajst-32576	86	32	,	,	PUNCT
ajst-32576	86	33	36	36	NUM
ajst-32576	86	34	]	]	PUNCT
ajst-32576	86	35	.	.	PUNCT
ajst-32576	87	1	consequently	consequently	ADV
ajst-32576	87	2	,	,	PUNCT
ajst-32576	87	3	wbrt	wbrt	PROPN
ajst-32576	87	4	is	be	AUX
ajst-32576	87	5	mainly	mainly	ADV
ajst-32576	87	6	reserved	reserve	VERB
ajst-32576	87	7	for	for	ADP
ajst-32576	87	8	patients	patient	NOUN
ajst-32576	87	9	with	with	ADP
ajst-32576	87	10	multiple	multiple	ADJ
ajst-32576	87	11	or	or	CCONJ
ajst-32576	87	12	diffuse	diffuse	VERB
ajst-32576	87	13	brain	brain	NOUN
ajst-32576	87	14	metastases	metastasis	NOUN
ajst-32576	87	15	,	,	PUNCT
ajst-32576	87	16	particularly	particularly	ADV
ajst-32576	87	17	those	those	PRON
ajst-32576	87	18	requiring	require	VERB
ajst-32576	87	19	rapid	rapid	ADJ
ajst-32576	87	20	symptom	symptom	NOUN
ajst-32576	87	21	relief	relief	NOUN
ajst-32576	87	22	.	.	PUNCT
ajst-32576	88	1	srs	srs	PROPN
ajst-32576	88	2	delivers	deliver	VERB
ajst-32576	88	3	highly	highly	ADV
ajst-32576	88	4	precise	precise	ADJ
ajst-32576	88	5	,	,	PUNCT
ajst-32576	88	6	focused	focused	ADJ
ajst-32576	88	7	radiation	radiation	NOUN
ajst-32576	88	8	to	to	ADP
ajst-32576	88	9	tumor	tumor	NOUN
ajst-32576	88	10	sites	site	NOUN
ajst-32576	88	11	while	while	SCONJ
ajst-32576	88	12	sparing	spare	VERB
ajst-32576	88	13	surrounding	surround	VERB
ajst-32576	88	14	normal	normal	ADJ
ajst-32576	88	15	brain	brain	NOUN
ajst-32576	88	16	tissue	tissue	NOUN
ajst-32576	88	17	.	.	PUNCT
ajst-32576	89	1	it	it	PRON
ajst-32576	89	2	can	can	AUX
ajst-32576	89	3	be	be	AUX
ajst-32576	89	4	applied	apply	VERB
ajst-32576	89	5	as	as	ADP
ajst-32576	89	6	a	a	DET
ajst-32576	89	7	standalone	standalone	ADJ
ajst-32576	89	8	treatment	treatment	NOUN
ajst-32576	89	9	,	,	PUNCT
ajst-32576	89	10	in	in	ADP
ajst-32576	89	11	combination	combination	NOUN
ajst-32576	89	12	with	with	ADP
ajst-32576	89	13	wbrt	wbrt	PROPN
ajst-32576	89	14	,	,	PUNCT
ajst-32576	89	15	or	or	CCONJ
ajst-32576	89	16	as	as	ADP
ajst-32576	89	17	an	an	DET
ajst-32576	89	18	adjuvant	adjuvant	ADJ
ajst-32576	89	19	therapy	therapy	NOUN
ajst-32576	89	20	following	follow	VERB
ajst-32576	89	21	surgery	surgery	NOUN
ajst-32576	89	22	,	,	PUNCT
ajst-32576	89	23	and	and	CCONJ
ajst-32576	89	24	is	be	AUX
ajst-32576	89	25	generally	generally	ADV
ajst-32576	89	26	more	more	ADV
ajst-32576	89	27	suitable	suitable	ADJ
ajst-32576	89	28	for	for	ADP
ajst-32576	89	29	patients	patient	NOUN
ajst-32576	89	30	with	with	ADP
ajst-32576	89	31	a	a	DET
ajst-32576	89	32	limited	limited	ADJ
ajst-32576	89	33	number	number	NOUN
ajst-32576	89	34	of	of	ADP
ajst-32576	89	35	lesions	lesion	NOUN
ajst-32576	89	36	.	.	PUNCT
ajst-32576	90	1	retrospective	retrospective	ADJ
ajst-32576	90	2	analyses	analysis	NOUN
ajst-32576	90	3	show	show	VERB
ajst-32576	90	4	a	a	DET
ajst-32576	90	5	mos	mos	NOUN
ajst-32576	90	6	of	of	ADP
ajst-32576	90	7	approximately	approximately	ADV
ajst-32576	90	8	8	8	NUM
ajst-32576	90	9	months	month	NOUN
ajst-32576	90	10	for	for	ADP
ajst-32576	90	11	patients	patient	NOUN
ajst-32576	90	12	receiving	receive	VERB
ajst-32576	90	13	single	single	ADJ
ajst-32576	90	14	-	-	PUNCT
ajst-32576	90	15	session	session	NOUN
ajst-32576	90	16	srs	srs	NOUN
ajst-32576	90	17	,	,	PUNCT
ajst-32576	90	18	while	while	SCONJ
ajst-32576	90	19	those	those	PRON
ajst-32576	90	20	undergoing	undergo	VERB
ajst-32576	90	21	multiple	multiple	ADJ
ajst-32576	90	22	srs	srs	PROPN
ajst-32576	90	23	sessions	session	NOUN
ajst-32576	90	24	may	may	AUX
ajst-32576	90	25	achieve	achieve	VERB
ajst-32576	90	26	survival	survival	NOUN
ajst-32576	90	27	exceeding	exceed	VERB
ajst-32576	90	28	3	3	NUM
ajst-32576	90	29	years	year	NOUN
ajst-32576	90	30	,	,	PUNCT
ajst-32576	90	31	underscoring	underscore	VERB
ajst-32576	90	32	its	its	PRON
ajst-32576	90	33	potential	potential	ADJ
ajst-32576	90	34	role	role	NOUN
ajst-32576	90	35	in	in	ADP
ajst-32576	90	36	long	long	ADJ
ajst-32576	90	37	-	-	PUNCT
ajst-32576	90	38	term	term	NOUN
ajst-32576	90	39	intracranial	intracranial	ADJ
ajst-32576	90	40	control	control	NOUN
ajst-32576	91	1	[	[	X
ajst-32576	91	2	37	37	NUM
ajst-32576	91	3	]	]	PUNCT
ajst-32576	91	4	.	.	PUNCT
ajst-32576	92	1	in	in	ADP
ajst-32576	92	2	summary	summary	NOUN
ajst-32576	92	3	,	,	PUNCT
ajst-32576	92	4	radiotherapy	radiotherapy	NOUN
ajst-32576	92	5	remains	remain	VERB
ajst-32576	92	6	an	an	DET
ajst-32576	92	7	indispensable	indispensable	ADJ
ajst-32576	92	8	component	component	NOUN
ajst-32576	92	9	of	of	ADP
ajst-32576	92	10	nsclc	nsclc	NOUN
ajst-32576	92	11	brain	brain	NOUN
ajst-32576	92	12	metastasis	metastasis	NOUN
ajst-32576	92	13	management	management	NOUN
ajst-32576	92	14	.	.	PUNCT
ajst-32576	93	1	evidence	evidence	NOUN
ajst-32576	93	2	from	from	ADP
ajst-32576	93	3	studies	study	NOUN
ajst-32576	93	4	such	such	ADJ
ajst-32576	93	5	as	as	ADP
ajst-32576	93	6	hybrid	hybrid	NOUN
ajst-32576	93	7	suggests	suggest	VERB
ajst-32576	93	8	that	that	SCONJ
ajst-32576	93	9	srs	srs	PROPN
ajst-32576	93	10	provides	provide	VERB
ajst-32576	93	11	superior	superior	ADJ
ajst-32576	93	12	intracranial	intracranial	ADJ
ajst-32576	93	13	disease	disease	NOUN
ajst-32576	93	14	control	control	NOUN
ajst-32576	93	15	and	and	CCONJ
ajst-32576	93	16	better	well	ADJ
ajst-32576	93	17	preservation	preservation	NOUN
ajst-32576	93	18	of	of	ADP
ajst-32576	93	19	neurocognitive	neurocognitive	ADJ
ajst-32576	93	20	function	function	NOUN
ajst-32576	93	21	,	,	PUNCT
ajst-32576	93	22	whereas	whereas	SCONJ
ajst-32576	93	23	wbrt	wbrt	PROPN
ajst-32576	93	24	remains	remain	VERB
ajst-32576	93	25	more	more	ADV
ajst-32576	93	26	appropriate	appropriate	ADJ
ajst-32576	93	27	for	for	ADP
ajst-32576	93	28	patients	patient	NOUN
ajst-32576	93	29	with	with	ADP
ajst-32576	93	30	diffuse	diffuse	ADJ
ajst-32576	93	31	or	or	CCONJ
ajst-32576	93	32	extensive	extensive	ADJ
ajst-32576	93	33	metastatic	metastatic	ADJ
ajst-32576	93	34	disease	disease	NOUN
ajst-32576	93	35	.	.	PUNCT
ajst-32576	94	1	3.1.4	3.1.4	NUM
ajst-32576	94	2	.	.	PUNCT
ajst-32576	94	3	immunotherapy	immunotherapy	NOUN
ajst-32576	94	4	immune	immune	ADJ
ajst-32576	94	5	checkpoint	checkpoint	NOUN
ajst-32576	94	6	inhibitors	inhibitor	NOUN
ajst-32576	94	7	(	(	PUNCT
ajst-32576	94	8	icis	icis	NOUN
ajst-32576	94	9	)	)	PUNCT
ajst-32576	94	10	restore	restore	VERB
ajst-32576	94	11	antitumor	antitumor	PROPN
ajst-32576	94	12	immunity	immunity	NOUN
ajst-32576	94	13	by	by	ADP
ajst-32576	94	14	blocking	block	VERB
ajst-32576	94	15	the	the	DET
ajst-32576	94	16	pd-1	pd-1	NOUN
ajst-32576	94	17	/	/	SYM
ajst-32576	94	18	pd	pd	NOUN
ajst-32576	94	19	-	-	PROPN
ajst-32576	94	20	l1	l1	PROPN
ajst-32576	94	21	or	or	CCONJ
ajst-32576	94	22	ctla-4	ctla-4	NOUN
ajst-32576	94	23	pathways	pathway	NOUN
ajst-32576	94	24	,	,	PUNCT
ajst-32576	94	25	thereby	thereby	ADV
ajst-32576	94	26	reactivating	reactivate	VERB
ajst-32576	94	27	exhausted	exhausted	ADJ
ajst-32576	94	28	t	t	NOUN
ajst-32576	94	29	cells	cell	NOUN
ajst-32576	94	30	.	.	PUNCT
ajst-32576	95	1	patients	patient	NOUN
ajst-32576	95	2	with	with	ADP
ajst-32576	95	3	nsclc	nsclc	NOUN
ajst-32576	95	4	brain	brain	NOUN
ajst-32576	95	5	metastases	metastasis	NOUN
ajst-32576	95	6	may	may	AUX
ajst-32576	95	7	be	be	AUX
ajst-32576	95	8	more	more	ADV
ajst-32576	95	9	responsive	responsive	ADJ
ajst-32576	95	10	to	to	ADP
ajst-32576	95	11	icis	icis	NOUN
ajst-32576	95	12	due	due	ADP
ajst-32576	95	13	to	to	ADP
ajst-32576	95	14	bbb	bbb	NOUN
ajst-32576	95	15	disruption	disruption	NOUN
ajst-32576	95	16	and	and	CCONJ
ajst-32576	95	17	increased	increase	VERB
ajst-32576	95	18	immune	immune	ADJ
ajst-32576	95	19	cell	cell	NOUN
ajst-32576	95	20	infiltration	infiltration	NOUN
ajst-32576	95	21	.	.	PUNCT
ajst-32576	96	1	multiple	multiple	ADJ
ajst-32576	96	2	studies	study	NOUN
ajst-32576	96	3	have	have	AUX
ajst-32576	96	4	confirmed	confirm	VERB
ajst-32576	96	5	that	that	SCONJ
ajst-32576	96	6	icis	icis	PROPN
ajst-32576	96	7	exert	exert	VERB
ajst-32576	96	8	durable	durable	ADJ
ajst-32576	96	9	intracranial	intracranial	ADJ
ajst-32576	96	10	activity	activity	NOUN
ajst-32576	96	11	and	and	CCONJ
ajst-32576	96	12	provide	provide	VERB
ajst-32576	96	13	meaningful	meaningful	ADJ
ajst-32576	96	14	survival	survival	NOUN
ajst-32576	96	15	benefits	benefit	NOUN
ajst-32576	96	16	.	.	PUNCT
ajst-32576	97	1	in	in	ADP
ajst-32576	97	2	particular	particular	ADJ
ajst-32576	97	3	,	,	PUNCT
ajst-32576	97	4	pd-1	pd-1	ADJ
ajst-32576	97	5	/	/	SYM
ajst-32576	97	6	pd	pd	ADJ
ajst-32576	97	7	-	-	PUNCT
ajst-32576	97	8	l1	l1	PROPN
ajst-32576	97	9	inhibitors	inhibitor	NOUN
ajst-32576	97	10	have	have	AUX
ajst-32576	97	11	shown	show	VERB
ajst-32576	97	12	clear	clear	ADJ
ajst-32576	97	13	efficacy	efficacy	NOUN
ajst-32576	97	14	,	,	PUNCT
ajst-32576	97	15	and	and	CCONJ
ajst-32576	97	16	their	their	PRON
ajst-32576	97	17	combination	combination	NOUN
ajst-32576	97	18	with	with	ADP
ajst-32576	97	19	chemotherapy	chemotherapy	NOUN
ajst-32576	97	20	or	or	CCONJ
ajst-32576	97	21	radiotherapy	radiotherapy	NOUN
ajst-32576	97	22	can	can	AUX
ajst-32576	97	23	further	far	ADV
ajst-32576	97	24	enhance	enhance	VERB
ajst-32576	97	25	both	both	PRON
ajst-32576	97	26	intracranial	intracranial	ADJ
ajst-32576	97	27	and	and	CCONJ
ajst-32576	97	28	systemic	systemic	ADJ
ajst-32576	97	29	responses	response	NOUN
ajst-32576	97	30	.	.	PUNCT
ajst-32576	98	1	among	among	ADP
ajst-32576	98	2	pd-1	pd-1	ADP
ajst-32576	98	3	inhibitors	inhibitor	NOUN
ajst-32576	98	4	,	,	PUNCT
ajst-32576	98	5	nivolumab	nivolumab	ADV
ajst-32576	98	6	was	be	AUX
ajst-32576	98	7	the	the	DET
ajst-32576	98	8	first	first	ADJ
ajst-32576	98	9	to	to	PART
ajst-32576	98	10	be	be	AUX
ajst-32576	98	11	applied	apply	VERB
ajst-32576	98	12	in	in	ADP
ajst-32576	98	13	patiens	patien	NOUN
ajst-32576	98	14	with	with	ADP
ajst-32576	98	15	brain	brain	NOUN
ajst-32576	98	16	metastases	metastasis	NOUN
ajst-32576	98	17	.	.	PUNCT
ajst-32576	99	1	retrospective	retrospective	ADJ
ajst-32576	99	2	cohort	cohort	NOUN
ajst-32576	99	3	studies	study	NOUN
ajst-32576	99	4	have	have	AUX
ajst-32576	99	5	reported	report	VERB
ajst-32576	99	6	an	an	DET
ajst-32576	99	7	mpfs	mpf	NOUN
ajst-32576	99	8	of	of	ADP
ajst-32576	99	9	approximately	approximately	ADV
ajst-32576	99	10	3	3	NUM
ajst-32576	99	11	months	month	NOUN
ajst-32576	99	12	and	and	CCONJ
ajst-32576	99	13	an	an	DET
ajst-32576	99	14	mos	mos	NOUN
ajst-32576	99	15	of	of	ADP
ajst-32576	99	16	nearly	nearly	ADV
ajst-32576	99	17	15	15	NUM
ajst-32576	99	18	months	month	NOUN
ajst-32576	99	19	,	,	PUNCT
ajst-32576	99	20	while	while	SCONJ
ajst-32576	99	21	clinical	clinical	ADJ
ajst-32576	99	22	studies	study	NOUN
ajst-32576	99	23	demonstrated	demonstrate	VERB
ajst-32576	99	24	an	an	DET
ajst-32576	99	25	mos	mos	NOUN
ajst-32576	99	26	exceeding	exceed	VERB
ajst-32576	99	27	9	9	NUM
ajst-32576	99	28	months	month	NOUN
ajst-32576	99	29	with	with	ADP
ajst-32576	99	30	favarable	favarable	ADJ
ajst-32576	99	31	safety	safety	NOUN
ajst-32576	99	32	profiles	profile	NOUN
ajst-32576	99	33	[	[	X
ajst-32576	99	34	38	38	NUM
ajst-32576	99	35	,	,	PUNCT
ajst-32576	99	36	39	39	NUM
ajst-32576	99	37	]	]	PUNCT
ajst-32576	99	38	.	.	PUNCT
ajst-32576	100	1	pembrolizumab	pembrolizumab	NOUN
ajst-32576	100	2	,	,	PUNCT
ajst-32576	100	3	in	in	ADP
ajst-32576	100	4	phase	phase	NOUN
ajst-32576	100	5	ii	ii	PROPN
ajst-32576	100	6	studies	study	NOUN
ajst-32576	100	7	,	,	PUNCT
ajst-32576	100	8	achieved	achieve	VERB
ajst-32576	100	9	an	an	DET
ajst-32576	100	10	intracranial	intracranial	ADJ
ajst-32576	100	11	pfs	pfs	NOUN
ajst-32576	100	12	of	of	ADP
ajst-32576	100	13	about	about	ADV
ajst-32576	100	14	2	2	NUM
ajst-32576	100	15	months	month	NOUN
ajst-32576	100	16	,	,	PUNCT
ajst-32576	100	17	however	however	ADV
ajst-32576	100	18	,	,	PUNCT
ajst-32576	100	19	real	real	ADJ
ajst-32576	100	20	-	-	PUNCT
ajst-32576	100	21	world	world	NOUN
ajst-32576	100	22	data	datum	NOUN
ajst-32576	100	23	suggest	suggest	VERB
ajst-32576	100	24	that	that	SCONJ
ajst-32576	100	25	when	when	SCONJ
ajst-32576	100	26	administered	administer	VERB
ajst-32576	100	27	as	as	ADP
ajst-32576	100	28	first	first	ADJ
ajst-32576	100	29	-	-	PUNCT
ajst-32576	100	30	line	line	NOUN
ajst-32576	100	31	therapy	therapy	NOUN
ajst-32576	100	32	,	,	PUNCT
ajst-32576	100	33	pfs	pfs	PROPN
ajst-32576	100	34	can	can	AUX
ajst-32576	100	35	be	be	AUX
ajst-32576	100	36	extended	extend	VERB
ajst-32576	100	37	to	to	ADP
ajst-32576	100	38	10	10	NUM
ajst-32576	100	39	months	month	NOUN
ajst-32576	100	40	,	,	PUNCT
ajst-32576	100	41	indicating	indicate	VERB
ajst-32576	100	42	greater	great	ADJ
ajst-32576	100	43	benefits	benefit	NOUN
ajst-32576	100	44	with	with	ADP
ajst-32576	100	45	earlier	early	ADJ
ajst-32576	100	46	use	use	NOUN
ajst-32576	100	47	[	[	X
ajst-32576	100	48	40	40	NUM
ajst-32576	100	49	,	,	PUNCT
ajst-32576	100	50	41	41	NUM
ajst-32576	100	51	]	]	PUNCT
ajst-32576	100	52	.	.	PUNCT
ajst-32576	101	1	the	the	DET
ajst-32576	101	2	pd	pd	PROPN
ajst-32576	101	3	-	-	PROPN
ajst-32576	101	4	l1	l1	PROPN
ajst-32576	101	5	inhibitor	inhibitor	NOUN
ajst-32576	101	6	atezolizumab	atezolizumab	PROPN
ajst-32576	101	7	,	,	PUNCT
ajst-32576	101	8	when	when	SCONJ
ajst-32576	101	9	conbined	conbine	VERB
ajst-32576	101	10	with	with	ADP
ajst-32576	101	11	chemotherapy	chemotherapy	NOUN
ajst-32576	101	12	and	and	CCONJ
ajst-32576	101	13	bevacizumab	bevacizumab	PROPN
ajst-32576	101	14	,	,	PUNCT
ajst-32576	101	15	achieved	achieve	VERB
ajst-32576	101	16	an	an	DET
ajst-32576	101	17	os	os	NOUN
ajst-32576	101	18	of	of	ADP
ajst-32576	101	19	11	11	NUM
ajst-32576	101	20	months	month	NOUN
ajst-32576	101	21	in	in	ADP
ajst-32576	101	22	patients	patient	NOUN
ajst-32576	101	23	with	with	ADP
ajst-32576	101	24	baseline	baseline	ADJ
ajst-32576	101	25	brain	brain	NOUN
ajst-32576	101	26	metastases	metastasis	NOUN
ajst-32576	101	27	.	.	PUNCT
ajst-32576	102	1	as	as	ADP
ajst-32576	102	2	monotherapy	monotherapy	NOUN
ajst-32576	102	3	,	,	PUNCT
ajst-32576	102	4	atezolizumab	atezolizumab	NOUN
ajst-32576	102	5	also	also	ADV
ajst-32576	102	6	conferred	confer	VERB
ajst-32576	102	7	survival	survival	NOUN
ajst-32576	102	8	benefits	benefit	NOUN
ajst-32576	102	9	in	in	ADP
ajst-32576	102	10	this	this	DET
ajst-32576	102	11	subgroup	subgroup	NOUN
ajst-32576	102	12	,	,	PUNCT
ajst-32576	102	13	with	with	ADP
ajst-32576	102	14	good	good	ADJ
ajst-32576	102	15	overall	overall	ADJ
ajst-32576	102	16	tolerability	tolerability	NOUN
ajst-32576	102	17	[	[	X
ajst-32576	102	18	42	42	NUM
ajst-32576	102	19	,	,	PUNCT
ajst-32576	102	20	43	43	NUM
ajst-32576	102	21	]	]	PUNCT
ajst-32576	102	22	.	.	PUNCT
ajst-32576	103	1	ctla-4	ctla-4	PRON
ajst-32576	103	2	inhibitors	inhibitor	NOUN
ajst-32576	103	3	have	have	VERB
ajst-32576	103	4	limited	limit	VERB
ajst-32576	103	5	efficacy	efficacy	NOUN
ajst-32576	103	6	as	as	ADP
ajst-32576	103	7	monotherapy	monotherapy	NOUN
ajst-32576	103	8	but	but	CCONJ
ajst-32576	103	9	demonstrate	demonstrate	VERB
ajst-32576	103	10	synergistic	synergistic	ADJ
ajst-32576	103	11	effect	effect	NOUN
ajst-32576	103	12	when	when	SCONJ
ajst-32576	103	13	combined	combine	VERB
ajst-32576	103	14	with	with	ADP
ajst-32576	103	15	pd-1	pd-1	ADP
ajst-32576	103	16	inhibitors	inhibitor	NOUN
ajst-32576	103	17	.	.	PUNCT
ajst-32576	104	1	for	for	ADP
ajst-32576	104	2	instance	instance	NOUN
ajst-32576	104	3	,	,	PUNCT
ajst-32576	104	4	the	the	DET
ajst-32576	104	5	combination	combination	NOUN
ajst-32576	104	6	of	of	ADP
ajst-32576	104	7	nivolumab	nivolumab	NOUN
ajst-32576	104	8	and	and	CCONJ
ajst-32576	104	9	ipilimumab	ipilimumab	NOUN
ajst-32576	104	10	resulted	result	VERB
ajst-32576	104	11	in	in	ADP
ajst-32576	104	12	an	an	DET
ajst-32576	104	13	mos	mos	NOUN
ajst-32576	104	14	of	of	ADP
ajst-32576	104	15	17	17	NUM
ajst-32576	104	16	months	month	NOUN
ajst-32576	104	17	in	in	ADP
ajst-32576	104	18	patients	patient	NOUN
ajst-32576	104	19	with	with	ADP
ajst-32576	104	20	brain	brain	NOUN
ajst-32576	104	21	metastases	metastasis	NOUN
ajst-32576	104	22	,	,	PUNCT
ajst-32576	104	23	outperforming	outperform	VERB
ajst-32576	104	24	single	single	ADJ
ajst-32576	104	25	-	-	PUNCT
ajst-32576	104	26	agent	agent	NOUN
ajst-32576	104	27	regimens	regimen	NOUN
ajst-32576	104	28	[	[	X
ajst-32576	104	29	44	44	NUM
ajst-32576	104	30	]	]	PUNCT
ajst-32576	104	31	.	.	PUNCT
ajst-32576	105	1	in	in	ADP
ajst-32576	105	2	conclusion	conclusion	NOUN
ajst-32576	105	3	,	,	PUNCT
ajst-32576	105	4	representative	representative	ADJ
ajst-32576	105	5	studies	study	NOUN
ajst-32576	105	6	such	such	ADJ
ajst-32576	105	7	as	as	ADP
ajst-32576	105	8	the	the	DET
ajst-32576	105	9	keynote	keynote	PROPN
ajst-32576	105	10	series	series	NOUN
ajst-32576	105	11	and	and	CCONJ
ajst-32576	105	12	checkmate	checkmate	VERB
ajst-32576	105	13	227	227	NUM
ajst-32576	105	14	highlight	highlight	NOUN
ajst-32576	105	15	that	that	SCONJ
ajst-32576	105	16	immunotherapy	immunotherapy	NOUN
ajst-32576	105	17	can	can	AUX
ajst-32576	105	18	induce	induce	VERB
ajst-32576	105	19	durable	durable	ADJ
ajst-32576	105	20	intracranial	intracranial	ADJ
ajst-32576	105	21	and	and	CCONJ
ajst-32576	105	22	extracranial	extracranial	ADJ
ajst-32576	105	23	responses	response	NOUN
ajst-32576	105	24	in	in	ADP
ajst-32576	105	25	selected	select	VERB
ajst-32576	105	26	patients	patient	NOUN
ajst-32576	105	27	with	with	ADP
ajst-32576	105	28	nsclc	nsclc	NOUN
ajst-32576	105	29	brain	brain	NOUN
ajst-32576	105	30	metastases	metastasis	NOUN
ajst-32576	105	31	,	,	PUNCT
ajst-32576	105	32	offering	offer	VERB
ajst-32576	105	33	the	the	DET
ajst-32576	105	34	potential	potential	NOUN
ajst-32576	105	35	for	for	ADP
ajst-32576	105	36	long	long	ADJ
ajst-32576	105	37	-	-	PUNCT
ajst-32576	105	38	term	term	NOUN
ajst-32576	105	39	survival	survival	NOUN
ajst-32576	105	40	.	.	PUNCT
ajst-32576	106	1	3.2	3.2	NUM
ajst-32576	106	2	combined	combine	VERB
ajst-32576	106	3	therapy	therapy	NOUN
ajst-32576	106	4	combined	combine	VERB
ajst-32576	106	5	therapy	therapy	NOUN
ajst-32576	106	6	plays	play	VERB
ajst-32576	106	7	an	an	DET
ajst-32576	106	8	important	important	ADJ
ajst-32576	106	9	role	role	NOUN
ajst-32576	106	10	in	in	ADP
ajst-32576	106	11	the	the	DET
ajst-32576	106	12	management	management	NOUN
ajst-32576	106	13	of	of	ADP
ajst-32576	106	14	nsclc	nsclc	NOUN
ajst-32576	106	15	brain	brain	NOUN
ajst-32576	106	16	metastases	metastasis	NOUN
ajst-32576	106	17	.	.	PUNCT
ajst-32576	107	1	monotherapy	monotherapy	NOUN
ajst-32576	107	2	has	have	VERB
ajst-32576	107	3	clear	clear	ADJ
ajst-32576	107	4	limitations	limitation	NOUN
ajst-32576	107	5	:	:	PUNCT
ajst-32576	107	6	although	although	SCONJ
ajst-32576	107	7	targeted	targeted	ADJ
ajst-32576	107	8	agents	agent	NOUN
ajst-32576	107	9	are	be	AUX
ajst-32576	107	10	effective	effective	ADJ
ajst-32576	107	11	,	,	PUNCT
ajst-32576	107	12	resistance	resistance	NOUN
ajst-32576	107	13	inevitably	inevitably	ADV
ajst-32576	107	14	224	224	NUM
ajst-32576	107	15	depelops	depelop	NOUN
ajst-32576	107	16	;	;	PUNCT
ajst-32576	107	17	chemotherapy	chemotherapy	NOUN
ajst-32576	107	18	and	and	CCONJ
ajst-32576	107	19	immunotherapy	immunotherapy	NOUN
ajst-32576	107	20	are	be	AUX
ajst-32576	107	21	hindered	hinder	VERB
ajst-32576	107	22	by	by	ADP
ajst-32576	107	23	bbb	bbb	PROPN
ajst-32576	107	24	penetration	penetration	NOUN
ajst-32576	107	25	;	;	PUNCT
ajst-32576	107	26	and	and	CCONJ
ajst-32576	107	27	radiotherapy	radiotherapy	NOUN
ajst-32576	107	28	is	be	AUX
ajst-32576	107	29	associated	associate	VERB
ajst-32576	107	30	with	with	ADP
ajst-32576	107	31	considerable	considerable	ADJ
ajst-32576	107	32	adverse	adverse	ADJ
ajst-32576	107	33	effects	effect	NOUN
ajst-32576	107	34	.	.	PUNCT
ajst-32576	108	1	by	by	ADP
ajst-32576	108	2	integrating	integrate	VERB
ajst-32576	108	3	different	different	ADJ
ajst-32576	108	4	treatment	treatment	NOUN
ajst-32576	108	5	modalities	modality	NOUN
ajst-32576	108	6	,	,	PUNCT
ajst-32576	108	7	combination	combination	NOUN
ajst-32576	108	8	strategies	strategy	NOUN
ajst-32576	108	9	can	can	AUX
ajst-32576	108	10	improve	improve	VERB
ajst-32576	108	11	intracranial	intracranial	ADJ
ajst-32576	108	12	control	control	NOUN
ajst-32576	108	13	rates	rate	NOUN
ajst-32576	108	14	,	,	PUNCT
ajst-32576	108	15	prolong	prolong	ADJ
ajst-32576	108	16	survival	survival	NOUN
ajst-32576	108	17	,	,	PUNCT
ajst-32576	108	18	and	and	CCONJ
ajst-32576	108	19	enhance	enhance	VERB
ajst-32576	108	20	overall	overall	ADJ
ajst-32576	108	21	prognosis	prognosis	NOUN
ajst-32576	108	22	.	.	PUNCT
ajst-32576	109	1	combining	combine	VERB
ajst-32576	109	2	tkis	tkis	NOUN
ajst-32576	109	3	directed	direct	VERB
ajst-32576	109	4	against	against	ADP
ajst-32576	109	5	the	the	DET
ajst-32576	109	6	same	same	ADJ
ajst-32576	109	7	molecular	molecular	ADJ
ajst-32576	109	8	target	target	NOUN
ajst-32576	109	9	results	result	NOUN
ajst-32576	109	10	in	in	ADP
ajst-32576	109	11	overlapping	overlap	VERB
ajst-32576	109	12	mechanisms	mechanism	NOUN
ajst-32576	109	13	,	,	PUNCT
ajst-32576	109	14	which	which	PRON
ajst-32576	109	15	increase	increase	VERB
ajst-32576	109	16	toxicity	toxicity	NOUN
ajst-32576	109	17	without	without	ADP
ajst-32576	109	18	conferring	confer	VERB
ajst-32576	109	19	meaningful	meaningful	ADJ
ajst-32576	109	20	benefits	benefit	NOUN
ajst-32576	109	21	.	.	PUNCT
ajst-32576	110	1	therefore	therefore	ADV
ajst-32576	110	2	,	,	PUNCT
ajst-32576	110	3	current	current	ADJ
ajst-32576	110	4	research	research	NOUN
ajst-32576	110	5	emphasizes	emphasize	VERB
ajst-32576	110	6	combinations	combination	NOUN
ajst-32576	110	7	targeting	target	VERB
ajst-32576	110	8	distinct	distinct	ADJ
ajst-32576	110	9	pathways	pathway	NOUN
ajst-32576	110	10	.	.	PUNCT
ajst-32576	111	1	for	for	ADP
ajst-32576	111	2	example	example	NOUN
ajst-32576	111	3	,	,	PUNCT
ajst-32576	111	4	met	meet	VERB
ajst-32576	111	5	amplification	amplification	NOUN
ajst-32576	111	6	is	be	AUX
ajst-32576	111	7	a	a	DET
ajst-32576	111	8	key	key	ADJ
ajst-32576	111	9	mechanism	mechanism	NOUN
ajst-32576	111	10	of	of	ADP
ajst-32576	111	11	resistance	resistance	NOUN
ajst-32576	111	12	to	to	ADP
ajst-32576	111	13	egfr	egfr	NOUN
ajst-32576	111	14	-	-	PUNCT
ajst-32576	111	15	tkis	tkis	NOUN
ajst-32576	111	16	.	.	PUNCT
ajst-32576	112	1	the	the	DET
ajst-32576	112	2	combination	combination	NOUN
ajst-32576	112	3	of	of	ADP
ajst-32576	112	4	tepotinib	tepotinib	NOUN
ajst-32576	112	5	and	and	CCONJ
ajst-32576	112	6	osimertinib	osimertinib	NOUN
ajst-32576	112	7	has	have	AUX
ajst-32576	112	8	been	be	AUX
ajst-32576	112	9	shown	show	VERB
ajst-32576	112	10	to	to	PART
ajst-32576	112	11	improve	improve	VERB
ajst-32576	112	12	the	the	DET
ajst-32576	112	13	iorr	iorr	NOUN
ajst-32576	112	14	in	in	ADP
ajst-32576	112	15	patients	patient	NOUN
ajst-32576	112	16	with	with	ADP
ajst-32576	112	17	baseline	baseline	ADJ
ajst-32576	112	18	brain	brain	NOUN
ajst-32576	112	19	metastases	metastasis	NOUN
ajst-32576	112	20	[	[	X
ajst-32576	112	21	45	45	NUM
ajst-32576	112	22	]	]	PUNCT
ajst-32576	112	23	.	.	PUNCT
ajst-32576	113	1	retrospective	retrospective	ADJ
ajst-32576	113	2	studies	study	NOUN
ajst-32576	113	3	of	of	ADP
ajst-32576	113	4	egfr	egfr	NOUN
ajst-32576	113	5	-	-	PUNCT
ajst-32576	113	6	tki	tki	NOUN
ajst-32576	113	7	combined	combine	VERB
ajst-32576	113	8	with	with	ADP
ajst-32576	113	9	vegfr	vegfr	NOUN
ajst-32576	113	10	-	-	PUNCT
ajst-32576	113	11	tki	tki	NOUN
ajst-32576	113	12	have	have	AUX
ajst-32576	113	13	reported	report	VERB
ajst-32576	113	14	an	an	DET
ajst-32576	113	15	mpfs	mpf	NOUN
ajst-32576	113	16	of	of	ADP
ajst-32576	113	17	18.8	18.8	NUM
ajst-32576	113	18	months	month	NOUN
ajst-32576	113	19	,	,	PUNCT
ajst-32576	113	20	while	while	SCONJ
ajst-32576	113	21	the	the	DET
ajst-32576	113	22	flalter	flalter	NOUN
ajst-32576	113	23	trial	trial	NOUN
ajst-32576	113	24	also	also	ADV
ajst-32576	113	25	demonstrated	demonstrate	VERB
ajst-32576	113	26	a	a	DET
ajst-32576	113	27	significant	significant	ADJ
ajst-32576	113	28	pfs	pfs	ADJ
ajst-32576	113	29	benefit	benefit	NOUN
ajst-32576	113	30	[	[	X
ajst-32576	113	31	46	46	NUM
ajst-32576	113	32	,	,	PUNCT
ajst-32576	113	33	47	47	NUM
ajst-32576	113	34	]	]	PUNCT
ajst-32576	113	35	.	.	PUNCT
ajst-32576	114	1	although	although	SCONJ
ajst-32576	114	2	this	this	DET
ajst-32576	114	3	approach	approach	NOUN
ajst-32576	114	4	shows	show	VERB
ajst-32576	114	5	promise	promise	NOUN
ajst-32576	114	6	for	for	ADP
ajst-32576	114	7	intracranial	intracranial	ADJ
ajst-32576	114	8	control	control	NOUN
ajst-32576	114	9	,	,	PUNCT
ajst-32576	114	10	its	its	PRON
ajst-32576	114	11	safety	safety	NOUN
ajst-32576	114	12	profile	profile	NOUN
ajst-32576	114	13	and	and	CCONJ
ajst-32576	114	14	long	long	ADJ
ajst-32576	114	15	-	-	PUNCT
ajst-32576	114	16	term	term	NOUN
ajst-32576	114	17	efficacy	efficacy	NOUN
ajst-32576	114	18	remain	remain	VERB
ajst-32576	114	19	to	to	PART
ajst-32576	114	20	be	be	AUX
ajst-32576	114	21	further	far	ADV
ajst-32576	114	22	validated	validate	VERB
ajst-32576	114	23	.	.	PUNCT
ajst-32576	115	1	the	the	DET
ajst-32576	115	2	combination	combination	NOUN
ajst-32576	115	3	of	of	ADP
ajst-32576	115	4	egfr	egfr	ADJ
ajst-32576	115	5	-	-	PUNCT
ajst-32576	115	6	tkis	tkis	NOUN
ajst-32576	115	7	and	and	CCONJ
ajst-32576	115	8	chemotherapy	chemotherapy	NOUN
ajst-32576	115	9	has	have	AUX
ajst-32576	115	10	also	also	ADV
ajst-32576	115	11	demonstrated	demonstrate	VERB
ajst-32576	115	12	clinical	clinical	ADJ
ajst-32576	115	13	benenfit	benenfit	NOUN
ajst-32576	115	14	,	,	PUNCT
ajst-32576	115	15	in	in	ADP
ajst-32576	115	16	patients	patient	NOUN
ajst-32576	115	17	with	with	ADP
ajst-32576	115	18	brain	brain	NOUN
ajst-32576	115	19	metastases	metastasis	NOUN
ajst-32576	115	20	,	,	PUNCT
ajst-32576	115	21	gefitinib	gefitinib	NOUN
ajst-32576	115	22	plus	plus	CCONJ
ajst-32576	115	23	chemotherapy	chemotherapy	NOUN
ajst-32576	115	24	prolonged	prolong	VERB
ajst-32576	115	25	mpfs	mpf	NOUN
ajst-32576	115	26	to	to	ADP
ajst-32576	115	27	16.3	16.3	NUM
ajst-32576	115	28	months	month	NOUN
ajst-32576	115	29	and	and	CCONJ
ajst-32576	115	30	the	the	DET
ajst-32576	115	31	mos	mos	NOUN
ajst-32576	115	32	to	to	ADP
ajst-32576	115	33	35.0	35.0	NUM
ajst-32576	115	34	months	month	NOUN
ajst-32576	115	35	[	[	X
ajst-32576	115	36	10	10	NUM
ajst-32576	115	37	]	]	PUNCT
ajst-32576	115	38	.	.	PUNCT
ajst-32576	116	1	similarly	similarly	ADV
ajst-32576	116	2	,	,	PUNCT
ajst-32576	116	3	osimertinib	osimertinib	NOUN
ajst-32576	116	4	combined	combine	VERB
ajst-32576	116	5	with	with	ADP
ajst-32576	116	6	chemotherapy	chemotherapy	NOUN
ajst-32576	116	7	yielded	yield	VERB
ajst-32576	116	8	an	an	DET
ajst-32576	116	9	mpfs	mpf	NOUN
ajst-32576	116	10	of	of	ADP
ajst-32576	116	11	24.9	24.9	NUM
ajst-32576	116	12	months	month	NOUN
ajst-32576	116	13	,	,	PUNCT
ajst-32576	116	14	which	which	PRON
ajst-32576	116	15	was	be	AUX
ajst-32576	116	16	significantly	significantly	ADV
ajst-32576	116	17	superior	superior	ADJ
ajst-32576	116	18	to	to	ADP
ajst-32576	116	19	osimertinib	osimertinib	NOUN
ajst-32576	116	20	monotherapy	monotherapy	NOUN
ajst-32576	116	21	[	[	X
ajst-32576	116	22	14	14	NUM
ajst-32576	116	23	]	]	PUNCT
ajst-32576	116	24	.	.	PUNCT
ajst-32576	117	1	however	however	ADV
ajst-32576	117	2	,	,	PUNCT
ajst-32576	117	3	the	the	DET
ajst-32576	117	4	incidence	incidence	NOUN
ajst-32576	117	5	of	of	ADP
ajst-32576	117	6	grade	grade	NOUN
ajst-32576	117	7	≥3	≥3	PROPN
ajst-32576	117	8	adverse	adverse	ADJ
ajst-32576	117	9	events	event	NOUN
ajst-32576	117	10	increased	increase	VERB
ajst-32576	117	11	to	to	ADP
ajst-32576	117	12	64	64	NUM
ajst-32576	117	13	%	%	NOUN
ajst-32576	117	14	in	in	ADP
ajst-32576	117	15	the	the	DET
ajst-32576	117	16	combination	combination	NOUN
ajst-32576	117	17	group	group	NOUN
ajst-32576	117	18	,	,	PUNCT
ajst-32576	117	19	presominantly	presominantly	ADV
ajst-32576	117	20	hematologic	hematologic	NOUN
ajst-32576	117	21	and	and	CCONJ
ajst-32576	117	22	cardiac	cardiac	ADJ
ajst-32576	117	23	toxicities	toxicity	NOUN
ajst-32576	117	24	.	.	PUNCT
ajst-32576	118	1	such	such	ADJ
ajst-32576	118	2	regimens	regimen	NOUN
ajst-32576	118	3	may	may	AUX
ajst-32576	118	4	be	be	AUX
ajst-32576	118	5	more	more	ADV
ajst-32576	118	6	appropriate	appropriate	ADJ
ajst-32576	118	7	for	for	ADP
ajst-32576	118	8	patients	patient	NOUN
ajst-32576	118	9	with	with	ADP
ajst-32576	118	10	a	a	DET
ajst-32576	118	11	high	high	ADJ
ajst-32576	118	12	tumor	tumor	NOUN
ajst-32576	118	13	burden	burden	NOUN
ajst-32576	118	14	or	or	CCONJ
ajst-32576	118	15	those	those	PRON
ajst-32576	118	16	who	who	PRON
ajst-32576	118	17	have	have	AUX
ajst-32576	118	18	not	not	PART
ajst-32576	118	19	received	receive	VERB
ajst-32576	118	20	prior	prior	ADJ
ajst-32576	118	21	local	local	ADJ
ajst-32576	118	22	therapy	therapy	NOUN
ajst-32576	118	23	.	.	PUNCT
ajst-32576	119	1	combining	combine	VERB
ajst-32576	119	2	tkis	tkis	NOUN
ajst-32576	119	3	with	with	ADP
ajst-32576	119	4	radiotherapy	radiotherapy	NOUN
ajst-32576	119	5	can	can	AUX
ajst-32576	119	6	further	far	ADV
ajst-32576	119	7	enhance	enhance	VERB
ajst-32576	119	8	local	local	ADJ
ajst-32576	119	9	control	control	NOUN
ajst-32576	119	10	.	.	PUNCT
ajst-32576	120	1	a	a	DET
ajst-32576	120	2	meta	meta	ADJ
ajst-32576	120	3	-	-	PUNCT
ajst-32576	120	4	analysis	analysis	NOUN
ajst-32576	120	5	revealed	reveal	VERB
ajst-32576	120	6	that	that	SCONJ
ajst-32576	120	7	third	third	ADJ
ajst-32576	120	8	-	-	PUNCT
ajst-32576	120	9	generation	generation	NOUN
ajst-32576	120	10	tkis	tkis	NOUN
ajst-32576	120	11	plus	plus	CCONJ
ajst-32576	120	12	radiotherapy	radiotherapy	NOUN
ajst-32576	120	13	significantly	significantly	ADV
ajst-32576	120	14	improved	improve	VERB
ajst-32576	120	15	intracranial	intracranial	ADJ
ajst-32576	120	16	disease	disease	NOUN
ajst-32576	120	17	control	control	NOUN
ajst-32576	120	18	and	and	CCONJ
ajst-32576	120	19	os	os	NOUN
ajst-32576	121	1	[	[	X
ajst-32576	121	2	48	48	NUM
ajst-32576	121	3	]	]	PUNCT
ajst-32576	121	4	.	.	PUNCT
ajst-32576	122	1	the	the	DET
ajst-32576	122	2	urbo	urbo	ADJ
ajst-32576	122	3	-	-	PUNCT
ajst-32576	122	4	nsclc	nsclc	NOUN
ajst-32576	122	5	study	study	NOUN
ajst-32576	122	6	suggested	suggest	VERB
ajst-32576	122	7	that	that	SCONJ
ajst-32576	122	8	combining	combine	VERB
ajst-32576	122	9	tki	tki	NOUN
ajst-32576	122	10	with	with	ADP
ajst-32576	122	11	srs	srs	PROPN
ajst-32576	122	12	increased	increase	VERB
ajst-32576	122	13	local	local	ADJ
ajst-32576	122	14	control	control	NOUN
ajst-32576	122	15	rate	rate	NOUN
ajst-32576	122	16	in	in	ADP
ajst-32576	122	17	patients	patient	NOUN
ajst-32576	122	18	with	with	ADP
ajst-32576	122	19	large	large	ADJ
ajst-32576	122	20	lesions	lesion	NOUN
ajst-32576	122	21	[	[	X
ajst-32576	122	22	49	49	NUM
ajst-32576	122	23	]	]	PUNCT
ajst-32576	122	24	.	.	PUNCT
ajst-32576	123	1	nevertheless	nevertheless	ADV
ajst-32576	123	2	,	,	PUNCT
ajst-32576	123	3	study	study	NOUN
ajst-32576	123	4	outcomes	outcome	NOUN
ajst-32576	123	5	remain	remain	VERB
ajst-32576	123	6	inconsistent	inconsistent	ADJ
ajst-32576	123	7	,	,	PUNCT
ajst-32576	123	8	and	and	CCONJ
ajst-32576	123	9	treatment	treatment	NOUN
ajst-32576	123	10	-	-	PUNCT
ajst-32576	123	11	related	relate	VERB
ajst-32576	123	12	toxicity	toxicity	NOUN
ajst-32576	123	13	is	be	AUX
ajst-32576	123	14	increased	increase	VERB
ajst-32576	123	15	,	,	PUNCT
ajst-32576	123	16	underscoring	underscore	VERB
ajst-32576	123	17	the	the	DET
ajst-32576	123	18	importance	importance	NOUN
ajst-32576	123	19	of	of	ADP
ajst-32576	123	20	carful	carful	ADJ
ajst-32576	123	21	patient	patient	ADJ
ajst-32576	123	22	selection	selection	NOUN
ajst-32576	123	23	.	.	PUNCT
ajst-32576	124	1	in	in	ADP
ajst-32576	124	2	patients	patient	NOUN
ajst-32576	124	3	with	with	ADP
ajst-32576	124	4	egfr	egfr	ADJ
ajst-32576	124	5	mutations	mutation	NOUN
ajst-32576	124	6	,	,	PUNCT
ajst-32576	124	7	the	the	DET
ajst-32576	124	8	efficacy	efficacy	NOUN
ajst-32576	124	9	of	of	ADP
ajst-32576	124	10	pd-1	pd-1	ADP
ajst-32576	124	11	/	/	SYM
ajst-32576	124	12	pd	pd	ADJ
ajst-32576	124	13	-	-	PUNCT
ajst-32576	124	14	l1	l1	PROPN
ajst-32576	124	15	inhibitors	inhibitor	NOUN
ajst-32576	124	16	is	be	AUX
ajst-32576	124	17	limited	limit	VERB
ajst-32576	124	18	.	.	PUNCT
ajst-32576	125	1	the	the	DET
ajst-32576	125	2	combination	combination	NOUN
ajst-32576	125	3	of	of	ADP
ajst-32576	125	4	tkis	tkis	NOUN
ajst-32576	125	5	with	with	ADP
ajst-32576	125	6	icis	icis	PROPN
ajst-32576	125	7	has	have	AUX
ajst-32576	125	8	not	not	PART
ajst-32576	125	9	demonstrate	demonstrate	VERB
ajst-32576	125	10	consistent	consistent	ADJ
ajst-32576	125	11	clinical	clinical	ADJ
ajst-32576	125	12	benefit	benefit	NOUN
ajst-32576	125	13	,	,	PUNCT
ajst-32576	125	14	with	with	ADP
ajst-32576	125	15	low	low	ADJ
ajst-32576	125	16	orr	orr	PROPN
ajst-32576	125	17	and	and	CCONJ
ajst-32576	125	18	high	high	ADJ
ajst-32576	125	19	rates	rate	NOUN
ajst-32576	125	20	of	of	ADP
ajst-32576	125	21	severe	severe	ADJ
ajst-32576	125	22	adverse	adverse	ADJ
ajst-32576	125	23	events	event	NOUN
ajst-32576	125	24	.	.	PUNCT
ajst-32576	126	1	as	as	ADP
ajst-32576	126	2	such	such	ADJ
ajst-32576	126	3	,	,	PUNCT
ajst-32576	126	4	this	this	DET
ajst-32576	126	5	approach	approach	NOUN
ajst-32576	126	6	is	be	AUX
ajst-32576	126	7	not	not	PART
ajst-32576	126	8	recommended	recommend	VERB
ajst-32576	126	9	for	for	ADP
ajst-32576	126	10	routine	routine	ADJ
ajst-32576	126	11	use	use	NOUN
ajst-32576	126	12	in	in	ADP
ajst-32576	126	13	patients	patient	NOUN
ajst-32576	126	14	with	with	ADP
ajst-32576	126	15	nsclc	nsclc	NOUN
ajst-32576	126	16	-	-	PUNCT
ajst-32576	126	17	bm	bm	NOUN
ajst-32576	127	1	[	[	X
ajst-32576	127	2	50	50	NUM
ajst-32576	127	3	]	]	PUNCT
ajst-32576	127	4	.	.	PUNCT
ajst-32576	128	1	anti	anti	ADJ
ajst-32576	128	2	-	-	ADJ
ajst-32576	128	3	vascular	vascular	ADJ
ajst-32576	128	4	endothelial	endothelial	ADJ
ajst-32576	128	5	growth	growth	NOUN
ajst-32576	128	6	factor	factor	NOUN
ajst-32576	128	7	(	(	PUNCT
ajst-32576	128	8	vegf	vegf	PROPN
ajst-32576	128	9	)	)	PUNCT
ajst-32576	128	10	drugs	drug	NOUN
ajst-32576	128	11	may	may	AUX
ajst-32576	128	12	normalized	normalize	VERB
ajst-32576	128	13	tumor	tumor	NOUN
ajst-32576	128	14	vasculated	vasculate	VERB
ajst-32576	128	15	and	and	CCONJ
ajst-32576	128	16	improve	improve	VERB
ajst-32576	128	17	drug	drug	NOUN
ajst-32576	128	18	delivery	delivery	NOUN
ajst-32576	128	19	.	.	PUNCT
ajst-32576	129	1	the	the	DET
ajst-32576	129	2	combination	combination	NOUN
ajst-32576	129	3	of	of	ADP
ajst-32576	129	4	erlotinib	erlotinib	NOUN
ajst-32576	129	5	and	and	CCONJ
ajst-32576	129	6	bevacizumab	bevacizumab	NOUN
ajst-32576	129	7	was	be	AUX
ajst-32576	129	8	shown	show	VERB
ajst-32576	129	9	to	to	PART
ajst-32576	129	10	extend	extend	VERB
ajst-32576	129	11	both	both	DET
ajst-32576	129	12	mpfs	mpf	NOUN
ajst-32576	129	13	and	and	CCONJ
ajst-32576	129	14	mos	mos	PROPN
ajst-32576	129	15	.	.	PROPN
ajst-32576	130	1	similarly	similarly	ADV
ajst-32576	130	2	,	,	PUNCT
ajst-32576	130	3	osimertinib	osimertinib	NOUN
ajst-32576	130	4	plus	plus	CCONJ
ajst-32576	130	5	bevacizumab	bevacizumab	NOUN
ajst-32576	130	6	as	as	ADP
ajst-32576	130	7	first	first	ADJ
ajst-32576	130	8	-	-	PUNCT
ajst-32576	130	9	line	line	NOUN
ajst-32576	130	10	treatment	treatment	NOUN
ajst-32576	130	11	achieved	achieve	VERB
ajst-32576	130	12	a	a	DET
ajst-32576	130	13	cns	cns	NOUN
ajst-32576	130	14	mpfs	mpf	NOUN
ajst-32576	130	15	of	of	ADP
ajst-32576	130	16	26.7	26.7	NUM
ajst-32576	130	17	months	month	NOUN
ajst-32576	130	18	,	,	PUNCT
ajst-32576	130	19	while	while	SCONJ
ajst-32576	130	20	combinations	combination	NOUN
ajst-32576	130	21	of	of	ADP
ajst-32576	130	22	alk	alk	NOUN
ajst-32576	130	23	inhibitor	inhibitor	NOUN
ajst-32576	130	24	with	with	ADP
ajst-32576	130	25	bevacizumab	bevacizumab	NOUN
ajst-32576	130	26	also	also	ADV
ajst-32576	130	27	demonstrated	demonstrate	VERB
ajst-32576	130	28	improve	improve	VERB
ajst-32576	130	29	disease	disease	NOUN
ajst-32576	130	30	control	control	NOUN
ajst-32576	131	1	[	[	X
ajst-32576	131	2	11	11	NUM
ajst-32576	131	3	,	,	PUNCT
ajst-32576	131	4	51	51	NUM
ajst-32576	131	5	,	,	PUNCT
ajst-32576	131	6	52	52	NUM
ajst-32576	131	7	]	]	PUNCT
ajst-32576	131	8	.	.	PUNCT
ajst-32576	132	1	however	however	ADV
ajst-32576	132	2	,	,	PUNCT
ajst-32576	132	3	attention	attention	NOUN
ajst-32576	132	4	must	must	AUX
ajst-32576	132	5	be	be	AUX
ajst-32576	132	6	paid	pay	VERB
ajst-32576	132	7	to	to	ADP
ajst-32576	132	8	the	the	DET
ajst-32576	132	9	risks	risk	NOUN
ajst-32576	132	10	of	of	ADP
ajst-32576	132	11	bleeding	bleeding	NOUN
ajst-32576	132	12	and	and	CCONJ
ajst-32576	132	13	vascular	vascular	NOUN
ajst-32576	132	14	-	-	PUNCT
ajst-32576	132	15	related	relate	VERB
ajst-32576	132	16	toxicities	toxicity	NOUN
ajst-32576	132	17	.	.	PUNCT
ajst-32576	133	1	4	4	X
ajst-32576	133	2	.	.	X
ajst-32576	133	3	discussion	discussion	NOUN
ajst-32576	133	4	lung	lung	NOUN
ajst-32576	133	5	cancer	cancer	NOUN
ajst-32576	133	6	remains	remain	VERB
ajst-32576	133	7	one	one	NUM
ajst-32576	133	8	of	of	ADP
ajst-32576	133	9	the	the	DET
ajst-32576	133	10	most	most	ADV
ajst-32576	133	11	common	common	ADJ
ajst-32576	133	12	malignancies	malignancy	NOUN
ajst-32576	133	13	worldwide	worldwide	ADV
ajst-32576	133	14	.	.	PUNCT
ajst-32576	134	1	with	with	ADP
ajst-32576	134	2	the	the	DET
ajst-32576	134	3	rising	rise	VERB
ajst-32576	134	4	incidence	incidence	NOUN
ajst-32576	134	5	of	of	ADP
ajst-32576	134	6	brain	brain	NOUN
ajst-32576	134	7	metastases	metastasis	NOUN
ajst-32576	134	8	,	,	PUNCT
ajst-32576	134	9	treatment	treatment	NOUN
ajst-32576	134	10	strategies	strategy	NOUN
ajst-32576	134	11	have	have	AUX
ajst-32576	134	12	continued	continue	VERB
ajst-32576	134	13	to	to	PART
ajst-32576	134	14	evolve	evolve	VERB
ajst-32576	134	15	.	.	PUNCT
ajst-32576	135	1	third	third	ADJ
ajst-32576	135	2	-	-	PUNCT
ajst-32576	135	3	generation	generation	NOUN
ajst-32576	135	4	egfr	egfr	NOUN
ajst-32576	135	5	-	-	PUNCT
ajst-32576	135	6	tkis	tkis	NOUN
ajst-32576	135	7	such	such	ADJ
ajst-32576	135	8	as	as	ADP
ajst-32576	135	9	osimertinib	osimertinib	NOUN
ajst-32576	135	10	and	and	CCONJ
ajst-32576	135	11	alk	alk	PROPN
ajst-32576	135	12	-	-	PUNCT
ajst-32576	135	13	tkis	tkis	NOUN
ajst-32576	135	14	such	such	ADJ
ajst-32576	135	15	as	as	ADP
ajst-32576	135	16	lorlatinib	lorlatinib	NOUN
ajst-32576	135	17	have	have	AUX
ajst-32576	135	18	significantly	significantly	ADV
ajst-32576	135	19	improved	improve	VERB
ajst-32576	135	20	intracranial	intracranial	ADJ
ajst-32576	135	21	disease	disease	NOUN
ajst-32576	135	22	control	control	NOUN
ajst-32576	135	23	rates	rate	NOUN
ajst-32576	135	24	and	and	CCONJ
ajst-32576	135	25	overall	overall	ADJ
ajst-32576	135	26	survival	survival	NOUN
ajst-32576	135	27	due	due	ADP
ajst-32576	135	28	to	to	ADP
ajst-32576	135	29	their	their	PRON
ajst-32576	135	30	strong	strong	ADJ
ajst-32576	135	31	bbb	bbb	NOUN
ajst-32576	135	32	penetration	penetration	NOUN
ajst-32576	135	33	and	and	CCONJ
ajst-32576	135	34	high	high	ADJ
ajst-32576	135	35	intracranial	intracranial	ADJ
ajst-32576	135	36	activity	activity	NOUN
ajst-32576	135	37	,	,	PUNCT
ajst-32576	135	38	but	but	CCONJ
ajst-32576	135	39	acquired	acquire	VERB
ajst-32576	135	40	drug	drug	NOUN
ajst-32576	135	41	resistance	resistance	NOUN
ajst-32576	135	42	remains	remain	VERB
ajst-32576	135	43	a	a	DET
ajst-32576	135	44	major	major	ADJ
ajst-32576	135	45	challenge	challenge	NOUN
ajst-32576	135	46	.	.	PUNCT
ajst-32576	136	1	fourth	fourth	ADJ
ajst-32576	136	2	-	-	PUNCT
ajst-32576	136	3	generation	generation	NOUN
ajst-32576	136	4	egfr	egfr	NOUN
ajst-32576	136	5	-	-	PUNCT
ajst-32576	136	6	tkis	tkis	NOUN
ajst-32576	136	7	,	,	PUNCT
ajst-32576	136	8	such	such	ADJ
ajst-32576	136	9	as	as	ADP
ajst-32576	136	10	blu-945	blu-945	NOUN
ajst-32576	136	11	,	,	PUNCT
ajst-32576	136	12	have	have	AUX
ajst-32576	136	13	shown	show	VERB
ajst-32576	136	14	preliminary	preliminary	ADJ
ajst-32576	136	15	anti	anti	ADJ
ajst-32576	136	16	-	-	ADJ
ajst-32576	136	17	tumor	tumor	ADJ
ajst-32576	136	18	activity	activity	NOUN
ajst-32576	136	19	in	in	ADP
ajst-32576	136	20	early	early	ADJ
ajst-32576	136	21	clinical	clinical	ADJ
ajst-32576	136	22	trials	trial	NOUN
ajst-32576	136	23	and	and	CCONJ
ajst-32576	136	24	may	may	AUX
ajst-32576	136	25	be	be	AUX
ajst-32576	136	26	combined	combine	VERB
ajst-32576	136	27	with	with	ADP
ajst-32576	136	28	osimertinib	osimertinib	NOUN
ajst-32576	136	29	,	,	PUNCT
ajst-32576	136	30	yet	yet	CCONJ
ajst-32576	136	31	their	their	PRON
ajst-32576	136	32	safety	safety	NOUN
ajst-32576	136	33	and	and	CCONJ
ajst-32576	136	34	intracranial	intracranial	ADJ
ajst-32576	136	35	efficacy	efficacy	NOUN
ajst-32576	136	36	still	still	ADV
ajst-32576	136	37	require	require	VERB
ajst-32576	136	38	further	further	ADJ
ajst-32576	136	39	validation	validation	NOUN
ajst-32576	137	1	[	[	X
ajst-32576	137	2	53	53	NUM
ajst-32576	137	3	]	]	PUNCT
ajst-32576	137	4	.	.	PUNCT
ajst-32576	138	1	radiotherapy	radiotherapy	NOUN
ajst-32576	138	2	remians	remian	VERB
ajst-32576	138	3	indispensable	indispensable	ADJ
ajst-32576	138	4	for	for	ADP
ajst-32576	138	5	local	local	ADJ
ajst-32576	138	6	control	control	NOUN
ajst-32576	138	7	,	,	PUNCT
ajst-32576	138	8	sympton	sympton	NOUN
ajst-32576	138	9	relief	relief	NOUN
ajst-32576	138	10	,	,	PUNCT
ajst-32576	138	11	and	and	CCONJ
ajst-32576	138	12	prevention	prevention	NOUN
ajst-32576	138	13	of	of	ADP
ajst-32576	138	14	new	new	ADJ
ajst-32576	138	15	lesions	lesion	NOUN
ajst-32576	138	16	.	.	PUNCT
ajst-32576	139	1	srs	srs	PROPN
ajst-32576	139	2	,	,	PUNCT
ajst-32576	139	3	with	with	ADP
ajst-32576	139	4	its	its	PRON
ajst-32576	139	5	high	high	ADJ
ajst-32576	139	6	precision	precision	NOUN
ajst-32576	139	7	and	and	CCONJ
ajst-32576	139	8	ability	ability	NOUN
ajst-32576	139	9	to	to	PART
ajst-32576	139	10	spare	spare	VERB
ajst-32576	139	11	normal	normal	ADJ
ajst-32576	139	12	brain	brain	NOUN
ajst-32576	139	13	tissue	tissue	NOUN
ajst-32576	139	14	,	,	PUNCT
ajst-32576	139	15	has	have	AUX
ajst-32576	139	16	become	become	VERB
ajst-32576	139	17	the	the	DET
ajst-32576	139	18	standard	standard	NOUN
ajst-32576	139	19	for	for	ADP
ajst-32576	139	20	patients	patient	NOUN
ajst-32576	139	21	with	with	ADP
ajst-32576	139	22	oligometastases	oligometastase	NOUN
ajst-32576	139	23	,	,	PUNCT
ajst-32576	139	24	while	while	SCONJ
ajst-32576	139	25	wbrt	wbrt	PROPN
ajst-32576	139	26	is	be	AUX
ajst-32576	139	27	reversed	reverse	VERB
ajst-32576	139	28	for	for	ADP
ajst-32576	139	29	diffuse	diffuse	NOUN
ajst-32576	139	30	or	or	CCONJ
ajst-32576	139	31	multiple	multiple	ADJ
ajst-32576	139	32	brain	brain	NOUN
ajst-32576	139	33	metastases	metastasis	NOUN
ajst-32576	139	34	,	,	PUNCT
ajst-32576	139	35	albeit	albeit	SCONJ
ajst-32576	139	36	at	at	ADP
ajst-32576	139	37	the	the	DET
ajst-32576	139	38	cost	cost	NOUN
ajst-32576	139	39	of	of	ADP
ajst-32576	139	40	a	a	DET
ajst-32576	139	41	high	high	ADJ
ajst-32576	139	42	risk	risk	NOUN
ajst-32576	139	43	of	of	ADP
ajst-32576	139	44	cognitive	cognitive	ADJ
ajst-32576	139	45	decline	decline	NOUN
ajst-32576	139	46	.	.	PUNCT
ajst-32576	140	1	memory	memory	NOUN
ajst-32576	140	2	-	-	PUNCT
ajst-32576	140	3	preserving	preserve	VERB
ajst-32576	140	4	wbrt	wbrt	NOUN
ajst-32576	140	5	can	can	AUX
ajst-32576	140	6	mitigate	mitigate	VERB
ajst-32576	140	7	neurotoxicity	neurotoxicity	NOUN
ajst-32576	140	8	,	,	PUNCT
ajst-32576	140	9	and	and	CCONJ
ajst-32576	140	10	hypofractionated	hypofractionate	VERB
ajst-32576	140	11	srs	srs	PROPN
ajst-32576	140	12	may	may	AUX
ajst-32576	140	13	be	be	AUX
ajst-32576	140	14	applied	apply	VERB
ajst-32576	140	15	to	to	ADP
ajst-32576	140	16	larger	large	ADJ
ajst-32576	140	17	lesions	lesion	NOUN
ajst-32576	140	18	or	or	CCONJ
ajst-32576	140	19	those	those	PRON
ajst-32576	140	20	located	locate	VERB
ajst-32576	140	21	in	in	ADP
ajst-32576	140	22	critical	critical	ADJ
ajst-32576	140	23	brain	brain	NOUN
ajst-32576	140	24	regions	region	NOUN
ajst-32576	140	25	.	.	PUNCT
ajst-32576	141	1	225	225	NUM
ajst-32576	141	2	for	for	ADP
ajst-32576	141	3	patients	patient	NOUN
ajst-32576	141	4	without	without	ADP
ajst-32576	141	5	actionable	actionable	ADJ
ajst-32576	141	6	driver	driver	NOUN
ajst-32576	141	7	gene	gene	NOUN
ajst-32576	141	8	mutations	mutation	NOUN
ajst-32576	141	9	but	but	CCONJ
ajst-32576	141	10	with	with	ADP
ajst-32576	141	11	high	high	ADJ
ajst-32576	141	12	pd	pd	PROPN
ajst-32576	141	13	-	-	PUNCT
ajst-32576	141	14	l1	l1	PROPN
ajst-32576	141	15	expression	expression	NOUN
ajst-32576	141	16	,	,	PUNCT
ajst-32576	141	17	ici	ici	PROPN
ajst-32576	141	18	,	,	PUNCT
ajst-32576	141	19	either	either	CCONJ
ajst-32576	141	20	alone	alone	ADV
ajst-32576	141	21	or	or	CCONJ
ajst-32576	141	22	combined	combine	VERB
ajst-32576	141	23	with	with	ADP
ajst-32576	141	24	chemotherapy	chemotherapy	NOUN
ajst-32576	141	25	or	or	CCONJ
ajst-32576	141	26	ctla-4	ctla-4	NOUN
ajst-32576	141	27	inhibitors	inhibitor	NOUN
ajst-32576	141	28	,	,	PUNCT
ajst-32576	141	29	can	can	AUX
ajst-32576	141	30	provide	provide	VERB
ajst-32576	141	31	durable	durable	ADJ
ajst-32576	141	32	systemic	systemic	ADJ
ajst-32576	141	33	and	and	CCONJ
ajst-32576	141	34	intracranial	intracranial	ADJ
ajst-32576	141	35	responses	response	NOUN
ajst-32576	141	36	.	.	PUNCT
ajst-32576	142	1	however	however	ADV
ajst-32576	142	2	,	,	PUNCT
ajst-32576	142	3	patients	patient	NOUN
ajst-32576	142	4	with	with	ADP
ajst-32576	142	5	egfr	egfr	NOUN
ajst-32576	142	6	or	or	CCONJ
ajst-32576	142	7	alk	alk	VERB
ajst-32576	142	8	alterations	alteration	NOUN
ajst-32576	142	9	derive	derive	VERB
ajst-32576	142	10	limited	limited	ADJ
ajst-32576	142	11	benefit	benefit	NOUN
ajst-32576	142	12	from	from	ADP
ajst-32576	142	13	icis	icis	PROPN
ajst-32576	142	14	,	,	PUNCT
ajst-32576	142	15	and	and	CCONJ
ajst-32576	142	16	evidence	evidence	NOUN
ajst-32576	142	17	for	for	ADP
ajst-32576	142	18	combining	combine	VERB
ajst-32576	142	19	icis	icis	NOUN
ajst-32576	142	20	with	with	ADP
ajst-32576	142	21	tkis	tkis	PROPN
ajst-32576	142	22	is	be	AUX
ajst-32576	142	23	scarce	scarce	ADJ
ajst-32576	142	24	and	and	CCONJ
ajst-32576	142	25	associated	associate	VERB
ajst-32576	142	26	with	with	ADP
ajst-32576	142	27	significant	significant	ADJ
ajst-32576	142	28	toxicity	toxicity	NOUN
ajst-32576	142	29	,	,	PUNCT
ajst-32576	142	30	making	make	VERB
ajst-32576	142	31	this	this	DET
ajst-32576	142	32	approach	approach	NOUN
ajst-32576	142	33	not	not	PART
ajst-32576	142	34	currently	currently	ADV
ajst-32576	142	35	recommended	recommend	VERB
ajst-32576	142	36	.	.	PUNCT
ajst-32576	143	1	systemic	systemic	ADJ
ajst-32576	143	2	chemotherapy	chemotherapy	NOUN
ajst-32576	143	3	is	be	AUX
ajst-32576	143	4	limited	limit	VERB
ajst-32576	143	5	by	by	ADP
ajst-32576	143	6	poor	poor	ADJ
ajst-32576	143	7	intracranial	intracranial	ADJ
ajst-32576	143	8	response	response	NOUN
ajst-32576	143	9	rates	rate	NOUN
ajst-32576	143	10	due	due	ADP
ajst-32576	143	11	to	to	ADP
ajst-32576	143	12	the	the	DET
ajst-32576	143	13	bbb	bbb	PROPN
ajst-32576	143	14	.	.	PUNCT
ajst-32576	144	1	pemetrexed	pemetrexed	PROPN
ajst-32576	144	2	and	and	CCONJ
ajst-32576	144	3	platinum	platinum	NOUN
ajst-32576	144	4	-	-	PUNCT
ajst-32576	144	5	based	base	VERB
ajst-32576	144	6	regimens	regimen	NOUN
ajst-32576	144	7	can	can	AUX
ajst-32576	144	8	be	be	AUX
ajst-32576	144	9	combined	combine	VERB
ajst-32576	144	10	with	with	ADP
ajst-32576	144	11	tkis	tkis	NOUN
ajst-32576	144	12	or	or	CCONJ
ajst-32576	144	13	icis	icis	PROPN
ajst-32576	144	14	,	,	PUNCT
ajst-32576	144	15	but	but	CCONJ
ajst-32576	144	16	systemic	systemic	ADJ
ajst-32576	144	17	toxicity	toxicity	NOUN
ajst-32576	144	18	requires	require	VERB
ajst-32576	144	19	close	close	ADJ
ajst-32576	144	20	monitoring	monitoring	NOUN
ajst-32576	144	21	.	.	PUNCT
ajst-32576	145	1	intrathecal	intrathecal	ADJ
ajst-32576	145	2	therapy	therapy	NOUN
ajst-32576	145	3	is	be	AUX
ajst-32576	145	4	particularly	particularly	ADV
ajst-32576	145	5	important	important	ADJ
ajst-32576	145	6	for	for	ADP
ajst-32576	145	7	leptomeningeal	leptomeningeal	NOUN
ajst-32576	145	8	metastases	metastasis	NOUN
ajst-32576	145	9	,	,	PUNCT
ajst-32576	145	10	yet	yet	CCONJ
ajst-32576	145	11	its	its	PRON
ajst-32576	145	12	efficacy	efficacy	NOUN
ajst-32576	145	13	against	against	ADP
ajst-32576	145	14	parenchymal	parenchymal	ADJ
ajst-32576	145	15	metastases	metastasis	NOUN
ajst-32576	145	16	is	be	AUX
ajst-32576	145	17	modest	modest	ADJ
ajst-32576	145	18	,	,	PUNCT
ajst-32576	145	19	and	and	CCONJ
ajst-32576	145	20	it	it	PRON
ajst-32576	145	21	carries	carry	VERB
ajst-32576	145	22	risks	risk	NOUN
ajst-32576	145	23	of	of	ADP
ajst-32576	145	24	procedural	procedural	ADJ
ajst-32576	145	25	complications	complication	NOUN
ajst-32576	145	26	and	and	CCONJ
ajst-32576	145	27	neurotoxicity	neurotoxicity	NOUN
ajst-32576	145	28	.	.	PUNCT
ajst-32576	146	1	monotherapy	monotherapy	NOUN
ajst-32576	146	2	is	be	AUX
ajst-32576	146	3	often	often	ADV
ajst-32576	146	4	insufficient	insufficient	ADJ
ajst-32576	146	5	for	for	ADP
ajst-32576	146	6	durable	durable	ADJ
ajst-32576	146	7	disease	disease	NOUN
ajst-32576	146	8	control	control	NOUN
ajst-32576	146	9	,	,	PUNCT
ajst-32576	146	10	highlighting	highlight	VERB
ajst-32576	146	11	the	the	DET
ajst-32576	146	12	importance	importance	NOUN
ajst-32576	146	13	of	of	ADP
ajst-32576	146	14	combinaton	combinaton	NOUN
ajst-32576	146	15	strategies	strategy	NOUN
ajst-32576	146	16	.	.	PUNCT
ajst-32576	147	1	combining	combine	VERB
ajst-32576	147	2	targeted	target	VERB
ajst-32576	147	3	therapy	therapy	NOUN
ajst-32576	147	4	with	with	ADP
ajst-32576	147	5	chemotherapy	chemotherapy	NOUN
ajst-32576	147	6	can	can	AUX
ajst-32576	147	7	prolong	prolong	VERB
ajst-32576	147	8	pfs	pfs	PROPN
ajst-32576	147	9	and	and	CCONJ
ajst-32576	147	10	os	os	PROPN
ajst-32576	147	11	;	;	PUNCT
ajst-32576	147	12	pairing	pair	VERB
ajst-32576	147	13	targeted	target	VERB
ajst-32576	147	14	therapy	therapy	NOUN
ajst-32576	147	15	and	and	CCONJ
ajst-32576	147	16	anti	anti	ADJ
ajst-32576	147	17	-	-	ADJ
ajst-32576	147	18	angiogenic	angiogenic	ADJ
ajst-32576	147	19	agents	agent	NOUN
ajst-32576	147	20	may	may	AUX
ajst-32576	147	21	further	far	ADV
ajst-32576	147	22	improve	improve	VERB
ajst-32576	147	23	outcomes	outcome	NOUN
ajst-32576	147	24	,	,	PUNCT
ajst-32576	147	25	though	though	SCONJ
ajst-32576	147	26	at	at	ADP
ajst-32576	147	27	the	the	DET
ajst-32576	147	28	cost	cost	NOUN
ajst-32576	147	29	of	of	ADP
ajst-32576	147	30	increased	increase	VERB
ajst-32576	147	31	toxicity	toxicity	NOUN
ajst-32576	147	32	.	.	PUNCT
ajst-32576	148	1	the	the	DET
ajst-32576	148	2	benefit	benefit	NOUN
ajst-32576	148	3	of	of	ADP
ajst-32576	148	4	combining	combine	VERB
ajst-32576	148	5	targeted	target	VERB
ajst-32576	148	6	therapy	therapy	NOUN
ajst-32576	148	7	with	with	ADP
ajst-32576	148	8	radiotherapy	radiotherapy	NOUN
ajst-32576	148	9	depends	depend	VERB
ajst-32576	148	10	on	on	ADP
ajst-32576	148	11	lesion	lesion	NOUN
ajst-32576	148	12	size	size	NOUN
ajst-32576	148	13	and	and	CCONJ
ajst-32576	148	14	treatment	treatment	NOUN
ajst-32576	148	15	timing	timing	NOUN
ajst-32576	148	16	,	,	PUNCT
ajst-32576	148	17	requiring	require	VERB
ajst-32576	148	18	individualized	individualized	ADJ
ajst-32576	148	19	planning	planning	NOUN
ajst-32576	148	20	.	.	PUNCT
ajst-32576	149	1	by	by	ADP
ajst-32576	149	2	contrast	contrast	NOUN
ajst-32576	149	3	,	,	PUNCT
ajst-32576	149	4	combining	combine	VERB
ajst-32576	149	5	targeted	target	VERB
ajst-32576	149	6	therapy	therapy	NOUN
ajst-32576	149	7	with	with	ADP
ajst-32576	149	8	immunotherapy	immunotherapy	NOUN
ajst-32576	149	9	remains	remains	AUX
ajst-32576	149	10	poorly	poorly	ADV
ajst-32576	149	11	supported	support	VERB
ajst-32576	149	12	by	by	ADP
ajst-32576	149	13	current	current	ADJ
ajst-32576	149	14	evidence	evidence	NOUN
ajst-32576	149	15	and	and	CCONJ
ajst-32576	149	16	is	be	AUX
ajst-32576	149	17	accociated	accociate	VERB
ajst-32576	149	18	with	with	ADP
ajst-32576	149	19	high	high	ADJ
ajst-32576	149	20	toxicity	toxicity	NOUN
ajst-32576	149	21	,	,	PUNCT
ajst-32576	149	22	and	and	CCONJ
ajst-32576	149	23	thus	thus	ADV
ajst-32576	149	24	s	s	AUX
ajst-32576	149	25	not	not	PART
ajst-32576	149	26	recommended	recommend	VERB
ajst-32576	149	27	in	in	ADP
ajst-32576	149	28	routine	routine	ADJ
ajst-32576	149	29	practice	practice	NOUN
ajst-32576	149	30	.	.	PUNCT
ajst-32576	150	1	key	key	ADJ
ajst-32576	150	2	challenges	challenge	NOUN
ajst-32576	150	3	of	of	ADP
ajst-32576	150	4	combination	combination	NOUN
ajst-32576	150	5	therapy	therapy	NOUN
ajst-32576	150	6	include	include	VERB
ajst-32576	150	7	accurate	accurate	ADJ
ajst-32576	150	8	patient	patient	ADJ
ajst-32576	150	9	selection	selection	NOUN
ajst-32576	150	10	,	,	PUNCT
ajst-32576	150	11	optimizion	optimizion	NOUN
ajst-32576	150	12	of	of	ADP
ajst-32576	150	13	drug	drug	NOUN
ajst-32576	150	14	choice	choice	NOUN
ajst-32576	150	15	,	,	PUNCT
ajst-32576	150	16	and	and	CCONJ
ajst-32576	150	17	sequencing	sequencing	NOUN
ajst-32576	150	18	,	,	PUNCT
ajst-32576	150	19	as	as	ADV
ajst-32576	150	20	well	well	ADV
ajst-32576	150	21	as	as	ADP
ajst-32576	150	22	management	management	NOUN
ajst-32576	150	23	of	of	ADP
ajst-32576	150	24	cumulative	cumulative	ADJ
ajst-32576	150	25	toxicity	toxicity	NOUN
ajst-32576	150	26	and	and	CCONJ
ajst-32576	150	27	financial	financial	ADJ
ajst-32576	150	28	burden	burden	NOUN
ajst-32576	150	29	.	.	PUNCT
ajst-32576	151	1	srs	srs	PROPN
ajst-32576	151	2	offers	offer	VERB
ajst-32576	151	3	both	both	PRON
ajst-32576	151	4	efficacy	efficacy	NOUN
ajst-32576	151	5	and	and	CCONJ
ajst-32576	151	6	cost	cost	NOUN
ajst-32576	151	7	-	-	PUNCT
ajst-32576	151	8	effectiveness	effectiveness	NOUN
ajst-32576	151	9	in	in	ADP
ajst-32576	151	10	patients	patient	NOUN
ajst-32576	151	11	with	with	ADP
ajst-32576	151	12	oligometastases	oligometastase	NOUN
ajst-32576	151	13	,	,	PUNCT
ajst-32576	151	14	whereas	whereas	SCONJ
ajst-32576	151	15	hippocampal	hippocampal	NOUN
ajst-32576	151	16	-	-	PUNCT
ajst-32576	151	17	avoidant	avoidant	ADJ
ajst-32576	151	18	wbrt	wbrt	NOUN
ajst-32576	151	19	(	(	PUNCT
ajst-32576	151	20	ha	ha	INTJ
ajst-32576	151	21	-	-	PUNCT
ajst-32576	151	22	wbrt	wbrt	NOUN
ajst-32576	151	23	)	)	PUNCT
ajst-32576	151	24	can	can	AUX
ajst-32576	151	25	preserve	preserve	VERB
ajst-32576	151	26	cognitive	cognitive	ADJ
ajst-32576	151	27	function	function	NOUN
ajst-32576	151	28	but	but	CCONJ
ajst-32576	151	29	increases	increase	VERB
ajst-32576	151	30	economic	economic	ADJ
ajst-32576	151	31	burden	burden	NOUN
ajst-32576	151	32	.	.	PUNCT
ajst-32576	152	1	bevacizumab	bevacizumab	PROPN
ajst-32576	152	2	may	may	AUX
ajst-32576	152	3	relieve	relieve	VERB
ajst-32576	152	4	radiation	radiation	NOUN
ajst-32576	152	5	necrosis	necrosis	NOUN
ajst-32576	152	6	,	,	PUNCT
ajst-32576	152	7	yet	yet	CCONJ
ajst-32576	152	8	its	its	PRON
ajst-32576	152	9	cost	cost	NOUN
ajst-32576	152	10	alsolimits	alsolimit	NOUN
ajst-32576	152	11	widespread	widespread	ADJ
ajst-32576	152	12	use	use	NOUN
ajst-32576	152	13	[	[	PUNCT
ajst-32576	152	14	54	54	NUM
ajst-32576	152	15	-	-	SYM
ajst-32576	152	16	56	56	NUM
ajst-32576	152	17	]	]	PUNCT
ajst-32576	152	18	.	.	PUNCT
ajst-32576	153	1	therefore	therefore	ADV
ajst-32576	153	2	,	,	PUNCT
ajst-32576	153	3	in	in	ADP
ajst-32576	153	4	clinical	clinical	ADJ
ajst-32576	153	5	decision	decision	NOUN
ajst-32576	153	6	-	-	PUNCT
ajst-32576	153	7	making	making	NOUN
ajst-32576	153	8	,	,	PUNCT
ajst-32576	153	9	efficacy	efficacy	NOUN
ajst-32576	153	10	,	,	PUNCT
ajst-32576	153	11	safety	safety	NOUN
ajst-32576	153	12	,	,	PUNCT
ajst-32576	153	13	and	and	CCONJ
ajst-32576	153	14	cost	cost	NOUN
ajst-32576	153	15	-	-	PUNCT
ajst-32576	153	16	effectiveness	effectiveness	NOUN
ajst-32576	153	17	must	must	AUX
ajst-32576	153	18	be	be	AUX
ajst-32576	153	19	carefully	carefully	ADV
ajst-32576	153	20	balanced	balanced	ADJ
ajst-32576	153	21	to	to	PART
ajst-32576	153	22	formulate	formulate	VERB
ajst-32576	153	23	individualized	individualized	ADJ
ajst-32576	153	24	treatment	treatment	NOUN
ajst-32576	153	25	strategies	strategy	NOUN
ajst-32576	153	26	tailored	tailor	VERB
ajst-32576	153	27	to	to	ADP
ajst-32576	153	28	survival	survival	NOUN
ajst-32576	153	29	expectations	expectation	NOUN
ajst-32576	153	30	and	and	CCONJ
ajst-32576	153	31	resource	resource	NOUN
ajst-32576	153	32	accessibility	accessibility	NOUN
ajst-32576	153	33	.	.	PUNCT
ajst-32576	154	1	future	future	ADJ
ajst-32576	154	2	research	research	NOUN
ajst-32576	154	3	should	should	AUX
ajst-32576	154	4	focus	focus	VERB
ajst-32576	154	5	on	on	ADP
ajst-32576	154	6	overcoming	overcome	VERB
ajst-32576	154	7	drug	drug	NOUN
ajst-32576	154	8	resistance	resistance	NOUN
ajst-32576	154	9	and	and	CCONJ
ajst-32576	154	10	bbb	bbb	NOUN
ajst-32576	154	11	-	-	PUNCT
ajst-32576	154	12	related	relate	VERB
ajst-32576	154	13	barriers	barrier	NOUN
ajst-32576	154	14	,	,	PUNCT
ajst-32576	154	15	advancing	advance	VERB
ajst-32576	154	16	next	next	ADJ
ajst-32576	154	17	-	-	PUNCT
ajst-32576	154	18	generation	generation	NOUN
ajst-32576	154	19	targeted	target	VERB
ajst-32576	154	20	therapies	therapy	NOUN
ajst-32576	154	21	,	,	PUNCT
ajst-32576	154	22	exploring	explore	VERB
ajst-32576	154	23	rational	rational	ADJ
ajst-32576	154	24	combination	combination	NOUN
ajst-32576	154	25	regiments	regiment	NOUN
ajst-32576	154	26	to	to	PART
ajst-32576	154	27	bypass	bypass	VERB
ajst-32576	154	28	resistance	resistance	NOUN
ajst-32576	154	29	,	,	PUNCT
ajst-32576	154	30	and	and	CCONJ
ajst-32576	154	31	developing	develop	VERB
ajst-32576	154	32	innovative	innovative	ADJ
ajst-32576	154	33	drug	drug	NOUN
ajst-32576	154	34	delivery	delivery	NOUN
ajst-32576	154	35	systems	system	NOUN
ajst-32576	154	36	to	to	PART
ajst-32576	154	37	enhance	enhance	VERB
ajst-32576	154	38	intracranial	intracranial	ADJ
ajst-32576	154	39	efficacy	efficacy	NOUN
ajst-32576	154	40	.	.	PUNCT
ajst-32576	155	1	dynamic	dynamic	ADJ
ajst-32576	155	2	monitoring	monitoring	NOUN
ajst-32576	155	3	of	of	ADP
ajst-32576	155	4	circulating	circulate	VERB
ajst-32576	155	5	tumor	tumor	NOUN
ajst-32576	155	6	dna	dna	PROPN
ajst-32576	155	7	(	(	PUNCT
ajst-32576	155	8	ctdna	ctdna	NOUN
ajst-32576	155	9	)	)	PUNCT
ajst-32576	155	10	in	in	ADP
ajst-32576	155	11	plasma	plasma	NOUN
ajst-32576	155	12	or	or	CCONJ
ajst-32576	155	13	cerebrospinal	cerebrospinal	ADJ
ajst-32576	155	14	fluid	fluid	NOUN
ajst-32576	155	15	may	may	AUX
ajst-32576	155	16	also	also	ADV
ajst-32576	155	17	enable	enable	VERB
ajst-32576	155	18	more	more	ADV
ajst-32576	155	19	precise	precise	ADJ
ajst-32576	155	20	and	and	CCONJ
ajst-32576	155	21	individualized	individualized	ADJ
ajst-32576	155	22	treatment	treatment	NOUN
ajst-32576	155	23	.	.	PUNCT
ajst-32576	156	1	although	although	SCONJ
ajst-32576	156	2	significant	significant	ADJ
ajst-32576	156	3	progress	progress	NOUN
ajst-32576	156	4	has	have	AUX
ajst-32576	156	5	been	be	AUX
ajst-32576	156	6	made	make	VERB
ajst-32576	156	7	in	in	ADP
ajst-32576	156	8	the	the	DET
ajst-32576	156	9	management	management	NOUN
ajst-32576	156	10	of	of	ADP
ajst-32576	156	11	nsclc	nsclc	NOUN
ajst-32576	156	12	-	-	PUNCT
ajst-32576	156	13	bm	bm	PROPN
ajst-32576	156	14	,	,	PUNCT
ajst-32576	156	15	challenges	challenge	NOUN
ajst-32576	156	16	remain	remain	VERB
ajst-32576	156	17	,	,	PUNCT
ajst-32576	156	18	including	include	VERB
ajst-32576	156	19	resistance	resistance	NOUN
ajst-32576	156	20	mechanisms	mechanism	NOUN
ajst-32576	156	21	,	,	PUNCT
ajst-32576	156	22	optimization	optimization	NOUN
ajst-32576	156	23	of	of	ADP
ajst-32576	156	24	combination	combination	NOUN
ajst-32576	156	25	approaches	approach	NOUN
ajst-32576	156	26	,	,	PUNCT
ajst-32576	156	27	preservation	preservation	NOUN
ajst-32576	156	28	of	of	ADP
ajst-32576	156	29	neurocognitive	neurocognitive	ADJ
ajst-32576	156	30	function	function	NOUN
ajst-32576	156	31	,	,	PUNCT
ajst-32576	156	32	and	and	CCONJ
ajst-32576	156	33	treatment	treatment	NOUN
ajst-32576	156	34	of	of	ADP
ajst-32576	156	35	patients	patient	NOUN
ajst-32576	156	36	with	with	ADP
ajst-32576	156	37	complex	complex	ADJ
ajst-32576	156	38	resistance	resistance	NOUN
ajst-32576	156	39	patterns	pattern	NOUN
ajst-32576	156	40	.	.	PUNCT
ajst-32576	157	1	moving	move	VERB
ajst-32576	157	2	forward	forward	ADV
ajst-32576	157	3	,	,	PUNCT
ajst-32576	157	4	individualized	individualized	ADJ
ajst-32576	157	5	strategies	strategy	NOUN
ajst-32576	157	6	that	that	PRON
ajst-32576	157	7	integrate	integrate	VERB
ajst-32576	157	8	novel	novel	ADJ
ajst-32576	157	9	drug	drug	NOUN
ajst-32576	157	10	development	development	NOUN
ajst-32576	157	11	,	,	PUNCT
ajst-32576	157	12	advanced	advanced	ADJ
ajst-32576	157	13	diagnostic	diagnostic	ADJ
ajst-32576	157	14	and	and	CCONJ
ajst-32576	157	15	therapeutic	therapeutic	ADJ
ajst-32576	157	16	technologies	technology	NOUN
ajst-32576	157	17	,	,	PUNCT
ajst-32576	157	18	and	and	CCONJ
ajst-32576	157	19	multidisciplinary	multidisciplinary	ADJ
ajst-32576	157	20	collaboration	collaboration	NOUN
ajst-32576	157	21	will	will	AUX
ajst-32576	157	22	be	be	AUX
ajst-32576	157	23	critical	critical	ADJ
ajst-32576	157	24	to	to	ADP
ajst-32576	157	25	improving	improve	VERB
ajst-32576	157	26	both	both	DET
ajst-32576	157	27	survival	survival	NOUN
ajst-32576	157	28	and	and	CCONJ
ajst-32576	157	29	quality	quality	NOUN
ajst-32576	157	30	of	of	ADP
ajst-32576	157	31	life	life	NOUN
ajst-32576	157	32	in	in	ADP
ajst-32576	157	33	this	this	DET
ajst-32576	157	34	population	population	NOUN
ajst-32576	157	35	.	.	PUNCT
ajst-32576	158	1	5	5	X
ajst-32576	158	2	.	.	X
ajst-32576	158	3	conclusion	conclusion	NOUN
ajst-32576	158	4	this	this	DET
ajst-32576	158	5	study	study	NOUN
ajst-32576	158	6	systematically	systematically	ADV
ajst-32576	158	7	reviews	review	VERB
ajst-32576	158	8	the	the	DET
ajst-32576	158	9	comprehensive	comprehensive	ADJ
ajst-32576	158	10	treatment	treatment	NOUN
ajst-32576	158	11	strategies	strategy	NOUN
ajst-32576	158	12	for	for	ADP
ajst-32576	158	13	non	non	ADJ
ajst-32576	158	14	-	-	ADJ
ajst-32576	158	15	small	small	ADJ
ajst-32576	158	16	cell	cell	NOUN
ajst-32576	158	17	lung	lung	NOUN
ajst-32576	158	18	cancer	cancer	NOUN
ajst-32576	158	19	with	with	ADP
ajst-32576	158	20	brain	brain	NOUN
ajst-32576	158	21	metastases	metastasis	NOUN
ajst-32576	158	22	.	.	PUNCT
ajst-32576	159	1	with	with	ADP
ajst-32576	159	2	the	the	DET
ajst-32576	159	3	growing	grow	VERB
ajst-32576	159	4	understanding	understanding	NOUN
ajst-32576	159	5	of	of	ADP
ajst-32576	159	6	molecular	molecular	ADJ
ajst-32576	159	7	driver	driver	NOUN
ajst-32576	159	8	genes	gene	NOUN
ajst-32576	159	9	and	and	CCONJ
ajst-32576	159	10	the	the	DET
ajst-32576	159	11	advancement	advancement	NOUN
ajst-32576	159	12	of	of	ADP
ajst-32576	159	13	therapeutic	therapeutic	ADJ
ajst-32576	159	14	approaches	approach	NOUN
ajst-32576	159	15	,	,	PUNCT
ajst-32576	159	16	the	the	DET
ajst-32576	159	17	management	management	NOUN
ajst-32576	159	18	of	of	ADP
ajst-32576	159	19	nsclc	nsclc	NOUN
ajst-32576	159	20	-	-	PUNCT
ajst-32576	159	21	bm	bm	PROPN
ajst-32576	159	22	has	have	AUX
ajst-32576	159	23	evolved	evolve	VERB
ajst-32576	159	24	from	from	ADP
ajst-32576	159	25	palliative	palliative	ADJ
ajst-32576	159	26	local	local	ADJ
ajst-32576	159	27	therapy	therapy	NOUN
ajst-32576	159	28	to	to	ADP
ajst-32576	159	29	a	a	DET
ajst-32576	159	30	multidisciplinary	multidisciplinary	ADJ
ajst-32576	159	31	model	model	NOUN
ajst-32576	159	32	integrating	integrate	VERB
ajst-32576	159	33	local	local	ADJ
ajst-32576	159	34	and	and	CCONJ
ajst-32576	159	35	systemic	systemic	ADJ
ajst-32576	159	36	treatments	treatment	NOUN
ajst-32576	159	37	.	.	PUNCT
ajst-32576	160	1	molecular	molecular	ADJ
ajst-32576	160	2	targeted	target	VERB
ajst-32576	160	3	agents	agent	NOUN
ajst-32576	160	4	,	,	PUNCT
ajst-32576	160	5	particularly	particularly	ADV
ajst-32576	160	6	third	third	ADJ
ajst-32576	160	7	-	-	PUNCT
ajst-32576	160	8	generation	generation	NOUN
ajst-32576	160	9	egfr	egfr	ADJ
ajst-32576	160	10	-	-	PUNCT
ajst-32576	160	11	tkis	tkis	NOUN
ajst-32576	160	12	and	and	CCONJ
ajst-32576	160	13	alk	alk	PROPN
ajst-32576	160	14	-	-	PUNCT
ajst-32576	160	15	tkis	tkis	NOUN
ajst-32576	160	16	,	,	PUNCT
ajst-32576	160	17	have	have	AUX
ajst-32576	160	18	become	become	VERB
ajst-32576	160	19	preferred	preferred	ADJ
ajst-32576	160	20	first	first	ADJ
ajst-32576	160	21	-	-	PUNCT
ajst-32576	160	22	line	line	NOUN
ajst-32576	160	23	options	option	NOUN
ajst-32576	160	24	owing	owe	VERB
ajst-32576	160	25	to	to	ADP
ajst-32576	160	26	their	their	PRON
ajst-32576	160	27	superior	superior	ADJ
ajst-32576	160	28	blood	blood	NOUN
ajst-32576	160	29	–	–	PUNCT
ajst-32576	160	30	brain	brain	NOUN
ajst-32576	160	31	barrier	barrier	NOUN
ajst-32576	160	32	penetration	penetration	NOUN
ajst-32576	160	33	and	and	CCONJ
ajst-32576	160	34	robust	robust	ADJ
ajst-32576	160	35	intracranial	intracranial	ADJ
ajst-32576	160	36	efficacy	efficacy	NOUN
ajst-32576	160	37	.	.	PUNCT
ajst-32576	161	1	radiotherapy	radiotherapy	NOUN
ajst-32576	161	2	remains	remain	VERB
ajst-32576	161	3	indispensable	indispensable	ADJ
ajst-32576	161	4	for	for	ADP
ajst-32576	161	5	local	local	ADJ
ajst-32576	161	6	control	control	NOUN
ajst-32576	161	7	and	and	CCONJ
ajst-32576	161	8	symptom	symptom	NOUN
ajst-32576	161	9	relief	relief	NOUN
ajst-32576	161	10	,	,	PUNCT
ajst-32576	161	11	while	while	SCONJ
ajst-32576	161	12	immune	immune	ADJ
ajst-32576	161	13	checkpoint	checkpoint	NOUN
ajst-32576	161	14	inhibitors	inhibitor	NOUN
ajst-32576	161	15	provide	provide	VERB
ajst-32576	161	16	durable	durable	ADJ
ajst-32576	161	17	benefit	benefit	NOUN
ajst-32576	161	18	in	in	ADP
ajst-32576	161	19	patients	patient	NOUN
ajst-32576	161	20	with	with	ADP
ajst-32576	161	21	high	high	ADJ
ajst-32576	161	22	pd	pd	PROPN
ajst-32576	161	23	-	-	PUNCT
ajst-32576	161	24	l1	l1	PROPN
ajst-32576	161	25	expression	expression	NOUN
ajst-32576	161	26	and	and	CCONJ
ajst-32576	161	27	no	no	DET
ajst-32576	161	28	driver	driver	NOUN
ajst-32576	161	29	mutations	mutation	NOUN
ajst-32576	161	30	.	.	PUNCT
ajst-32576	162	1	chemotherapy	chemotherapy	NOUN
ajst-32576	162	2	and	and	CCONJ
ajst-32576	162	3	intrathecal	intrathecal	ADJ
ajst-32576	162	4	therapy	therapy	NOUN
ajst-32576	162	5	also	also	ADV
ajst-32576	162	6	retain	retain	VERB
ajst-32576	162	7	value	value	NOUN
ajst-32576	162	8	,	,	PUNCT
ajst-32576	162	9	particularly	particularly	ADV
ajst-32576	162	10	for	for	ADP
ajst-32576	162	11	systemic	systemic	ADJ
ajst-32576	162	12	disease	disease	NOUN
ajst-32576	162	13	control	control	NOUN
ajst-32576	162	14	and	and	CCONJ
ajst-32576	162	15	leptomeningeal	leptomeningeal	ADJ
ajst-32576	162	16	metastases	metastasis	NOUN
ajst-32576	162	17	.	.	PUNCT
ajst-32576	163	1	nevertheless	nevertheless	ADV
ajst-32576	163	2	,	,	PUNCT
ajst-32576	163	3	significant	significant	ADJ
ajst-32576	163	4	challenges	challenge	NOUN
ajst-32576	163	5	persist	persist	VERB
ajst-32576	163	6	,	,	PUNCT
ajst-32576	163	7	including	include	VERB
ajst-32576	163	8	blood	blood	NOUN
ajst-32576	163	9	–	–	PUNCT
ajst-32576	163	10	brain	brain	NOUN
ajst-32576	163	11	barrier	barrier	NOUN
ajst-32576	163	12	limitations	limitation	NOUN
ajst-32576	163	13	,	,	PUNCT
ajst-32576	163	14	acquired	acquire	VERB
ajst-32576	163	15	resistance	resistance	NOUN
ajst-32576	163	16	,	,	PUNCT
ajst-32576	163	17	optimization	optimization	NOUN
ajst-32576	163	18	of	of	ADP
ajst-32576	163	19	combination	combination	NOUN
ajst-32576	163	20	strategies	strategy	NOUN
ajst-32576	163	21	,	,	PUNCT
ajst-32576	163	22	scarcity	scarcity	NOUN
ajst-32576	163	23	of	of	ADP
ajst-32576	163	24	dedicated	dedicated	ADJ
ajst-32576	163	25	evidence	evidence	NOUN
ajst-32576	163	26	-	-	PUNCT
ajst-32576	163	27	based	base	VERB
ajst-32576	163	28	data	datum	NOUN
ajst-32576	163	29	,	,	PUNCT
ajst-32576	163	30	and	and	CCONJ
ajst-32576	163	31	risks	risk	NOUN
ajst-32576	163	32	of	of	ADP
ajst-32576	163	33	long	long	ADJ
ajst-32576	163	34	-	-	PUNCT
ajst-32576	163	35	term	term	NOUN
ajst-32576	163	36	neurotoxicity	neurotoxicity	NOUN
ajst-32576	163	37	.	.	PUNCT
ajst-32576	164	1	future	future	ADJ
ajst-32576	164	2	research	research	NOUN
ajst-32576	164	3	should	should	AUX
ajst-32576	164	4	prioritize	prioritize	VERB
ajst-32576	164	5	strategies	strategy	NOUN
ajst-32576	164	6	to	to	PART
ajst-32576	164	7	overcome	overcome	VERB
ajst-32576	164	8	bbb	bbb	NOUN
ajst-32576	164	9	-	-	PUNCT
ajst-32576	164	10	related	relate	VERB
ajst-32576	164	11	barriers	barrier	NOUN
ajst-32576	164	12	and	and	CCONJ
ajst-32576	164	13	resistance	resistance	NOUN
ajst-32576	164	14	mechanisms	mechanism	NOUN
ajst-32576	164	15	,	,	PUNCT
ajst-32576	164	16	refine	refine	VERB
ajst-32576	164	17	individualized	individualized	ADJ
ajst-32576	164	18	combination	combination	NOUN
ajst-32576	164	19	regimens	regimen	NOUN
ajst-32576	164	20	,	,	PUNCT
ajst-32576	164	21	generate	generate	VERB
ajst-32576	164	22	high226	high226	PROPN
ajst-32576	164	23	quality	quality	NOUN
ajst-32576	164	24	data	datum	NOUN
ajst-32576	164	25	specific	specific	ADJ
ajst-32576	164	26	to	to	PART
ajst-32576	164	27	brain	brain	VERB
ajst-32576	164	28	metastasis	metastasis	NOUN
ajst-32576	164	29	populations	population	NOUN
ajst-32576	164	30	,	,	PUNCT
ajst-32576	164	31	and	and	CCONJ
ajst-32576	164	32	balance	balance	NOUN
ajst-32576	164	33	efficacy	efficacy	NOUN
ajst-32576	164	34	with	with	ADP
ajst-32576	164	35	safety	safety	NOUN
ajst-32576	164	36	.	.	PUNCT
ajst-32576	165	1	these	these	DET
ajst-32576	165	2	efforts	effort	NOUN
ajst-32576	165	3	will	will	AUX
ajst-32576	165	4	be	be	AUX
ajst-32576	165	5	critical	critical	ADJ
ajst-32576	165	6	to	to	ADP
ajst-32576	165	7	further	far	ADV
ajst-32576	165	8	improving	improve	VERB
ajst-32576	165	9	prognosis	prognosis	NOUN
ajst-32576	165	10	and	and	CCONJ
ajst-32576	165	11	quality	quality	NOUN
ajst-32576	165	12	of	of	ADP
ajst-32576	165	13	life	life	NOUN
ajst-32576	165	14	for	for	ADP
ajst-32576	165	15	patients	patient	NOUN
ajst-32576	165	16	with	with	ADP
ajst-32576	165	17	nsclc	nsclc	NOUN
ajst-32576	165	18	-	-	PUNCT
ajst-32576	165	19	bm	bm	PROPN
ajst-32576	165	20	.	.	PUNCT
ajst-32576	165	21	declarations	declaration	NOUN
ajst-32576	165	22	ethics	ethic	NOUN
ajst-32576	165	23	approval	approval	NOUN
ajst-32576	165	24	and	and	CCONJ
ajst-32576	165	25	consent	consent	NOUN
ajst-32576	165	26	to	to	PART
ajst-32576	165	27	participate	participate	VERB
ajst-32576	165	28	:	:	PUNCT
ajst-32576	165	29	not	not	PART
ajst-32576	165	30	applicable	applicable	ADJ
ajst-32576	165	31	.	.	PUNCT
ajst-32576	166	1	consent	consent	NOUN
ajst-32576	166	2	for	for	ADP
ajst-32576	166	3	publication	publication	NOUN
ajst-32576	166	4	:	:	PUNCT
ajst-32576	166	5	not	not	PART
ajst-32576	166	6	applicable	applicable	ADJ
ajst-32576	166	7	.	.	PUNCT
ajst-32576	167	1	author	author	NOUN
ajst-32576	167	2	contributions	contribution	VERB
ajst-32576	167	3	yuzhu	yuzhu	PROPN
ajst-32576	167	4	chen	chen	PROPN
ajst-32576	167	5	:	:	PUNCT
ajst-32576	167	6	data	datum	NOUN
ajst-32576	167	7	curation	curation	NOUN
ajst-32576	167	8	;	;	PUNCT
ajst-32576	167	9	resources	resource	NOUN
ajst-32576	167	10	;	;	PUNCT
ajst-32576	167	11	writing	writing	NOUN
ajst-32576	167	12	,	,	PUNCT
ajst-32576	167	13	review	review	NOUN
ajst-32576	167	14	&	&	CCONJ
ajst-32576	167	15	editing	editing	NOUN
ajst-32576	167	16	.	.	PUNCT
ajst-32576	168	1	ziyu	ziyu	NOUN
ajst-32576	168	2	:	:	PUNCT
ajst-32576	168	3	writing	write	VERB
ajst-32576	168	4	–	–	PUNCT
ajst-32576	168	5	review	review	NOUN
ajst-32576	168	6	&	&	CCONJ
ajst-32576	168	7	editing	editing	NOUN
ajst-32576	168	8	.	.	PUNCT
ajst-32576	169	1	competing	compete	VERB
ajst-32576	169	2	interests	interest	NOUN
ajst-32576	169	3	the	the	DET
ajst-32576	169	4	authors	author	NOUN
ajst-32576	169	5	declare	declare	VERB
ajst-32576	169	6	that	that	SCONJ
ajst-32576	169	7	there	there	PRON
ajst-32576	169	8	is	be	VERB
ajst-32576	169	9	no	no	DET
ajst-32576	169	10	conflict	conflict	NOUN
ajst-32576	169	11	of	of	ADP
ajst-32576	169	12	interest	interest	NOUN
ajst-32576	169	13	.	.	PUNCT
ajst-32576	170	1	references	reference	NOUN
ajst-32576	170	2	[	[	X
ajst-32576	170	3	1	1	NUM
ajst-32576	170	4	]	]	X
ajst-32576	170	5	jingsong	jingsong	PROPN
ajst-32576	170	6	zeng	zeng	PROPN
ajst-32576	170	7	.	.	PUNCT
ajst-32576	171	1	(	(	PUNCT
ajst-32576	171	2	2017	2017	NUM
ajst-32576	171	3	)	)	PUNCT
ajst-32576	171	4	.	.	PUNCT
ajst-32576	172	1	“	"	PUNCT
ajst-32576	172	2	approaches	approach	NOUN
ajst-32576	172	3	to	to	PART
ajst-32576	172	4	solve	solve	VERB
ajst-32576	172	5	problem	problem	NOUN
ajst-32576	172	6	of	of	ADP
ajst-32576	172	7	electrostatic	electrostatic	ADJ
ajst-32576	172	8	precipitator	precipitator	NOUN
ajst-32576	172	9	high	high	ADJ
ajst-32576	172	10	-	-	PUNCT
ajst-32576	172	11	voltage	voltage	NOUN
ajst-32576	172	12	switch	switch	NOUN
ajst-32576	172	13	box	box	NOUN
ajst-32576	172	14	,	,	PUNCT
ajst-32576	172	15	”	"	PUNCT
ajst-32576	172	16	proc.2017	proc.2017	PROPN
ajst-32576	172	17	3rd	3rd	ADJ
ajst-32576	172	18	ieee	ieee	NOUN
ajst-32576	172	19	international	international	ADJ
ajst-32576	172	20	conference	conference	NOUN
ajst-32576	172	21	on	on	ADP
ajst-32576	172	22	control	control	NOUN
ajst-32576	172	23	science	science	NOUN
ajst-32576	172	24	and	and	CCONJ
ajst-32576	172	25	systems	system	NOUN
ajst-32576	172	26	engineering	engineering	NOUN
ajst-32576	172	27	(	(	PUNCT
ajst-32576	172	28	iccsse	iccsse	NOUN
ajst-32576	172	29	)	)	PUNCT
ajst-32576	172	30	(	(	PUNCT
ajst-32576	172	31	2017):330	2017):330	NUM
ajst-32576	172	32	-	-	SYM
ajst-32576	172	33	335	335	NUM
ajst-32576	172	34	.	.	PUNCT
ajst-32576	173	1	[	[	X
ajst-32576	173	2	2	2	NUM
ajst-32576	173	3	]	]	X
ajst-32576	173	4	jingsong	jingsong	ADJ
ajst-32576	173	5	zeng	zeng	PROPN
ajst-32576	173	6	.	.	PUNCT
ajst-32576	174	1	(	(	PUNCT
ajst-32576	174	2	2017	2017	NUM
ajst-32576	174	3	)	)	PUNCT
ajst-32576	174	4	.	.	PUNCT
ajst-32576	175	1	“	"	PUNCT
ajst-32576	175	2	one	one	NUM
ajst-32576	175	3	approach	approach	NOUN
ajst-32576	175	4	to	to	PART
ajst-32576	175	5	efficiently	efficiently	ADV
ajst-32576	175	6	remove	remove	VERB
ajst-32576	175	7	the	the	DET
ajst-32576	175	8	dust	dust	NOUN
ajst-32576	175	9	stratification	stratification	NOUN
ajst-32576	175	10	attached	attach	VERB
ajst-32576	175	11	to	to	ADP
ajst-32576	175	12	the	the	DET
ajst-32576	175	13	flow	flow	NOUN
ajst-32576	175	14	distribution	distribution	NOUN
ajst-32576	175	15	plate	plate	NOUN
ajst-32576	175	16	of	of	ADP
ajst-32576	175	17	electrostatic	electrostatic	ADJ
ajst-32576	175	18	precipitator	precipitator	NOUN
ajst-32576	175	19	,	,	PUNCT
ajst-32576	175	20	”	"	PUNCT
ajst-32576	175	21	journal	journal	NOUN
ajst-32576	175	22	of	of	ADP
ajst-32576	175	23	anyang	anyang	PROPN
ajst-32576	175	24	institute	institute	PROPN
ajst-32576	175	25	of	of	ADP
ajst-32576	175	26	technology	technology	PROPN
ajst-32576	175	27	02(2017	02(2017	NUM
ajst-32576	175	28	):	):	PUNCT
ajst-32576	175	29	5	5	NUM
ajst-32576	175	30	-	-	SYM
ajst-32576	175	31	7	7	NUM
ajst-32576	175	32	.	.	PUNCT
ajst-32576	176	1	[	[	X
ajst-32576	176	2	3	3	NUM
ajst-32576	176	3	]	]	SYM
ajst-32576	176	4	li	li	PROPN
ajst-32576	176	5	,	,	PUNCT
ajst-32576	176	6	q.	q.	PROPN
ajst-32576	176	7	,	,	PUNCT
ajst-32576	176	8	et	et	PROPN
ajst-32576	176	9	al	al	PROPN
ajst-32576	176	10	.	.	PROPN
ajst-32576	176	11	,	,	PUNCT
ajst-32576	176	12	molecular	molecular	ADJ
ajst-32576	176	13	profiling	profiling	NOUN
ajst-32576	176	14	of	of	ADP
ajst-32576	176	15	human	human	ADJ
ajst-32576	176	16	non	non	ADJ
ajst-32576	176	17	-	-	ADJ
ajst-32576	176	18	small	small	ADJ
ajst-32576	176	19	cell	cell	NOUN
ajst-32576	176	20	lung	lung	NOUN
ajst-32576	176	21	cancer	cancer	NOUN
ajst-32576	176	22	by	by	ADP
ajst-32576	176	23	single	single	ADJ
ajst-32576	176	24	-	-	PUNCT
ajst-32576	176	25	cell	cell	NOUN
ajst-32576	176	26	rna	rna	NOUN
ajst-32576	176	27	-	-	PUNCT
ajst-32576	176	28	seq	seq	NOUN
ajst-32576	176	29	.	.	PUNCT
ajst-32576	176	30	genome	genome	NOUN
ajst-32576	176	31	med	me	VERB
ajst-32576	176	32	,	,	PUNCT
ajst-32576	176	33	2022	2022	NUM
ajst-32576	176	34	.	.	PUNCT
ajst-32576	177	1	14(1	14(1	NUM
ajst-32576	177	2	):	):	PUNCT
ajst-32576	177	3	p.	p.	NOUN
ajst-32576	177	4	87	87	NUM
ajst-32576	177	5	.	.	PUNCT
ajst-32576	178	1	[	[	X
ajst-32576	178	2	4	4	NUM
ajst-32576	178	3	]	]	X
ajst-32576	178	4	ulahannan	ulahannan	NOUN
ajst-32576	178	5	,	,	PUNCT
ajst-32576	178	6	d.	d.	PROPN
ajst-32576	178	7	,	,	PUNCT
ajst-32576	178	8	et	et	PROPN
ajst-32576	178	9	al	al	PROPN
ajst-32576	178	10	.	.	PROPN
ajst-32576	178	11	,	,	PUNCT
ajst-32576	178	12	emerging	emerge	VERB
ajst-32576	178	13	treatment	treatment	NOUN
ajst-32576	178	14	paradigms	paradigm	NOUN
ajst-32576	178	15	for	for	ADP
ajst-32576	178	16	brain	brain	NOUN
ajst-32576	178	17	metastasis	metastasis	NOUN
ajst-32576	178	18	in	in	ADP
ajst-32576	178	19	non	non	ADJ
ajst-32576	178	20	-	-	ADJ
ajst-32576	178	21	small	small	ADJ
ajst-32576	178	22	-	-	PUNCT
ajst-32576	178	23	cell	cell	NOUN
ajst-32576	178	24	lung	lung	NOUN
ajst-32576	178	25	cancer	cancer	NOUN
ajst-32576	178	26	:	:	PUNCT
ajst-32576	178	27	an	an	DET
ajst-32576	178	28	overview	overview	NOUN
ajst-32576	178	29	of	of	ADP
ajst-32576	178	30	the	the	DET
ajst-32576	178	31	current	current	ADJ
ajst-32576	178	32	landscape	landscape	NOUN
ajst-32576	178	33	and	and	CCONJ
ajst-32576	178	34	challenges	challenge	NOUN
ajst-32576	178	35	ahead	ahead	ADV
ajst-32576	178	36	.	.	PUNCT
ajst-32576	179	1	ann	ann	PROPN
ajst-32576	179	2	oncol	oncol	PROPN
ajst-32576	179	3	,	,	PUNCT
ajst-32576	179	4	2017	2017	NUM
ajst-32576	179	5	.	.	PUNCT
ajst-32576	180	1	28(12	28(12	NUM
ajst-32576	180	2	):	):	PUNCT
ajst-32576	180	3	p.	p.	NOUN
ajst-32576	180	4	2923	2923	NUM
ajst-32576	180	5	-	-	SYM
ajst-32576	180	6	2931	2931	NUM
ajst-32576	180	7	.	.	PUNCT
ajst-32576	181	1	[	[	X
ajst-32576	181	2	5	5	NUM
ajst-32576	181	3	]	]	PUNCT
ajst-32576	181	4	page	page	NOUN
ajst-32576	181	5	,	,	PUNCT
ajst-32576	181	6	s.	s.	PROPN
ajst-32576	181	7	,	,	PUNCT
ajst-32576	181	8	et	et	PROPN
ajst-32576	181	9	al	al	PROPN
ajst-32576	181	10	.	.	PROPN
ajst-32576	181	11	,	,	PUNCT
ajst-32576	181	12	systemic	systemic	ADJ
ajst-32576	181	13	treatment	treatment	NOUN
ajst-32576	181	14	of	of	ADP
ajst-32576	181	15	brain	brain	NOUN
ajst-32576	181	16	metastases	metastasis	NOUN
ajst-32576	181	17	in	in	ADP
ajst-32576	181	18	non	non	ADJ
ajst-32576	181	19	-	-	ADJ
ajst-32576	181	20	small	small	ADJ
ajst-32576	181	21	cell	cell	NOUN
ajst-32576	181	22	lung	lung	NOUN
ajst-32576	181	23	cancer	cancer	NOUN
ajst-32576	181	24	.	.	PUNCT
ajst-32576	182	1	eur	eur	PROPN
ajst-32576	182	2	j	j	PROPN
ajst-32576	182	3	cancer	cancer	NOUN
ajst-32576	182	4	,	,	PUNCT
ajst-32576	182	5	2020	2020	NUM
ajst-32576	182	6	.	.	PUNCT
ajst-32576	183	1	132	132	NUM
ajst-32576	183	2	:	:	PUNCT
ajst-32576	183	3	p.	p.	NOUN
ajst-32576	183	4	187	187	NUM
ajst-32576	183	5	-	-	SYM
ajst-32576	183	6	198	198	NUM
ajst-32576	183	7	.	.	PUNCT
ajst-32576	184	1	[	[	X
ajst-32576	184	2	6	6	NUM
ajst-32576	184	3	]	]	X
ajst-32576	184	4	arvanitis	arvanitis	NOUN
ajst-32576	184	5	,	,	PUNCT
ajst-32576	184	6	c.d	c.d	PROPN
ajst-32576	184	7	.	.	PROPN
ajst-32576	184	8	,	,	PUNCT
ajst-32576	184	9	g.b	g.b	PROPN
ajst-32576	184	10	.	.	PROPN
ajst-32576	184	11	ferraro	ferraro	PROPN
ajst-32576	184	12	,	,	PUNCT
ajst-32576	184	13	and	and	CCONJ
ajst-32576	184	14	r.k	r.k	PROPN
ajst-32576	184	15	.	.	PROPN
ajst-32576	184	16	jain	jain	PROPN
ajst-32576	184	17	,	,	PUNCT
ajst-32576	184	18	the	the	DET
ajst-32576	184	19	blood	blood	NOUN
ajst-32576	184	20	-	-	PUNCT
ajst-32576	184	21	brain	brain	NOUN
ajst-32576	184	22	barrier	barrier	NOUN
ajst-32576	184	23	and	and	CCONJ
ajst-32576	184	24	blood	blood	NOUN
ajst-32576	184	25	-	-	PUNCT
ajst-32576	184	26	tumour	tumour	NOUN
ajst-32576	184	27	barrier	barrier	NOUN
ajst-32576	184	28	in	in	ADP
ajst-32576	184	29	brain	brain	NOUN
ajst-32576	184	30	tumours	tumour	NOUN
ajst-32576	184	31	and	and	CCONJ
ajst-32576	184	32	metastases	metastasis	NOUN
ajst-32576	184	33	.	.	PUNCT
ajst-32576	185	1	nat	nat	PROPN
ajst-32576	185	2	rev	rev	PROPN
ajst-32576	185	3	cancer	cancer	NOUN
ajst-32576	185	4	,	,	PUNCT
ajst-32576	185	5	2020	2020	NUM
ajst-32576	185	6	.	.	PUNCT
ajst-32576	186	1	20(1	20(1	NUM
ajst-32576	186	2	):	):	PUNCT
ajst-32576	186	3	p.	p.	NOUN
ajst-32576	186	4	26	26	NUM
ajst-32576	186	5	-	-	SYM
ajst-32576	186	6	41	41	NUM
ajst-32576	186	7	.	.	PUNCT
ajst-32576	187	1	[	[	X
ajst-32576	187	2	7	7	NUM
ajst-32576	187	3	]	]	X
ajst-32576	187	4	sprowls	sprowl	NOUN
ajst-32576	187	5	,	,	PUNCT
ajst-32576	187	6	s.a	s.a	PROPN
ajst-32576	187	7	.	.	PROPN
ajst-32576	187	8	,	,	PUNCT
ajst-32576	187	9	et	et	PROPN
ajst-32576	187	10	al	al	PROPN
ajst-32576	187	11	.	.	PROPN
ajst-32576	187	12	,	,	PUNCT
ajst-32576	187	13	improving	improve	VERB
ajst-32576	187	14	cns	cns	NOUN
ajst-32576	187	15	delivery	delivery	NOUN
ajst-32576	187	16	to	to	PART
ajst-32576	187	17	brain	brain	NOUN
ajst-32576	187	18	metastases	metastasis	NOUN
ajst-32576	187	19	by	by	ADP
ajst-32576	187	20	blood	blood	NOUN
ajst-32576	187	21	-	-	PUNCT
ajst-32576	187	22	tumor	tumor	NOUN
ajst-32576	187	23	barrier	barrier	NOUN
ajst-32576	187	24	disruption	disruption	NOUN
ajst-32576	187	25	.	.	PUNCT
ajst-32576	188	1	trends	trend	NOUN
ajst-32576	188	2	cancer	cancer	NOUN
ajst-32576	188	3	,	,	PUNCT
ajst-32576	188	4	2019	2019	NUM
ajst-32576	188	5	.	.	PUNCT
ajst-32576	189	1	5(8	5(8	NUM
ajst-32576	189	2	):	):	PUNCT
ajst-32576	189	3	p.	p.	NOUN
ajst-32576	189	4	495	495	NUM
ajst-32576	189	5	-	-	SYM
ajst-32576	189	6	505	505	NUM
ajst-32576	189	7	.	.	PUNCT
ajst-32576	190	1	[	[	X
ajst-32576	190	2	8	8	NUM
ajst-32576	190	3	]	]	X
ajst-32576	190	4	gaebe	gaebe	NOUN
ajst-32576	190	5	,	,	PUNCT
ajst-32576	190	6	k.	k.	PROPN
ajst-32576	190	7	,	,	PUNCT
ajst-32576	190	8	et	et	PROPN
ajst-32576	190	9	al	al	PROPN
ajst-32576	190	10	.	.	PROPN
ajst-32576	190	11	,	,	PUNCT
ajst-32576	190	12	stereotactic	stereotactic	ADJ
ajst-32576	190	13	radiosurgery	radiosurgery	NOUN
ajst-32576	190	14	versus	versus	ADP
ajst-32576	190	15	whole	whole	ADJ
ajst-32576	190	16	brain	brain	NOUN
ajst-32576	190	17	radiotherapy	radiotherapy	NOUN
ajst-32576	190	18	in	in	ADP
ajst-32576	190	19	patients	patient	NOUN
ajst-32576	190	20	with	with	ADP
ajst-32576	190	21	intracranial	intracranial	ADJ
ajst-32576	190	22	metastatic	metastatic	ADJ
ajst-32576	190	23	disease	disease	NOUN
ajst-32576	190	24	and	and	CCONJ
ajst-32576	190	25	small	small	ADJ
ajst-32576	190	26	-	-	PUNCT
ajst-32576	190	27	cell	cell	NOUN
ajst-32576	190	28	lung	lung	NOUN
ajst-32576	190	29	cancer	cancer	NOUN
ajst-32576	190	30	:	:	PUNCT
ajst-32576	190	31	a	a	DET
ajst-32576	190	32	systematic	systematic	ADJ
ajst-32576	190	33	review	review	NOUN
ajst-32576	190	34	and	and	CCONJ
ajst-32576	190	35	meta	meta	ADJ
ajst-32576	190	36	-	-	PUNCT
ajst-32576	190	37	analysis	analysis	NOUN
ajst-32576	190	38	.	.	PUNCT
ajst-32576	191	1	lancet	lancet	PROPN
ajst-32576	191	2	oncol	oncol	PROPN
ajst-32576	191	3	,	,	PUNCT
ajst-32576	191	4	2022	2022	NUM
ajst-32576	191	5	.	.	PUNCT
ajst-32576	192	1	23(7	23(7	NUM
ajst-32576	192	2	):	):	PUNCT
ajst-32576	193	1	p.	p.	NOUN
ajst-32576	193	2	931	931	NUM
ajst-32576	193	3	-	-	SYM
ajst-32576	193	4	939	939	NUM
ajst-32576	193	5	.	.	PUNCT
ajst-32576	194	1	[	[	X
ajst-32576	194	2	9	9	NUM
ajst-32576	194	3	]	]	SYM
ajst-32576	194	4	reck	reck	NOUN
ajst-32576	194	5	,	,	PUNCT
ajst-32576	194	6	m.	m.	NOUN
ajst-32576	194	7	,	,	PUNCT
ajst-32576	194	8	j.	j.	PROPN
ajst-32576	194	9	remon	remon	PROPN
ajst-32576	194	10	,	,	PUNCT
ajst-32576	194	11	and	and	CCONJ
ajst-32576	194	12	m.d	m.d	PROPN
ajst-32576	194	13	.	.	PROPN
ajst-32576	194	14	hellmann	hellmann	PROPN
ajst-32576	194	15	,	,	PUNCT
ajst-32576	194	16	first	first	ADJ
ajst-32576	194	17	-	-	PUNCT
ajst-32576	194	18	line	line	NOUN
ajst-32576	194	19	immunotherapy	immunotherapy	NOUN
ajst-32576	194	20	for	for	ADP
ajst-32576	194	21	non	non	ADJ
ajst-32576	194	22	-	-	ADJ
ajst-32576	194	23	small	small	ADJ
ajst-32576	194	24	-	-	PUNCT
ajst-32576	194	25	cell	cell	NOUN
ajst-32576	194	26	lung	lung	NOUN
ajst-32576	194	27	cancer	cancer	NOUN
ajst-32576	194	28	.	.	PUNCT
ajst-32576	195	1	j	j	PROPN
ajst-32576	195	2	clin	clin	PROPN
ajst-32576	195	3	oncol	oncol	PROPN
ajst-32576	195	4	,	,	PUNCT
ajst-32576	195	5	2022	2022	NUM
ajst-32576	195	6	.	.	PUNCT
ajst-32576	196	1	40(6	40(6	NOUN
ajst-32576	196	2	):	):	PUNCT
ajst-32576	197	1	p.	p.	NOUN
ajst-32576	197	2	586	586	NUM
ajst-32576	197	3	-	-	SYM
ajst-32576	197	4	597	597	NUM
ajst-32576	197	5	.	.	PUNCT
ajst-32576	198	1	[	[	X
ajst-32576	198	2	10	10	NUM
ajst-32576	198	3	]	]	X
ajst-32576	198	4	tan	tan	PROPN
ajst-32576	198	5	,	,	PUNCT
ajst-32576	198	6	d.s	d.s	PROPN
ajst-32576	198	7	.	.	PROPN
ajst-32576	198	8	,	,	PUNCT
ajst-32576	198	9	t.s	t.s	PROPN
ajst-32576	198	10	.	.	PROPN
ajst-32576	198	11	mok	mok	PROPN
ajst-32576	198	12	,	,	PUNCT
ajst-32576	198	13	and	and	CCONJ
ajst-32576	198	14	t.r	t.r	PROPN
ajst-32576	198	15	.	.	PROPN
ajst-32576	198	16	rebbeck	rebbeck	PROPN
ajst-32576	198	17	,	,	PUNCT
ajst-32576	198	18	cancer	cancer	NOUN
ajst-32576	198	19	genomics	genomic	NOUN
ajst-32576	198	20	:	:	PUNCT
ajst-32576	198	21	diversity	diversity	NOUN
ajst-32576	198	22	and	and	CCONJ
ajst-32576	198	23	disparity	disparity	NOUN
ajst-32576	198	24	across	across	ADP
ajst-32576	198	25	ethnicity	ethnicity	NOUN
ajst-32576	198	26	and	and	CCONJ
ajst-32576	198	27	geography	geography	NOUN
ajst-32576	198	28	.	.	PUNCT
ajst-32576	199	1	j	j	PROPN
ajst-32576	199	2	clin	clin	PROPN
ajst-32576	199	3	oncol	oncol	PROPN
ajst-32576	199	4	,	,	PUNCT
ajst-32576	199	5	2016	2016	NUM
ajst-32576	199	6	.	.	PUNCT
ajst-32576	200	1	34(1	34(1	NUM
ajst-32576	200	2	):	):	PUNCT
ajst-32576	201	1	p.	p.	NOUN
ajst-32576	201	2	91	91	NUM
ajst-32576	201	3	-	-	SYM
ajst-32576	201	4	101	101	NUM
ajst-32576	201	5	.	.	PUNCT
ajst-32576	202	1	[	[	X
ajst-32576	202	2	11	11	NUM
ajst-32576	202	3	]	]	X
ajst-32576	202	4	lu	lu	PROPN
ajst-32576	202	5	,	,	PUNCT
ajst-32576	202	6	s.	s.	PROPN
ajst-32576	202	7	,	,	PUNCT
ajst-32576	202	8	et	et	PROPN
ajst-32576	202	9	al	al	PROPN
ajst-32576	202	10	.	.	PROPN
ajst-32576	202	11	,	,	PUNCT
ajst-32576	202	12	central	central	ADJ
ajst-32576	202	13	nervous	nervous	ADJ
ajst-32576	202	14	system	system	NOUN
ajst-32576	202	15	efficacy	efficacy	NOUN
ajst-32576	202	16	of	of	ADP
ajst-32576	202	17	aumolertinib	aumolertinib	NOUN
ajst-32576	202	18	versus	versus	ADP
ajst-32576	202	19	gefitinib	gefitinib	NOUN
ajst-32576	202	20	in	in	ADP
ajst-32576	202	21	patients	patient	NOUN
ajst-32576	202	22	with	with	ADP
ajst-32576	202	23	untreated	untreated	ADJ
ajst-32576	202	24	,	,	PUNCT
ajst-32576	202	25	egfr	egfr	NOUN
ajst-32576	202	26	-	-	PUNCT
ajst-32576	202	27	mutated	mutate	VERB
ajst-32576	202	28	,	,	PUNCT
ajst-32576	202	29	advanced	advanced	ADJ
ajst-32576	202	30	non	non	ADJ
ajst-32576	202	31	-	-	ADJ
ajst-32576	202	32	small	small	ADJ
ajst-32576	202	33	cell	cell	NOUN
ajst-32576	202	34	lung	lung	NOUN
ajst-32576	202	35	cancer	cancer	NOUN
ajst-32576	202	36	:	:	PUNCT
ajst-32576	202	37	data	datum	NOUN
ajst-32576	202	38	from	from	ADP
ajst-32576	202	39	a	a	DET
ajst-32576	202	40	randomized	randomized	ADJ
ajst-32576	202	41	phase	phase	NOUN
ajst-32576	202	42	iii	iii	NOUN
ajst-32576	202	43	trial	trial	NOUN
ajst-32576	202	44	(	(	PUNCT
ajst-32576	202	45	aeneas	aeneas	PROPN
ajst-32576	202	46	)	)	PUNCT
ajst-32576	202	47	.	.	PUNCT
ajst-32576	203	1	cancer	cancer	NOUN
ajst-32576	203	2	commun	commun	PROPN
ajst-32576	203	3	(	(	PUNCT
ajst-32576	203	4	lond	lond	PROPN
ajst-32576	203	5	)	)	PUNCT
ajst-32576	203	6	,	,	PUNCT
ajst-32576	203	7	2024	2024	NUM
ajst-32576	203	8	.	.	PUNCT
ajst-32576	204	1	44(9	44(9	NUM
ajst-32576	204	2	):	):	PUNCT
ajst-32576	204	3	p.	p.	NOUN
ajst-32576	204	4	1005	1005	NUM
ajst-32576	204	5	-	-	SYM
ajst-32576	204	6	1017	1017	NUM
ajst-32576	204	7	.	.	PUNCT
ajst-32576	205	1	[	[	X
ajst-32576	205	2	12	12	NUM
ajst-32576	205	3	]	]	X
ajst-32576	205	4	hou	hou	NOUN
ajst-32576	205	5	,	,	PUNCT
ajst-32576	205	6	x.	x.	PROPN
ajst-32576	205	7	,	,	PUNCT
ajst-32576	205	8	et	et	PROPN
ajst-32576	205	9	al	al	PROPN
ajst-32576	205	10	.	.	PROPN
ajst-32576	205	11	,	,	PUNCT
ajst-32576	205	12	gefitinib	gefitinib	NOUN
ajst-32576	205	13	plus	plus	CCONJ
ajst-32576	205	14	chemotherapy	chemotherapy	NOUN
ajst-32576	205	15	vs	vs	ADP
ajst-32576	205	16	gefitinib	gefitinib	NOUN
ajst-32576	205	17	alone	alone	ADJ
ajst-32576	205	18	in	in	ADP
ajst-32576	205	19	untreated	untreated	ADJ
ajst-32576	205	20	egfr	egfr	ADJ
ajst-32576	205	21	-	-	PUNCT
ajst-32576	205	22	mutant	mutant	ADJ
ajst-32576	205	23	non	non	ADJ
ajst-32576	205	24	-	-	ADJ
ajst-32576	205	25	small	small	ADJ
ajst-32576	205	26	cell	cell	NOUN
ajst-32576	205	27	lung	lung	NOUN
ajst-32576	205	28	cancer	cancer	NOUN
ajst-32576	205	29	in	in	ADP
ajst-32576	205	30	patients	patient	NOUN
ajst-32576	205	31	with	with	ADP
ajst-32576	205	32	brain	brain	NOUN
ajst-32576	205	33	metastases	metastasis	NOUN
ajst-32576	205	34	:	:	PUNCT
ajst-32576	205	35	the	the	DET
ajst-32576	205	36	gap	gap	NOUN
ajst-32576	205	37	brain	brain	NOUN
ajst-32576	205	38	open	open	ADJ
ajst-32576	205	39	-	-	PUNCT
ajst-32576	205	40	label	label	NOUN
ajst-32576	205	41	,	,	PUNCT
ajst-32576	205	42	randomized	randomize	VERB
ajst-32576	205	43	,	,	PUNCT
ajst-32576	205	44	multicenter	multicenter	NOUN
ajst-32576	205	45	,	,	PUNCT
ajst-32576	205	46	phase	phase	NOUN
ajst-32576	205	47	3	3	NUM
ajst-32576	205	48	study	study	NOUN
ajst-32576	205	49	.	.	PUNCT
ajst-32576	206	1	jama	jama	PROPN
ajst-32576	206	2	netw	netw	PROPN
ajst-32576	206	3	open	open	ADJ
ajst-32576	206	4	,	,	PUNCT
ajst-32576	206	5	2023	2023	NUM
ajst-32576	206	6	.	.	PUNCT
ajst-32576	207	1	6(2	6(2	NUM
ajst-32576	207	2	):	):	PUNCT
ajst-32576	208	1	p.	p.	NOUN
ajst-32576	208	2	e2255050	e2255050	PROPN
ajst-32576	208	3	.	.	PUNCT
ajst-32576	209	1	[	[	X
ajst-32576	209	2	13	13	NUM
ajst-32576	209	3	]	]	X
ajst-32576	209	4	zhou	zhou	PROPN
ajst-32576	209	5	,	,	PUNCT
ajst-32576	209	6	q.	q.	PROPN
ajst-32576	209	7	,	,	PUNCT
ajst-32576	209	8	et	et	PROPN
ajst-32576	209	9	al	al	PROPN
ajst-32576	209	10	.	.	PROPN
ajst-32576	209	11	,	,	PUNCT
ajst-32576	209	12	bevacizumab	bevacizumab	NOUN
ajst-32576	209	13	plus	plus	CCONJ
ajst-32576	209	14	erlotinib	erlotinib	NOUN
ajst-32576	209	15	in	in	ADP
ajst-32576	209	16	chinese	chinese	ADJ
ajst-32576	209	17	patients	patient	NOUN
ajst-32576	209	18	with	with	ADP
ajst-32576	209	19	untreated	untreated	ADJ
ajst-32576	209	20	,	,	PUNCT
ajst-32576	209	21	egfr	egfr	NOUN
ajst-32576	209	22	-	-	PUNCT
ajst-32576	209	23	mutated	mutate	VERB
ajst-32576	209	24	,	,	PUNCT
ajst-32576	209	25	advanced	advanced	ADJ
ajst-32576	209	26	nsclc	nsclc	NOUN
ajst-32576	209	27	(	(	PUNCT
ajst-32576	209	28	artemis	artemis	NOUN
ajst-32576	209	29	-	-	PUNCT
ajst-32576	209	30	ctong1509	ctong1509	PROPN
ajst-32576	209	31	):	):	PUNCT
ajst-32576	209	32	a	a	DET
ajst-32576	209	33	multicenter	multicenter	ADJ
ajst-32576	209	34	phase	phase	NOUN
ajst-32576	209	35	3	3	NUM
ajst-32576	209	36	study	study	NOUN
ajst-32576	209	37	.	.	PUNCT
ajst-32576	210	1	cancer	cancer	NOUN
ajst-32576	210	2	cell	cell	NOUN
ajst-32576	210	3	,	,	PUNCT
ajst-32576	210	4	2021	2021	NUM
ajst-32576	210	5	.	.	PUNCT
ajst-32576	211	1	39(9	39(9	NOUN
ajst-32576	211	2	):	):	PUNCT
ajst-32576	211	3	p.	p.	NOUN
ajst-32576	211	4	12791291.e3	12791291.e3	NUM
ajst-32576	211	5	.	.	PUNCT
ajst-32576	212	1	227	227	NUM
ajst-32576	213	1	[	[	SYM
ajst-32576	213	2	14	14	NUM
ajst-32576	213	3	]	]	X
ajst-32576	213	4	kim	kim	PROPN
ajst-32576	213	5	,	,	PUNCT
ajst-32576	213	6	j.	j.	PROPN
ajst-32576	213	7	,	,	PUNCT
ajst-32576	213	8	et	et	PROPN
ajst-32576	213	9	al	al	PROPN
ajst-32576	213	10	.	.	PROPN
ajst-32576	213	11	,	,	PUNCT
ajst-32576	213	12	real	real	ADJ
ajst-32576	213	13	-	-	PUNCT
ajst-32576	213	14	world	world	NOUN
ajst-32576	213	15	analysis	analysis	NOUN
ajst-32576	213	16	of	of	ADP
ajst-32576	213	17	first	first	ADJ
ajst-32576	213	18	-	-	PUNCT
ajst-32576	213	19	line	line	NOUN
ajst-32576	213	20	afatinib	afatinib	NOUN
ajst-32576	213	21	in	in	ADP
ajst-32576	213	22	patients	patient	NOUN
ajst-32576	213	23	with	with	ADP
ajst-32576	213	24	egfr	egfr	ADJ
ajst-32576	213	25	-	-	PUNCT
ajst-32576	213	26	mutant	mutant	ADJ
ajst-32576	213	27	non	non	ADJ
ajst-32576	213	28	-	-	ADJ
ajst-32576	213	29	small	small	ADJ
ajst-32576	213	30	cell	cell	NOUN
ajst-32576	213	31	lung	lung	NOUN
ajst-32576	213	32	cancer	cancer	NOUN
ajst-32576	213	33	and	and	CCONJ
ajst-32576	213	34	brain	brain	NOUN
ajst-32576	213	35	metastasis	metastasis	NOUN
ajst-32576	213	36	:	:	PUNCT
ajst-32576	213	37	survival	survival	NOUN
ajst-32576	213	38	and	and	CCONJ
ajst-32576	213	39	prognostic	prognostic	ADJ
ajst-32576	213	40	factors	factor	NOUN
ajst-32576	213	41	.	.	PUNCT
ajst-32576	214	1	transl	transl	PROPN
ajst-32576	214	2	lung	lung	NOUN
ajst-32576	214	3	cancer	cancer	NOUN
ajst-32576	214	4	res	re	NOUN
ajst-32576	214	5	,	,	PUNCT
ajst-32576	214	6	2023	2023	NUM
ajst-32576	214	7	.	.	PUNCT
ajst-32576	215	1	12(6	12(6	NUM
ajst-32576	215	2	):	):	PUNCT
ajst-32576	215	3	p.	p.	NOUN
ajst-32576	215	4	1197	1197	NUM
ajst-32576	215	5	-	-	SYM
ajst-32576	215	6	1209	1209	NUM
ajst-32576	215	7	.	.	PUNCT
ajst-32576	216	1	[	[	X
ajst-32576	216	2	15	15	NUM
ajst-32576	216	3	]	]	X
ajst-32576	216	4	jänne	jänne	PROPN
ajst-32576	216	5	,	,	PUNCT
ajst-32576	216	6	p.a	p.a	PROPN
ajst-32576	216	7	.	.	PROPN
ajst-32576	216	8	,	,	PUNCT
ajst-32576	216	9	et	et	PROPN
ajst-32576	216	10	al	al	PROPN
ajst-32576	216	11	.	.	PROPN
ajst-32576	216	12	,	,	PUNCT
ajst-32576	216	13	cns	cns	PROPN
ajst-32576	216	14	efficacy	efficacy	NOUN
ajst-32576	216	15	of	of	ADP
ajst-32576	216	16	osimertinib	osimertinib	NOUN
ajst-32576	216	17	with	with	ADP
ajst-32576	216	18	or	or	CCONJ
ajst-32576	216	19	without	without	ADP
ajst-32576	216	20	chemotherapy	chemotherapy	NOUN
ajst-32576	216	21	in	in	ADP
ajst-32576	216	22	epidermal	epidermal	ADJ
ajst-32576	216	23	growth	growth	NOUN
ajst-32576	216	24	factor	factor	NOUN
ajst-32576	216	25	receptor	receptor	NOUN
ajst-32576	216	26	-	-	PUNCT
ajst-32576	216	27	mutated	mutate	VERB
ajst-32576	216	28	advanced	advanced	ADJ
ajst-32576	216	29	non	non	ADJ
ajst-32576	216	30	-	-	ADJ
ajst-32576	216	31	small	small	ADJ
ajst-32576	216	32	-	-	PUNCT
ajst-32576	216	33	cell	cell	NOUN
ajst-32576	216	34	lung	lung	NOUN
ajst-32576	216	35	cancer	cancer	NOUN
ajst-32576	216	36	.	.	PUNCT
ajst-32576	217	1	j	j	PROPN
ajst-32576	217	2	clin	clin	PROPN
ajst-32576	217	3	oncol	oncol	PROPN
ajst-32576	217	4	,	,	PUNCT
ajst-32576	217	5	2024	2024	NUM
ajst-32576	217	6	.	.	PUNCT
ajst-32576	218	1	42(7	42(7	NOUN
ajst-32576	218	2	):	):	PUNCT
ajst-32576	218	3	p.	p.	NOUN
ajst-32576	218	4	808	808	NUM
ajst-32576	218	5	-	-	SYM
ajst-32576	218	6	820	820	NUM
ajst-32576	218	7	.	.	PUNCT
ajst-32576	219	1	[	[	X
ajst-32576	219	2	16	16	NUM
ajst-32576	219	3	]	]	X
ajst-32576	219	4	planchard	planchard	NOUN
ajst-32576	219	5	,	,	PUNCT
ajst-32576	219	6	d.	d.	PROPN
ajst-32576	219	7	,	,	PUNCT
ajst-32576	219	8	et	et	PROPN
ajst-32576	219	9	al	al	PROPN
ajst-32576	219	10	.	.	PROPN
ajst-32576	219	11	,	,	PUNCT
ajst-32576	219	12	osimertinib	osimertinib	NOUN
ajst-32576	219	13	with	with	ADP
ajst-32576	219	14	or	or	CCONJ
ajst-32576	219	15	without	without	ADP
ajst-32576	219	16	chemotherapy	chemotherapy	NOUN
ajst-32576	219	17	in	in	ADP
ajst-32576	219	18	egfr	egfr	NOUN
ajst-32576	219	19	-	-	PUNCT
ajst-32576	219	20	mutated	mutate	VERB
ajst-32576	219	21	advanced	advanced	ADJ
ajst-32576	219	22	nsclc	nsclc	NOUN
ajst-32576	219	23	.	.	PUNCT
ajst-32576	220	1	n	n	PROPN
ajst-32576	220	2	engl	engl	PROPN
ajst-32576	220	3	j	j	PROPN
ajst-32576	220	4	med	med	PROPN
ajst-32576	220	5	,	,	PUNCT
ajst-32576	220	6	2023	2023	NUM
ajst-32576	220	7	.	.	PUNCT
ajst-32576	221	1	389(21	389(21	NUM
ajst-32576	221	2	):	):	PUNCT
ajst-32576	221	3	p.	p.	NOUN
ajst-32576	221	4	1935	1935	NUM
ajst-32576	221	5	-	-	SYM
ajst-32576	221	6	1948	1948	NUM
ajst-32576	221	7	.	.	PUNCT
ajst-32576	222	1	[	[	X
ajst-32576	222	2	17	17	NUM
ajst-32576	222	3	]	]	X
ajst-32576	222	4	shaw	shaw	PROPN
ajst-32576	222	5	,	,	PUNCT
ajst-32576	222	6	a.t	a.t	PROPN
ajst-32576	222	7	.	.	PROPN
ajst-32576	222	8	and	and	CCONJ
ajst-32576	222	9	j.a	j.a	PROPN
ajst-32576	222	10	.	.	PROPN
ajst-32576	222	11	engelman	engelman	PROPN
ajst-32576	222	12	,	,	PUNCT
ajst-32576	222	13	alk	alk	VERB
ajst-32576	222	14	in	in	ADP
ajst-32576	222	15	lung	lung	NOUN
ajst-32576	222	16	cancer	cancer	NOUN
ajst-32576	222	17	:	:	PUNCT
ajst-32576	222	18	past	past	ADJ
ajst-32576	222	19	,	,	PUNCT
ajst-32576	222	20	present	present	ADJ
ajst-32576	222	21	,	,	PUNCT
ajst-32576	222	22	and	and	CCONJ
ajst-32576	222	23	future	future	NOUN
ajst-32576	222	24	.	.	PUNCT
ajst-32576	223	1	j	j	PROPN
ajst-32576	223	2	clin	clin	PROPN
ajst-32576	223	3	oncol	oncol	PROPN
ajst-32576	223	4	,	,	PUNCT
ajst-32576	223	5	2013	2013	NUM
ajst-32576	223	6	.	.	PUNCT
ajst-32576	224	1	31(8	31(8	NUM
ajst-32576	224	2	):	):	PUNCT
ajst-32576	225	1	p.	p.	NOUN
ajst-32576	225	2	1105	1105	NUM
ajst-32576	225	3	-	-	SYM
ajst-32576	225	4	11	11	NUM
ajst-32576	225	5	.	.	PUNCT
ajst-32576	226	1	[	[	X
ajst-32576	226	2	18	18	NUM
ajst-32576	226	3	]	]	X
ajst-32576	226	4	shi	shi	PROPN
ajst-32576	226	5	,	,	PUNCT
ajst-32576	226	6	y.	y.	PROPN
ajst-32576	226	7	,	,	PUNCT
ajst-32576	226	8	et	et	PROPN
ajst-32576	226	9	al	al	PROPN
ajst-32576	226	10	.	.	PROPN
ajst-32576	226	11	,	,	PUNCT
ajst-32576	226	12	iruplinalkib	iruplinalkib	PROPN
ajst-32576	226	13	(	(	PUNCT
ajst-32576	226	14	wx-0593	wx-0593	PROPN
ajst-32576	226	15	)	)	PUNCT
ajst-32576	226	16	versus	versus	ADP
ajst-32576	226	17	crizotinib	crizotinib	VERB
ajst-32576	226	18	in	in	ADP
ajst-32576	226	19	alk	alk	PROPN
ajst-32576	226	20	tki	tki	NOUN
ajst-32576	226	21	-	-	ADJ
ajst-32576	226	22	naive	naive	ADJ
ajst-32576	226	23	locally	locally	ADV
ajst-32576	226	24	advanced	advanced	ADJ
ajst-32576	226	25	or	or	CCONJ
ajst-32576	226	26	metastatic	metastatic	ADJ
ajst-32576	226	27	alk	alk	VERB
ajst-32576	226	28	-	-	PUNCT
ajst-32576	226	29	positive	positive	ADJ
ajst-32576	226	30	nsclc	nsclc	NOUN
ajst-32576	226	31	:	:	PUNCT
ajst-32576	226	32	interim	interim	ADJ
ajst-32576	226	33	analysis	analysis	NOUN
ajst-32576	226	34	of	of	ADP
ajst-32576	226	35	a	a	DET
ajst-32576	226	36	randomized	randomized	ADJ
ajst-32576	226	37	,	,	PUNCT
ajst-32576	226	38	open	open	ADJ
ajst-32576	226	39	-	-	PUNCT
ajst-32576	226	40	label	label	NOUN
ajst-32576	226	41	,	,	PUNCT
ajst-32576	226	42	phase	phase	NOUN
ajst-32576	226	43	3	3	NUM
ajst-32576	226	44	study	study	NOUN
ajst-32576	226	45	(	(	PUNCT
ajst-32576	226	46	inspire	inspire	NOUN
ajst-32576	226	47	)	)	PUNCT
ajst-32576	226	48	.	.	PUNCT
ajst-32576	227	1	j	j	PROPN
ajst-32576	227	2	thorac	thorac	PROPN
ajst-32576	227	3	oncol	oncol	ADJ
ajst-32576	227	4	,	,	PUNCT
ajst-32576	227	5	2024	2024	NUM
ajst-32576	227	6	.	.	PUNCT
ajst-32576	228	1	19(6	19(6	NUM
ajst-32576	228	2	):	):	PUNCT
ajst-32576	228	3	p.	p.	NOUN
ajst-32576	228	4	912	912	NUM
ajst-32576	228	5	-	-	SYM
ajst-32576	228	6	927	927	NUM
ajst-32576	228	7	.	.	PUNCT
ajst-32576	229	1	[	[	X
ajst-32576	229	2	19	19	NUM
ajst-32576	229	3	]	]	X
ajst-32576	229	4	solomon	solomon	PROPN
ajst-32576	229	5	,	,	PUNCT
ajst-32576	229	6	b.j	b.j	PROPN
ajst-32576	229	7	.	.	PROPN
ajst-32576	229	8	,	,	PUNCT
ajst-32576	229	9	et	et	PROPN
ajst-32576	229	10	al	al	PROPN
ajst-32576	229	11	.	.	PROPN
ajst-32576	229	12	,	,	PUNCT
ajst-32576	229	13	post	post	VERB
ajst-32576	229	14	hoc	hoc	ADJ
ajst-32576	229	15	analysis	analysis	NOUN
ajst-32576	229	16	of	of	ADP
ajst-32576	229	17	lorlatinib	lorlatinib	NOUN
ajst-32576	229	18	intracranial	intracranial	ADJ
ajst-32576	229	19	efficacy	efficacy	NOUN
ajst-32576	229	20	and	and	CCONJ
ajst-32576	229	21	safety	safety	NOUN
ajst-32576	229	22	in	in	ADP
ajst-32576	229	23	patients	patient	NOUN
ajst-32576	229	24	with	with	ADP
ajst-32576	229	25	alk	alk	NOUN
ajst-32576	229	26	-	-	PUNCT
ajst-32576	229	27	positive	positive	ADJ
ajst-32576	229	28	advanced	advanced	ADJ
ajst-32576	229	29	non	non	ADJ
ajst-32576	229	30	-	-	ADJ
ajst-32576	229	31	small	small	ADJ
ajst-32576	229	32	-	-	PUNCT
ajst-32576	229	33	cell	cell	NOUN
ajst-32576	229	34	lung	lung	NOUN
ajst-32576	229	35	cancer	cancer	NOUN
ajst-32576	229	36	from	from	ADP
ajst-32576	229	37	the	the	DET
ajst-32576	229	38	phase	phase	NOUN
ajst-32576	229	39	iii	iii	NUM
ajst-32576	229	40	crown	crown	NOUN
ajst-32576	229	41	study	study	NOUN
ajst-32576	229	42	.	.	PUNCT
ajst-32576	230	1	j	j	PROPN
ajst-32576	230	2	clin	clin	PROPN
ajst-32576	230	3	oncol	oncol	PROPN
ajst-32576	230	4	,	,	PUNCT
ajst-32576	230	5	2022	2022	NUM
ajst-32576	230	6	.	.	PUNCT
ajst-32576	231	1	40(31	40(31	NUM
ajst-32576	231	2	):	):	PUNCT
ajst-32576	231	3	p.	p.	NOUN
ajst-32576	231	4	3593	3593	NUM
ajst-32576	231	5	-	-	SYM
ajst-32576	231	6	3602	3602	NUM
ajst-32576	231	7	.	.	PUNCT
ajst-32576	232	1	[	[	X
ajst-32576	232	2	20	20	NUM
ajst-32576	232	3	]	]	PUNCT
ajst-32576	232	4	gadgeel	gadgeel	NOUN
ajst-32576	232	5	,	,	PUNCT
ajst-32576	232	6	s.	s.	PROPN
ajst-32576	232	7	,	,	PUNCT
ajst-32576	232	8	et	et	PROPN
ajst-32576	232	9	al	al	PROPN
ajst-32576	232	10	.	.	PROPN
ajst-32576	232	11	,	,	PUNCT
ajst-32576	232	12	alectinib	alectinib	NOUN
ajst-32576	232	13	versus	versus	ADP
ajst-32576	232	14	crizotinib	crizotinib	VERB
ajst-32576	232	15	in	in	ADP
ajst-32576	232	16	treatment	treatment	NOUN
ajst-32576	232	17	-	-	PUNCT
ajst-32576	232	18	naive	naive	ADJ
ajst-32576	232	19	anaplastic	anaplastic	ADJ
ajst-32576	232	20	lymphoma	lymphoma	NOUN
ajst-32576	232	21	kinase	kinase	NOUN
ajst-32576	232	22	-	-	PUNCT
ajst-32576	232	23	positive	positive	ADJ
ajst-32576	232	24	(	(	PUNCT
ajst-32576	232	25	alk+	alk+	NOUN
ajst-32576	232	26	)	)	PUNCT
ajst-32576	232	27	non	non	ADJ
ajst-32576	232	28	-	-	ADJ
ajst-32576	232	29	small	small	ADJ
ajst-32576	232	30	-	-	PUNCT
ajst-32576	232	31	cell	cell	NOUN
ajst-32576	232	32	lung	lung	NOUN
ajst-32576	232	33	cancer	cancer	NOUN
ajst-32576	232	34	:	:	PUNCT
ajst-32576	232	35	cns	cns	PROPN
ajst-32576	232	36	efficacy	efficacy	NOUN
ajst-32576	232	37	results	result	NOUN
ajst-32576	232	38	from	from	ADP
ajst-32576	232	39	the	the	DET
ajst-32576	232	40	alex	alex	PROPN
ajst-32576	232	41	study	study	PROPN
ajst-32576	232	42	.	.	PUNCT
ajst-32576	233	1	ann	ann	PROPN
ajst-32576	233	2	oncol	oncol	PROPN
ajst-32576	233	3	,	,	PUNCT
ajst-32576	233	4	2018	2018	NUM
ajst-32576	233	5	.	.	PUNCT
ajst-32576	234	1	29(11	29(11	NUM
ajst-32576	234	2	):	):	PUNCT
ajst-32576	235	1	p.	p.	NOUN
ajst-32576	235	2	2214	2214	NUM
ajst-32576	235	3	-	-	SYM
ajst-32576	235	4	2222	2222	NUM
ajst-32576	235	5	.	.	PUNCT
ajst-32576	236	1	[	[	X
ajst-32576	236	2	21	21	NUM
ajst-32576	236	3	]	]	X
ajst-32576	236	4	camidge	camidge	NOUN
ajst-32576	236	5	,	,	PUNCT
ajst-32576	236	6	d.r	d.r	PROPN
ajst-32576	236	7	.	.	PROPN
ajst-32576	236	8	,	,	PUNCT
ajst-32576	236	9	et	et	PROPN
ajst-32576	236	10	al	al	PROPN
ajst-32576	236	11	.	.	PROPN
ajst-32576	236	12	,	,	PUNCT
ajst-32576	236	13	updated	update	VERB
ajst-32576	236	14	efficacy	efficacy	NOUN
ajst-32576	236	15	and	and	CCONJ
ajst-32576	236	16	safety	safety	NOUN
ajst-32576	236	17	data	datum	NOUN
ajst-32576	236	18	and	and	CCONJ
ajst-32576	236	19	impact	impact	NOUN
ajst-32576	236	20	of	of	ADP
ajst-32576	236	21	the	the	DET
ajst-32576	236	22	eml4	eml4	PROPN
ajst-32576	236	23	-	-	PUNCT
ajst-32576	236	24	alk	alk	PROPN
ajst-32576	236	25	fusion	fusion	NOUN
ajst-32576	236	26	variant	variant	NOUN
ajst-32576	236	27	on	on	ADP
ajst-32576	236	28	the	the	DET
ajst-32576	236	29	efficacy	efficacy	NOUN
ajst-32576	236	30	of	of	ADP
ajst-32576	236	31	alectinib	alectinib	NOUN
ajst-32576	236	32	in	in	ADP
ajst-32576	236	33	untreated	untreated	ADJ
ajst-32576	236	34	alk	alk	PROPN
ajst-32576	236	35	-	-	PUNCT
ajst-32576	236	36	positive	positive	ADJ
ajst-32576	236	37	advanced	advanced	ADJ
ajst-32576	236	38	non	non	ADJ
ajst-32576	236	39	-	-	ADJ
ajst-32576	236	40	small	small	ADJ
ajst-32576	236	41	cell	cell	NOUN
ajst-32576	236	42	lung	lung	NOUN
ajst-32576	236	43	cancer	cancer	NOUN
ajst-32576	236	44	in	in	ADP
ajst-32576	236	45	the	the	DET
ajst-32576	236	46	global	global	ADJ
ajst-32576	236	47	phase	phase	NOUN
ajst-32576	236	48	iii	iii	NUM
ajst-32576	236	49	alex	alex	PROPN
ajst-32576	236	50	study	study	PROPN
ajst-32576	236	51	.	.	PUNCT
ajst-32576	237	1	j	j	PROPN
ajst-32576	237	2	thorac	thorac	PROPN
ajst-32576	237	3	oncol	oncol	ADJ
ajst-32576	237	4	,	,	PUNCT
ajst-32576	237	5	2019	2019	NUM
ajst-32576	237	6	.	.	PUNCT
ajst-32576	238	1	14(7	14(7	NUM
ajst-32576	238	2	):	):	PUNCT
ajst-32576	238	3	p.	p.	NOUN
ajst-32576	238	4	1233	1233	NUM
ajst-32576	238	5	-	-	SYM
ajst-32576	238	6	1243	1243	NUM
ajst-32576	238	7	.	.	PUNCT
ajst-32576	239	1	[	[	X
ajst-32576	239	2	22	22	NUM
ajst-32576	239	3	]	]	PUNCT
ajst-32576	239	4	camidge	camidge	NOUN
ajst-32576	239	5	,	,	PUNCT
ajst-32576	239	6	d.r	d.r	PROPN
ajst-32576	239	7	.	.	PROPN
ajst-32576	239	8	,	,	PUNCT
ajst-32576	239	9	et	et	PROPN
ajst-32576	239	10	al	al	PROPN
ajst-32576	239	11	.	.	PROPN
ajst-32576	239	12	,	,	PUNCT
ajst-32576	239	13	brigatinib	brigatinib	NOUN
ajst-32576	239	14	versus	versus	ADP
ajst-32576	239	15	crizotinib	crizotinib	VERB
ajst-32576	239	16	in	in	ADP
ajst-32576	239	17	alk	alk	NOUN
ajst-32576	239	18	inhibitor	inhibitor	NOUN
ajst-32576	239	19	-	-	PUNCT
ajst-32576	239	20	naive	naive	ADJ
ajst-32576	239	21	advanced	advanced	ADJ
ajst-32576	239	22	alk	alk	VERB
ajst-32576	239	23	-	-	PUNCT
ajst-32576	239	24	positive	positive	ADJ
ajst-32576	239	25	nsclc	nsclc	NOUN
ajst-32576	239	26	:	:	PUNCT
ajst-32576	239	27	final	final	ADJ
ajst-32576	239	28	results	result	NOUN
ajst-32576	239	29	of	of	ADP
ajst-32576	239	30	phase	phase	NOUN
ajst-32576	239	31	3	3	NUM
ajst-32576	239	32	alta-1l	alta-1l	PUNCT
ajst-32576	239	33	trial	trial	NOUN
ajst-32576	239	34	.	.	PUNCT
ajst-32576	240	1	j	j	PROPN
ajst-32576	240	2	thorac	thorac	PROPN
ajst-32576	240	3	oncol	oncol	ADJ
ajst-32576	240	4	,	,	PUNCT
ajst-32576	240	5	2021	2021	NUM
ajst-32576	240	6	.	.	PUNCT
ajst-32576	241	1	16(12	16(12	NUM
ajst-32576	241	2	):	):	PUNCT
ajst-32576	241	3	p.	p.	NOUN
ajst-32576	241	4	2091	2091	NUM
ajst-32576	241	5	-	-	SYM
ajst-32576	241	6	2108	2108	NUM
ajst-32576	241	7	.	.	PUNCT
ajst-32576	242	1	[	[	X
ajst-32576	242	2	23	23	NUM
ajst-32576	242	3	]	]	X
ajst-32576	242	4	solomon	solomon	PROPN
ajst-32576	242	5	,	,	PUNCT
ajst-32576	242	6	b.j	b.j	PROPN
ajst-32576	242	7	.	.	PROPN
ajst-32576	242	8	,	,	PUNCT
ajst-32576	242	9	et	et	PROPN
ajst-32576	242	10	al	al	PROPN
ajst-32576	242	11	.	.	PROPN
ajst-32576	242	12	,	,	PUNCT
ajst-32576	242	13	lorlatinib	lorlatinib	NOUN
ajst-32576	242	14	versus	versus	ADP
ajst-32576	242	15	crizotinib	crizotinib	NOUN
ajst-32576	242	16	in	in	ADP
ajst-32576	242	17	patients	patient	NOUN
ajst-32576	242	18	with	with	ADP
ajst-32576	242	19	advanced	advanced	ADJ
ajst-32576	242	20	alk	alk	VERB
ajst-32576	242	21	-	-	PUNCT
ajst-32576	242	22	positive	positive	ADJ
ajst-32576	242	23	non	non	ADJ
ajst-32576	242	24	-	-	ADJ
ajst-32576	242	25	small	small	ADJ
ajst-32576	242	26	cell	cell	NOUN
ajst-32576	242	27	lung	lung	NOUN
ajst-32576	242	28	cancer	cancer	NOUN
ajst-32576	242	29	:	:	PUNCT
ajst-32576	242	30	5	5	NUM
ajst-32576	242	31	-	-	PUNCT
ajst-32576	242	32	year	year	NOUN
ajst-32576	242	33	outcomes	outcome	NOUN
ajst-32576	242	34	from	from	ADP
ajst-32576	242	35	the	the	DET
ajst-32576	242	36	phase	phase	NOUN
ajst-32576	242	37	iii	iii	NUM
ajst-32576	242	38	crown	crown	NOUN
ajst-32576	242	39	study	study	NOUN
ajst-32576	242	40	.	.	PUNCT
ajst-32576	243	1	j	j	PROPN
ajst-32576	243	2	clin	clin	PROPN
ajst-32576	243	3	oncol	oncol	PROPN
ajst-32576	243	4	,	,	PUNCT
ajst-32576	243	5	2024	2024	NUM
ajst-32576	243	6	.	.	PUNCT
ajst-32576	244	1	42(29	42(29	NUM
ajst-32576	244	2	):	):	PUNCT
ajst-32576	244	3	p.	p.	NOUN
ajst-32576	244	4	3400	3400	NUM
ajst-32576	244	5	-	-	SYM
ajst-32576	244	6	3409	3409	NUM
ajst-32576	244	7	.	.	PUNCT
ajst-32576	245	1	[	[	X
ajst-32576	245	2	24	24	NUM
ajst-32576	245	3	]	]	SYM
ajst-32576	245	4	drilon	drilon	NOUN
ajst-32576	245	5	,	,	PUNCT
ajst-32576	245	6	a.	a.	PROPN
ajst-32576	245	7	,	,	PUNCT
ajst-32576	245	8	s.	s.	PROPN
ajst-32576	245	9	siena	siena	PROPN
ajst-32576	245	10	,	,	PUNCT
ajst-32576	245	11	and	and	CCONJ
ajst-32576	245	12	r.	r.	PROPN
ajst-32576	245	13	dziadziuszko	dziadziuszko	PROPN
ajst-32576	245	14	,	,	PUNCT
ajst-32576	245	15	entrectinib	entrectinib	NOUN
ajst-32576	245	16	in	in	ADP
ajst-32576	245	17	ros1	ros1	PROPN
ajst-32576	245	18	fusionpositive	fusionpositive	ADJ
ajst-32576	245	19	non	non	ADJ
ajst-32576	245	20	-	-	ADJ
ajst-32576	245	21	small	small	ADJ
ajst-32576	245	22	-	-	PUNCT
ajst-32576	245	23	cell	cell	NOUN
ajst-32576	245	24	lung	lung	NOUN
ajst-32576	245	25	cancer	cancer	NOUN
ajst-32576	245	26	:	:	PUNCT
ajst-32576	245	27	integrated	integrate	VERB
ajst-32576	245	28	analysis	analysis	NOUN
ajst-32576	245	29	of	of	ADP
ajst-32576	245	30	three	three	NUM
ajst-32576	245	31	phase	phase	NOUN
ajst-32576	245	32	1	1	NUM
ajst-32576	245	33	-	-	SYM
ajst-32576	245	34	2	2	NUM
ajst-32576	245	35	trials	trial	NOUN
ajst-32576	245	36	.	.	PUNCT
ajst-32576	246	1	lancet	lancet	PROPN
ajst-32576	246	2	oncol	oncol	PROPN
ajst-32576	246	3	,	,	PUNCT
ajst-32576	246	4	2020	2020	NUM
ajst-32576	246	5	.	.	PUNCT
ajst-32576	247	1	21	21	NUM
ajst-32576	247	2	:	:	PUNCT
ajst-32576	248	1	p.	p.	NOUN
ajst-32576	248	2	261	261	NUM
ajst-32576	248	3	-	-	SYM
ajst-32576	248	4	270	270	NUM
ajst-32576	248	5	.	.	PUNCT
ajst-32576	249	1	[	[	X
ajst-32576	249	2	25	25	NUM
ajst-32576	249	3	]	]	X
ajst-32576	249	4	drilon	drilon	NOUN
ajst-32576	249	5	,	,	PUNCT
ajst-32576	249	6	a.	a.	PROPN
ajst-32576	249	7	,	,	PUNCT
ajst-32576	249	8	d.	d.	PROPN
ajst-32576	249	9	camidge	camidge	PROPN
ajst-32576	249	10	,	,	PUNCT
ajst-32576	249	11	and	and	CCONJ
ajst-32576	249	12	j.	j.	PROPN
ajst-32576	249	13	lin	lin	PROPN
ajst-32576	249	14	,	,	PUNCT
ajst-32576	249	15	repotrectinib	repotrectinib	NOUN
ajst-32576	249	16	in	in	ADP
ajst-32576	249	17	ros1	ros1	PROPN
ajst-32576	249	18	fusion	fusion	NOUN
ajst-32576	249	19	-	-	PUNCT
ajst-32576	249	20	positive	positive	ADJ
ajst-32576	249	21	non	non	ADJ
ajst-32576	249	22	-	-	ADJ
ajst-32576	249	23	small	small	ADJ
ajst-32576	249	24	-	-	PUNCT
ajst-32576	249	25	cell	cell	NOUN
ajst-32576	249	26	lung	lung	NOUN
ajst-32576	249	27	cancer	cancer	NOUN
ajst-32576	249	28	.	.	PUNCT
ajst-32576	250	1	n	n	PROPN
ajst-32576	250	2	engl	engl	PROPN
ajst-32576	250	3	j	j	PROPN
ajst-32576	250	4	med	med	PROPN
ajst-32576	250	5	,	,	PUNCT
ajst-32576	250	6	2024	2024	NUM
ajst-32576	250	7	.	.	PUNCT
ajst-32576	251	1	390	390	NUM
ajst-32576	251	2	:	:	PUNCT
ajst-32576	252	1	p.	p.	NOUN
ajst-32576	252	2	118	118	NUM
ajst-32576	252	3	-	-	SYM
ajst-32576	252	4	131	131	NUM
ajst-32576	252	5	.	.	PUNCT
ajst-32576	253	1	[	[	X
ajst-32576	253	2	26	26	NUM
ajst-32576	253	3	]	]	X
ajst-32576	253	4	planchard	planchard	NOUN
ajst-32576	253	5	,	,	PUNCT
ajst-32576	253	6	d.	d.	PROPN
ajst-32576	253	7	,	,	PUNCT
ajst-32576	253	8	et	et	PROPN
ajst-32576	253	9	al	al	PROPN
ajst-32576	253	10	.	.	PROPN
ajst-32576	253	11	,	,	PUNCT
ajst-32576	253	12	braf(v600e)-mutant	braf(v600e)-mutant	PROPN
ajst-32576	253	13	metastatic	metastatic	ADJ
ajst-32576	253	14	nsclc	nsclc	NOUN
ajst-32576	253	15	:	:	PUNCT
ajst-32576	253	16	disease	disease	NOUN
ajst-32576	253	17	overview	overview	NOUN
ajst-32576	253	18	and	and	CCONJ
ajst-32576	253	19	treatment	treatment	NOUN
ajst-32576	253	20	landscape	landscape	NOUN
ajst-32576	253	21	.	.	PUNCT
ajst-32576	254	1	npj	npj	PROPN
ajst-32576	254	2	precis	precis	PROPN
ajst-32576	254	3	oncol	oncol	ADJ
ajst-32576	254	4	,	,	PUNCT
ajst-32576	254	5	2024	2024	NUM
ajst-32576	254	6	.	.	PUNCT
ajst-32576	255	1	8(1	8(1	NOUN
ajst-32576	255	2	):	):	PUNCT
ajst-32576	255	3	p.	p.	NOUN
ajst-32576	255	4	90	90	NUM
ajst-32576	255	5	.	.	PUNCT
ajst-32576	256	1	[	[	X
ajst-32576	256	2	27	27	NUM
ajst-32576	256	3	]	]	X
ajst-32576	256	4	planchard	planchard	NOUN
ajst-32576	256	5	,	,	PUNCT
ajst-32576	256	6	d.	d.	PROPN
ajst-32576	256	7	,	,	PUNCT
ajst-32576	256	8	et	et	PROPN
ajst-32576	256	9	al	al	PROPN
ajst-32576	256	10	.	.	PROPN
ajst-32576	256	11	,	,	PUNCT
ajst-32576	256	12	dabrafenib	dabrafenib	NOUN
ajst-32576	256	13	plus	plus	CCONJ
ajst-32576	256	14	trametinib	trametinib	NOUN
ajst-32576	256	15	in	in	ADP
ajst-32576	256	16	patients	patient	NOUN
ajst-32576	256	17	with	with	ADP
ajst-32576	256	18	previously	previously	ADV
ajst-32576	256	19	treated	treat	VERB
ajst-32576	256	20	braf(v600e)-mutant	braf(v600e)-mutant	NOUN
ajst-32576	256	21	metastatic	metastatic	ADJ
ajst-32576	256	22	non	non	ADJ
ajst-32576	256	23	-	-	ADJ
ajst-32576	256	24	small	small	ADJ
ajst-32576	256	25	cell	cell	NOUN
ajst-32576	256	26	lung	lung	NOUN
ajst-32576	256	27	cancer	cancer	NOUN
ajst-32576	256	28	:	:	PUNCT
ajst-32576	256	29	an	an	DET
ajst-32576	256	30	open	open	ADJ
ajst-32576	256	31	-	-	PUNCT
ajst-32576	256	32	label	label	NOUN
ajst-32576	256	33	,	,	PUNCT
ajst-32576	256	34	multicentre	multicentre	NOUN
ajst-32576	256	35	phase	phase	NOUN
ajst-32576	256	36	2	2	NUM
ajst-32576	256	37	trial	trial	NOUN
ajst-32576	256	38	.	.	PUNCT
ajst-32576	257	1	lancet	lancet	PROPN
ajst-32576	257	2	oncol	oncol	PROPN
ajst-32576	257	3	,	,	PUNCT
ajst-32576	257	4	2016	2016	NUM
ajst-32576	257	5	.	.	PUNCT
ajst-32576	258	1	17(7	17(7	NUM
ajst-32576	258	2	):	):	PUNCT
ajst-32576	259	1	p.	p.	NOUN
ajst-32576	259	2	984	984	NUM
ajst-32576	259	3	-	-	SYM
ajst-32576	259	4	993	993	NUM
ajst-32576	259	5	.	.	PUNCT
ajst-32576	260	1	[	[	X
ajst-32576	260	2	28	28	NUM
ajst-32576	260	3	]	]	X
ajst-32576	260	4	doebele	doebele	PROPN
ajst-32576	260	5	,	,	PUNCT
ajst-32576	260	6	r.c	r.c	PROPN
ajst-32576	260	7	.	.	PROPN
ajst-32576	260	8	,	,	PUNCT
ajst-32576	260	9	et	et	PROPN
ajst-32576	260	10	al	al	PROPN
ajst-32576	260	11	.	.	PROPN
ajst-32576	260	12	,	,	PUNCT
ajst-32576	260	13	entrectinib	entrectinib	NOUN
ajst-32576	260	14	in	in	ADP
ajst-32576	260	15	patients	patient	NOUN
ajst-32576	260	16	with	with	ADP
ajst-32576	260	17	advanced	advanced	ADJ
ajst-32576	260	18	or	or	CCONJ
ajst-32576	260	19	metastatic	metastatic	ADJ
ajst-32576	260	20	ntrk	ntrk	NOUN
ajst-32576	260	21	fusion	fusion	NOUN
ajst-32576	260	22	-	-	PUNCT
ajst-32576	260	23	positive	positive	ADJ
ajst-32576	260	24	solid	solid	ADJ
ajst-32576	260	25	tumours	tumour	NOUN
ajst-32576	260	26	:	:	PUNCT
ajst-32576	260	27	integrated	integrate	VERB
ajst-32576	260	28	analysis	analysis	NOUN
ajst-32576	260	29	of	of	ADP
ajst-32576	260	30	three	three	NUM
ajst-32576	260	31	phase	phase	NOUN
ajst-32576	260	32	1	1	NUM
ajst-32576	260	33	-	-	SYM
ajst-32576	260	34	2	2	NUM
ajst-32576	260	35	trials	trial	NOUN
ajst-32576	260	36	.	.	PUNCT
ajst-32576	261	1	lancet	lancet	PROPN
ajst-32576	261	2	oncol	oncol	PROPN
ajst-32576	261	3	,	,	PUNCT
ajst-32576	261	4	2020	2020	NUM
ajst-32576	261	5	.	.	PUNCT
ajst-32576	262	1	21(2	21(2	NUM
ajst-32576	262	2	):	):	PUNCT
ajst-32576	262	3	p.	p.	NOUN
ajst-32576	262	4	271	271	NUM
ajst-32576	262	5	-	-	SYM
ajst-32576	262	6	282	282	NUM
ajst-32576	262	7	.	.	PUNCT
ajst-32576	263	1	[	[	X
ajst-32576	263	2	29	29	NUM
ajst-32576	263	3	]	]	X
ajst-32576	263	4	wolf	wolf	PROPN
ajst-32576	263	5	,	,	PUNCT
ajst-32576	263	6	j.	j.	PROPN
ajst-32576	263	7	,	,	PUNCT
ajst-32576	263	8	et	et	PROPN
ajst-32576	263	9	al	al	PROPN
ajst-32576	263	10	.	.	PROPN
ajst-32576	263	11	,	,	PUNCT
ajst-32576	263	12	capmatinib	capmatinib	NOUN
ajst-32576	263	13	in	in	ADP
ajst-32576	263	14	met	meet	VERB
ajst-32576	263	15	exon	exon	PROPN
ajst-32576	263	16	14	14	NUM
ajst-32576	263	17	-	-	PUNCT
ajst-32576	263	18	mutated	mutate	VERB
ajst-32576	263	19	or	or	CCONJ
ajst-32576	263	20	met	met	AUX
ajst-32576	263	21	-	-	PUNCT
ajst-32576	263	22	amplified	amplify	VERB
ajst-32576	263	23	non	non	ADJ
ajst-32576	263	24	-	-	ADJ
ajst-32576	263	25	small	small	ADJ
ajst-32576	263	26	-	-	PUNCT
ajst-32576	263	27	cell	cell	NOUN
ajst-32576	263	28	lung	lung	NOUN
ajst-32576	263	29	cancer	cancer	NOUN
ajst-32576	263	30	.	.	PUNCT
ajst-32576	264	1	n	n	PROPN
ajst-32576	264	2	engl	engl	PROPN
ajst-32576	264	3	j	j	PROPN
ajst-32576	264	4	med	med	PROPN
ajst-32576	264	5	,	,	PUNCT
ajst-32576	264	6	2020	2020	NUM
ajst-32576	264	7	.	.	PUNCT
ajst-32576	265	1	383(10	383(10	NUM
ajst-32576	265	2	):	):	PUNCT
ajst-32576	266	1	p.	p.	NOUN
ajst-32576	266	2	944	944	NUM
ajst-32576	266	3	-	-	SYM
ajst-32576	266	4	957	957	NUM
ajst-32576	266	5	.	.	PUNCT
ajst-32576	267	1	[	[	X
ajst-32576	267	2	30	30	NUM
ajst-32576	267	3	]	]	X
ajst-32576	267	4	schrock	schrock	NOUN
ajst-32576	267	5	,	,	PUNCT
ajst-32576	267	6	a.b	a.b	PROPN
ajst-32576	267	7	.	.	PROPN
ajst-32576	267	8	,	,	PUNCT
ajst-32576	267	9	et	et	PROPN
ajst-32576	267	10	al	al	PROPN
ajst-32576	267	11	.	.	PROPN
ajst-32576	267	12	,	,	PUNCT
ajst-32576	267	13	characterization	characterization	NOUN
ajst-32576	267	14	of	of	ADP
ajst-32576	267	15	298	298	NUM
ajst-32576	267	16	patients	patient	NOUN
ajst-32576	267	17	with	with	ADP
ajst-32576	267	18	lung	lung	NOUN
ajst-32576	267	19	cancer	cancer	NOUN
ajst-32576	267	20	harboring	harboring	NOUN
ajst-32576	267	21	met	meet	VERB
ajst-32576	267	22	exon	exon	NOUN
ajst-32576	267	23	14	14	NUM
ajst-32576	267	24	skipping	skip	VERB
ajst-32576	267	25	alterations	alteration	NOUN
ajst-32576	267	26	.	.	PUNCT
ajst-32576	268	1	j	j	PROPN
ajst-32576	268	2	thorac	thorac	PROPN
ajst-32576	268	3	oncol	oncol	ADJ
ajst-32576	268	4	,	,	PUNCT
ajst-32576	268	5	2016	2016	NUM
ajst-32576	268	6	.	.	PUNCT
ajst-32576	269	1	11(9	11(9	NUM
ajst-32576	269	2	):	):	PUNCT
ajst-32576	269	3	p.	p.	NOUN
ajst-32576	269	4	1493	1493	NUM
ajst-32576	269	5	-	-	SYM
ajst-32576	269	6	502	502	NUM
ajst-32576	269	7	.	.	PUNCT
ajst-32576	270	1	[	[	X
ajst-32576	270	2	31	31	NUM
ajst-32576	270	3	]	]	X
ajst-32576	270	4	zhou	zhou	PROPN
ajst-32576	270	5	,	,	PUNCT
ajst-32576	270	6	c.	c.	PROPN
ajst-32576	270	7	,	,	PUNCT
ajst-32576	270	8	et	et	PROPN
ajst-32576	270	9	al	al	PROPN
ajst-32576	270	10	.	.	PROPN
ajst-32576	270	11	,	,	PUNCT
ajst-32576	270	12	first	first	ADJ
ajst-32576	270	13	-	-	PUNCT
ajst-32576	270	14	line	line	NOUN
ajst-32576	270	15	selpercatinib	selpercatinib	NOUN
ajst-32576	270	16	or	or	CCONJ
ajst-32576	270	17	chemotherapy	chemotherapy	NOUN
ajst-32576	270	18	and	and	CCONJ
ajst-32576	270	19	pembrolizumab	pembrolizumab	NOUN
ajst-32576	270	20	in	in	ADP
ajst-32576	270	21	ret	ret	NOUN
ajst-32576	270	22	fusion	fusion	NOUN
ajst-32576	270	23	-	-	PUNCT
ajst-32576	270	24	positive	positive	ADJ
ajst-32576	270	25	nsclc	nsclc	NOUN
ajst-32576	270	26	.	.	PUNCT
ajst-32576	271	1	n	n	PROPN
ajst-32576	271	2	engl	engl	PROPN
ajst-32576	271	3	j	j	PROPN
ajst-32576	271	4	med	med	PROPN
ajst-32576	271	5	,	,	PUNCT
ajst-32576	271	6	2023	2023	NUM
ajst-32576	271	7	.	.	PUNCT
ajst-32576	272	1	389(20	389(20	NUM
ajst-32576	272	2	):	):	PUNCT
ajst-32576	272	3	p.	p.	NOUN
ajst-32576	272	4	1839	1839	NUM
ajst-32576	272	5	-	-	SYM
ajst-32576	272	6	1850	1850	NUM
ajst-32576	272	7	.	.	PUNCT
ajst-32576	273	1	[	[	X
ajst-32576	273	2	32	32	NUM
ajst-32576	273	3	]	]	SYM
ajst-32576	273	4	li	li	PROPN
ajst-32576	273	5	,	,	PUNCT
ajst-32576	273	6	b.	b.	PROPN
ajst-32576	273	7	,	,	PUNCT
ajst-32576	273	8	e.	e.	PROPN
ajst-32576	273	9	smit	smit	PROPN
ajst-32576	273	10	,	,	PUNCT
ajst-32576	273	11	and	and	CCONJ
ajst-32576	273	12	y.	y.	PROPN
ajst-32576	273	13	goto	goto	PROPN
ajst-32576	273	14	,	,	PUNCT
ajst-32576	273	15	trastuzumab	trastuzumab	NOUN
ajst-32576	273	16	deruxtecan	deruxtecan	NOUN
ajst-32576	273	17	in	in	ADP
ajst-32576	273	18	her2	her2	NOUN
ajst-32576	273	19	-	-	PUNCT
ajst-32576	273	20	mutant	mutant	ADJ
ajst-32576	273	21	non	non	ADJ
ajst-32576	273	22	-	-	ADJ
ajst-32576	273	23	small	small	ADJ
ajst-32576	273	24	-	-	PUNCT
ajst-32576	273	25	cell	cell	NOUN
ajst-32576	273	26	lung	lung	NOUN
ajst-32576	273	27	cancer	cancer	NOUN
ajst-32576	273	28	.	.	PUNCT
ajst-32576	274	1	n	n	PROPN
ajst-32576	274	2	engl	engl	PROPN
ajst-32576	274	3	j	j	PROPN
ajst-32576	274	4	med	med	PROPN
ajst-32576	274	5	,	,	PUNCT
ajst-32576	274	6	2022	2022	NUM
ajst-32576	274	7	.	.	PUNCT
ajst-32576	275	1	386	386	NUM
ajst-32576	275	2	:	:	PUNCT
ajst-32576	275	3	p.	p.	NOUN
ajst-32576	275	4	241	241	NUM
ajst-32576	275	5	-	-	SYM
ajst-32576	275	6	251	251	NUM
ajst-32576	275	7	.	.	PUNCT
ajst-32576	276	1	[	[	X
ajst-32576	276	2	33	33	NUM
ajst-32576	276	3	]	]	X
ajst-32576	276	4	powell	powell	PROPN
ajst-32576	276	5	,	,	PUNCT
ajst-32576	276	6	s.f	s.f	PROPN
ajst-32576	276	7	.	.	PROPN
ajst-32576	276	8	,	,	PUNCT
ajst-32576	276	9	et	et	PROPN
ajst-32576	276	10	al	al	PROPN
ajst-32576	276	11	.	.	PROPN
ajst-32576	276	12	,	,	PUNCT
ajst-32576	276	13	outcomes	outcome	NOUN
ajst-32576	276	14	with	with	ADP
ajst-32576	276	15	pembrolizumab	pembrolizumab	NOUN
ajst-32576	276	16	plus	plus	CCONJ
ajst-32576	276	17	platinum	platinum	NOUN
ajst-32576	276	18	-	-	PUNCT
ajst-32576	276	19	based	base	VERB
ajst-32576	276	20	chemotherapy	chemotherapy	NOUN
ajst-32576	276	21	for	for	ADP
ajst-32576	276	22	patients	patient	NOUN
ajst-32576	276	23	with	with	ADP
ajst-32576	276	24	nsclc	nsclc	NOUN
ajst-32576	276	25	and	and	CCONJ
ajst-32576	276	26	stable	stable	ADJ
ajst-32576	276	27	brain	brain	NOUN
ajst-32576	276	28	metastases	metastasis	NOUN
ajst-32576	276	29	:	:	PUNCT
ajst-32576	276	30	pooled	pool	VERB
ajst-32576	276	31	analysis	analysis	NOUN
ajst-32576	276	32	of	of	ADP
ajst-32576	276	33	keynote-021	keynote-021	NOUN
ajst-32576	276	34	,	,	PUNCT
ajst-32576	276	35	-189	-189	PROPN
ajst-32576	276	36	,	,	PUNCT
ajst-32576	276	37	and	and	CCONJ
ajst-32576	276	38	-407	-407	PROPN
ajst-32576	276	39	.	.	PUNCT
ajst-32576	277	1	j	j	PROPN
ajst-32576	277	2	thorac	thorac	PROPN
ajst-32576	277	3	oncol	oncol	ADJ
ajst-32576	277	4	,	,	PUNCT
ajst-32576	277	5	2021	2021	NUM
ajst-32576	277	6	.	.	PUNCT
ajst-32576	278	1	16(11	16(11	NUM
ajst-32576	278	2	):	):	PUNCT
ajst-32576	278	3	p.	p.	NOUN
ajst-32576	278	4	1883	1883	NUM
ajst-32576	278	5	-	-	SYM
ajst-32576	278	6	1892	1892	NUM
ajst-32576	278	7	.	.	PUNCT
ajst-32576	279	1	[	[	X
ajst-32576	279	2	34	34	NUM
ajst-32576	279	3	]	]	X
ajst-32576	279	4	de	de	X
ajst-32576	279	5	langen	langen	PROPN
ajst-32576	279	6	,	,	PUNCT
ajst-32576	279	7	a.j	a.j	PROPN
ajst-32576	279	8	.	.	PROPN
ajst-32576	279	9	,	,	PUNCT
ajst-32576	279	10	et	et	PROPN
ajst-32576	279	11	al	al	PROPN
ajst-32576	279	12	.	.	PROPN
ajst-32576	279	13	,	,	PUNCT
ajst-32576	279	14	sotorasib	sotorasib	PROPN
ajst-32576	279	15	versus	versus	ADP
ajst-32576	279	16	docetaxel	docetaxel	PROPN
ajst-32576	279	17	for	for	ADP
ajst-32576	279	18	previously	previously	ADV
ajst-32576	279	19	treated	treat	VERB
ajst-32576	279	20	non	non	ADJ
ajst-32576	279	21	-	-	ADJ
ajst-32576	279	22	small	small	ADJ
ajst-32576	279	23	-	-	PUNCT
ajst-32576	279	24	cell	cell	NOUN
ajst-32576	279	25	lung	lung	NOUN
ajst-32576	279	26	cancer	cancer	NOUN
ajst-32576	279	27	with	with	ADP
ajst-32576	279	28	kras(g12c	kras(g12c	PROPN
ajst-32576	279	29	)	)	PUNCT
ajst-32576	279	30	mutation	mutation	NOUN
ajst-32576	279	31	:	:	PUNCT
ajst-32576	279	32	a	a	DET
ajst-32576	279	33	randomised	randomised	ADJ
ajst-32576	279	34	,	,	PUNCT
ajst-32576	279	35	open	open	ADJ
ajst-32576	279	36	-	-	PUNCT
ajst-32576	279	37	label	label	NOUN
ajst-32576	279	38	,	,	PUNCT
ajst-32576	279	39	phase	phase	NOUN
ajst-32576	279	40	3	3	NUM
ajst-32576	279	41	trial	trial	NOUN
ajst-32576	279	42	.	.	PUNCT
ajst-32576	280	1	lancet	lancet	NOUN
ajst-32576	280	2	,	,	PUNCT
ajst-32576	280	3	2023	2023	NUM
ajst-32576	280	4	.	.	PUNCT
ajst-32576	281	1	401(10378	401(10378	NUM
ajst-32576	281	2	):	):	PUNCT
ajst-32576	281	3	p.	p.	NOUN
ajst-32576	281	4	733	733	NUM
ajst-32576	281	5	-	-	SYM
ajst-32576	281	6	746	746	NUM
ajst-32576	281	7	.	.	PUNCT
ajst-32576	282	1	228	228	NUM
ajst-32576	283	1	[	[	SYM
ajst-32576	283	2	35	35	NUM
ajst-32576	283	3	]	]	X
ajst-32576	283	4	fang	fang	X
ajst-32576	283	5	,	,	PUNCT
ajst-32576	283	6	w.	w.	PROPN
ajst-32576	283	7	,	,	PUNCT
ajst-32576	283	8	et	et	PROPN
ajst-32576	283	9	al	al	PROPN
ajst-32576	283	10	.	.	PROPN
ajst-32576	283	11	,	,	PUNCT
ajst-32576	283	12	ivonescimab	ivonescimab	NOUN
ajst-32576	283	13	plus	plus	CCONJ
ajst-32576	283	14	chemotherapy	chemotherapy	NOUN
ajst-32576	283	15	in	in	ADP
ajst-32576	283	16	non	non	ADJ
ajst-32576	283	17	-	-	ADJ
ajst-32576	283	18	small	small	ADJ
ajst-32576	283	19	cell	cell	NOUN
ajst-32576	283	20	lung	lung	NOUN
ajst-32576	283	21	cancer	cancer	NOUN
ajst-32576	283	22	with	with	ADP
ajst-32576	283	23	egfr	egfr	ADJ
ajst-32576	283	24	variant	variant	NOUN
ajst-32576	283	25	:	:	PUNCT
ajst-32576	283	26	a	a	DET
ajst-32576	283	27	randomized	randomized	ADJ
ajst-32576	283	28	clinical	clinical	ADJ
ajst-32576	283	29	trial	trial	NOUN
ajst-32576	283	30	.	.	PUNCT
ajst-32576	284	1	jama	jama	NOUN
ajst-32576	284	2	,	,	PUNCT
ajst-32576	284	3	2024	2024	NUM
ajst-32576	284	4	.	.	PUNCT
ajst-32576	285	1	332(7	332(7	NUM
ajst-32576	285	2	):	):	PUNCT
ajst-32576	285	3	p.	p.	NOUN
ajst-32576	285	4	561	561	NUM
ajst-32576	285	5	-	-	SYM
ajst-32576	285	6	570	570	NUM
ajst-32576	285	7	.	.	PUNCT
ajst-32576	286	1	[	[	X
ajst-32576	286	2	36	36	NUM
ajst-32576	286	3	]	]	X
ajst-32576	286	4	fan	fan	PROPN
ajst-32576	286	5	,	,	PUNCT
ajst-32576	286	6	c.	c.	PROPN
ajst-32576	286	7	,	,	PUNCT
ajst-32576	286	8	et	et	PROPN
ajst-32576	286	9	al	al	PROPN
ajst-32576	286	10	.	.	PROPN
ajst-32576	286	11	,	,	PUNCT
ajst-32576	286	12	efficacy	efficacy	NOUN
ajst-32576	286	13	and	and	CCONJ
ajst-32576	286	14	safety	safety	NOUN
ajst-32576	286	15	of	of	ADP
ajst-32576	286	16	intrathecal	intrathecal	ADJ
ajst-32576	286	17	pemetrexed	pemetrexed	NOUN
ajst-32576	286	18	for	for	ADP
ajst-32576	286	19	tki	tki	NOUN
ajst-32576	286	20	-	-	ADJ
ajst-32576	286	21	failed	fail	VERB
ajst-32576	286	22	leptomeningeal	leptomeningeal	ADJ
ajst-32576	286	23	metastases	metastasis	NOUN
ajst-32576	286	24	from	from	ADP
ajst-32576	286	25	egfr+	egfr+	DET
ajst-32576	286	26	nsclc	nsclc	NOUN
ajst-32576	286	27	:	:	PUNCT
ajst-32576	286	28	an	an	DET
ajst-32576	286	29	expanded	expand	VERB
ajst-32576	286	30	,	,	PUNCT
ajst-32576	286	31	single	single	ADJ
ajst-32576	286	32	-	-	PUNCT
ajst-32576	286	33	arm	arm	NOUN
ajst-32576	286	34	,	,	PUNCT
ajst-32576	286	35	phase	phase	NOUN
ajst-32576	286	36	ii	ii	NOUN
ajst-32576	286	37	clinical	clinical	ADJ
ajst-32576	286	38	trial	trial	NOUN
ajst-32576	286	39	.	.	PUNCT
ajst-32576	287	1	esmo	esmo	NOUN
ajst-32576	287	2	open	open	ADJ
ajst-32576	287	3	,	,	PUNCT
ajst-32576	287	4	2024	2024	NUM
ajst-32576	287	5	.	.	PUNCT
ajst-32576	288	1	9(4	9(4	NUM
ajst-32576	288	2	):	):	PUNCT
ajst-32576	288	3	p.	p.	NOUN
ajst-32576	288	4	102384	102384	NUM
ajst-32576	288	5	.	.	PUNCT
ajst-32576	289	1	[	[	X
ajst-32576	289	2	37	37	NUM
ajst-32576	289	3	]	]	SYM
ajst-32576	289	4	nardone	nardone	NOUN
ajst-32576	289	5	,	,	PUNCT
ajst-32576	289	6	v.	v.	PROPN
ajst-32576	289	7	,	,	PUNCT
ajst-32576	289	8	et	et	PROPN
ajst-32576	289	9	al	al	PROPN
ajst-32576	289	10	.	.	PROPN
ajst-32576	289	11	,	,	PUNCT
ajst-32576	289	12	the	the	DET
ajst-32576	289	13	role	role	NOUN
ajst-32576	289	14	of	of	ADP
ajst-32576	289	15	brain	brain	NOUN
ajst-32576	289	16	radiotherapy	radiotherapy	NOUN
ajst-32576	289	17	for	for	ADP
ajst-32576	289	18	egfrand	egfrand	ADJ
ajst-32576	289	19	alk	alk	PROPN
ajst-32576	289	20	-	-	PUNCT
ajst-32576	289	21	positive	positive	ADJ
ajst-32576	289	22	non	non	ADJ
ajst-32576	289	23	-	-	ADJ
ajst-32576	289	24	small	small	ADJ
ajst-32576	289	25	-	-	PUNCT
ajst-32576	289	26	cell	cell	NOUN
ajst-32576	289	27	lung	lung	NOUN
ajst-32576	289	28	cancer	cancer	NOUN
ajst-32576	289	29	with	with	ADP
ajst-32576	289	30	brain	brain	NOUN
ajst-32576	289	31	metastases	metastasis	NOUN
ajst-32576	289	32	:	:	PUNCT
ajst-32576	289	33	a	a	DET
ajst-32576	289	34	review	review	NOUN
ajst-32576	289	35	.	.	PUNCT
ajst-32576	290	1	radiol	radiol	PROPN
ajst-32576	290	2	med	me	VERB
ajst-32576	290	3	,	,	PUNCT
ajst-32576	290	4	2023	2023	NUM
ajst-32576	290	5	.	.	PUNCT
ajst-32576	291	1	128(3	128(3	NUM
ajst-32576	291	2	):	):	PUNCT
ajst-32576	291	3	p.	p.	NOUN
ajst-32576	291	4	316	316	NUM
ajst-32576	291	5	-	-	SYM
ajst-32576	291	6	329	329	NUM
ajst-32576	291	7	.	.	PUNCT
ajst-32576	292	1	[	[	X
ajst-32576	292	2	38	38	NUM
ajst-32576	292	3	]	]	X
ajst-32576	292	4	zeng	zeng	PROPN
ajst-32576	292	5	,	,	PUNCT
ajst-32576	292	6	m.	m.	NOUN
ajst-32576	292	7	,	,	PUNCT
ajst-32576	292	8	et	et	PROPN
ajst-32576	292	9	al	al	PROPN
ajst-32576	292	10	.	.	PROPN
ajst-32576	292	11	,	,	PUNCT
ajst-32576	292	12	stereotactic	stereotactic	PROPN
ajst-32576	292	13	radiotherapy	radiotherapy	NOUN
ajst-32576	292	14	vs	vs	ADP
ajst-32576	292	15	whole	whole	ADJ
ajst-32576	292	16	brain	brain	NOUN
ajst-32576	292	17	radiation	radiation	NOUN
ajst-32576	292	18	therapy	therapy	NOUN
ajst-32576	292	19	in	in	ADP
ajst-32576	292	20	egfr	egfr	PROPN
ajst-32576	292	21	mutated	mutate	VERB
ajst-32576	292	22	nsclc	nsclc	NOUN
ajst-32576	292	23	:	:	PUNCT
ajst-32576	292	24	results	result	NOUN
ajst-32576	292	25	&	&	CCONJ
ajst-32576	292	26	reflections	reflection	NOUN
ajst-32576	292	27	from	from	ADP
ajst-32576	292	28	the	the	DET
ajst-32576	292	29	prematurely	prematurely	ADV
ajst-32576	292	30	closed	closed	ADJ
ajst-32576	292	31	phase	phase	NOUN
ajst-32576	292	32	iii	iii	NUM
ajst-32576	292	33	hybrid	hybrid	ADJ
ajst-32576	292	34	trial	trial	NOUN
ajst-32576	292	35	.	.	PUNCT
ajst-32576	293	1	radiother	radiother	PROPN
ajst-32576	293	2	oncol	oncol	PROPN
ajst-32576	293	3	,	,	PUNCT
ajst-32576	293	4	2024	2024	NUM
ajst-32576	293	5	.	.	PUNCT
ajst-32576	294	1	197	197	NUM
ajst-32576	294	2	:	:	PUNCT
ajst-32576	294	3	p.	p.	NOUN
ajst-32576	294	4	110334	110334	NUM
ajst-32576	294	5	.	.	PUNCT
ajst-32576	295	1	[	[	X
ajst-32576	295	2	39	39	NUM
ajst-32576	295	3	]	]	X
ajst-32576	295	4	mcmahon	mcmahon	PROPN
ajst-32576	295	5	,	,	PUNCT
ajst-32576	295	6	d.	d.	PROPN
ajst-32576	295	7	,	,	PUNCT
ajst-32576	295	8	et	et	PROPN
ajst-32576	295	9	al	al	PROPN
ajst-32576	295	10	.	.	PROPN
ajst-32576	295	11	,	,	PUNCT
ajst-32576	295	12	stereotactic	stereotactic	ADJ
ajst-32576	295	13	radiosurgery	radiosurgery	NOUN
ajst-32576	295	14	(	(	PUNCT
ajst-32576	295	15	srs	srs	PROPN
ajst-32576	295	16	)	)	PUNCT
ajst-32576	295	17	for	for	ADP
ajst-32576	295	18	non	non	ADJ
ajst-32576	295	19	-	-	ADJ
ajst-32576	295	20	small	small	ADJ
ajst-32576	295	21	cell	cell	NOUN
ajst-32576	295	22	lung	lung	NOUN
ajst-32576	295	23	cancer	cancer	NOUN
ajst-32576	295	24	(	(	PUNCT
ajst-32576	295	25	nsclc	nsclc	NOUN
ajst-32576	295	26	)	)	PUNCT
ajst-32576	295	27	in	in	ADP
ajst-32576	295	28	the	the	DET
ajst-32576	295	29	oncogene	oncogene	NOUN
ajst-32576	295	30	-	-	PUNCT
ajst-32576	295	31	addicted	addict	VERB
ajst-32576	295	32	era	era	NOUN
ajst-32576	295	33	:	:	PUNCT
ajst-32576	295	34	a	a	DET
ajst-32576	295	35	real	real	ADJ
ajst-32576	295	36	-	-	PUNCT
ajst-32576	295	37	world	world	NOUN
ajst-32576	295	38	uk	uk	PROPN
ajst-32576	295	39	tertiary	tertiary	ADJ
ajst-32576	295	40	center	center	NOUN
ajst-32576	295	41	experience	experience	NOUN
ajst-32576	295	42	.	.	PUNCT
ajst-32576	296	1	journal	journal	NOUN
ajst-32576	296	2	of	of	ADP
ajst-32576	296	3	clinical	clinical	ADJ
ajst-32576	296	4	oncology	oncology	NOUN
ajst-32576	296	5	,	,	PUNCT
ajst-32576	296	6	2024	2024	NUM
ajst-32576	296	7	.	.	PUNCT
ajst-32576	297	1	42(16_suppl	42(16_suppl	NUM
ajst-32576	297	2	):	):	PUNCT
ajst-32576	298	1	p.	p.	PROPN
ajst-32576	298	2	e14011	e14011	PROPN
ajst-32576	298	3	-	-	PUNCT
ajst-32576	298	4	e14011	e14011	PROPN
ajst-32576	298	5	.	.	PUNCT
ajst-32576	299	1	[	[	X
ajst-32576	299	2	40	40	NUM
ajst-32576	299	3	]	]	X
ajst-32576	299	4	zhang	zhang	PROPN
ajst-32576	299	5	,	,	PUNCT
ajst-32576	299	6	g.	g.	PROPN
ajst-32576	299	7	,	,	PUNCT
ajst-32576	299	8	et	et	PROPN
ajst-32576	299	9	al	al	PROPN
ajst-32576	299	10	.	.	PROPN
ajst-32576	299	11	,	,	PUNCT
ajst-32576	299	12	comparable	comparable	ADJ
ajst-32576	299	13	outcomes	outcome	NOUN
ajst-32576	299	14	of	of	ADP
ajst-32576	299	15	nivolumab	nivolumab	NOUN
ajst-32576	299	16	in	in	ADP
ajst-32576	299	17	patients	patient	NOUN
ajst-32576	299	18	with	with	ADP
ajst-32576	299	19	advanced	advanced	ADJ
ajst-32576	299	20	nsclc	nsclc	NOUN
ajst-32576	299	21	presenting	present	VERB
ajst-32576	299	22	with	with	ADP
ajst-32576	299	23	or	or	CCONJ
ajst-32576	299	24	without	without	ADP
ajst-32576	299	25	brain	brain	NOUN
ajst-32576	299	26	metastases	metastasis	NOUN
ajst-32576	299	27	:	:	PUNCT
ajst-32576	299	28	a	a	DET
ajst-32576	299	29	retrospective	retrospective	ADJ
ajst-32576	299	30	cohort	cohort	NOUN
ajst-32576	299	31	study	study	NOUN
ajst-32576	299	32	.	.	PUNCT
ajst-32576	300	1	cancer	cancer	NOUN
ajst-32576	300	2	immunol	immunol	PROPN
ajst-32576	300	3	immunother	immunother	PROPN
ajst-32576	300	4	,	,	PUNCT
ajst-32576	300	5	2020	2020	NUM
ajst-32576	300	6	.	.	PUNCT
ajst-32576	301	1	69(3	69(3	NUM
ajst-32576	301	2	):	):	PUNCT
ajst-32576	302	1	p.	p.	NOUN
ajst-32576	302	2	399	399	NUM
ajst-32576	302	3	-	-	SYM
ajst-32576	302	4	405	405	NUM
ajst-32576	302	5	.	.	PUNCT
ajst-32576	303	1	[	[	X
ajst-32576	303	2	41	41	NUM
ajst-32576	303	3	]	]	X
ajst-32576	303	4	sebastian	sebastian	PROPN
ajst-32576	303	5	,	,	PUNCT
ajst-32576	303	6	m.	m.	NOUN
ajst-32576	303	7	,	,	PUNCT
ajst-32576	303	8	et	et	PROPN
ajst-32576	303	9	al	al	PROPN
ajst-32576	303	10	.	.	PROPN
ajst-32576	303	11	,	,	PUNCT
ajst-32576	303	12	prospective	prospective	ADJ
ajst-32576	303	13	,	,	PUNCT
ajst-32576	303	14	noninterventional	noninterventional	ADJ
ajst-32576	303	15	study	study	NOUN
ajst-32576	303	16	of	of	ADP
ajst-32576	303	17	nivolumab	nivolumab	NOUN
ajst-32576	303	18	in	in	ADP
ajst-32576	303	19	real	real	ADJ
ajst-32576	303	20	-	-	PUNCT
ajst-32576	303	21	world	world	NOUN
ajst-32576	303	22	patients	patient	NOUN
ajst-32576	303	23	with	with	ADP
ajst-32576	303	24	locally	locally	ADV
ajst-32576	303	25	advanced	advanced	ADJ
ajst-32576	303	26	or	or	CCONJ
ajst-32576	303	27	metastatic	metastatic	ADJ
ajst-32576	303	28	non	non	ADJ
ajst-32576	303	29	-	-	ADJ
ajst-32576	303	30	small	small	ADJ
ajst-32576	303	31	cell	cell	NOUN
ajst-32576	303	32	lung	lung	NOUN
ajst-32576	303	33	cancer	cancer	NOUN
ajst-32576	303	34	after	after	ADP
ajst-32576	303	35	prior	prior	ADJ
ajst-32576	303	36	chemotherapy	chemotherapy	NOUN
ajst-32576	303	37	(	(	PUNCT
ajst-32576	303	38	enlargelung	enlargelung	PROPN
ajst-32576	303	39	)	)	PUNCT
ajst-32576	303	40	.	.	PUNCT
ajst-32576	304	1	j	j	PROPN
ajst-32576	304	2	immunother	immunother	PROPN
ajst-32576	304	3	,	,	PUNCT
ajst-32576	304	4	2022	2022	NUM
ajst-32576	304	5	.	.	PUNCT
ajst-32576	305	1	45(2	45(2	NOUN
ajst-32576	305	2	):	):	PUNCT
ajst-32576	305	3	p.	p.	NOUN
ajst-32576	305	4	89	89	NUM
ajst-32576	305	5	-	-	SYM
ajst-32576	305	6	99	99	NUM
ajst-32576	305	7	.	.	PUNCT
ajst-32576	306	1	[	[	X
ajst-32576	306	2	42	42	NUM
ajst-32576	306	3	]	]	X
ajst-32576	306	4	goldberg	goldberg	PROPN
ajst-32576	306	5	,	,	PUNCT
ajst-32576	306	6	s.b	s.b	PROPN
ajst-32576	306	7	.	.	PROPN
ajst-32576	306	8	,	,	PUNCT
ajst-32576	306	9	et	et	PROPN
ajst-32576	306	10	al	al	PROPN
ajst-32576	306	11	.	.	PROPN
ajst-32576	306	12	,	,	PUNCT
ajst-32576	306	13	pembrolizumab	pembrolizumab	NOUN
ajst-32576	306	14	for	for	ADP
ajst-32576	306	15	management	management	NOUN
ajst-32576	306	16	of	of	ADP
ajst-32576	306	17	patients	patient	NOUN
ajst-32576	306	18	with	with	ADP
ajst-32576	306	19	nsclc	nsclc	NOUN
ajst-32576	306	20	and	and	CCONJ
ajst-32576	306	21	brain	brain	NOUN
ajst-32576	306	22	metastases	metastasis	NOUN
ajst-32576	306	23	:	:	PUNCT
ajst-32576	306	24	long	long	ADJ
ajst-32576	306	25	-	-	PUNCT
ajst-32576	306	26	term	term	NOUN
ajst-32576	306	27	results	result	NOUN
ajst-32576	306	28	and	and	CCONJ
ajst-32576	306	29	biomarker	biomarker	VERB
ajst-32576	306	30	analysis	analysis	NOUN
ajst-32576	306	31	from	from	ADP
ajst-32576	306	32	a	a	DET
ajst-32576	306	33	non	non	ADJ
ajst-32576	306	34	-	-	ADJ
ajst-32576	306	35	randomised	randomised	ADJ
ajst-32576	306	36	,	,	PUNCT
ajst-32576	306	37	open	open	ADJ
ajst-32576	306	38	-	-	PUNCT
ajst-32576	306	39	label	label	NOUN
ajst-32576	306	40	,	,	PUNCT
ajst-32576	306	41	phase	phase	NOUN
ajst-32576	306	42	2	2	NUM
ajst-32576	306	43	trial	trial	NOUN
ajst-32576	306	44	.	.	PUNCT
ajst-32576	307	1	lancet	lancet	PROPN
ajst-32576	307	2	oncol	oncol	PROPN
ajst-32576	307	3	,	,	PUNCT
ajst-32576	307	4	2020	2020	NUM
ajst-32576	307	5	.	.	PUNCT
ajst-32576	308	1	21(5	21(5	NUM
ajst-32576	308	2	):	):	PUNCT
ajst-32576	308	3	p.	p.	NOUN
ajst-32576	308	4	655	655	NUM
ajst-32576	308	5	-	-	SYM
ajst-32576	308	6	663	663	NUM
ajst-32576	308	7	.	.	PUNCT
ajst-32576	309	1	[	[	X
ajst-32576	309	2	43	43	NUM
ajst-32576	309	3	]	]	PUNCT
ajst-32576	309	4	amrane	amrane	NOUN
ajst-32576	309	5	,	,	PUNCT
ajst-32576	309	6	k.	k.	PROPN
ajst-32576	309	7	,	,	PUNCT
ajst-32576	309	8	et	et	PROPN
ajst-32576	309	9	al	al	PROPN
ajst-32576	309	10	.	.	PROPN
ajst-32576	309	11	,	,	PUNCT
ajst-32576	309	12	first	first	ADJ
ajst-32576	309	13	-	-	PUNCT
ajst-32576	309	14	line	line	NOUN
ajst-32576	309	15	pembrolizumab	pembrolizumab	NOUN
ajst-32576	309	16	for	for	ADP
ajst-32576	309	17	non	non	ADJ
ajst-32576	309	18	-	-	ADJ
ajst-32576	309	19	small	small	ADJ
ajst-32576	309	20	cell	cell	NOUN
ajst-32576	309	21	lung	lung	NOUN
ajst-32576	309	22	cancer	cancer	NOUN
ajst-32576	309	23	patients	patient	NOUN
ajst-32576	309	24	with	with	ADP
ajst-32576	309	25	pd	pd	PROPN
ajst-32576	309	26	-	-	PROPN
ajst-32576	309	27	l1	l1	PROPN
ajst-32576	309	28	≥50	≥50	NUM
ajst-32576	309	29	%	%	NOUN
ajst-32576	309	30	in	in	ADP
ajst-32576	309	31	a	a	DET
ajst-32576	309	32	multicenter	multicenter	ADJ
ajst-32576	309	33	real	real	ADJ
ajst-32576	309	34	-	-	PUNCT
ajst-32576	309	35	life	life	NOUN
ajst-32576	309	36	cohort	cohort	NOUN
ajst-32576	309	37	:	:	PUNCT
ajst-32576	309	38	the	the	DET
ajst-32576	309	39	pembreizh	pembreizh	PROPN
ajst-32576	309	40	study	study	NOUN
ajst-32576	309	41	.	.	PUNCT
ajst-32576	310	1	cancer	cancer	NOUN
ajst-32576	310	2	med	med	PROPN
ajst-32576	310	3	,	,	PUNCT
ajst-32576	310	4	2020	2020	NUM
ajst-32576	310	5	.	.	PUNCT
ajst-32576	311	1	9(7	9(7	NUM
ajst-32576	311	2	):	):	PUNCT
ajst-32576	311	3	p.	p.	NOUN
ajst-32576	311	4	2309	2309	NUM
ajst-32576	311	5	-	-	SYM
ajst-32576	311	6	2316	2316	NUM
ajst-32576	311	7	.	.	PUNCT
ajst-32576	312	1	[	[	X
ajst-32576	312	2	44	44	NUM
ajst-32576	312	3	]	]	PUNCT
ajst-32576	312	4	itchins	itchin	NOUN
ajst-32576	312	5	,	,	PUNCT
ajst-32576	312	6	m.	m.	NOUN
ajst-32576	312	7	,	,	PUNCT
ajst-32576	312	8	et	et	PROPN
ajst-32576	312	9	al	al	PROPN
ajst-32576	312	10	.	.	PROPN
ajst-32576	312	11	,	,	PUNCT
ajst-32576	312	12	a	a	DET
ajst-32576	312	13	multi	multi	ADJ
ajst-32576	312	14	-	-	ADJ
ajst-32576	312	15	center	center	ADJ
ajst-32576	312	16	real	real	ADJ
ajst-32576	312	17	-	-	PUNCT
ajst-32576	312	18	world	world	NOUN
ajst-32576	312	19	experience	experience	NOUN
ajst-32576	312	20	of	of	ADP
ajst-32576	312	21	impower150	impower150	PROPN
ajst-32576	312	22	in	in	ADP
ajst-32576	312	23	oncogene	oncogene	NOUN
ajst-32576	312	24	driven	drive	VERB
ajst-32576	312	25	tumors	tumor	NOUN
ajst-32576	312	26	and	and	CCONJ
ajst-32576	312	27	cns	cns	NOUN
ajst-32576	312	28	metastases	metastasis	NOUN
ajst-32576	312	29	.	.	PUNCT
ajst-32576	312	30	clin	clin	PROPN
ajst-32576	312	31	lung	lung	PROPN
ajst-32576	312	32	cancer	cancer	NOUN
ajst-32576	312	33	,	,	PUNCT
ajst-32576	312	34	2022	2022	NUM
ajst-32576	312	35	.	.	PUNCT
ajst-32576	313	1	23(8	23(8	NUM
ajst-32576	313	2	):	):	PUNCT
ajst-32576	314	1	p.	p.	NOUN
ajst-32576	314	2	702	702	NUM
ajst-32576	314	3	-	-	SYM
ajst-32576	314	4	708	708	NUM
ajst-32576	314	5	.	.	PUNCT
ajst-32576	315	1	[	[	X
ajst-32576	315	2	45	45	NUM
ajst-32576	315	3	]	]	SYM
ajst-32576	315	4	rittmeyer	rittmeyer	NOUN
ajst-32576	315	5	,	,	PUNCT
ajst-32576	315	6	a.	a.	PROPN
ajst-32576	315	7	,	,	PUNCT
ajst-32576	315	8	et	et	PROPN
ajst-32576	315	9	al	al	PROPN
ajst-32576	315	10	.	.	PROPN
ajst-32576	315	11	,	,	PUNCT
ajst-32576	315	12	atezolizumab	atezolizumab	PROPN
ajst-32576	315	13	versus	versus	ADP
ajst-32576	315	14	docetaxel	docetaxel	NOUN
ajst-32576	315	15	in	in	ADP
ajst-32576	315	16	patients	patient	NOUN
ajst-32576	315	17	with	with	ADP
ajst-32576	315	18	previously	previously	ADV
ajst-32576	315	19	treated	treat	VERB
ajst-32576	315	20	non	non	ADJ
ajst-32576	315	21	-	-	ADJ
ajst-32576	315	22	small	small	ADJ
ajst-32576	315	23	-	-	PUNCT
ajst-32576	315	24	cell	cell	NOUN
ajst-32576	315	25	lung	lung	NOUN
ajst-32576	315	26	cancer	cancer	NOUN
ajst-32576	315	27	(	(	PUNCT
ajst-32576	315	28	oak	oak	NOUN
ajst-32576	315	29	):	):	PUNCT
ajst-32576	315	30	a	a	DET
ajst-32576	315	31	phase	phase	NOUN
ajst-32576	315	32	3	3	NUM
ajst-32576	315	33	,	,	PUNCT
ajst-32576	315	34	open	open	ADJ
ajst-32576	315	35	-	-	PUNCT
ajst-32576	315	36	label	label	NOUN
ajst-32576	315	37	,	,	PUNCT
ajst-32576	315	38	multicentre	multicentre	NOUN
ajst-32576	315	39	randomised	randomise	VERB
ajst-32576	315	40	controlled	control	VERB
ajst-32576	315	41	trial	trial	NOUN
ajst-32576	315	42	.	.	PUNCT
ajst-32576	316	1	lancet	lancet	PROPN
ajst-32576	316	2	,	,	PUNCT
ajst-32576	316	3	2017	2017	NUM
ajst-32576	316	4	.	.	PUNCT
ajst-32576	317	1	389(10066	389(10066	NUM
ajst-32576	317	2	):	):	PUNCT
ajst-32576	318	1	p.	p.	NOUN
ajst-32576	318	2	255	255	NUM
ajst-32576	318	3	-	-	SYM
ajst-32576	318	4	265	265	NUM
ajst-32576	318	5	.	.	PUNCT
ajst-32576	319	1	[	[	X
ajst-32576	319	2	46	46	NUM
ajst-32576	319	3	]	]	X
ajst-32576	319	4	reck	reck	NOUN
ajst-32576	319	5	,	,	PUNCT
ajst-32576	319	6	m.	m.	NOUN
ajst-32576	319	7	,	,	PUNCT
ajst-32576	319	8	et	et	PROPN
ajst-32576	319	9	al	al	PROPN
ajst-32576	319	10	.	.	PROPN
ajst-32576	319	11	,	,	PUNCT
ajst-32576	319	12	systemic	systemic	ADJ
ajst-32576	319	13	and	and	CCONJ
ajst-32576	319	14	intracranial	intracranial	ADJ
ajst-32576	319	15	outcomes	outcome	NOUN
ajst-32576	319	16	with	with	ADP
ajst-32576	319	17	first	first	ADJ
ajst-32576	319	18	-	-	PUNCT
ajst-32576	319	19	line	line	NOUN
ajst-32576	319	20	nivolumab	nivolumab	NOUN
ajst-32576	319	21	plus	plus	CCONJ
ajst-32576	319	22	ipilimumab	ipilimumab	VERB
ajst-32576	319	23	in	in	ADP
ajst-32576	319	24	patients	patient	NOUN
ajst-32576	319	25	with	with	ADP
ajst-32576	319	26	metastatic	metastatic	ADJ
ajst-32576	319	27	nsclc	nsclc	NOUN
ajst-32576	319	28	and	and	CCONJ
ajst-32576	319	29	baseline	baseline	ADJ
ajst-32576	319	30	brain	brain	NOUN
ajst-32576	319	31	metastases	metastasis	NOUN
ajst-32576	319	32	from	from	ADP
ajst-32576	319	33	checkmate	checkmate	NOUN
ajst-32576	319	34	227	227	NUM
ajst-32576	319	35	part	part	NOUN
ajst-32576	319	36	1	1	NUM
ajst-32576	319	37	.	.	PUNCT
ajst-32576	319	38	j	j	PROPN
ajst-32576	319	39	thorac	thorac	PROPN
ajst-32576	319	40	oncol	oncol	ADJ
ajst-32576	319	41	,	,	PUNCT
ajst-32576	319	42	2023	2023	NUM
ajst-32576	319	43	.	.	PUNCT
ajst-32576	320	1	18(8	18(8	NUM
ajst-32576	320	2	):	):	PUNCT
ajst-32576	320	3	p.	p.	NOUN
ajst-32576	320	4	1055	1055	NUM
ajst-32576	320	5	-	-	SYM
ajst-32576	320	6	1069	1069	NUM
ajst-32576	320	7	.	.	PUNCT
ajst-32576	321	1	[	[	X
ajst-32576	321	2	47	47	NUM
ajst-32576	321	3	]	]	SYM
ajst-32576	321	4	wu	wu	PROPN
ajst-32576	321	5	,	,	PUNCT
ajst-32576	321	6	y.l	y.l	PROPN
ajst-32576	321	7	.	.	PROPN
ajst-32576	321	8	,	,	PUNCT
ajst-32576	321	9	et	et	PROPN
ajst-32576	321	10	al	al	PROPN
ajst-32576	321	11	.	.	PROPN
ajst-32576	321	12	,	,	PUNCT
ajst-32576	321	13	tepotinib	tepotinib	NOUN
ajst-32576	321	14	plus	plus	CCONJ
ajst-32576	321	15	osimertinib	osimertinib	NOUN
ajst-32576	321	16	in	in	ADP
ajst-32576	321	17	patients	patient	NOUN
ajst-32576	321	18	with	with	ADP
ajst-32576	321	19	egfr	egfr	NOUN
ajst-32576	321	20	-	-	PUNCT
ajst-32576	321	21	mutated	mutate	VERB
ajst-32576	321	22	non	non	ADJ
ajst-32576	321	23	-	-	ADJ
ajst-32576	321	24	small	small	ADJ
ajst-32576	321	25	-	-	PUNCT
ajst-32576	321	26	cell	cell	NOUN
ajst-32576	321	27	lung	lung	NOUN
ajst-32576	321	28	cancer	cancer	NOUN
ajst-32576	321	29	with	with	ADP
ajst-32576	321	30	met	meet	VERB
ajst-32576	321	31	amplification	amplification	NOUN
ajst-32576	321	32	following	follow	VERB
ajst-32576	321	33	progression	progression	NOUN
ajst-32576	321	34	on	on	ADP
ajst-32576	321	35	first	first	ADJ
ajst-32576	321	36	-	-	PUNCT
ajst-32576	321	37	line	line	NOUN
ajst-32576	321	38	osimertinib	osimertinib	NOUN
ajst-32576	321	39	(	(	PUNCT
ajst-32576	321	40	insight	insight	NOUN
ajst-32576	321	41	2	2	NUM
ajst-32576	321	42	):	):	PUNCT
ajst-32576	321	43	a	a	DET
ajst-32576	321	44	multicentre	multicentre	NOUN
ajst-32576	321	45	,	,	PUNCT
ajst-32576	321	46	open	open	ADJ
ajst-32576	321	47	-	-	PUNCT
ajst-32576	321	48	label	label	NOUN
ajst-32576	321	49	,	,	PUNCT
ajst-32576	321	50	phase	phase	NOUN
ajst-32576	321	51	2	2	NUM
ajst-32576	321	52	trial	trial	NOUN
ajst-32576	321	53	.	.	PUNCT
ajst-32576	322	1	lancet	lancet	PROPN
ajst-32576	322	2	oncol	oncol	PROPN
ajst-32576	322	3	,	,	PUNCT
ajst-32576	322	4	2024	2024	NUM
ajst-32576	322	5	.	.	PUNCT
ajst-32576	323	1	25(8	25(8	NUM
ajst-32576	323	2	):	):	PUNCT
ajst-32576	323	3	p.	p.	NOUN
ajst-32576	323	4	989	989	NUM
ajst-32576	323	5	-	-	PUNCT
ajst-32576	323	6	1002	1002	NUM
ajst-32576	323	7	.	.	PUNCT
ajst-32576	324	1	[	[	X
ajst-32576	324	2	48	48	NUM
ajst-32576	324	3	]	]	X
ajst-32576	324	4	zhou	zhou	PROPN
ajst-32576	324	5	,	,	PUNCT
ajst-32576	324	6	b.	b.	PROPN
ajst-32576	324	7	,	,	PUNCT
ajst-32576	324	8	et	et	PROPN
ajst-32576	324	9	al	al	PROPN
ajst-32576	324	10	.	.	PROPN
ajst-32576	324	11	,	,	PUNCT
ajst-32576	324	12	clinical	clinical	ADJ
ajst-32576	324	13	outcomes	outcome	NOUN
ajst-32576	324	14	and	and	CCONJ
ajst-32576	324	15	safety	safety	NOUN
ajst-32576	324	16	of	of	ADP
ajst-32576	324	17	osimertinib	osimertinib	NOUN
ajst-32576	324	18	plus	plus	CCONJ
ajst-32576	324	19	anlotinib	anlotinib	NOUN
ajst-32576	324	20	for	for	ADP
ajst-32576	324	21	patients	patient	NOUN
ajst-32576	324	22	with	with	ADP
ajst-32576	324	23	previously	previously	ADV
ajst-32576	324	24	treated	treat	VERB
ajst-32576	324	25	egfr	egfr	ADJ
ajst-32576	324	26	t790m	t790m	NOUN
ajst-32576	324	27	-	-	PUNCT
ajst-32576	324	28	positive	positive	ADJ
ajst-32576	324	29	nsclc	nsclc	NOUN
ajst-32576	324	30	:	:	PUNCT
ajst-32576	324	31	a	a	DET
ajst-32576	324	32	retrospective	retrospective	ADJ
ajst-32576	324	33	study	study	NOUN
ajst-32576	324	34	.	.	PUNCT
ajst-32576	325	1	j	j	PROPN
ajst-32576	325	2	clin	clin	PROPN
ajst-32576	325	3	pharm	pharm	PROPN
ajst-32576	325	4	ther	ther	ADV
ajst-32576	325	5	,	,	PUNCT
ajst-32576	325	6	2022	2022	NUM
ajst-32576	325	7	.	.	PUNCT
ajst-32576	326	1	47(5	47(5	NOUN
ajst-32576	326	2	):	):	PUNCT
ajst-32576	326	3	p.	p.	NOUN
ajst-32576	326	4	643651	643651	NUM
ajst-32576	326	5	.	.	PUNCT
ajst-32576	327	1	[	[	X
ajst-32576	327	2	49	49	NUM
ajst-32576	327	3	]	]	X
ajst-32576	327	4	zhou	zhou	X
ajst-32576	327	5	,	,	PUNCT
ajst-32576	327	6	h.q	h.q	PROPN
ajst-32576	327	7	.	.	PROPN
ajst-32576	327	8	,	,	PUNCT
ajst-32576	327	9	et	et	PROPN
ajst-32576	327	10	al	al	PROPN
ajst-32576	327	11	.	.	PROPN
ajst-32576	327	12	,	,	PUNCT
ajst-32576	327	13	gefitinib	gefitinib	NOUN
ajst-32576	327	14	(	(	PUNCT
ajst-32576	327	15	an	an	DET
ajst-32576	327	16	egfr	egfr	ADJ
ajst-32576	327	17	tyrosine	tyrosine	NOUN
ajst-32576	327	18	kinase	kinase	PROPN
ajst-32576	327	19	inhibitor	inhibitor	PROPN
ajst-32576	327	20	)	)	PUNCT
ajst-32576	327	21	plus	plus	CCONJ
ajst-32576	327	22	anlotinib	anlotinib	NOUN
ajst-32576	327	23	(	(	PUNCT
ajst-32576	327	24	an	an	DET
ajst-32576	327	25	multikinase	multikinase	NOUN
ajst-32576	327	26	inhibitor	inhibitor	NOUN
ajst-32576	327	27	)	)	PUNCT
ajst-32576	327	28	for	for	ADP
ajst-32576	327	29	untreated	untreated	ADJ
ajst-32576	327	30	,	,	PUNCT
ajst-32576	327	31	egfr	egfr	NOUN
ajst-32576	327	32	-	-	PUNCT
ajst-32576	327	33	mutated	mutate	VERB
ajst-32576	327	34	,	,	PUNCT
ajst-32576	327	35	advanced	advanced	ADJ
ajst-32576	327	36	non	non	ADJ
ajst-32576	327	37	-	-	ADJ
ajst-32576	327	38	small	small	ADJ
ajst-32576	327	39	cell	cell	NOUN
ajst-32576	327	40	lung	lung	NOUN
ajst-32576	327	41	cancer	cancer	NOUN
ajst-32576	327	42	(	(	PUNCT
ajst-32576	327	43	fl	fl	NOUN
ajst-32576	327	44	-	-	PUNCT
ajst-32576	327	45	alter	alter	NOUN
ajst-32576	327	46	):	):	PUNCT
ajst-32576	327	47	a	a	DET
ajst-32576	327	48	multicenter	multicenter	ADJ
ajst-32576	327	49	phase	phase	NOUN
ajst-32576	327	50	iii	iii	NOUN
ajst-32576	327	51	trial	trial	NOUN
ajst-32576	327	52	.	.	PUNCT
ajst-32576	328	1	signal	signal	PROPN
ajst-32576	328	2	transduct	transduct	NOUN
ajst-32576	328	3	target	target	NOUN
ajst-32576	328	4	ther	ther	ADV
ajst-32576	328	5	,	,	PUNCT
ajst-32576	328	6	2024	2024	NUM
ajst-32576	328	7	.	.	PUNCT
ajst-32576	329	1	9(1	9(1	NUM
ajst-32576	329	2	):	):	PUNCT
ajst-32576	330	1	p.	p.	NOUN
ajst-32576	330	2	215	215	NUM
ajst-32576	330	3	.	.	PUNCT
ajst-32576	331	1	[	[	X
ajst-32576	331	2	50	50	NUM
ajst-32576	331	3	]	]	X
ajst-32576	331	4	nepote	nepote	NOUN
ajst-32576	331	5	,	,	PUNCT
ajst-32576	331	6	a.	a.	NOUN
ajst-32576	331	7	,	,	PUNCT
ajst-32576	331	8	et	et	PROPN
ajst-32576	331	9	al	al	PROPN
ajst-32576	331	10	.	.	PROPN
ajst-32576	331	11	,	,	PUNCT
ajst-32576	331	12	role	role	NOUN
ajst-32576	331	13	of	of	ADP
ajst-32576	331	14	osimertinib	osimertinib	NOUN
ajst-32576	331	15	plus	plus	CCONJ
ajst-32576	331	16	brain	brain	NOUN
ajst-32576	331	17	radiotherapy	radiotherapy	NOUN
ajst-32576	331	18	versus	versus	ADP
ajst-32576	331	19	osimertinib	osimertinib	NOUN
ajst-32576	331	20	single	single	ADJ
ajst-32576	331	21	therapy	therapy	NOUN
ajst-32576	331	22	in	in	ADP
ajst-32576	331	23	egfrmutated	egfrmutate	VERB
ajst-32576	331	24	non	non	ADJ
ajst-32576	331	25	-	-	ADJ
ajst-32576	331	26	small	small	ADJ
ajst-32576	331	27	-	-	PUNCT
ajst-32576	331	28	cell	cell	NOUN
ajst-32576	331	29	lung	lung	NOUN
ajst-32576	331	30	cancer	cancer	NOUN
ajst-32576	331	31	with	with	ADP
ajst-32576	331	32	brain	brain	NOUN
ajst-32576	331	33	metastases	metastasis	NOUN
ajst-32576	331	34	:	:	PUNCT
ajst-32576	331	35	a	a	DET
ajst-32576	331	36	meta	meta	ADJ
ajst-32576	331	37	-	-	PUNCT
ajst-32576	331	38	analysis	analysis	NOUN
ajst-32576	331	39	and	and	CCONJ
ajst-32576	331	40	systematic	systematic	ADJ
ajst-32576	331	41	review	review	NOUN
ajst-32576	331	42	.	.	PUNCT
ajst-32576	332	1	crit	crit	PROPN
ajst-32576	332	2	rev	rev	PROPN
ajst-32576	332	3	oncol	oncol	ADJ
ajst-32576	332	4	hematol	hematol	NOUN
ajst-32576	332	5	,	,	PUNCT
ajst-32576	332	6	2025	2025	NUM
ajst-32576	332	7	.	.	PUNCT
ajst-32576	333	1	205	205	NUM
ajst-32576	333	2	:	:	PUNCT
ajst-32576	334	1	p.	p.	NOUN
ajst-32576	334	2	104540	104540	NUM
ajst-32576	334	3	.	.	PUNCT
ajst-32576	335	1	[	[	X
ajst-32576	335	2	51	51	NUM
ajst-32576	335	3	]	]	X
ajst-32576	335	4	pike	pike	NOUN
ajst-32576	335	5	,	,	PUNCT
ajst-32576	335	6	l.r.g	l.r.g	PROPN
ajst-32576	335	7	.	.	PROPN
ajst-32576	335	8	,	,	PUNCT
ajst-32576	335	9	et	et	PROPN
ajst-32576	335	10	al	al	PROPN
ajst-32576	335	11	.	.	PROPN
ajst-32576	335	12	,	,	PUNCT
ajst-32576	335	13	tyrosine	tyrosine	PROPN
ajst-32576	335	14	kinase	kinase	VERB
ajst-32576	335	15	inhibitors	inhibitor	NOUN
ajst-32576	335	16	with	with	ADP
ajst-32576	335	17	and	and	CCONJ
ajst-32576	335	18	without	without	ADP
ajst-32576	335	19	up	up	ADP
ajst-32576	335	20	-	-	PUNCT
ajst-32576	335	21	front	front	NOUN
ajst-32576	335	22	stereotactic	stereotactic	NOUN
ajst-32576	335	23	radiosurgery	radiosurgery	NOUN
ajst-32576	335	24	for	for	ADP
ajst-32576	335	25	brain	brain	NOUN
ajst-32576	335	26	metastases	metastasis	NOUN
ajst-32576	335	27	from	from	ADP
ajst-32576	335	28	egfr	egfr	NOUN
ajst-32576	335	29	and	and	CCONJ
ajst-32576	335	30	alk	alk	VERB
ajst-32576	335	31	oncogene	oncogene	NOUN
ajst-32576	335	32	-	-	PUNCT
ajst-32576	335	33	driven	drive	VERB
ajst-32576	335	34	non	non	ADJ
ajst-32576	335	35	-	-	ADJ
ajst-32576	335	36	small	small	ADJ
ajst-32576	335	37	cell	cell	NOUN
ajst-32576	335	38	lung	lung	NOUN
ajst-32576	335	39	cancer	cancer	NOUN
ajst-32576	335	40	(	(	PUNCT
ajst-32576	335	41	turbonsclc	turbonsclc	NOUN
ajst-32576	335	42	)	)	PUNCT
ajst-32576	335	43	.	.	PUNCT
ajst-32576	336	1	j	j	PROPN
ajst-32576	336	2	clin	clin	PROPN
ajst-32576	336	3	oncol	oncol	PROPN
ajst-32576	336	4	,	,	PUNCT
ajst-32576	336	5	2024	2024	NUM
ajst-32576	336	6	.	.	PUNCT
ajst-32576	337	1	42(30	42(30	NUM
ajst-32576	337	2	):	):	PUNCT
ajst-32576	337	3	p.	p.	NOUN
ajst-32576	337	4	3606	3606	NUM
ajst-32576	337	5	-	-	SYM
ajst-32576	337	6	3617	3617	NUM
ajst-32576	337	7	.	.	PUNCT
ajst-32576	338	1	[	[	X
ajst-32576	338	2	52	52	NUM
ajst-32576	338	3	]	]	SYM
ajst-32576	338	4	yang	yang	PROPN
ajst-32576	338	5	,	,	PUNCT
ajst-32576	338	6	j.c	j.c	PROPN
ajst-32576	338	7	.	.	PROPN
ajst-32576	338	8	,	,	PUNCT
ajst-32576	338	9	et	et	PROPN
ajst-32576	338	10	al	al	PROPN
ajst-32576	338	11	.	.	PROPN
ajst-32576	338	12	,	,	PUNCT
ajst-32576	338	13	osimertinib	osimertinib	NOUN
ajst-32576	338	14	plus	plus	CCONJ
ajst-32576	338	15	durvalumab	durvalumab	X
ajst-32576	338	16	versus	versus	ADP
ajst-32576	338	17	osimertinib	osimertinib	NOUN
ajst-32576	338	18	monotherapy	monotherapy	NOUN
ajst-32576	338	19	in	in	ADP
ajst-32576	338	20	egfr	egfr	NOUN
ajst-32576	338	21	t790mpositive	t790mpositive	SYM
ajst-32576	338	22	nsclc	nsclc	NOUN
ajst-32576	338	23	following	follow	VERB
ajst-32576	338	24	previous	previous	ADJ
ajst-32576	338	25	egfr	egfr	NOUN
ajst-32576	338	26	tki	tki	X
ajst-32576	338	27	therapy	therapy	NOUN
ajst-32576	338	28	:	:	PUNCT
ajst-32576	338	29	caural	caural	ADJ
ajst-32576	338	30	brief	brief	ADJ
ajst-32576	338	31	report	report	NOUN
ajst-32576	338	32	.	.	PUNCT
ajst-32576	339	1	j	j	PROPN
ajst-32576	339	2	thorac	thorac	PROPN
ajst-32576	339	3	oncol	oncol	ADJ
ajst-32576	339	4	,	,	PUNCT
ajst-32576	339	5	2019	2019	NUM
ajst-32576	339	6	.	.	PUNCT
ajst-32576	340	1	14(5	14(5	NUM
ajst-32576	340	2	):	):	PUNCT
ajst-32576	341	1	p.	p.	NOUN
ajst-32576	341	2	933	933	NUM
ajst-32576	341	3	-	-	SYM
ajst-32576	341	4	939	939	NUM
ajst-32576	341	5	.	.	PUNCT
ajst-32576	342	1	[	[	X
ajst-32576	342	2	53	53	NUM
ajst-32576	342	3	]	]	X
ajst-32576	342	4	wei	wei	PROPN
ajst-32576	342	5	,	,	PUNCT
ajst-32576	342	6	f.	f.	PROPN
ajst-32576	342	7	,	,	PUNCT
ajst-32576	342	8	et	et	PROPN
ajst-32576	342	9	al	al	PROPN
ajst-32576	342	10	.	.	PROPN
ajst-32576	342	11	,	,	PUNCT
ajst-32576	342	12	safety	safety	NOUN
ajst-32576	342	13	and	and	CCONJ
ajst-32576	342	14	efficacy	efficacy	NOUN
ajst-32576	342	15	of	of	ADP
ajst-32576	342	16	osimertinib	osimertinib	NOUN
ajst-32576	342	17	plus	plus	CCONJ
ajst-32576	342	18	bevacizumab	bevacizumab	NOUN
ajst-32576	342	19	as	as	ADP
ajst-32576	342	20	first	first	ADJ
ajst-32576	342	21	-	-	PUNCT
ajst-32576	342	22	line	line	NOUN
ajst-32576	342	23	treatment	treatment	NOUN
ajst-32576	342	24	in	in	ADP
ajst-32576	342	25	egfr	egfr	ADJ
ajst-32576	342	26	-	-	PUNCT
ajst-32576	342	27	mutant	mutant	NOUN
ajst-32576	342	28	nsclc	nsclc	NOUN
ajst-32576	342	29	with	with	ADP
ajst-32576	342	30	brain	brain	NOUN
ajst-32576	342	31	metastases	metastasis	NOUN
ajst-32576	342	32	:	:	PUNCT
ajst-32576	342	33	a	a	DET
ajst-32576	342	34	dynamic	dynamic	ADJ
ajst-32576	342	35	ctdna	ctdna	NOUN
ajst-32576	342	36	-	-	PUNCT
ajst-32576	342	37	guided	guide	VERB
ajst-32576	342	38	study	study	NOUN
ajst-32576	342	39	.	.	PUNCT
ajst-32576	342	40	journal	journal	NOUN
ajst-32576	342	41	of	of	ADP
ajst-32576	342	42	clinical	clinical	ADJ
ajst-32576	342	43	oncology	oncology	NOUN
ajst-32576	342	44	,	,	PUNCT
ajst-32576	342	45	2024	2024	NUM
ajst-32576	342	46	.	.	PUNCT
ajst-32576	343	1	42(16_suppl	42(16_suppl	NUM
ajst-32576	343	2	):	):	PUNCT
ajst-32576	343	3	p.	p.	NOUN
ajst-32576	343	4	e20606	e20606	PROPN
ajst-32576	343	5	-	-	PUNCT
ajst-32576	343	6	e20606	e20606	PROPN
ajst-32576	343	7	.	.	PUNCT
ajst-32576	344	1	229	229	NUM
ajst-32576	345	1	[	[	X
ajst-32576	345	2	54	54	NUM
ajst-32576	345	3	]	]	X
ajst-32576	345	4	lin	lin	PROPN
ajst-32576	345	5	,	,	PUNCT
ajst-32576	345	6	j.j	j.j	PROPN
ajst-32576	345	7	.	.	PROPN
ajst-32576	345	8	,	,	PUNCT
ajst-32576	345	9	et	et	PROPN
ajst-32576	345	10	al	al	PROPN
ajst-32576	345	11	.	.	PROPN
ajst-32576	345	12	,	,	PUNCT
ajst-32576	345	13	safety	safety	NOUN
ajst-32576	345	14	and	and	CCONJ
ajst-32576	345	15	activity	activity	NOUN
ajst-32576	345	16	of	of	ADP
ajst-32576	345	17	alectinib	alectinib	NOUN
ajst-32576	345	18	plus	plus	CCONJ
ajst-32576	345	19	bevacizumab	bevacizumab	NOUN
ajst-32576	345	20	in	in	ADP
ajst-32576	345	21	patients	patient	NOUN
ajst-32576	345	22	with	with	ADP
ajst-32576	345	23	advanced	advanced	ADJ
ajst-32576	345	24	alkrearranged	alkrearrange	VERB
ajst-32576	345	25	non	non	ADJ
ajst-32576	345	26	-	-	ADJ
ajst-32576	345	27	small	small	ADJ
ajst-32576	345	28	-	-	PUNCT
ajst-32576	345	29	cell	cell	NOUN
ajst-32576	345	30	lung	lung	NOUN
ajst-32576	345	31	cancer	cancer	NOUN
ajst-32576	345	32	:	:	PUNCT
ajst-32576	345	33	a	a	DET
ajst-32576	345	34	phase	phase	NOUN
ajst-32576	345	35	i	i	NOUN
ajst-32576	345	36	/	/	SYM
ajst-32576	345	37	ii	ii	PROPN
ajst-32576	345	38	study	study	NOUN
ajst-32576	345	39	.	.	PUNCT
ajst-32576	346	1	esmo	esmo	NOUN
ajst-32576	346	2	open	open	ADJ
ajst-32576	346	3	,	,	PUNCT
ajst-32576	346	4	2022	2022	NUM
ajst-32576	346	5	.	.	PUNCT
ajst-32576	347	1	7(1	7(1	NUM
ajst-32576	347	2	):	):	PUNCT
ajst-32576	347	3	p.	p.	NOUN
ajst-32576	347	4	100342	100342	NUM
ajst-32576	347	5	.	.	PUNCT
ajst-32576	348	1	[	[	X
ajst-32576	348	2	55	55	NUM
ajst-32576	348	3	]	]	X
ajst-32576	348	4	elamin	elamin	NOUN
ajst-32576	348	5	,	,	PUNCT
ajst-32576	348	6	y.y	y.y	PROPN
ajst-32576	348	7	.	.	PROPN
ajst-32576	348	8	,	,	PUNCT
ajst-32576	348	9	et	et	PROPN
ajst-32576	348	10	al	al	PROPN
ajst-32576	348	11	.	.	PROPN
ajst-32576	348	12	,	,	PUNCT
ajst-32576	348	13	blu-945	blu-945	VERB
ajst-32576	348	14	monotherapy	monotherapy	NOUN
ajst-32576	348	15	and	and	CCONJ
ajst-32576	348	16	in	in	ADP
ajst-32576	348	17	combination	combination	NOUN
ajst-32576	348	18	with	with	ADP
ajst-32576	348	19	osimertinib	osimertinib	NOUN
ajst-32576	348	20	(	(	PUNCT
ajst-32576	348	21	osi	osi	PROPN
ajst-32576	348	22	)	)	PUNCT
ajst-32576	348	23	in	in	ADP
ajst-32576	348	24	previously	previously	ADV
ajst-32576	348	25	treated	treat	VERB
ajst-32576	348	26	patients	patient	NOUN
ajst-32576	348	27	with	with	ADP
ajst-32576	348	28	advanced	advanced	ADJ
ajst-32576	348	29	<	<	X
ajst-32576	348	30	i	i	X
ajst-32576	348	31	>	>	X
ajst-32576	348	32	egfr</i>-mutant	egfr</i>-mutant	PROPN
ajst-32576	348	33	(	(	PUNCT
ajst-32576	348	34	<	<	X
ajst-32576	348	35	i	i	X
ajst-32576	348	36	>	>	X
ajst-32576	348	37	egfrm</i	egfrm</i	PROPN
ajst-32576	348	38	>	>	NOUN
ajst-32576	348	39	)	)	PUNCT
ajst-32576	348	40	nsclc	nsclc	NOUN
ajst-32576	348	41	in	in	ADP
ajst-32576	348	42	the	the	DET
ajst-32576	348	43	phase	phase	NOUN
ajst-32576	348	44	1/2	1/2	NUM
ajst-32576	348	45	symphony	symphony	ADJ
ajst-32576	348	46	study	study	NOUN
ajst-32576	348	47	.	.	PUNCT
ajst-32576	349	1	journal	journal	NOUN
ajst-32576	349	2	of	of	ADP
ajst-32576	349	3	clinical	clinical	ADJ
ajst-32576	349	4	oncology	oncology	NOUN
ajst-32576	349	5	,	,	PUNCT
ajst-32576	349	6	2023	2023	NUM
ajst-32576	349	7	.	.	PUNCT
ajst-32576	350	1	41(16_suppl	41(16_suppl	NOUN
ajst-32576	350	2	):	):	PUNCT
ajst-32576	350	3	p.	p.	NOUN
ajst-32576	350	4	9011	9011	NUM
ajst-32576	350	5	-	-	SYM
ajst-32576	350	6	9011	9011	NUM
ajst-32576	350	7	.	.	PUNCT
ajst-32576	351	1	[	[	X
ajst-32576	351	2	56	56	NUM
ajst-32576	351	3	]	]	X
ajst-32576	351	4	lester	lester	PROPN
ajst-32576	351	5	-	-	PUNCT
ajst-32576	351	6	coll	coll	PROPN
ajst-32576	351	7	,	,	PUNCT
ajst-32576	351	8	n.h	n.h	PROPN
ajst-32576	351	9	.	.	PROPN
ajst-32576	351	10	,	,	PUNCT
ajst-32576	351	11	et	et	PROPN
ajst-32576	351	12	al	al	PROPN
ajst-32576	351	13	.	.	PROPN
ajst-32576	351	14	,	,	PUNCT
ajst-32576	351	15	cost	cost	NOUN
ajst-32576	351	16	-	-	PUNCT
ajst-32576	351	17	effectiveness	effectiveness	NOUN
ajst-32576	351	18	of	of	ADP
ajst-32576	351	19	stereotactic	stereotactic	ADJ
ajst-32576	351	20	radiosurgery	radiosurgery	NOUN
ajst-32576	351	21	versus	versus	ADP
ajst-32576	351	22	whole	whole	ADJ
ajst-32576	351	23	-	-	PUNCT
ajst-32576	351	24	brain	brain	NOUN
ajst-32576	351	25	radiation	radiation	NOUN
ajst-32576	351	26	therapy	therapy	NOUN
ajst-32576	351	27	for	for	ADP
ajst-32576	351	28	up	up	ADP
ajst-32576	351	29	to	to	PART
ajst-32576	351	30	10	10	NUM
ajst-32576	351	31	brain	brain	NOUN
ajst-32576	351	32	metastases	metastasis	NOUN
ajst-32576	351	33	.	.	PUNCT
ajst-32576	352	1	j	j	PROPN
ajst-32576	352	2	neurosurg	neurosurg	PROPN
ajst-32576	352	3	,	,	PUNCT
ajst-32576	352	4	2016	2016	NUM
ajst-32576	352	5	.	.	PUNCT
ajst-32576	353	1	125(suppl	125(suppl	NUM
ajst-32576	353	2	1	1	NUM
ajst-32576	353	3	):	):	PUNCT
ajst-32576	353	4	p.	p.	NOUN
ajst-32576	353	5	18	18	NUM
ajst-32576	353	6	-	-	SYM
ajst-32576	353	7	25	25	NUM
ajst-32576	353	8	.	.	PUNCT
ajst-32576	354	1	[	[	X
ajst-32576	354	2	57	57	NUM
ajst-32576	354	3	]	]	X
ajst-32576	354	4	chen	chen	PROPN
ajst-32576	354	5	,	,	PUNCT
ajst-32576	354	6	v.e	v.e	PROPN
ajst-32576	354	7	.	.	PROPN
ajst-32576	354	8	,	,	PUNCT
ajst-32576	354	9	et	et	PROPN
ajst-32576	354	10	al	al	PROPN
ajst-32576	354	11	.	.	PROPN
ajst-32576	354	12	,	,	PUNCT
ajst-32576	354	13	cost	cost	NOUN
ajst-32576	354	14	-	-	PUNCT
ajst-32576	354	15	effectiveness	effectiveness	NOUN
ajst-32576	354	16	analysis	analysis	NOUN
ajst-32576	354	17	of	of	ADP
ajst-32576	354	18	3	3	NUM
ajst-32576	354	19	radiation	radiation	NOUN
ajst-32576	354	20	treatment	treatment	NOUN
ajst-32576	354	21	strategies	strategy	NOUN
ajst-32576	354	22	for	for	ADP
ajst-32576	354	23	patients	patient	NOUN
ajst-32576	354	24	with	with	ADP
ajst-32576	354	25	multiple	multiple	ADJ
ajst-32576	354	26	brain	brain	NOUN
ajst-32576	354	27	metastases	metastasis	NOUN
ajst-32576	354	28	.	.	PUNCT
ajst-32576	355	1	neurooncol	neurooncol	ADJ
ajst-32576	355	2	pract	pract	NOUN
ajst-32576	355	3	,	,	PUNCT
ajst-32576	355	4	2023	2023	NUM
ajst-32576	355	5	.	.	PUNCT
ajst-32576	356	1	10(4	10(4	NUM
ajst-32576	356	2	):	):	PUNCT
ajst-32576	356	3	p.	p.	NOUN
ajst-32576	356	4	344	344	NUM
ajst-32576	356	5	-	-	SYM
ajst-32576	356	6	351	351	NUM
ajst-32576	356	7	.	.	PUNCT
ajst-32576	357	1	[	[	X
ajst-32576	357	2	58	58	NUM
ajst-32576	357	3	]	]	X
ajst-32576	357	4	levin	levin	PROPN
ajst-32576	357	5	,	,	PUNCT
ajst-32576	357	6	v.a	v.a	PROPN
ajst-32576	357	7	.	.	PROPN
ajst-32576	357	8	,	,	PUNCT
ajst-32576	357	9	et	et	PROPN
ajst-32576	357	10	al	al	PROPN
ajst-32576	357	11	.	.	PROPN
ajst-32576	357	12	,	,	PUNCT
ajst-32576	357	13	randomized	randomize	VERB
ajst-32576	357	14	double	double	ADJ
ajst-32576	357	15	-	-	PUNCT
ajst-32576	357	16	blind	blind	ADJ
ajst-32576	357	17	placebo	placebo	NOUN
ajst-32576	357	18	-	-	PUNCT
ajst-32576	357	19	controlled	control	VERB
ajst-32576	357	20	trial	trial	NOUN
ajst-32576	357	21	of	of	ADP
ajst-32576	357	22	bevacizumab	bevacizumab	NOUN
ajst-32576	357	23	therapy	therapy	NOUN
ajst-32576	357	24	for	for	ADP
ajst-32576	357	25	radiation	radiation	NOUN
ajst-32576	357	26	necrosis	necrosis	NOUN
ajst-32576	357	27	of	of	ADP
ajst-32576	357	28	the	the	DET
ajst-32576	357	29	central	central	ADJ
ajst-32576	357	30	nervous	nervous	ADJ
ajst-32576	357	31	system	system	NOUN
ajst-32576	357	32	.	.	PUNCT
ajst-32576	358	1	int	int	PROPN
ajst-32576	358	2	j	j	PROPN
ajst-32576	358	3	radiat	radiat	PROPN
ajst-32576	358	4	oncol	oncol	ADJ
ajst-32576	358	5	biol	biol	PROPN
ajst-32576	358	6	phys	phy	NOUN
ajst-32576	358	7	,	,	PUNCT
ajst-32576	358	8	2011	2011	NUM
ajst-32576	358	9	.	.	PUNCT
ajst-32576	359	1	79(5	79(5	NOUN
ajst-32576	359	2	):	):	PUNCT
ajst-32576	359	3	p.	p.	NOUN
ajst-32576	359	4	1487	1487	NUM
ajst-32576	359	5	-	-	SYM
ajst-32576	359	6	95	95	NUM
ajst-32576	359	7	.	.	PUNCT
ajst-32576	360	1	[	[	X
ajst-32576	360	2	59	59	NUM
ajst-32576	360	3	]	]	PUNCT
ajst-32576	360	4	drilon	drilon	NOUN
ajst-32576	360	5	,	,	PUNCT
ajst-32576	360	6	a.	a.	NOUN
ajst-32576	360	7	,	,	PUNCT
ajst-32576	360	8	et	et	PROPN
ajst-32576	360	9	al	al	PROPN
ajst-32576	360	10	.	.	PROPN
ajst-32576	360	11	,	,	PUNCT
ajst-32576	360	12	efficacy	efficacy	NOUN
ajst-32576	360	13	and	and	CCONJ
ajst-32576	360	14	safety	safety	NOUN
ajst-32576	360	15	of	of	ADP
ajst-32576	360	16	larotrectinib	larotrectinib	NOUN
ajst-32576	360	17	in	in	ADP
ajst-32576	360	18	patients	patient	NOUN
ajst-32576	360	19	with	with	ADP
ajst-32576	360	20	tropomyosin	tropomyosin	PROPN
ajst-32576	360	21	receptor	receptor	NOUN
ajst-32576	360	22	kinase	kinase	PROPN
ajst-32576	360	23	fusion	fusion	NOUN
ajst-32576	360	24	-	-	PUNCT
ajst-32576	360	25	positive	positive	ADJ
ajst-32576	360	26	lung	lung	NOUN
ajst-32576	360	27	cancers	cancer	NOUN
ajst-32576	360	28	.	.	PUNCT
ajst-32576	361	1	jco	jco	PROPN
ajst-32576	361	2	precis	precis	PROPN
ajst-32576	361	3	oncol	oncol	PROPN
ajst-32576	361	4	,	,	PUNCT
ajst-32576	361	5	2022	2022	NUM
ajst-32576	361	6	.	.	PUNCT
ajst-32576	362	1	6	6	NUM
ajst-32576	362	2	:	:	PUNCT
ajst-32576	362	3	p.	p.	NOUN
ajst-32576	362	4	e2100418	e2100418	PROPN
ajst-32576	362	5	.	.	PUNCT
ajst-32576	363	1	[	[	X
ajst-32576	363	2	60	60	NUM
ajst-32576	363	3	]	]	SYM
ajst-32576	363	4	le	le	X
ajst-32576	363	5	,	,	PUNCT
ajst-32576	363	6	x.	x.	PROPN
ajst-32576	363	7	,	,	PUNCT
ajst-32576	363	8	et	et	PROPN
ajst-32576	363	9	al	al	PROPN
ajst-32576	363	10	.	.	PROPN
ajst-32576	363	11	,	,	PUNCT
ajst-32576	363	12	tepotinib	tepotinib	NOUN
ajst-32576	363	13	efficacy	efficacy	NOUN
ajst-32576	363	14	and	and	CCONJ
ajst-32576	363	15	safety	safety	NOUN
ajst-32576	363	16	in	in	ADP
ajst-32576	363	17	patients	patient	NOUN
ajst-32576	363	18	with	with	ADP
ajst-32576	363	19	met	meet	VERB
ajst-32576	363	20	exon	exon	NOUN
ajst-32576	363	21	14	14	NUM
ajst-32576	363	22	skipping	skip	VERB
ajst-32576	363	23	nsclc	nsclc	NOUN
ajst-32576	363	24	:	:	PUNCT
ajst-32576	363	25	outcomes	outcome	NOUN
ajst-32576	363	26	in	in	ADP
ajst-32576	363	27	patient	patient	ADJ
ajst-32576	363	28	subgroups	subgroup	NOUN
ajst-32576	363	29	from	from	ADP
ajst-32576	363	30	the	the	DET
ajst-32576	363	31	vision	vision	NOUN
ajst-32576	363	32	study	study	NOUN
ajst-32576	363	33	with	with	ADP
ajst-32576	363	34	relevance	relevance	NOUN
ajst-32576	363	35	for	for	ADP
ajst-32576	363	36	clinical	clinical	ADJ
ajst-32576	363	37	practice	practice	NOUN
ajst-32576	363	38	.	.	PUNCT
ajst-32576	364	1	clin	clin	PROPN
ajst-32576	364	2	cancer	cancer	NOUN
ajst-32576	364	3	res	re	NOUN
ajst-32576	364	4	,	,	PUNCT
ajst-32576	364	5	2022	2022	NUM
ajst-32576	364	6	.	.	PUNCT
ajst-32576	365	1	28(6	28(6	NUM
ajst-32576	365	2	):	):	PUNCT
ajst-32576	366	1	p.	p.	NOUN
ajst-32576	366	2	1117	1117	NUM
ajst-32576	366	3	-	-	SYM
ajst-32576	366	4	1126	1126	NUM
ajst-32576	366	5	.	.	PUNCT
ajst-32576	367	1	[	[	X
ajst-32576	367	2	61	61	NUM
ajst-32576	367	3	]	]	SYM
ajst-32576	367	4	yang	yang	PROPN
ajst-32576	367	5	,	,	PUNCT
ajst-32576	367	6	z.	z.	PROPN
ajst-32576	367	7	,	,	PUNCT
ajst-32576	367	8	et	et	PROPN
ajst-32576	367	9	al	al	PROPN
ajst-32576	367	10	.	.	PROPN
ajst-32576	367	11	,	,	PUNCT
ajst-32576	367	12	whole	whole	ADJ
ajst-32576	367	13	-	-	PUNCT
ajst-32576	367	14	brain	brain	NOUN
ajst-32576	367	15	radiotherapy	radiotherapy	NOUN
ajst-32576	367	16	with	with	ADP
ajst-32576	367	17	and	and	CCONJ
ajst-32576	367	18	without	without	ADP
ajst-32576	367	19	concurrent	concurrent	ADJ
ajst-32576	367	20	erlotinib	erlotinib	NOUN
ajst-32576	367	21	in	in	ADP
ajst-32576	367	22	nsclc	nsclc	NOUN
ajst-32576	367	23	with	with	ADP
ajst-32576	367	24	brain	brain	NOUN
ajst-32576	367	25	metastases	metastasis	NOUN
ajst-32576	367	26	:	:	PUNCT
ajst-32576	367	27	a	a	DET
ajst-32576	367	28	multicenter	multicenter	NOUN
ajst-32576	367	29	,	,	PUNCT
ajst-32576	367	30	open	open	ADJ
ajst-32576	367	31	-	-	PUNCT
ajst-32576	367	32	label	label	NOUN
ajst-32576	367	33	,	,	PUNCT
ajst-32576	367	34	randomized	randomize	VERB
ajst-32576	367	35	,	,	PUNCT
ajst-32576	367	36	controlled	control	VERB
ajst-32576	367	37	phase	phase	NOUN
ajst-32576	367	38	iii	iii	NOUN
ajst-32576	367	39	trial	trial	NOUN
ajst-32576	367	40	.	.	PUNCT
ajst-32576	367	41	neuro	neuro	PROPN
ajst-32576	367	42	oncol	oncol	PROPN
ajst-32576	367	43	,	,	PUNCT
ajst-32576	367	44	2021	2021	NUM
ajst-32576	367	45	.	.	PUNCT
ajst-32576	368	1	23(6	23(6	NUM
ajst-32576	368	2	):	):	PUNCT
ajst-32576	369	1	p.	p.	NOUN
ajst-32576	369	2	967	967	NUM
ajst-32576	369	3	-	-	SYM
ajst-32576	369	4	978	978	NUM
ajst-32576	369	5	.	.	PUNCT
ajst-32576	370	1	[	[	X
ajst-32576	370	2	62	62	NUM
ajst-32576	370	3	]	]	X
ajst-32576	370	4	chen	chen	PROPN
ajst-32576	370	5	,	,	PUNCT
ajst-32576	370	6	l.	l.	PROPN
ajst-32576	370	7	,	,	PUNCT
ajst-32576	370	8	et	et	PROPN
ajst-32576	370	9	al	al	PROPN
ajst-32576	370	10	.	.	PROPN
ajst-32576	370	11	,	,	PUNCT
ajst-32576	370	12	efficacy	efficacy	NOUN
ajst-32576	370	13	and	and	CCONJ
ajst-32576	370	14	safety	safety	NOUN
ajst-32576	370	15	of	of	ADP
ajst-32576	370	16	recombinant	recombinant	ADJ
ajst-32576	370	17	human	human	ADJ
ajst-32576	370	18	endostatin	endostatin	NOUN
ajst-32576	370	19	combined	combine	VERB
ajst-32576	370	20	with	with	ADP
ajst-32576	370	21	whole	whole	ADJ
ajst-32576	370	22	-	-	PUNCT
ajst-32576	370	23	brain	brain	NOUN
ajst-32576	370	24	radiation	radiation	NOUN
ajst-32576	370	25	therapy	therapy	NOUN
ajst-32576	370	26	in	in	ADP
ajst-32576	370	27	patients	patient	NOUN
ajst-32576	370	28	with	with	ADP
ajst-32576	370	29	brain	brain	NOUN
ajst-32576	370	30	metastases	metastasis	NOUN
ajst-32576	370	31	from	from	ADP
ajst-32576	370	32	non	non	ADJ
ajst-32576	370	33	-	-	ADJ
ajst-32576	370	34	small	small	ADJ
ajst-32576	370	35	cell	cell	NOUN
ajst-32576	370	36	lung	lung	NOUN
ajst-32576	370	37	cancer	cancer	NOUN
ajst-32576	370	38	.	.	PUNCT
ajst-32576	371	1	radiother	radiother	PROPN
ajst-32576	371	2	oncol	oncol	PROPN
ajst-32576	371	3	,	,	PUNCT
ajst-32576	371	4	2022	2022	NUM
ajst-32576	371	5	.	.	PUNCT
ajst-32576	372	1	174	174	NUM
ajst-32576	372	2	:	:	PUNCT
ajst-32576	373	1	p.	p.	NOUN
ajst-32576	373	2	44	44	NUM
ajst-32576	373	3	-	-	SYM
ajst-32576	373	4	51	51	NUM
ajst-32576	373	5	.	.	PUNCT
ajst-32576	374	1	availability	availability	NOUN
ajst-32576	374	2	of	of	ADP
ajst-32576	374	3	data	datum	NOUN
ajst-32576	374	4	and	and	CCONJ
ajst-32576	374	5	materials	material	NOUN
ajst-32576	374	6	table	table	NOUN
ajst-32576	374	7	1	1	NUM
ajst-32576	374	8	.	.	PUNCT
ajst-32576	375	1	clinical	clinical	ADJ
ajst-32576	375	2	trials	trial	NOUN
ajst-32576	375	3	of	of	ADP
ajst-32576	375	4	targeted	target	VERB
ajst-32576	375	5	therapy	therapy	NOUN
ajst-32576	375	6	for	for	ADP
ajst-32576	375	7	brain	brain	NOUN
ajst-32576	375	8	metastases	metastasis	NOUN
ajst-32576	375	9	in	in	ADP
ajst-32576	375	10	non	non	ADJ
ajst-32576	375	11	-	-	ADJ
ajst-32576	375	12	small	small	ADJ
ajst-32576	375	13	cell	cell	NOUN
ajst-32576	375	14	lung	lung	NOUN
ajst-32576	375	15	cancer	cancer	NOUN
ajst-32576	375	16	references	reference	NOUN
ajst-32576	375	17	registration	registration	NOUN
ajst-32576	375	18	number	number	NOUN
ajst-32576	375	19	study	study	NOUN
ajst-32576	375	20	name	name	NOUN
ajst-32576	375	21	intervetion	intervetion	NOUN
ajst-32576	375	22	group	group	NOUN
ajst-32576	375	23	control	control	PROPN
ajst-32576	375	24	group	group	PROPN
ajst-32576	375	25	study	study	NOUN
ajst-32576	375	26	design	design	NOUN
ajst-32576	375	27	n	n	CCONJ
ajst-32576	375	28	intracranial/	intracranial/	PRON
ajst-32576	375	29	cns	cns	PROPN
ajst-32576	375	30	efficacy	efficacy	NOUN
ajst-32576	375	31	systemic	systemic	ADJ
ajst-32576	375	32	efficacy	efficacy	NOUN
ajst-32576	375	33	[	[	X
ajst-32576	375	34	9	9	NUM
ajst-32576	375	35	]	]	PUNCT
ajst-32576	375	36	nct03849768	nct03849768	VERB
ajst-32576	375	37	aeneas	aeneas	PROPN
ajst-32576	375	38	aumolertinib	aumolertinib	NOUN
ajst-32576	375	39	gefitinib	gefitinib	NOUN
ajst-32576	375	40	phase	phase	NOUN
ajst-32576	375	41	ⅲ	ⅲ	PROPN
ajst-32576	375	42	51	51	NUM
ajst-32576	375	43	(	(	PUNCT
ajst-32576	375	44	cg:55	cg:55	PROPN
ajst-32576	375	45	)	)	PUNCT
ajst-32576	375	46	mcns	mcns	PROPN
ajst-32576	375	47	pfs:29.0m(cg:8.3	pfs:29.0m(cg:8.3	PROPN
ajst-32576	375	48	m	m	NOUN
ajst-32576	375	49	)	)	PUNCT
ajst-32576	375	50	cns	cns	PROPN
ajst-32576	375	51	orr:62.7%(cg:49.1	orr:62.7%(cg:49.1	PROPN
ajst-32576	375	52	%	%	NOUN
ajst-32576	375	53	)	)	PUNCT
ajst-32576	375	54	cns	cns	NOUN
ajst-32576	375	55	dcr:94.1%(cg:96.4	dcr:94.1%(cg:96.4	ADJ
ajst-32576	375	56	%	%	NOUN
ajst-32576	375	57	)	)	PUNCT
ajst-32576	376	1	mcns	mcns	PROPN
ajst-32576	376	2	dor:27.7m(cg:6.9	dor:27.7m(cg:6.9	PROPN
ajst-32576	376	3	m	m	PROPN
ajst-32576	376	4	)	)	PUNCT
ajst-32576	376	5	6	6	NUM
ajst-32576	376	6	-	-	PUNCT
ajst-32576	376	7	month	month	NOUN
ajst-32576	376	8	pfs:86.0%(cg:71.8	pfs:86.0%(cg:71.8	PROPN
ajst-32576	376	9	%	%	NOUN
ajst-32576	376	10	)	)	PUNCT
ajst-32576	376	11	12	12	NUM
ajst-32576	376	12	-	-	PUNCT
ajst-32576	376	13	month	month	NOUN
ajst-32576	376	14	pfs:72.5%(cg:30.4	pfs:72.5%(cg:30.4	NOUN
ajst-32576	376	15	%	%	NOUN
ajst-32576	376	16	)	)	PUNCT
ajst-32576	376	17	18	18	NUM
ajst-32576	376	18	-	-	PUNCT
ajst-32576	376	19	month	month	NOUN
ajst-32576	376	20	pfs:59.9%(cg:8.9	pfs:59.9%(cg:8.9	PROPN
ajst-32576	376	21	%	%	NOUN
ajst-32576	376	22	)	)	PUNCT
ajst-32576	376	23	24	24	NUM
ajst-32576	376	24	-	-	PUNCT
ajst-32576	376	25	month	month	NOUN
ajst-32576	376	26	pfs:56.8%(cg:8.9	pfs:56.8%(cg:8.9	PROPN
ajst-32576	376	27	%	%	NOUN
ajst-32576	376	28	)	)	PUNCT
ajst-32576	377	1	[	[	X
ajst-32576	377	2	10	10	NUM
ajst-32576	377	3	]	]	SYM
ajst-32576	377	4	nct01951469	nct01951469	NOUN
ajst-32576	377	5	gap	gap	NOUN
ajst-32576	377	6	brain	brain	NOUN
ajst-32576	377	7	gefitinib	gefitinib	NOUN
ajst-32576	377	8	plus	plus	CCONJ
ajst-32576	377	9	chemotherapy	chemotherapy	NOUN
ajst-32576	377	10	gefitinib	gefitinib	NOUN
ajst-32576	377	11	phase	phase	NOUN
ajst-32576	377	12	ⅲ	ⅲ	PROPN
ajst-32576	377	13	80	80	NUM
ajst-32576	377	14	(	(	PUNCT
ajst-32576	377	15	cg:81	cg:81	PROPN
ajst-32576	377	16	)	)	PUNCT
ajst-32576	377	17	mipfs:15.6m(cg:9.1	mipfs:15.6m(cg:9.1	PROPN
ajst-32576	377	18	m	m	NOUN
ajst-32576	377	19	)	)	PUNCT
ajst-32576	377	20	iorr:85.0%(cg:63.0	iorr:85.0%(cg:63.0	PROPN
ajst-32576	377	21	%	%	NOUN
ajst-32576	377	22	)	)	PUNCT
ajst-32576	377	23	idcr:95.0%(cg:93.8	idcr:95.0%(cg:93.8	ADJ
ajst-32576	377	24	%	%	NOUN
ajst-32576	377	25	)	)	PUNCT
ajst-32576	377	26	mpfs:16.3m(cg:9.3	mpfs:16.3m(cg:9.3	PROPN
ajst-32576	377	27	m	m	NOUN
ajst-32576	377	28	)	)	PUNCT
ajst-32576	377	29	mos:35.0m(cg:28.9	mos:35.0m(cg:28.9	PROPN
ajst-32576	377	30	m	m	NOUN
ajst-32576	377	31	)	)	PUNCT
ajst-32576	377	32	orr:76.3%(cg:58.0	orr:76.3%(cg:58.0	PROPN
ajst-32576	377	33	%	%	NOUN
ajst-32576	377	34	)	)	PUNCT
ajst-32576	378	1	dcr:97.5%(cg:95.1	dcr:97.5%(cg:95.1	PROPN
ajst-32576	378	2	%	%	NOUN
ajst-32576	378	3	)	)	PUNCT
ajst-32576	379	1	[	[	X
ajst-32576	379	2	47	47	NUM
ajst-32576	379	3	]	]	PUNCT
ajst-32576	379	4	nct04028778	nct04028778	NOUN
ajst-32576	379	5	fl	fl	PROPN
ajst-32576	379	6	-	-	PUNCT
ajst-32576	379	7	alter	alter	NOUN
ajst-32576	379	8	gefitinib	gefitinib	NOUN
ajst-32576	379	9	plus	plus	CCONJ
ajst-32576	379	10	anlotinib	anlotinib	VERB
ajst-32576	379	11	gefitinib	gefitinib	NOUN
ajst-32576	379	12	phase	phase	NOUN
ajst-32576	379	13	ⅲ	ⅲ	PROPN
ajst-32576	379	14	49	49	NUM
ajst-32576	379	15	(	(	PUNCT
ajst-32576	379	16	cg:50	cg:50	PROPN
ajst-32576	379	17	)	)	PUNCT
ajst-32576	379	18	mpfs:13.8m(cg:8.3	mpfs:13.8m(cg:8.3	PROPN
ajst-32576	379	19	m	m	NOUN
ajst-32576	379	20	)	)	PUNCT
ajst-32576	380	1	[	[	X
ajst-32576	380	2	11	11	NUM
ajst-32576	380	3	]	]	PUNCT
ajst-32576	380	4	nct02759614	nct02759614	NOUN
ajst-32576	380	5	artemis	artemis	PROPN
ajst-32576	380	6	ctong1509	ctong1509	PROPN
ajst-32576	380	7	erlotinib	erlotinib	PROPN
ajst-32576	380	8	plus	plus	CCONJ
ajst-32576	380	9	bevacizumab	bevacizumab	NOUN
ajst-32576	380	10	erlotinib	erlotinib	NOUN
ajst-32576	380	11	phase	phase	NOUN
ajst-32576	380	12	ⅲ	ⅲ	PROPN
ajst-32576	380	13	44	44	NUM
ajst-32576	380	14	(	(	PUNCT
ajst-32576	380	15	cg:47	cg:47	PROPN
ajst-32576	380	16	)	)	PUNCT
ajst-32576	380	17	mpfs:17.9m(cg:11.1	mpfs:17.9m(cg:11.1	NOUN
ajst-32576	380	18	m	m	NOUN
ajst-32576	380	19	)	)	PUNCT
ajst-32576	380	20	mos:31.6m(cg:26.8	mos:31.6m(cg:26.8	NOUN
ajst-32576	380	21	m	m	NOUN
ajst-32576	380	22	)	)	PUNCT
ajst-32576	381	1	[	[	X
ajst-32576	381	2	13	13	NUM
ajst-32576	381	3	,	,	PUNCT
ajst-32576	381	4	14	14	NUM
ajst-32576	381	5	]	]	PUNCT
ajst-32576	381	6	nct04035486	nct04035486	ADJ
ajst-32576	381	7	flaura2	flaura2	PROPN
ajst-32576	381	8	osimertinib	osimertinib	NOUN
ajst-32576	381	9	plus	plus	CCONJ
ajst-32576	381	10	chemotherapy	chemotherapy	NOUN
ajst-32576	381	11	osimertinib	osimertinib	NOUN
ajst-32576	381	12	phase	phase	NOUN
ajst-32576	381	13	ⅲ	ⅲ	PROPN
ajst-32576	381	14	118	118	NUM
ajst-32576	381	15	(	(	PUNCT
ajst-32576	381	16	cg:104	cg:104	PROPN
ajst-32576	381	17	)	)	PUNCT
ajst-32576	381	18	116	116	NUM
ajst-32576	381	19	(	(	PUNCT
ajst-32576	381	20	cg:110	cg:110	NOUN
ajst-32576	381	21	)	)	PUNCT
ajst-32576	381	22	mcns	mcns	PROPN
ajst-32576	381	23	pfs:30.2m(cg:27.6	pfs:30.2m(cg:27.6	PROPN
ajst-32576	381	24	m	m	PROPN
ajst-32576	381	25	)	)	PUNCT
ajst-32576	381	26	cns	cns	PROPN
ajst-32576	381	27	orr:73%(cg:69	orr:73%(cg:69	PROPN
ajst-32576	381	28	%	%	NOUN
ajst-32576	381	29	)	)	PUNCT
ajst-32576	381	30	cns	cns	PROPN
ajst-32576	381	31	dcr:91%(cg:93	dcr:91%(cg:93	PROPN
ajst-32576	381	32	%	%	NOUN
ajst-32576	381	33	)	)	PUNCT
ajst-32576	382	1	mcns	mcns	PROPN
ajst-32576	382	2	dor	dor	PROPN
ajst-32576	382	3	:	:	PUNCT
ajst-32576	382	4	nr(cg:26.2	nr(cg:26.2	NOUN
ajst-32576	382	5	m	m	NOUN
ajst-32576	382	6	)	)	PUNCT
ajst-32576	382	7	mpfs:24.9m(cg:13.8	mpfs:24.9m(cg:13.8	NOUN
ajst-32576	382	8	m	m	NOUN
ajst-32576	382	9	)	)	PUNCT
ajst-32576	383	1	[	[	X
ajst-32576	383	2	16	16	NUM
ajst-32576	383	3	]	]	PUNCT
ajst-32576	383	4	nct04632758	nct04632758	NOUN
ajst-32576	383	5	inspire	inspire	PROPN
ajst-32576	383	6	iruplinalkib	iruplinalkib	PROPN
ajst-32576	383	7	crizotinib	crizotinib	NOUN
ajst-32576	383	8	phase	phase	NOUN
ajst-32576	383	9	ⅲ	ⅲ	PROPN
ajst-32576	383	10	37	37	NUM
ajst-32576	383	11	(	(	PUNCT
ajst-32576	383	12	cg:44	cg:44	NOUN
ajst-32576	383	13	)	)	PUNCT
ajst-32576	383	14	iorr:90.9%(cg:60.0	iorr:90.9%(cg:60.0	NOUN
ajst-32576	383	15	%	%	NOUN
ajst-32576	383	16	)	)	PUNCT
ajst-32576	383	17	midor:20.1m(cg:9.3	midor:20.1m(cg:9.3	PROPN
ajst-32576	383	18	m	m	NOUN
ajst-32576	383	19	)	)	PUNCT
ajst-32576	383	20	mpfs:22m(cg:11	mpfs:22m(cg:11	PROPN
ajst-32576	383	21	m	m	NOUN
ajst-32576	383	22	)	)	PUNCT
ajst-32576	383	23	24	24	NUM
ajst-32576	383	24	-	-	PUNCT
ajst-32576	383	25	month	month	NOUN
ajst-32576	383	26	pfs:49.0%(cg:4.4	pfs:49.0%(cg:4.4	NUM
ajst-32576	383	27	%	%	NOUN
ajst-32576	383	28	)	)	PUNCT
ajst-32576	383	29	24	24	NUM
ajst-32576	383	30	-	-	PUNCT
ajst-32576	383	31	month	month	NOUN
ajst-32576	383	32	os:85.6%(cg:84.0	os:85.6%(cg:84.0	NUM
ajst-32576	383	33	%	%	NOUN
ajst-32576	383	34	)	)	PUNCT
ajst-32576	384	1	[	[	X
ajst-32576	384	2	17	17	NUM
ajst-32576	384	3	,	,	PUNCT
ajst-32576	384	4	21	21	NUM
ajst-32576	384	5	]	]	PUNCT
ajst-32576	384	6	nct03052608	nct03052608	ADJ
ajst-32576	384	7	crown	crown	NOUN
ajst-32576	384	8	lorlatinib	lorlatinib	NOUN
ajst-32576	384	9	crizotinib	crizotinib	VERB
ajst-32576	384	10	phase	phase	NOUN
ajst-32576	384	11	ⅲ	ⅲ	PROPN
ajst-32576	384	12	38	38	NUM
ajst-32576	384	13	(	(	PUNCT
ajst-32576	384	14	cg:40	cg:40	PROPN
ajst-32576	384	15	)	)	PUNCT
ajst-32576	384	16	5	5	NUM
ajst-32576	384	17	-	-	PUNCT
ajst-32576	384	18	year	year	NOUN
ajst-32576	384	19	ipfs:83%(cg	ipfs:83%(cg	NOUN
ajst-32576	384	20	:	:	PUNCT
ajst-32576	384	21	ne	ne	ADJ
ajst-32576	384	22	)	)	PUNCT
ajst-32576	384	23	iorr:92%(cg:33	iorr:92%(cg:33	NOUN
ajst-32576	384	24	%	%	NOUN
ajst-32576	384	25	)	)	PUNCT
ajst-32576	384	26	mpfs	mpf	VERB
ajst-32576	384	27	:	:	PUNCT
ajst-32576	384	28	nr(cg:6.0	nr(cg:6.0	NOUN
ajst-32576	384	29	m	m	NOUN
ajst-32576	384	30	)	)	PUNCT
ajst-32576	384	31	12	12	NUM
ajst-32576	384	32	-	-	PUNCT
ajst-32576	384	33	month	month	NOUN
ajst-32576	384	34	pfs:78%(cg:22	pfs:78%(cg:22	NOUN
ajst-32576	384	35	%	%	NOUN
ajst-32576	384	36	)	)	PUNCT
ajst-32576	384	37	5	5	NUM
ajst-32576	384	38	-	-	PUNCT
ajst-32576	384	39	year	year	NOUN
ajst-32576	384	40	pfs:53%(cg	pfs:53%(cg	NOUN
ajst-32576	384	41	:	:	PUNCT
ajst-32576	384	42	ne	ne	X
ajst-32576	384	43	)	)	PUNCT
ajst-32576	385	1	[	[	X
ajst-32576	385	2	18	18	NUM
ajst-32576	385	3	,	,	PUNCT
ajst-32576	385	4	19	19	NUM
ajst-32576	385	5	]	]	PUNCT
ajst-32576	385	6	nct02075840	nct02075840	NOUN
ajst-32576	385	7	alex	alex	PROPN
ajst-32576	385	8	alectinib	alectinib	PROPN
ajst-32576	385	9	crizotinib	crizotinib	VERB
ajst-32576	385	10	phase	phase	NOUN
ajst-32576	385	11	ⅲ	ⅲ	PROPN
ajst-32576	385	12	64	64	NUM
ajst-32576	385	13	(	(	PUNCT
ajst-32576	385	14	cg:58	cg:58	PROPN
ajst-32576	385	15	)	)	PUNCT
ajst-32576	385	16	cns	cns	NOUN
ajst-32576	385	17	orr:81.0%(cg:50.0	orr:81.0%(cg:50.0	NOUN
ajst-32576	385	18	%	%	NOUN
ajst-32576	385	19	)	)	PUNCT
ajst-32576	386	1	mpfs:27.7m(cg:7.4	mpfs:27.7m(cg:7.4	PROPN
ajst-32576	386	2	m	m	NOUN
ajst-32576	386	3	)	)	PUNCT
ajst-32576	387	1	[	[	X
ajst-32576	387	2	20	20	NUM
ajst-32576	387	3	]	]	PUNCT
ajst-32576	387	4	nct02737501	nct02737501	PROPN
ajst-32576	387	5	alta-1l	alta-1l	PUNCT
ajst-32576	388	1	brigatinib	brigatinib	NOUN
ajst-32576	388	2	crizotinib	crizotinib	VERB
ajst-32576	388	3	phase	phase	NOUN
ajst-32576	388	4	ⅲ	ⅲ	PROPN
ajst-32576	388	5	47	47	NUM
ajst-32576	388	6	(	(	PUNCT
ajst-32576	388	7	cg:49	cg:49	PROPN
ajst-32576	388	8	)	)	PUNCT
ajst-32576	388	9	3	3	NUM
ajst-32576	388	10	-	-	PUNCT
ajst-32576	388	11	year	year	NOUN
ajst-32576	388	12	mipfs:31%(cg:9	mipfs:31%(cg:9	PROPN
ajst-32576	388	13	%	%	NOUN
ajst-32576	388	14	)	)	PUNCT
ajst-32576	388	15	4	4	NUM
ajst-32576	388	16	-	-	PUNCT
ajst-32576	388	17	year	year	NOUN
ajst-32576	388	18	mipfs:22%(cg	mipfs:22%(cg	PROPN
ajst-32576	388	19	:	:	PUNCT
ajst-32576	388	20	ne	ne	ADJ
ajst-32576	388	21	)	)	PUNCT
ajst-32576	388	22	midor:27.9m(cg:9.2	midor:27.9m(cg:9.2	NOUN
ajst-32576	388	23	m	m	NOUN
ajst-32576	388	24	)	)	PUNCT
ajst-32576	388	25	3	3	NUM
ajst-32576	388	26	-	-	PUNCT
ajst-32576	388	27	year	year	NOUN
ajst-32576	388	28	os:74%(cg:55	os:74%(cg:55	PROPN
ajst-32576	388	29	%	%	NOUN
ajst-32576	388	30	)	)	PUNCT
ajst-32576	388	31	4	4	NUM
ajst-32576	388	32	-	-	PUNCT
ajst-32576	388	33	year	year	NOUN
ajst-32576	388	34	os:71%(cg:44	os:71%(cg:44	ADJ
ajst-32576	388	35	%	%	NOUN
ajst-32576	388	36	)	)	PUNCT
ajst-32576	389	1	[	[	X
ajst-32576	389	2	22	22	NUM
ajst-32576	389	3	]	]	SYM
ajst-32576	389	4	nct02097810	nct02097810	PROPN
ajst-32576	389	5	nct02568267	nct02568267	ADJ
ajst-32576	389	6	eudract	eudract	NOUN
ajst-32576	389	7	,	,	PUNCT
ajst-32576	389	8	2012000148	2012000148	NUM
ajst-32576	389	9	-	-	SYM
ajst-32576	389	10	88	88	NUM
ajst-32576	389	11	startrk-1	startrk-1	NUM
ajst-32576	389	12	startrk-2	startrk-2	NUM
ajst-32576	389	13	alka-372001	alka-372001	ADJ
ajst-32576	389	14	entrectinib	entrectinib	NOUN
ajst-32576	389	15	phase	phase	NOUN
ajst-32576	389	16	ⅰ	ⅰ	X
ajst-32576	389	17	phase	phase	NOUN
ajst-32576	389	18	ⅱ	ⅱ	PROPN
ajst-32576	389	19	phase	phase	NOUN
ajst-32576	389	20	ⅰ	ⅰ	PROPN
ajst-32576	389	21	23	23	NUM
ajst-32576	389	22	mipfs:7.7	mipfs:7.7	PROPN
ajst-32576	389	23	m	m	PROPN
ajst-32576	389	24	iorr:55	iorr:55	NOUN
ajst-32576	389	25	%	%	NOUN
ajst-32576	389	26	midor:12.9	midor:12.9	NOUN
ajst-32576	389	27	m	m	PROPN
ajst-32576	389	28	mpfs:13.6	mpfs:13.6	PROPN
ajst-32576	389	29	m	m	PROPN
ajst-32576	389	30	230	230	NUM
ajst-32576	389	31	continue	continue	VERB
ajst-32576	389	32	from	from	ADP
ajst-32576	389	33	table	table	NOUN
ajst-32576	389	34	1	1	NUM
ajst-32576	389	35	[	[	X
ajst-32576	389	36	23	23	NUM
ajst-32576	389	37	]	]	PUNCT
ajst-32576	389	38	nct03093116	nct03093116	ADV
ajst-32576	389	39	trident-1	trident-1	NUM
ajst-32576	389	40	repotrectinib	repotrectinib	NOUN
ajst-32576	389	41	(	(	PUNCT
ajst-32576	389	42	ros1	ros1	PROPN
ajst-32576	389	43	tkinaïve	tkinaïve	PROPN
ajst-32576	389	44	)	)	PUNCT
ajst-32576	390	1	repotrectinib	repotrectinib	NOUN
ajst-32576	390	2	(	(	PUNCT
ajst-32576	390	3	ros1	ros1	PROPN
ajst-32576	390	4	-	-	PUNCT
ajst-32576	390	5	tki	tki	NOUN
ajst-32576	390	6	pretreated	pretreate	VERB
ajst-32576	390	7	and	and	CCONJ
ajst-32576	390	8	chemotherapynaïve	chemotherapynaïve	ADJ
ajst-32576	390	9	)	)	PUNCT
ajst-32576	390	10	phase	phase	NOUN
ajst-32576	390	11	ⅱ	ⅱ	PROPN
ajst-32576	390	12	17	17	NUM
ajst-32576	390	13	(	(	PUNCT
ajst-32576	390	14	cg:26	cg:26	PROPN
ajst-32576	390	15	)	)	PUNCT
ajst-32576	390	16	iorr:89%(cg:38	iorr:89%(cg:38	NUM
ajst-32576	390	17	%	%	NOUN
ajst-32576	390	18	)	)	PUNCT
ajst-32576	391	1	[	[	X
ajst-32576	391	2	57	57	NUM
ajst-32576	391	3	]	]	PUNCT
ajst-32576	391	4	nct02576431	nct02576431	NOUN
ajst-32576	391	5	nct02122913	nct02122913	PROPN
ajst-32576	391	6	larotrectinib	larotrectinib	PROPN
ajst-32576	391	7	phase	phase	VERB
ajst-32576	391	8	ⅱ	ⅱ	PROPN
ajst-32576	391	9	phase	phase	NOUN
ajst-32576	391	10	ⅰ	ⅰ	PROPN
ajst-32576	392	1	10	10	NUM
ajst-32576	392	2	cns	cns	PROPN
ajst-32576	392	3	orr:63	orr:63	NOUN
ajst-32576	392	4	%	%	NOUN
ajst-32576	393	1	[	[	X
ajst-32576	393	2	58	58	NUM
ajst-32576	393	3	]	]	PUNCT
ajst-32576	393	4	nct02864992	nct02864992	NOUN
ajst-32576	393	5	vision	vision	PROPN
ajst-32576	393	6	tepotinib	tepotinib	NOUN
ajst-32576	393	7	phase	phase	VERB
ajst-32576	393	8	ⅱ	ⅱ	PROPN
ajst-32576	393	9	23	23	NUM
ajst-32576	393	10	mpfs:9.5	mpfs:9.5	NOUN
ajst-32576	393	11	m	m	PART
ajst-32576	393	12	[	[	X
ajst-32576	393	13	29	29	NUM
ajst-32576	393	14	]	]	PUNCT
ajst-32576	393	15	nct04194944	nct04194944	PROPN
ajst-32576	393	16	selpercatinib	selpercatinib	PROPN
ajst-32576	393	17	pemetrexed	pemetrexe	VERB
ajst-32576	393	18	plus	plus	CCONJ
ajst-32576	393	19	platinum	platinum	NOUN
ajst-32576	393	20	therapy	therapy	NOUN
ajst-32576	393	21	phase	phase	NOUN
ajst-32576	393	22	ⅲ	ⅲ	PROPN
ajst-32576	393	23	17	17	NUM
ajst-32576	393	24	(	(	PUNCT
ajst-32576	393	25	cg:12	cg:12	PROPN
ajst-32576	393	26	)	)	PUNCT
ajst-32576	394	1	iorr:82%(cg:58	iorr:82%(cg:58	PROPN
ajst-32576	394	2	%	%	NOUN
ajst-32576	394	3	)	)	PUNCT
ajst-32576	395	1	[	[	X
ajst-32576	395	2	30	30	NUM
ajst-32576	395	3	]	]	X
ajst-32576	395	4	nct03505710	nct03505710	ADJ
ajst-32576	395	5	destiny	destiny	NOUN
ajst-32576	395	6	lung01	lung01	PROPN
ajst-32576	395	7	trastuzumab	trastuzumab	NOUN
ajst-32576	395	8	deruxtecan	deruxtecan	PROPN
ajst-32576	395	9	phase	phase	NOUN
ajst-32576	395	10	ⅱ	ⅱ	PROPN
ajst-32576	395	11	33	33	NUM
ajst-32576	395	12	mpfs:7.1	mpfs:7.1	NOUN
ajst-32576	395	13	m	m	VERB
ajst-32576	395	14	mos:13.8	mos:13.8	ADJ
ajst-32576	395	15	m	m	VERB
ajst-32576	395	16	cns	cns	NOUN
ajst-32576	395	17	,	,	PUNCT
ajst-32576	395	18	central	central	ADJ
ajst-32576	395	19	nervous	nervous	ADJ
ajst-32576	395	20	system	system	NOUN
ajst-32576	395	21	;	;	PUNCT
ajst-32576	395	22	pfs	pfs	PROPN
ajst-32576	395	23	,	,	PUNCT
ajst-32576	395	24	progression	progression	NOUN
ajst-32576	395	25	free	free	ADJ
ajst-32576	395	26	survival	survival	NOUN
ajst-32576	395	27	;	;	PUNCT
ajst-32576	395	28	orr	orr	PROPN
ajst-32576	395	29	,	,	PUNCT
ajst-32576	395	30	objective	objective	ADJ
ajst-32576	395	31	response	response	NOUN
ajst-32576	395	32	rate	rate	NOUN
ajst-32576	395	33	;	;	PUNCT
ajst-32576	395	34	dcr	dcr	NOUN
ajst-32576	395	35	,	,	PUNCT
ajst-32576	395	36	disease	disease	NOUN
ajst-32576	395	37	control	control	NOUN
ajst-32576	395	38	rate	rate	NOUN
ajst-32576	395	39	;	;	PUNCT
ajst-32576	395	40	dor	dor	NOUN
ajst-32576	395	41	,	,	PUNCT
ajst-32576	395	42	duration	duration	NOUN
ajst-32576	395	43	of	of	ADP
ajst-32576	395	44	response	response	NOUN
ajst-32576	395	45	;	;	PUNCT
ajst-32576	395	46	os	os	ADJ
ajst-32576	395	47	,	,	PUNCT
ajst-32576	395	48	overall	overall	ADJ
ajst-32576	395	49	survival	survival	NOUN
ajst-32576	395	50	table	table	NOUN
ajst-32576	395	51	2	2	NUM
ajst-32576	395	52	.	.	PUNCT
ajst-32576	396	1	clinical	clinical	ADJ
ajst-32576	396	2	trials	trial	NOUN
ajst-32576	396	3	of	of	ADP
ajst-32576	396	4	chemotherapy	chemotherapy	NOUN
ajst-32576	396	5	for	for	ADP
ajst-32576	396	6	brain	brain	NOUN
ajst-32576	396	7	metastases	metastasis	NOUN
ajst-32576	396	8	in	in	ADP
ajst-32576	396	9	non	non	ADJ
ajst-32576	396	10	-	-	ADJ
ajst-32576	396	11	small	small	ADJ
ajst-32576	396	12	cell	cell	NOUN
ajst-32576	396	13	lung	lung	NOUN
ajst-32576	396	14	cancer	cancer	NOUN
ajst-32576	396	15	references	reference	NOUN
ajst-32576	396	16	registration	registration	NOUN
ajst-32576	396	17	number	number	NOUN
ajst-32576	396	18	study	study	NOUN
ajst-32576	396	19	name	name	NOUN
ajst-32576	396	20	intervetion	intervetion	NOUN
ajst-32576	396	21	group	group	NOUN
ajst-32576	396	22	control	control	PROPN
ajst-32576	396	23	group	group	PROPN
ajst-32576	396	24	study	study	NOUN
ajst-32576	396	25	design	design	NOUN
ajst-32576	396	26	n	n	DET
ajst-32576	396	27	systemic	systemic	ADJ
ajst-32576	396	28	efficacy	efficacy	NOUN
ajst-32576	396	29	[	[	X
ajst-32576	396	30	31	31	NUM
ajst-32576	396	31	]	]	PUNCT
ajst-32576	396	32	nct02039674	nct02039674	NOUN
ajst-32576	396	33	nct02578680	nct02578680	ADV
ajst-32576	396	34	nct02775435	nct02775435	PROPN
ajst-32576	396	35	keynote021	keynote021	PROPN
ajst-32576	396	36	keynote189	keynote189	PROPN
ajst-32576	396	37	keynote407	keynote407	PROPN
ajst-32576	396	38	pembrolizumab	pembrolizumab	NOUN
ajst-32576	396	39	plus	plus	CCONJ
ajst-32576	396	40	platinum	platinum	NOUN
ajst-32576	396	41	-	-	PUNCT
ajst-32576	396	42	based	base	VERB
ajst-32576	396	43	chemotherapy	chemotherapy	NOUN
ajst-32576	396	44	platinum	platinum	NOUN
ajst-32576	396	45	-	-	PUNCT
ajst-32576	396	46	based	base	VERB
ajst-32576	396	47	chemotherapy	chemotherapy	NOUN
ajst-32576	396	48	phase	phase	NOUN
ajst-32576	396	49	ⅲ	ⅲ	PROPN
ajst-32576	396	50	105	105	NUM
ajst-32576	396	51	(	(	PUNCT
ajst-32576	396	52	cg:66	cg:66	PROPN
ajst-32576	396	53	)	)	PUNCT
ajst-32576	396	54	mpfs:6.9m(cg:4.1	mpfs:6.9m(cg:4.1	PROPN
ajst-32576	396	55	m	m	NOUN
ajst-32576	396	56	)	)	PUNCT
ajst-32576	396	57	mos:18.8m(cg:7.6	mos:18.8m(cg:7.6	NOUN
ajst-32576	396	58	m	m	NOUN
ajst-32576	396	59	)	)	PUNCT
ajst-32576	397	1	[	[	X
ajst-32576	397	2	33	33	NUM
ajst-32576	397	3	]	]	PUNCT
ajst-32576	397	4	nct05184712	nct05184712	NOUN
ajst-32576	397	5	harmonia	harmonia	PROPN
ajst-32576	397	6	ivonescimab	ivonescimab	NOUN
ajst-32576	397	7	plus	plus	CCONJ
ajst-32576	397	8	pemetrexed	pemetrexed	NOUN
ajst-32576	397	9	and	and	CCONJ
ajst-32576	397	10	carboplatin	carboplatin	NOUN
ajst-32576	397	11	pemetrexed	pemetrexed	PROPN
ajst-32576	397	12	and	and	CCONJ
ajst-32576	397	13	carboplatin	carboplatin	NOUN
ajst-32576	397	14	phase	phase	NOUN
ajst-32576	397	15	ⅲ	ⅲ	PROPN
ajst-32576	397	16	35	35	NUM
ajst-32576	397	17	(	(	PUNCT
ajst-32576	397	18	cg:37	cg:37	NOUN
ajst-32576	397	19	)	)	PUNCT
ajst-32576	397	20	mpfs:5.75m(cg:4.14	mpfs:5.75m(cg:4.14	PROPN
ajst-32576	397	21	m	m	NOUN
ajst-32576	397	22	)	)	PUNCT
ajst-32576	398	1	[	[	X
ajst-32576	398	2	34	34	NUM
ajst-32576	398	3	]	]	SYM
ajst-32576	398	4	chictr1800016615	chictr1800016615	NOUN
ajst-32576	398	5	intrathecal	intrathecal	ADJ
ajst-32576	398	6	pemetrexed	pemetrexed	NOUN
ajst-32576	398	7	phase	phase	NOUN
ajst-32576	398	8	ⅱ	ⅱ	PROPN
ajst-32576	398	9	132	132	NUM
ajst-32576	398	10	mos:12.0	mos:12.0	PROPN
ajst-32576	398	11	m	m	VERB
ajst-32576	398	12	pfs	pfs	PROPN
ajst-32576	398	13	,	,	PUNCT
ajst-32576	398	14	progression	progression	NOUN
ajst-32576	398	15	free	free	ADJ
ajst-32576	398	16	survival	survival	NOUN
ajst-32576	398	17	;	;	PUNCT
ajst-32576	398	18	os	os	ADJ
ajst-32576	398	19	,	,	PUNCT
ajst-32576	398	20	overall	overall	ADJ
ajst-32576	398	21	survival	survival	NOUN
ajst-32576	398	22	table	table	NOUN
ajst-32576	398	23	3	3	NUM
ajst-32576	398	24	.	.	PUNCT
ajst-32576	399	1	clinical	clinical	ADJ
ajst-32576	399	2	trials	trial	NOUN
ajst-32576	399	3	of	of	ADP
ajst-32576	399	4	radiotherapy	radiotherapy	NOUN
ajst-32576	399	5	for	for	ADP
ajst-32576	399	6	brain	brain	NOUN
ajst-32576	399	7	metastases	metastasis	NOUN
ajst-32576	399	8	in	in	ADP
ajst-32576	399	9	non	non	ADJ
ajst-32576	399	10	-	-	ADJ
ajst-32576	399	11	small	small	ADJ
ajst-32576	399	12	cell	cell	NOUN
ajst-32576	399	13	lung	lung	NOUN
ajst-32576	399	14	cancer	cancer	NOUN
ajst-32576	399	15	references	reference	NOUN
ajst-32576	399	16	registration	registration	NOUN
ajst-32576	399	17	number	number	NOUN
ajst-32576	399	18	study	study	NOUN
ajst-32576	399	19	name	name	NOUN
ajst-32576	399	20	intervention	intervention	PROPN
ajst-32576	399	21	group	group	PROPN
ajst-32576	399	22	control	control	PROPN
ajst-32576	399	23	group	group	PROPN
ajst-32576	399	24	study	study	NOUN
ajst-32576	399	25	design	design	NOUN
ajst-32576	399	26	n	n	CCONJ
ajst-32576	399	27	intracranial	intracranial	ADJ
ajst-32576	399	28	efficacy	efficacy	NOUN
ajst-32576	399	29	systemic	systemic	ADJ
ajst-32576	399	30	efficacy	efficacy	NOUN
ajst-32576	399	31	[	[	X
ajst-32576	399	32	36	36	NUM
ajst-32576	399	33	]	]	PUNCT
ajst-32576	399	34	nct02882984	nct02882984	NOUN
ajst-32576	399	35	hybrid	hybrid	PROPN
ajst-32576	399	36	wbrt	wbrt	PROPN
ajst-32576	399	37	srs	srs	PROPN
ajst-32576	399	38	phase	phase	NOUN
ajst-32576	399	39	ⅲ	ⅲ	PROPN
ajst-32576	399	40	41	41	NUM
ajst-32576	399	41	(	(	PUNCT
ajst-32576	399	42	cg:44	cg:44	PROPN
ajst-32576	399	43	)	)	PUNCT
ajst-32576	399	44	month	month	NOUN
ajst-32576	399	45	ipfs:91.7%(cg:91.1	ipfs:91.7%(cg:91.1	PROPN
ajst-32576	399	46	%	%	NOUN
ajst-32576	399	47	)	)	PUNCT
ajst-32576	399	48	mipfs:21.4m(cg:22.3	mipfs:21.4m(cg:22.3	NOUN
ajst-32576	399	49	m	m	NOUN
ajst-32576	399	50	)	)	PUNCT
ajst-32576	399	51	2	2	NUM
ajst-32576	399	52	-	-	PUNCT
ajst-32576	399	53	year	year	NOUN
ajst-32576	399	54	os:75.6%(cg:90.9	os:75.6%(cg:90.9	NOUN
ajst-32576	399	55	%	%	NOUN
ajst-32576	399	56	)	)	PUNCT
ajst-32576	399	57	3	3	NUM
ajst-32576	399	58	-	-	PUNCT
ajst-32576	399	59	year	year	NOUN
ajst-32576	399	60	os:36.6%(cg:52.3	os:36.6%(cg:52.3	PROPN
ajst-32576	399	61	%	%	NOUN
ajst-32576	399	62	)	)	PUNCT
ajst-32576	400	1	[	[	X
ajst-32576	400	2	59	59	NUM
ajst-32576	400	3	]	]	PUNCT
ajst-32576	400	4	nct01887795	nct01887795	NOUN
ajst-32576	400	5	wbrt	wbrt	PROPN
ajst-32576	400	6	plus	plus	CCONJ
ajst-32576	400	7	erlotinib	erlotinib	VERB
ajst-32576	400	8	wbrt	wbrt	NOUN
ajst-32576	400	9	phase	phase	NOUN
ajst-32576	400	10	ⅲ	ⅲ	PROPN
ajst-32576	400	11	109	109	NUM
ajst-32576	400	12	(	(	PUNCT
ajst-32576	400	13	cg:115	cg:115	X
ajst-32576	400	14	)	)	PUNCT
ajst-32576	401	1	mipfs:11.2m(cg:9.1	mipfs:11.2m(cg:9.1	PROPN
ajst-32576	401	2	m	m	NOUN
ajst-32576	401	3	)	)	PUNCT
ajst-32576	401	4	mpfs:5.3m(cg:4.0	mpfs:5.3m(cg:4.0	NOUN
ajst-32576	401	5	m	m	NOUN
ajst-32576	401	6	)	)	PUNCT
ajst-32576	402	1	[	[	X
ajst-32576	402	2	60	60	NUM
ajst-32576	402	3	]	]	PUNCT
ajst-32576	402	4	nct03614065	nct03614065	NOUN
ajst-32576	402	5	rhendostatin	rhendostatin	NOUN
ajst-32576	402	6	plus	plus	CCONJ
ajst-32576	402	7	wbrt	wbrt	NOUN
ajst-32576	402	8	wbrt	wbrt	NOUN
ajst-32576	402	9	phase	phase	NOUN
ajst-32576	402	10	ⅲ	ⅲ	PROPN
ajst-32576	402	11	19	19	NUM
ajst-32576	402	12	(	(	PUNCT
ajst-32576	402	13	cg:24	cg:24	PROPN
ajst-32576	402	14	)	)	PUNCT
ajst-32576	402	15	mipfs:11.6m(cg:4.8	mipfs:11.6m(cg:4.8	PROPN
ajst-32576	402	16	m	m	NOUN
ajst-32576	402	17	)	)	PUNCT
ajst-32576	402	18	mpfs:8.1m(cg:4.9	mpfs:8.1m(cg:4.9	NUM
ajst-32576	402	19	m	m	NOUN
ajst-32576	402	20	)	)	PUNCT
ajst-32576	402	21	mos:14.2m(cg:6.4	mos:14.2m(cg:6.4	PROPN
ajst-32576	402	22	m	m	NOUN
ajst-32576	402	23	)	)	PUNCT
ajst-32576	402	24	wbrt	wbrt	PROPN
ajst-32576	402	25	,	,	PUNCT
ajst-32576	402	26	whole	whole	ADJ
ajst-32576	402	27	brain	brain	NOUN
ajst-32576	402	28	radiation	radiation	NOUN
ajst-32576	402	29	therapy	therapy	NOUN
ajst-32576	402	30	;	;	PUNCT
ajst-32576	402	31	srs	srs	PROPN
ajst-32576	402	32	,	,	PUNCT
ajst-32576	402	33	stereotactic	stereotactic	PROPN
ajst-32576	402	34	radiosurgery	radiosurgery	NOUN
ajst-32576	402	35	;	;	PUNCT
ajst-32576	402	36	pfs	pfs	PROPN
ajst-32576	402	37	,	,	PUNCT
ajst-32576	402	38	progression	progression	NOUN
ajst-32576	402	39	free	free	ADJ
ajst-32576	402	40	survival	survival	NOUN
ajst-32576	402	41	;	;	PUNCT
ajst-32576	402	42	os	os	ADJ
ajst-32576	402	43	,	,	PUNCT
ajst-32576	402	44	overall	overall	ADJ
ajst-32576	402	45	survival	survival	NOUN
ajst-32576	402	46	table	table	NOUN
ajst-32576	402	47	4	4	NUM
ajst-32576	402	48	.	.	PUNCT
ajst-32576	403	1	clinical	clinical	ADJ
ajst-32576	403	2	trials	trial	NOUN
ajst-32576	403	3	of	of	ADP
ajst-32576	403	4	immunotherapy	immunotherapy	NOUN
ajst-32576	403	5	for	for	ADP
ajst-32576	403	6	brain	brain	NOUN
ajst-32576	403	7	metastases	metastasis	NOUN
ajst-32576	403	8	in	in	ADP
ajst-32576	403	9	non	non	ADJ
ajst-32576	403	10	-	-	ADJ
ajst-32576	403	11	small	small	ADJ
ajst-32576	403	12	cell	cell	NOUN
ajst-32576	403	13	lung	lung	NOUN
ajst-32576	403	14	cancer	cancer	NOUN
ajst-32576	403	15	references	reference	NOUN
ajst-32576	403	16	registration	registration	NOUN
ajst-32576	403	17	number	number	NOUN
ajst-32576	403	18	study	study	NOUN
ajst-32576	403	19	name	name	NOUN
ajst-32576	403	20	intervetion	intervetion	NOUN
ajst-32576	403	21	group	group	NOUN
ajst-32576	403	22	control	control	PROPN
ajst-32576	403	23	group	group	PROPN
ajst-32576	403	24	study	study	NOUN
ajst-32576	403	25	design	design	NOUN
ajst-32576	403	26	n	n	CCONJ
ajst-32576	403	27	intracranial/	intracranial/	PRON
ajst-32576	403	28	cns	cns	PROPN
ajst-32576	403	29	efficacy	efficacy	NOUN
ajst-32576	403	30	systemic	systemic	ADJ
ajst-32576	403	31	efficacy	efficacy	NOUN
ajst-32576	403	32	[	[	X
ajst-32576	403	33	40	40	NUM
ajst-32576	403	34	]	]	PUNCT
ajst-32576	403	35	nct02085070	nct02085070	NOUN
ajst-32576	403	36	pembrolizumab	pembrolizumab	NOUN
ajst-32576	403	37	phase	phase	NOUN
ajst-32576	403	38	ⅱ	ⅱ	PROPN
ajst-32576	403	39	42	42	NUM
ajst-32576	403	40	medium	medium	ADJ
ajst-32576	403	41	cns	cns	NOUN
ajst-32576	403	42	pfs:2.3	pfs:2.3	PROPN
ajst-32576	403	43	m	m	PROPN
ajst-32576	403	44	mpfs:1.9	mpfs:1.9	NOUN
ajst-32576	403	45	m	m	PROPN
ajst-32576	403	46	1	1	NUM
ajst-32576	403	47	-	-	PUNCT
ajst-32576	403	48	year	year	NOUN
ajst-32576	403	49	os:40	os:40	NOUN
ajst-32576	403	50	%	%	NOUN
ajst-32576	403	51	2	2	NUM
ajst-32576	403	52	-	-	PUNCT
ajst-32576	403	53	year	year	NOUN
ajst-32576	403	54	os:34	os:34	PROPN
ajst-32576	403	55	%	%	NOUN
ajst-32576	404	1	mos:9.9	mos:9.9	PROPN
ajst-32576	404	2	m	m	PROPN
ajst-32576	405	1	[	[	X
ajst-32576	405	2	44	44	NUM
ajst-32576	405	3	]	]	PUNCT
ajst-32576	405	4	nct02477826	nct02477826	NOUN
ajst-32576	405	5	checkmate	checkmate	VERB
ajst-32576	405	6	227	227	NUM
ajst-32576	405	7	nivolumab	nivolumab	NOUN
ajst-32576	405	8	plus	plus	CCONJ
ajst-32576	405	9	ipilimumab	ipilimumab	ADJ
ajst-32576	405	10	platinumdoublet	platinumdoublet	NOUN
ajst-32576	405	11	chemotherapy	chemotherapy	NOUN
ajst-32576	405	12	phase	phase	NOUN
ajst-32576	405	13	ⅲ	ⅲ	PROPN
ajst-32576	405	14	68	68	NUM
ajst-32576	405	15	(	(	PUNCT
ajst-32576	405	16	cg:66	cg:66	PROPN
ajst-32576	405	17	)	)	PUNCT
ajst-32576	405	18	5	5	NUM
ajst-32576	405	19	-	-	PUNCT
ajst-32576	405	20	year	year	NOUN
ajst-32576	405	21	ipfs:16%(cg:6	ipfs:16%(cg:6	PROPN
ajst-32576	405	22	%	%	NOUN
ajst-32576	405	23	)	)	PUNCT
ajst-32576	405	24	5	5	NUM
ajst-32576	405	25	-	-	PUNCT
ajst-32576	405	26	year	year	NOUN
ajst-32576	405	27	pfs:12%(cg:0	pfs:12%(cg:0	NOUN
ajst-32576	405	28	%	%	NOUN
ajst-32576	405	29	)	)	PUNCT
ajst-32576	405	30	mos:17.4m(cg:13.9	mos:17.4m(cg:13.9	PROPN
ajst-32576	405	31	m	m	NOUN
ajst-32576	405	32	)	)	PUNCT
ajst-32576	405	33	5	5	NUM
ajst-32576	405	34	-	-	PUNCT
ajst-32576	405	35	year	year	NOUN
ajst-32576	405	36	os:23%(cg:13	os:23%(cg:13	PROPN
ajst-32576	405	37	%	%	NOUN
ajst-32576	405	38	)	)	PUNCT
ajst-32576	405	39	cns	cns	NOUN
ajst-32576	405	40	,	,	PUNCT
ajst-32576	405	41	central	central	ADJ
ajst-32576	405	42	nervous	nervous	ADJ
ajst-32576	405	43	system	system	NOUN
ajst-32576	405	44	;	;	PUNCT
ajst-32576	405	45	pfs	pfs	PROPN
ajst-32576	405	46	,	,	PUNCT
ajst-32576	405	47	progression	progression	NOUN
ajst-32576	405	48	free	free	ADJ
ajst-32576	405	49	survival	survival	NOUN
ajst-32576	405	50	;	;	PUNCT
ajst-32576	405	51	os	os	ADJ
ajst-32576	405	52	,	,	PUNCT
ajst-32576	405	53	overall	overall	ADJ
ajst-32576	405	54	survival	survival	NOUN
ajst-32576	405	55	231	231	NUM
ajst-32576	405	56	figure	figure	NOUN
ajst-32576	405	57	1	1	NUM
ajst-32576	405	58	.	.	PUNCT
ajst-32576	406	1	|	|	ADV
ajst-32576	406	2	schematic	schematic	ADJ
ajst-32576	406	3	representation	representation	NOUN
ajst-32576	406	4	of	of	ADP
ajst-32576	406	5	the	the	DET
ajst-32576	406	6	structure	structure	NOUN
ajst-32576	406	7	and	and	CCONJ
ajst-32576	406	8	function	function	NOUN
ajst-32576	406	9	of	of	ADP
ajst-32576	406	10	the	the	DET
ajst-32576	406	11	blood	blood	NOUN
ajst-32576	406	12	–	–	PUNCT
ajst-32576	406	13	brain	brain	NOUN
ajst-32576	406	14	barrier	barrier	NOUN
ajst-32576	406	15	(	(	PUNCT
ajst-32576	406	16	bbb	bbb	PROPN
ajst-32576	406	17	)	)	PUNCT
ajst-32576	406	18	.	.	PUNCT
ajst-32576	407	1	the	the	DET
ajst-32576	407	2	bbb	bbb	PROPN
ajst-32576	407	3	is	be	AUX
ajst-32576	407	4	primarily	primarily	ADV
ajst-32576	407	5	composed	compose	VERB
ajst-32576	407	6	of	of	ADP
ajst-32576	407	7	brain	brain	NOUN
ajst-32576	407	8	microvascular	microvascular	ADJ
ajst-32576	407	9	endothelial	endothelial	ADJ
ajst-32576	407	10	cells	cell	NOUN
ajst-32576	407	11	,	,	PUNCT
ajst-32576	407	12	pericytes	pericyte	NOUN
ajst-32576	407	13	,	,	PUNCT
ajst-32576	407	14	astrocytes	astrocyte	NOUN
ajst-32576	407	15	,	,	PUNCT
ajst-32576	407	16	and	and	CCONJ
ajst-32576	407	17	the	the	DET
ajst-32576	407	18	basement	basement	NOUN
ajst-32576	407	19	membrane	membrane	NOUN
ajst-32576	407	20	.	.	PUNCT
ajst-32576	408	1	tight	tight	ADJ
ajst-32576	408	2	junctions	junction	NOUN
ajst-32576	408	3	between	between	ADP
ajst-32576	408	4	endothelial	endothelial	ADJ
ajst-32576	408	5	cells	cell	NOUN
ajst-32576	408	6	establish	establish	VERB
ajst-32576	408	7	a	a	DET
ajst-32576	408	8	physical	physical	ADJ
ajst-32576	408	9	barrier	barrier	NOUN
ajst-32576	408	10	,	,	PUNCT
ajst-32576	408	11	while	while	SCONJ
ajst-32576	408	12	uptake	uptake	ADJ
ajst-32576	408	13	and	and	CCONJ
ajst-32576	408	14	efflux	efflux	VERB
ajst-32576	408	15	transporters	transporter	NOUN
ajst-32576	408	16	regulate	regulate	VERB
ajst-32576	408	17	transmembrane	transmembrane	ADJ
ajst-32576	408	18	substance	substance	NOUN
ajst-32576	408	19	exchange	exchange	NOUN
ajst-32576	408	20	.	.	PUNCT
ajst-32576	409	1	this	this	DET
ajst-32576	409	2	highly	highly	ADV
ajst-32576	409	3	selective	selective	ADJ
ajst-32576	409	4	system	system	NOUN
ajst-32576	409	5	restricts	restrict	VERB
ajst-32576	409	6	the	the	DET
ajst-32576	409	7	entry	entry	NOUN
ajst-32576	409	8	of	of	ADP
ajst-32576	409	9	harmful	harmful	ADJ
ajst-32576	409	10	compounds	compound	NOUN
ajst-32576	409	11	while	while	SCONJ
ajst-32576	409	12	permitting	permit	VERB
ajst-32576	409	13	essential	essential	ADJ
ajst-32576	409	14	nutrients	nutrient	NOUN
ajst-32576	409	15	to	to	PART
ajst-32576	409	16	maintain	maintain	VERB
ajst-32576	409	17	cerebral	cerebral	ADJ
ajst-32576	409	18	homeostasis	homeostasis	NOUN
ajst-32576	409	19	.	.	PUNCT
ajst-32576	410	1	during	during	ADP
ajst-32576	410	2	tumorigenesis	tumorigenesis	NOUN
ajst-32576	410	3	and	and	CCONJ
ajst-32576	410	4	the	the	DET
ajst-32576	410	5	development	development	NOUN
ajst-32576	410	6	of	of	ADP
ajst-32576	410	7	brain	brain	NOUN
ajst-32576	410	8	metastases	metastasis	NOUN
ajst-32576	410	9	,	,	PUNCT
ajst-32576	410	10	structural	structural	ADJ
ajst-32576	410	11	and	and	CCONJ
ajst-32576	410	12	functional	functional	ADJ
ajst-32576	410	13	alterations	alteration	NOUN
ajst-32576	410	14	in	in	ADP
ajst-32576	410	15	the	the	DET
ajst-32576	410	16	bbb	bbb	PROPN
ajst-32576	410	17	lead	lead	NOUN
ajst-32576	410	18	to	to	ADP
ajst-32576	410	19	the	the	DET
ajst-32576	410	20	formation	formation	NOUN
ajst-32576	410	21	of	of	ADP
ajst-32576	410	22	the	the	DET
ajst-32576	410	23	blood	blood	NOUN
ajst-32576	410	24	–	–	PUNCT
ajst-32576	410	25	tumor	tumor	NOUN
ajst-32576	410	26	barrier	barrier	NOUN
ajst-32576	410	27	(	(	PUNCT
ajst-32576	410	28	btb	btb	NOUN
ajst-32576	410	29	)	)	PUNCT
ajst-32576	410	30	,	,	PUNCT
ajst-32576	410	31	which	which	PRON
ajst-32576	410	32	exhibits	exhibit	VERB
ajst-32576	410	33	distinct	distinct	ADJ
ajst-32576	410	34	permeability	permeability	NOUN
ajst-32576	410	35	and	and	CCONJ
ajst-32576	410	36	transport	transport	NOUN
ajst-32576	410	37	properties	property	NOUN
ajst-32576	410	38	compared	compare	VERB
ajst-32576	410	39	with	with	ADP
ajst-32576	410	40	the	the	DET
ajst-32576	410	41	normal	normal	ADJ
ajst-32576	410	42	bbb	bbb	PROPN
ajst-32576	410	43	.	.	PUNCT
ajst-32576	411	1	figure	figure	NOUN
ajst-32576	411	2	2	2	NUM
ajst-32576	411	3	.	.	PUNCT
ajst-32576	412	1	|	|	ADV
ajst-32576	412	2	epidermal	epidermal	ADJ
ajst-32576	412	3	growth	growth	NOUN
ajst-32576	412	4	factor	factor	NOUN
ajst-32576	412	5	receptor	receptor	NOUN
ajst-32576	412	6	(	(	PUNCT
ajst-32576	412	7	egfr	egfr	X
ajst-32576	412	8	)	)	PUNCT
ajst-32576	412	9	signaling	signal	VERB
ajst-32576	412	10	pathway	pathway	NOUN
ajst-32576	412	11	and	and	CCONJ
ajst-32576	412	12	the	the	DET
ajst-32576	412	13	mechanism	mechanism	NOUN
ajst-32576	412	14	of	of	ADP
ajst-32576	412	15	action	action	NOUN
ajst-32576	412	16	of	of	ADP
ajst-32576	412	17	tyrosine	tyrosine	NOUN
ajst-32576	412	18	kinase	kinase	PROPN
ajst-32576	412	19	inhibitors	inhibitor	NOUN
ajst-32576	412	20	(	(	PUNCT
ajst-32576	412	21	egfr	egfr	NOUN
ajst-32576	412	22	-	-	PUNCT
ajst-32576	412	23	tkis	tkis	NOUN
ajst-32576	412	24	)	)	PUNCT
ajst-32576	412	25	.	.	PUNCT
ajst-32576	413	1	ligand	ligand	NOUN
ajst-32576	413	2	binding	bind	VERB
ajst-32576	413	3	induces	induce	VERB
ajst-32576	413	4	egfr	egfr	ADJ
ajst-32576	413	5	dimerization	dimerization	NOUN
ajst-32576	413	6	and	and	CCONJ
ajst-32576	413	7	autophosphorylation	autophosphorylation	NOUN
ajst-32576	413	8	,	,	PUNCT
ajst-32576	413	9	which	which	PRON
ajst-32576	413	10	subsequently	subsequently	ADV
ajst-32576	413	11	activate	activate	VERB
ajst-32576	413	12	multiple	multiple	ADJ
ajst-32576	413	13	downstream	downstream	ADJ
ajst-32576	413	14	pathways	pathway	NOUN
ajst-32576	413	15	,	,	PUNCT
ajst-32576	413	16	including	include	VERB
ajst-32576	413	17	pi3k	pi3k	PROPN
ajst-32576	413	18	/	/	SYM
ajst-32576	413	19	akt	akt	PROPN
ajst-32576	413	20	/	/	SYM
ajst-32576	413	21	mtor	mtor	PROPN
ajst-32576	413	22	and	and	CCONJ
ajst-32576	413	23	ras	ras	PROPN
ajst-32576	413	24	/	/	SYM
ajst-32576	413	25	raf	raf	PROPN
ajst-32576	413	26	/	/	SYM
ajst-32576	413	27	mek	mek	PROPN
ajst-32576	413	28	/	/	SYM
ajst-32576	413	29	erk	erk	PROPN
ajst-32576	413	30	.	.	PUNCT
ajst-32576	414	1	these	these	DET
ajst-32576	414	2	cascades	cascade	NOUN
ajst-32576	414	3	regulate	regulate	VERB
ajst-32576	414	4	cell	cell	NOUN
ajst-32576	414	5	survival	survival	NOUN
ajst-32576	414	6	,	,	PUNCT
ajst-32576	414	7	proliferation	proliferation	NOUN
ajst-32576	414	8	,	,	PUNCT
ajst-32576	414	9	and	and	CCONJ
ajst-32576	414	10	cell	cell	NOUN
ajst-32576	414	11	-	-	PUNCT
ajst-32576	414	12	cycle	cycle	NOUN
ajst-32576	414	13	progression	progression	NOUN
ajst-32576	414	14	.	.	PUNCT
ajst-32576	415	1	egfr	egfr	PROPN
ajst-32576	415	2	-	-	PUNCT
ajst-32576	415	3	tkis	tkis	PROPN
ajst-32576	415	4	exert	exert	PROPN
ajst-32576	415	5	antitumor	antitumor	PROPN
ajst-32576	415	6	effects	effect	NOUN
ajst-32576	415	7	by	by	ADP
ajst-32576	415	8	blocking	block	VERB
ajst-32576	415	9	egfr	egfr	ADJ
ajst-32576	415	10	activation	activation	NOUN
ajst-32576	415	11	and	and	CCONJ
ajst-32576	415	12	downstream	downstream	ADJ
ajst-32576	415	13	signal	signal	NOUN
ajst-32576	415	14	transduction	transduction	NOUN
ajst-32576	415	15	,	,	PUNCT
ajst-32576	415	16	thereby	thereby	ADV
ajst-32576	415	17	suppressing	suppress	VERB
ajst-32576	415	18	tumor	tumor	NOUN
ajst-32576	415	19	growth	growth	NOUN
ajst-32576	415	20	and	and	CCONJ
ajst-32576	415	21	progression	progression	NOUN
ajst-32576	415	22	.	.	PUNCT